daunorubicin profile

Daunorubicin is an anthracycline antibiotic that is used to treat a variety of cancers, including acute leukemia, lymphoma, and solid tumors. It is produced by the bacterium Streptomyces peucetius. Daunorubicin works by inhibiting the synthesis of DNA and RNA, which is essential for cell growth and division. It is also thought to be able to cause DNA damage, which leads to cell death. Daunorubicin is a potent anticancer drug but can also have serious side effects, including heart damage, bone marrow suppression, and hair loss. It is typically administered intravenously, and the dosage is adjusted based on the patient's age, weight, and overall health. Daunorubicin has been studied extensively for its anticancer properties, and research continues to investigate its mechanism of action and potential new uses. It is a valuable tool in the fight against cancer and is used widely in cancer treatment regimens.'

Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

daunorubicin : A natural product found in Actinomadura roseola. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	30323
CHEMBL ID	178
CHEBI ID	41977
SCHEMBL ID	3041
MeSH ID	M0005683

Synonym
AB00514669-09
BRD-K43389675-003-02-7
(1s,3s)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranoside
(7s,9r)-9-acetyl-7-[(2s,4s,5s,6s)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione
NCGC00025173-01
tocris-1467
BPBIO1_000389
PRESTWICK3_000487
BSPBIO_000353
rp 13057
vs-103
(7s,9s)-9-acetyl-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione
(8s-cis)-8-acetyl-10-[(3-amino-2,3,6-trideoxy-.alpha.-l-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro--6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione
fi 6339
anthracyline
rubidomycin
AB00514669
brn 1445583
5,12-naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8s,10s)-
nci-c04693
daunarubicinum
daunorubicin [inn:ban]
ai3-52942
hsdb 5095
daunorrubicina
rcra waste no. u059
5,12-naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8s-cis)-
einecs 244-069-7
daunamycin
daunorubicinum [inn-latin]
ccris 914
nsc 83142
20830-81-3
(+)-daunomycin
daunomycin
daunorubicin
C01907
(1s,3s)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranoside
CHEBI:41977 ,
acetyladriamycin
leukaemomycin c
(8s-cis)-8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione
daunorubicinum
DB00694
NCGC00024246-05
NCGC00024246-06
anthracycline
(1s,3s)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-l-lyxo-hexopyranoside
LMPK13050002
HMS2089H04
HMS2091K06
daunoxome (tn)
D07776
daunorubicin (inn)
fi-6339
valrubicin impurity, daunorubicin
CHEMBL178
epirubicin hydrochloride impurity, daunorubicin-
ndc-0082-4155
(7s,9s)-9-acetyl-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione
NCGC00024246-10
NCGC00024246-09
NCGC00024246-07
(7s,9s)-9-acetyl-7-(4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl)oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione chloride
A814957
nsc-756717
nsc756717
pharmakon1600-01500223
cas-20830-81-3
dtxcid402883
tox21_110896
dtxsid7022883 ,
unii-zs7284e0zp
zs7284e0zp ,
bdbm50368352
gtpl7063
(8s,10s)-8-acetyl-10-{[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,8,11-trihydroxy-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione
daunomycin [iarc]
epirubicin hydrochloride impurity d [ep impurity]
daunorubicin [inn]
doxorubicin hydrochloride impurity a [ep impurity]
epirubicin impurity d
daunorubicin [who-dd]
vyxeos component daunorubicin
epirubicin hydrochloride impurity, daunorubicin- [usp impurity]
(8s,10s)-8-acetyl-10-((3-amino-2,3,6-trideoxy-.alpha.-l-lyxo-hexopyranosyl)oxy)-6,8,11-trihydroxy-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione
daunorubicin [mi]
valrubicin impurity, daunorubicin [usp impurity]
daunorubicin [mart.]
daunorubicin [hsdb]
daunorubicin [vandf]
5,12-naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-.alpha.-l-lyxo-hexopyranosyl))oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8s-cis)-
daunorubicin [orange book]
(1s,3s)-3-acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1-naphthacenyl 3-amino-2,3,6-trideoxy-.alpha.-l-lyxo-hexopyranoside
CCG-212559
GR-318
CS-2004
HY-13062A
SCHEMBL3041
tox21_110896_1
BRD-K43389675-001-01-3
NCGC00024246-15
STQGQHZAVUOBTE-VGBVRHCVSA-N
(7s,9s)-9-acetyl-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride
(7s,9s)-9-acetyl-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-quinone;hydrochloride
bdbm32017
cid_62770
(7s,9s)-7-[(2r,4s,5s,6s)-4-azanyl-6-methyl-5-oxidanyl-oxan-2-yl]oxy-9-ethanoyl-4-methoxy-6,9,11-tris(oxidanyl)-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride
(7s,9s)-9-acetyl-7-[[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyl-2-oxanyl]oxy]-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride
AB01644616_10
AB01644616_09
(8s,10s)-8-acetyl-10-(((2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyltetrahydro-2h-pyran-2-yl)oxy)-6,8,11-trihydroxy-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione
mfcd00866340
SR-05000001600-1
SR-05000001600-2
SR-01000000033-4
SBI-0206677.P002
daunorubicin(daunomycin)
Q411659
BRD-K43389675-003-03-5
BRD-K43389675-003-20-9
2-hydroxy-5-(4-nitro-phenylsulfamoyl)-benzoicacid
NCGC00024246-18
5,12-naphthacenedione,8-acetyl-10-[(3-amino-2,3,6-trideoxy-a-l-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8s,10s)-
NCGC00024246-12
EX-A1337A
EN300-7479232
daunomycin;rp 13057;rubidomycin

Excerpt	Reference	Relevance
"Daunorubicin (DNR) is a chemotherapeutic drug associated with multiple side effects, including drug resistance. "	( A comparative analysis of daunorubicin and its metabolite daunorubicinol interaction with apoptotic and drug resistance proteins using Rai, AK; Satija, NK, 2023)	2.65
"Daunorubicin is a chemotherapy medication used to treat cancer, specifically for AML."	( Encapsulation of daunorubicin into Saccharomyces cerevisiae-derived lysosome as drug delivery vehicles for acute myeloid leukemia (AML) treatment. Choi, W; Heo, MY; Kim, SY; Kim, YH; Min, J; Wee, JH, 2020)	1.62
"Daunorubicin (DR) is a hydrophobic chemical that requires robust vectors to efficiently encapsulate and avoid its free dispersion in water, biological media and cell culture."	( Synthetic NRG-1 functionalized DNA nanospindels towards HER2/neu targets for in vitro anti-cancer activity assessment against breast cancer MCF-7 cells. Abbas, M; Ahsan, A; Ansari, MT; Baig, MMFA; Farooq, MA; Jabeen, M; Kassim, SA; Khan, GJ; Lai, WF; Mikrani, R; Naveed, M, 2020)	1.28
"Daunorubicin (DNR) is an indispensable drug for the treatment of MDS and AML."	( Daunorubicin-Loaded CdTe QDs Conjugated with Anti-CD123 mAbs: A Novel Delivery System for Myelodysplastic Syndromes Treatment. Chen, B; Chen, D; Guo, D; Wang, L; Xu, P; Zhu, Y; Zuo, Y, 2020)	2.72
"Daunorubicin (DNR) is an anti-cancer drug which is used for the treatment of certain cancers including the treatment of leukemia."	( Electrochemical monitoring of the interaction between anticancer drug and DNA in the presence of antioxidant. Muti, M, 2018)	1.2
"Daunorubicin is a type II polyketide, one of a large class of polyaromatic natural products with anticancer, antibiotic, and antiviral activity. "	( Structural and Functional Studies of the Daunorubicin Priming Ketosynthase DpsC. Crosby, J; Crump, MP; Jackson, DR; Milligan, JC; Mohammed, LY; Patel, AB; Shakya, G; Tsai, SC; Valentic, TR; Vasilakis, K; Wattana-Amorn, P, 2018)	2.19
"Daunorubicin is an anticancer drug, and cholesterol is involved in cancer progression, but their relationship has not been defined. "	( Nuclear Lipid Microdomains Regulate Daunorubicin Resistance in Hepatoma Cells. Albi, E; Ambesi-Impiombato, FS; Arcuri, C; Beccari, T; Cataldi, S; Ceccarini, MR; Codini, M; Conte, C; Curcio, F; Floridi, A; Lazzarini, A; Mecca, C; Patria, F, 2018)	2.2
"Daunorubicin is a chemotherapeutic agent for treatment of certain types of cancer, which is produced as a secondary metabolite by S."	( Regulation of daunorubicin biosynthesis in Streptomyces peucetius - feed forward and feedback transcriptional control. Kattusamy, K; Prasad, R; Vasanthakumar, A, 2013)	1.47
"Daunorubicin (DNR) is a widely used antitumor drug, but its application is limited because of its cardiotoxic side effects. "	( Administration of chromium(III) and manganese(II) as a potential protective approach against daunorubicin-induced cardiotoxicity: in vitro and in vivo experimental evidence. Liu, Y; Wang, D, 2013)	2.05
"Daunorubicin (DNR) is a widely used chemotherapeutic agent; however, its clinical use is limited because of its cardiotoxicity. "	( Sodium ferulate protects against daunorubicin-induced cardiotoxicity by inhibition of mitochondrial apoptosis in juvenile rats. Fang, QJ; He, RL; Lian, JB; Lin, MJ; Wang, RX; Wu, ZJ; Yu, J, 2014)	2.13
"Daunorubicin (DNR) is an effective inhibitor of an array of proteins involved in neovascularization, including VEGF and PDGF. "	( Tunable sustained intravitreal drug delivery system for daunorubicin using oxidized porous silicon. Cheng, L; Freeman, WR; Hou, H; Ma, F; Nieto, A; Sailor, MJ, 2014)	2.09
"Daunorubicin (DNR) is a representative anthracycline with anti-tumor bioactivity. "	( Bioconversion of deoxysugar moieties to the biosynthetic intermediates of daunorubicin in an engineered strain of Streptomyces coeruleobidus. Hu, Y; Xie, L; Yuan, T; Zhu, B, 2014)	2.08
"Daunorubicin (DNR) is an anthracyline antibiotic which induces a well-described but incompletely understood cardiac toxicity. "	( Effect of zinc and copper on the interaction of daunorubicin with cardiac myosin. Li, B; Lin, A; Liu, Y; Sun, X, 2008)	2.04
"Daunorubicin is a cornerstone of the induction regimen, but the optimal dose is unknown."	( High-dose daunorubicin in older patients with acute myeloid leukemia. Beck, J; Biemond, BJ; Döhner, H; Ferrant, A; Gratwohl, A; Graux, C; Jongen-Lavrencic, M; Löwenberg, B; Maertens, J; Ossenkoppele, GJ; Pabst, T; Schouten, HC; Sonneveld, P; van Marwijk Kooy, M; van Putten, W; Vellenga, E; Verdonck, LF; Verhoef, G; von Lilienfeld-Toal, M, 2009)	1.48
"Daunorubicin (DNR) is an important anthracycline antibiotic. "	( Improvement of antibiotic productivity by knock-out of dauW in Streptomyces coeruleobidus. Hu, Y; Yin, C; Yuan, T; Zhu, B; Zhu, C, 2011)	1.81
"Daunorubicin is a chemotherapeutic antibiotic of the anthracycline family used for the treatment of many type of cancers when doxorubicin or other less effective drugs cannot be used. "	( (99m)Tc-daunorubicin a potential brain imaging and theranostic agent: synthesis, quality control, characterization, biodistribution and scintigraphy. Bokhari, TH; Faheem, AR; Mushtaq, A; Roohi, S; Sohaib, M, 2013)	2.27
"Daunorubicin (DNR) is an anthracyline antibiotic used in the treatment of a variety of human cancers. "	( Induction of metallothionein by zinc protects from daunorubicin toxicity in rats. Ali, MM; Breuer, A; Frei, E; Straub, J; Wiessler, M, 2002)	2.01
"Daunorubicin is an anthracycline anti-tumor agent; anthracycline chemotherapy in cancer can cause severe cardiomyopathy leading to a frequently fatal congestive heart failure; the first-line treatment is diuretics and digoxin. "	( Effects of angiotensin II receptor blocker (candesartan) in daunorubicin-induced cardiomyopathic rats. Aizawa, Y; Kamal, FA; Kodama, M; Kunisaki, M; Ma, M; Mito, S; Palaniyandi, S; Prakash, P; Soga, M; Tachikawa, H; Veeraveedu, P; Watanabe, K, 2006)	2.02
"Daunorubicin (DNR) is a significant antineoplastic antibiotic, which is usually applied to a chemotherapy of acute lymphatic and myelogenous leukaemia. "	( Determination of daunomycin in human plasma and urine by using an interference-free analysis of excitation-emission matrix fluorescence data with second-order calibration. Ding, YJ; Fang, DM; Hu, LQ; Wu, HL; Xia, AL; Yu, RQ, 2006)	1.78
"Daunorubicin is an anthracycline antitumour agent that can cause severe cardiomyopathy leading to a frequently fatal congestive heart failure. "	( Cardioprotective effects of subcutaneous ebselen against daunorubicin-induced cardiomyopathy in rats. Arafah, MM; Najjar, TA; Saad, SY, 2006)	2.02
"Daunorubicin is an anthracycline antibiotic agent used in the treatment of hematopoietic malignancies. "	( Mapping genes that contribute to daunorubicin-induced cytotoxicity. Badner, JA; Bleibel, WK; Dolan, ME; Duan, S; Huang, RS; Shukla, SJ; Wu, X, 2007)	2.06
"Daunorubicin (DNR) is a well known anticancer drug believed to act mainly by topoisomerase II inhibition and mitochondria-mediated free radical generation. "	( Existence of a distinct concentration window governing daunorubicin-induced mammalian liver mitotoxicity--implication for determining therapeutic window. Mukhopadhayay, AK; Patkari, M; Paul, MK, 2007)	2.03
"Daunorubicin is a highly potent trypanocide in vitro but lacks significant in vivo activity. "	( Distribution of daunorubicin, a potent in vitro trypanocide which lacks in vivo activity, in the blood of trypanosome-infected mice. Brown, JE; Brown, JR; Williamson, J, 1982)	2.05
"Daunorubicin is an effective agent against this leukemia during pregnancy."	( Successful pregnancy in acute promyelocytic leukemia. Alegre, A; Chunchurreta, R; Cruz, E; Prada, M; Rodriguez-Alarcon, J, 1982)	0.99
"Daunorubicin (DNR) is a major front-line drug in the treatment of childhood acute lymphoblastic leukaemia (ALL). "	( In vitro anthracycline cross-resistance pattern in childhood acute lymphoblastic leukaemia. den Boer, ML; Huismans, DR; Klumper, E; Loonen, AH; Pieters, R; Veerman, AJ, 1995)	1.73
"Daunorubicin is a cytotoxic drug, which, in nontoxic doses, is effective in preventing cellular proliferation in experimental vitreoretinopathy. "	( Noninvasive monitoring of intraocular pharmacokinetics of daunorubicin using fluorophotometry. el-Sayed, S; Khoobehi, B; Kizhakkethara, I; Li, X; Moshfeghi, DM; Peyman, GA; Rahimy, M, )	1.82
"Daunorubicin is a highly potent trypanocide in-vitro but is inactive in-vivo. "	( Method for analysis, and distribution profile, of covalently-linked ferritin-daunorubicin conjugate in the blood of trypanosome-infected mice. Brown, JE; Brown, JR; Patterson, LH; Williamson, J, 1992)	1.96

Excerpt	Reference	Relevance
"Daunorubicin (DNR) has a broad spectrum of anticancer activity, but is limited in clinical application due to its serious side effects. "	( Daunorubicin-TiO2 nanocomposites as a "smart" pH-responsive drug delivery system. Chen, B; Wang, C; Wang, X; Zhang, H, 2012)	3.26
"Daunorubicin (DAUN) has served as an anticancer drug in chemotherapy regimens for decades and is still irreplaceable in treatment of acute leukemias. "	( Cyclin-dependent kinase inhibitors AZD5438 and R547 show potential for enhancing efficacy of daunorubicin-based anticancer therapy: Interaction with carbonyl-reducing enzymes and ABC transporters. Ceckova, M; Hofman, J; Morell, A; Novotna, E; Sorf, A; Staud, F; Wsol, V, 2019)	2.18
"Daunorubicin has historically been considered the anthracycline of choice at many cancer centers for the treatment of acute myeloid leukemia (AML). "	( Idarubicin appears equivalent to dose-intense daunorubicin for remission induction in patients with acute myeloid leukemia. Altman, J; Czerniak, C; Greenberg, D; Koslosky, M; Mehta, J; Pantiru, M; Pi, J; Trifilio, S; Zhou, Z, 2013)	2.09
"Daunorubicin (DNR) has shown the strongest efficacy in proliferation inhibition in vitro."	( A Novel Approach of Daunorubicin Application on Formation of Proliferative Retinopathy Using a Porous Silicon Controlled Delivery System: Pharmacodynamics. Cheng, L; Freeman, WR; Hou, H; Huffman, K; Rios, S; Sailor, MJ, 2015)	1.46
"Daunorubicin (DNR) has a broad spectrum of anticancer activity, but is limited in clinical application due to its serious side effects. "	( Daunorubicin-TiO2 nanocomposites as a "smart" pH-responsive drug delivery system. Chen, B; Wang, C; Wang, X; Zhang, H, 2012)	3.26
"Daunorubicin has been widely discussed as the antimetabolic drug for PVR treatment for recent 20 years."	( [Vitrectomy with daunorubicin]. Ciechanowski, C; Gebka, A; Iwaszkiewicz-Bilikiewicz, B; Raczyńska, K, 2004)	1.38
"Daunorubicin (DNR) has been conjugated to succinylated serum albumin by an amide bond joining the amino group of the drug and a carboxyl side chain of the protein either directly or with the intercalation of a peptide spacer arm varying from one to four amino acids. "	( A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies. Baurain, R; Deprez-De Campeneere, D; Masquelier, M; Trouet, A, 1982)	2
"Daunorubicin has been in clinical trials in the United States for the past 15 years. "	( Risk factors for development of daunorubicin cardiotoxicity. Layard, M; Von Hoff, DD, 1981)	1.99
"If daunorubicinol has equivalent or greater potency than daunorubicin in causing impairment of myocardial function, it may make an important contribution to the pathogenesis of cardiotoxicity."	( Daunorubicin and daunorubicinol pharmacokinetics in plasma and tissues in the rat. Cusack, BJ; Olson, RD; Young, SP, 1995)	2.25
"Daunorubicinol has been assumed also to be more cardiotoxic than unchanged daunorubicin but its direct effect on cardiac function has never been evaluated in preclinical models."	( Role of daunorubicinol in daunorubicin-induced cardiotoxicity as evaluated with the model of isolated perfused rat heart. Bonoron-Adèle, S; Platel, D; Robert, J, 2001)	1.47
"Daunorubicin has been reported to cause hyperpigmentation of sun-exposed skin and/or transverse nail pigmentation (3 cases). "	( Generalized hyperpigmentation with daunorubicin chemotherapy. Allan, A; Kroumpouzos, G; Travers, R, 2002)	2.03
"Daunorubicin has been used in the treatment of advanced cases of human posttraumatic proliferative vitreoretinopathy. "	( Intraocular daunorubicin for the treatment and prophylaxis of traumatic proliferative vitreoretinopathy. Heimann, K; Lemmen, K; Schmiedl, R; Wiedemann, P, 1987)	2.09

Excerpt	Reference	Relevance
"Daunorubicin levels were lower in heart tissue and significantly higher in brain tissue after administration of the dual-targeting liposomes compared with the free drug."	( Pharmacokinetics and tissue distribution of dual-targeting daunorubicin liposomes in mice. Ju, RJ; Lu, WL; Tian, W; Wang, XX; Wen, H; Yao, HJ; Ying, X; Yu, Y; Zhang, L; Zhang, Y, 2011)	1.33
"Daunorubicin was shown to inhibit Collagen and Thrombin induced platelet aggregation and the intensity of inhibition on both drug concentration and the time of preincubation."	( Daunorubicin and platelet function. Cofrancesco, E; Fantasia, R; Lambertenghi-Deliliers, G; Pogliani, EM, 1981)	2.43
"Daunorubicin does not inhibit the binding of RNA polymerases to the DNA template, but prevents the transformation of the DNA-daunorubicin-RNA-polymerase unstable complex into the highly stable one."	( Daunorubicin inhibition of DNA-dependent RNA polymerases from Ehrlich ascites tumor cells. Aubel-Sadron, G; Barthelemy-Clavey, V; Maral, R; Molinier, C, 1976)	2.42
"Daunorubicin was found to inhibit the phosphorylation of the 40 K PKC substrate induced by thrombin and 12-O-tetradecanoyl-phorbol-13-acetate as well as the phosphorylation of the 20 K protein induced by thrombin."	( Diversity of effects of two antitumor anthracycline analogs on the pathway of activation of PKC in intact human platelets. Banfi, P; Gambetta, RA; Lanzi, C; Ravagnani, F, 1988)	1
"Daunorubicin appears to inhibit VA transcription only if added prior to both transcription fractions, but inhibits tRNA synthesis before and during transcription factor binding."	( Effects of antibiotics on RNA polymerase III transcription. Ackerman, S; Logan, K, 1988)	1

Excerpt	Reference	Relevance
"Daunorubicin treatment increased procoagulant activity of red blood cells regardless of the cell origin. "	( Daunorubicin induces procoagulant response through phosphatidylserine exposure in red blood cells. Gilbert, GE; Hou, J; Lu, C; Qi, S; Qiao, X; Shi, J; Yu, H; Zheng, Y; Zhou, J, 2010)	3.25
"Daunorubicin-treated rats showed cardiac toxicity, evidenced by worsening cardiac function, evaluated by haemodynamic status and echocardiography, elevation of malondialdehyde level and a decreased level of total glutathione peroxidase activity in the heart tissue. "	( Effect of telmisartan in limiting the cardiotoxic effect of daunorubicin in rats. Aizawa, Y; Arozal, W; Harima, M; Kodama, M; Sukumaran, V; Suzuki, K; Thandavarayan, RA; Veeraveedu, PT; Watanabe, K, 2010)	2.05
"Daunorubicin treatment alone demonstrated ROS (reactive oxygen species) induction and cellular morphological changes more consistent with chemical damage in a total of 93% of the cells and apoptotic changes in 20% of the cell population."	( An effective in vitro antitumor response against human pancreatic carcinoma with paclitaxel and daunorubicin by induction of both necrosis and apoptosis. Gervasoni, JE; Hindenburg, AA; Mehta, S; Schulze, S; Vezeridis, MP; Wanebo, HJ, )	1.07
"Daunorubicin treatment failed to significantly alter concentrations of GSH or GSSG or activities of glutathione peroxidase in the heart."	( Daunorubicin-induced cardiac injury in the rabbit: a role for daunorubicinol? Boucek, RJ; Cusack, BJ; Li, X; Mushlin, PS; Olson, RD; Voulelis, LD, 1993)	2.45
"Treatment with daunorubicin (DNR), one of the main chemotherapeutics for AML, upregulated P2X7RB expression while reducing P2X7RA mRNA in AML blasts."	( Differential sensitivity of acute myeloid leukemia cells to daunorubicin depends on P2X7A versus P2X7B receptor expression. Adinolfi, E; Curti, A; De Marchi, E; Di Virgilio, F; Milani, A; Orioli, E; Pegoraro, A; Salvestrini, V, 2020)	1.14
"Treatment with daunorubicin (DNR) in acute myeloid leukemia is moderately effective and associated with significant side effects, including cardiac toxicity. "	( Nanomicelle formulation modifies the pharmacokinetic profiles and cardiac toxicity of daunorubicin. Chen, M; Haddad, AS; Henderson, PT; Jonas, BA; Lam, KS; Li, Y; Lin, TY; Liu, R; Pan, CX; Xiao, K; Xiao, W; Zhang, H, 2014)	0.98
"Treatment with daunorubicin, but not ara-C, resulted in a significant increase in the proportion of topo IIalpha negative cells (p=0.0023)."	( Topoisomerase IIalpha expression in acute myeloid leukaemia cells that survive after exposure to daunorubicin or ara-C. Höglund, M; Paul, C; Prenkert, M; Tidefelt, U; Tina, E, 2009)	0.91
"Pretreatment with daunorubicin at a higher concentration (50 microM) or with aclarubicin (20 microM) strongly attenuated the relaxing response to acetylcholine; this attenuation was unaffected by the presence of tetraethylammonium."	( Inhibitory effects of daunorubicin on endothelium-dependent vasorelaxing response to acetylcholine of rat aorta. Hatake, K; Sakamoto, K; Wakabayashi, I; Yoshimoto, S, 1994)	0.93
"Treatment with daunorubicin-DNA (DNR-DNA) or adriamycin-DNA (ADM-DNA) has been evaluated in acute lymphoblastic leukemia of childhood (ALL), acute nonlymphoblastic leukemia (ANLL) and bronchogenic carcinoma (BC). "	( Clinical trials with daunorubicin-DNA and adriamycin-DNA in acute lymphoblastic leukemia of childhood, acute nonlymphoblastic leukemia, and bronchogenic carcinoma. Bosly, A; Cornu, G; Ferrant, A; Hulhoven, R; Michaux, JL; Sokal, G, 1979)	0.93
"Treatment of daunorubicin with methanolic ammonia affords 5-iminodaunorubicin, the first quinone-modified analogue of either daunorubicin or adriamycin. "	( 5-Iminodaunorubicin. Reduced cardiotoxic properties in an antitumor anthracycline. Acton, EM; Henry, DW; Tong, GL, 1979)	1.08
"Both treatments (daunorubicin alone and in combination with triamcinolone acetonide) effectively prevented retinal detachment."	( The effect of combined daunorubicin and triamcinolone acetonide treatment on a refined experimental model of proliferative vitreoretinopathy. Chen, EP; Hatchell, DL; Saloupis, PT; Samsa, GP; Steinhorst, UH, 1992)	0.92

Excerpt	Reference	Relevance
" These conjugates were tested for their toxic effects on various tumor target cells as measured either by their inhibition of RNA synthesis or by their reduction of the growth of the tumor cells after transplantation."	( The specific cytotoxic effects of daunomycin conjugated to antitumor antibodies. Arnon, R; Hurwitz, E; Levy, R; Maron, R; Sela, M, 1975)	0.25
" The overall toxicity of doxorubicin is significantly reduced after IV injection as a DNA complex while daunorubicin-DNA is as toxic as free daunorubicin."	( Comparative study in mice of the toxicity, pharmacology, and therapeutic activity of daunorubicin-DNA and doxorubicin-DNA complexes. Baurain, R; Deprez-De Campeneere, D; Huybrechts, M; Trouet, A, 1979)	0.7
"The experiments on albino mice treated with rubomycin, carminomycin or dihydrocarminomycin on its 5-fold intravenous administration in doses equal to similar portions of LD50 of the respective antibiotic on its use in a single dose showed that all the 3 antibiotics induced changes in the myocardium close by their character."	( [Comparative study of the cardiotoxicity of the anthracycline antibiotics, rubomycin, carminomycin and dihydrocarminomycin, in experiments on white mice]. Belova, IP; Gol'dberg, LE; Shepelevtseva, NG; Vertogradova, TP, 1978)	0.26
" However, when the in vitro effects of the two drugs on macrophage monolayers were investigated, DM was found to be at least four times more toxic than AM."	( In vitro and in vivo cytotoxicity of adriamycin and daunomycin for murine macrophages. Mantovani, A, 1977)	0.26
"Rubidazone, the new semi-synthetic benzol hydrazone hydrochloride derivative of dauorubicin, has proved on a molecular weight basis to be less toxic than adriamycin and similar to daunorubicin in cardiac toxicity studies in the hamster as well as in other in vivo and in vitro test systems."	( Rubidazone vs adriamycin: an evaluation of their differential toxicity in the spleen colony assay system. Alberts, DS; Van Daalen Wetters, T, 1976)	0.45
"Karminomycin was more toxic with respect to 2-6 week mice than to adult animals when administered both intravenously or orally."	( [Dependence of the toxicity of the antineoplastic antibiotics rubomycin and carminomycin, on the age and sex of white mice and rats]. Filippos'iants, ST; Gol'dberg, LE, 1976)	0.26
" In addition, detailed histopathological examination shows that treatment of mice with chemotherapeutic drugs and R-verapamil does not change the organ-related toxicity pattern but only moderately accentuates inherent toxic side effects of the chemotherapeutic agents."	( Chemotherapy and chemosensitization of transgenic mice which express the human multidrug resistance gene in bone marrow: efficacy, potency, and toxicity. Gottesman, MM; Licht, T; Merlino, GT; Mickisch, GH; Pastan, I, 1991)	0.28
" This indicates that, in the association of antineoplastic drugs with agents that reverse multidrug resistance, the potential exists for enhanced damage of normal cells and tissues; further studies are needed to evaluate the relevance of this adverse interaction."	( Increased toxicity of anthracycline antibiotics induced by calcium entry blockers in cultured cardiomyocytes. Krishna, G; Kutty, RK; Santostasi, G, 1991)	0.28
" The authors suggest a procedure of routine monitoring of patients treated with anthracycline cytostatics and methods of supportive therapy to ensure safe treatment."	( [Cardiotoxicity of anthracycline cytostatic agents--a proposal for routine monitoring and supportive therapy]. Hůla, J; Slechtová, J; Svojgrová, M, 1991)	0.28
"7 X 10(-7) M for 50% cell survival) which were not toxic if administered in the dark."	( Photocytotoxicity of anthracyclines upon laser excitation in their long-wavelength absorption bands. Andreoni, A; Colasanti, A; Malatesta, V; Roberti, G, 1991)	0.28
"The de novo synthesis of 'shock proteins' is a cellular reaction towards toxic agents."	( In vitro studies on the cardiotoxicity of chemotherapeutics. Löw-Friedrich, I; Schoeppe, W; von Bredow, F, 1990)	0.28
" concentration of the SH-groups, activity of glutathione reductase and glutathione-S-transferase, carminomycin antitumor and toxic effects was studied under conditions of tumor growth and carminomycin therapy with the use of prophylactic rations (PR) aimed at stimulating the cell thiol-dependent and antioxidant systems for decreasing the drug toxic action."	( [Thiol-dependent protective systems in alimentary prevention of the toxic effect of carminomycin]. Alekseeva, NR; Karsybekova, NM; Lenskaia, EG; Monakhov, BV; Sarbaev, BT; Sisemalieva, ZhS; Tazhibaev, ShS, 1990)	0.28
"The authors report a case of fatal Daunorubicin cardiotoxicity on initial phase of therapy for Acute Myeloblastic Leukemia at cumulative doses (225 mg/mq) considered still safe from the current literature."	( [Early daunorubicin cardiotoxicity and fatal outcome in a child with acute myeloblastic leukemia (M2)]. Galli, MA; Jankovic, M; Rizzari, C; Santamaria, M; Uderzo, C, )	0.86
" Continuous infusion is less toxic than IV bolus."	( [Cardiotoxicity of anthracyclines in children. Contribution of anthracyclines in pediatric oncology]. Biron, P; Bouffet, E; Brunat-Mentigny, M; Favrot, MC; Philip, T; Pinkerton, R, 1987)	0.27
" When used intravenously in a single dose RCH was 2 times less toxic than rubomycin."	( [Toxicity of rubomycin 13-cyclohexylidene hydrazone]. Gol'dberg, LE; Shepelevtseva, NG; Shevniuk, LA; Stepanova, ES; Vertogradova, TP, 1987)	0.27
" DR-16 appeared to be more toxic compound than rubidomycin and DR-19 was found to possess the lowest toxicity."	( Comparison of subacute toxicity of rubidomycine and its four derivatives. Chibowski, D; Chmielewska, B; Chodkowska, A; Kleinrok, Z; Rajtar, G; Sawiniec, Z; Siezieniewska, Z, 1986)	0.27
" But probably the increased incidence of toxic deaths is not due to increased cardiac toxicity."	( Effects of nifedipine on cell resistance and cardiac toxicity--in vitro and in vivo experiments. Arndt, D; Fichtner, I; Nissen, E; Oettel, P; Tanneberger, S; Weiss, H, 1986)	0.27
" LD50 and LD2 values of dau-dex are about threefold higher than those of the free drug."	( Reduced toxicity of daunorubicin by conjugation to dextran. Arnon, R; Bernstein, A; Levi-Schaffer, F; Meshorer, A, 1982)	0.59
" These data, together with reports indicating a protective effect of ruthenium red against vinblastine and anthracycline toxicity, suggest that the dye promotes tight binding of m-AMSA and other agents to cellular loci on which toxic effects are not exerted."	( Effects of ruthenium red on accumulation and cytotoxicity of m-AMSA, vinblastine and daunorubicin in leukemia cells. Kessel, D; Wilberding, C, 1984)	0.49
"5 times less toxic than carminomycin on its intravenous or oral administration, respectively."	( [Study of the toxicity of carminomycin 13-cyclohexylidenhydrazone]. Belova, IP; Gol'dberg, LE; Shepelevtseva, NG; Vertogradova, TP, 1983)	0.27
"Anthracycline antibiotics are principal agents in the treatment of acute non-lymphocytic leukemia, although the usefulness are limited by their adverse side effects, especially by the cardiotoxicity."	( [Cardiotoxicity of daunorubicin and aclacinomycin A in patients with acute leukemia]. Hamami, T; Haruyama, H; Ijichi, H; Isemura, T; Katsume, H; Nakagawa, M; Nakanishi, S; Nisio, A; Shimazaki, C, 1982)	0.59
" When the in vivo cell survival was related to the cellular retention of daunorubicin, the DNA complex was slightly more toxic than free drug, which can be explained by the higher peak concentration obtained."	( Significance of cellular pharmacokinetics for the cytotoxic effects of daunorubicin. Andersson, B; Beran, M; Peterson, C; Tribukait, B, 1982)	0.73
" The carminomycin derivatives containing the residues of L-leucine and L-alanine were less toxic than the initial antibiotic, still they had a markedly pronounced retarded toxicity."	( [Acute toxicity of the N-acyl derivatives of carminomycin and rubomycin]. Gol'dberg, LE; Olsuf'eva, EN; Povarov, LS; Shepelevtsev, NG, 1982)	0.26
" The toxic effects on the myocytes were evaluated by studying morphological changes, trypan blue exclusion and cell membrane permeability to NADH, as determined by LDH-activity."	( Toxic effects of free and DNA-linked daunorubicin on isolated rat cardiac myocytes. Anundi, I; Högberg, J; Paul, C; Peterson, C; Rajs, J; Tomingas, A, 1982)	0.54
" By pairing a moderately toxic concentration of one drug with a nontoxic concentration of the other, we observed sequence-dependent differences in survival."	( Kinetic and cytotoxic effects of cytarabine and daunorubicin on cells in culture. Clarkson, BD; Doblin, J; Fried, J; Perez, AG, )	0.39
" On an equimolar basis DET appears to be less toxic than DOX for both the pluripotent stem cells and the granulocytic progenitor cells."	( Comparative toxicity of detorubicin and doxorubicin, free and DNA-bound, for hemopoietic stem cells. Huybrechts, M; Trouet, A, 1980)	0.26
" The extent of enhancement was different among the triterpene compounds; the 4- to 46-fold increase in DAU cytotoxicity was observed in P388/ADM cells in the presence of non-toxic or marginally toxic concentrations of individual compounds, while those for VBL were in the ratios of 2- to 37-fold."	( Reversal of daunomycin and vinblastine resistance in multidrug-resistant P388 leukemia in vitro through enhanced cytotoxicity by triterpenoids. Hasegawa, H; Inouye, Y; Kasai, R; Matsumiya, S; Sung, JH; Uchiyama, M; Yamasaki, K, 1995)	0.29
" Other CBR substrates such as menadione, phenanthrenequinone, and doxorubicin were equally toxic to both the CBR expresser cells and the control cells under the conditions tested."	( Protection against daunorubicin cytotoxicity by expression of a cloned human carbonyl reductase cDNA in K562 leukemia cells. Akman, S; Doroshow, J; Forrest, GL; Gonzalez, B; Kaplan, WD; Rivera, H, 1995)	0.62
" Daunomycin proved to be more toxic to differentiated Friend cells than to their undifferentiated counterparts."	( Enhancement of daunomycin toxicity by the differentiation inducer hexamethylene bisacetamide in erythroleukemia cells. Marcocci, L; Mavelli, I; Mondovì, B; Pedersen, JZ; Pietrangeli, P; Steinkühler, C, 1994)	0.29
" However, toxic effects on the rabbit retina have been reported even for the lowest effective doses."	( Ocular toxicity of daunomycin: effects of subdivided doses on the rabbit retina after vitreous gas compression. Chen, EP; Hatchell, DL; Machemer, R; Steinhorst, UH, 1993)	0.29
" Acute toxic effects on survival rates and body weights were more profound in DM-infused mice than in DM-heparin-infused mice."	( Attenuation of cardiotoxicity of daunomycin using a complex with heparin. Hara, T; Kawaoto, H; Mizuno, Y; Ueda, K, 1996)	0.29
" This suggests that there may be no safe anthracycline dose to avoid late cardiotoxicity, but reinforces the use of the protocol that affords best survival within the dose range studied."	( Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity. Bull, C; Chessells, J; Levitt, G; Sorensen, K; Sullivan, I, 1997)	0.3
" More than 3-fold the lethal dose of free Daunomycin could be applied without serious toxic effect when the drug was attached to EAK."	( Low toxicity and high antitumour activity of daunomycin by conjugation to an immunopotential amphoteric branched polypeptide. Gaál, D; Hudecz, F, 1998)	0.3
" Commercial gamma-glutamyl-p-nitroanilide (GGPNA) was not toxic or mutagenic."	( Gamma-glutamyl transpeptidase-dependent mutagenicity and cytotoxicity of gamma-glutamyl derivatives: a model for biochemical targeting of chemotherapeutic agents. Keren, R; Stark, AA, 1998)	0.3
"Idarubicin (IDR) is one of the most effective, but also toxic drugs in the treatment of AML."	( Toxicity and effectiveness of high-dose idarubicin during AML induction therapy: results of a pilot study in children. Behnisch, W; Bender-Götze, C; Creutzig, U; Graf, N; Hermann, J; Kabisch, H; Körholz, D; Mann, G; Niemeyer, CM; Reiter, A; Ritter, J; Scheel-Walter, H; Zimmermann, M, )	0.13
"Anthracyclines, such as daunorubicin (Daun), and other quinone-containing compounds can stimulate the formation of toxic free radicals."	( Daunorubicin cardiotoxicity: evidence for the importance of the quinone moiety in a free-radical-independent mechanism. Bammel, BP; Cusack, BJ; Knighton, RA; Mushlin, PS; Olson, RD; Olson, SJ; Shadle, SE, 2000)	2.06
"Cardiotoxicity is the major side-effect and limits the clinical use of the anthracyclines, doxorubicin and daunorubicin."	( Role of daunorubicinol in daunorubicin-induced cardiotoxicity as evaluated with the model of isolated perfused rat heart. Bonoron-Adèle, S; Platel, D; Robert, J, 2001)	0.96
" The distribution of adverse prognostic factors was comparable in the two-induction arm."	( Daunorubicin continuous infusion induces more toxicity than bolus infusion in acute lymphoblastic leukemia induction regimen: a randomized study. Bernard, M; Casassus, P; Delain, M; Desablens, B; Guilhot, F; Hunault-Berger, M; Ifrah, N; Jouet, JP; Milpied, N; Sadoun, A, 2001)	1.75
" This regimen is a safe approach in patients < 60 years but produced severe neurotoxicity in the elderly."	( A novel effective and safe consolidation for patients over 60 years with acute myeloid leukemia: intermediate dose cytarabine (2 x 1 g/m2 on days 1, 3, and 5). Fonatsch, C; Geissler, K; Jäger, U; Knöbl, P; Lechner, K; Piribauer, M; Schwarzinger, I; Sperr, WR; Thalhammer-Scherrer, R; Valent, P; Wimazal, F, 2004)	0.32
"IDAC is a safe and effective postremission therapy for elderly patients with AML."	( A novel effective and safe consolidation for patients over 60 years with acute myeloid leukemia: intermediate dose cytarabine (2 x 1 g/m2 on days 1, 3, and 5). Fonatsch, C; Geissler, K; Jäger, U; Knöbl, P; Lechner, K; Piribauer, M; Schwarzinger, I; Sperr, WR; Thalhammer-Scherrer, R; Valent, P; Wimazal, F, 2004)	0.32
" The aim of this study was to evaluate and compare the toxic effects of Daunorubicin, in normal or liposomal formulation, used in combination with WR1065, the active metabolite of Amifostine, against normal and tumor cells."	( Effect of amifostine on the cytotoxicity of daunorubicin and daunoxome in tumor and normal cells. Calistri, E; Candoni, A; Damiani, D; Fanin, R; Michelutti, A; Russo, D; Stocchi, R; Tiribelli, M, 2006)	0.83
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."	( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004)	0.32
"Anthracyclines, such as doxorubicin and daunorubicin, continue to be widely used in the treatment of cancer, although they share the adverse effect of chronic, cumulative dose-related cardiotoxicity."	( Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism. Charlier, H; Cusack, BJ; Gambliel, H; Hadjokas, N; Musser, B; Olson, RD; Shadle, SE, 2006)	0.6
"The authors feel that intraoperative daunorubicin is safe and effective in lowering IOP in high-risk surgical cases of glaucoma."	( Evaluation of efficacy and safety of daunorubicin in glaucoma filtering surgery. Agarwal, HC; Sihota, R; Varma, D, 2007)	0.89
" There was no significant difference in drug-related adverse events between treatment arms."	( High-dose homoharringtonine versus standard-dose daunorubicin is effective and safe as induction and post-induction chemotherapy for elderly patients with acute myeloid leukemia: a multicenter experience from China. Huang, BT; Liu, XL; Xiao, Z; Yu, J; Zeng, QC; Zhu, HQ, 2012)	0.63
" Interestingly, the latter changes reflected the intensity of toxic damage in whole hearts as well as in individual cells."	( Proteomic insights into chronic anthracycline cardiotoxicity. Adamcová, M; Brčáková, E; Fučíková, A; Geršl, V; Jirkovský, E; Lenčo, J; Mazurová, Y; Mičuda, S; Popelová, O; Simůnek, T; Stěrba, M; Stulík, J, 2011)	0.37
"This trial determined that it is safe and feasible to include gemtuzumab ozogamicin in combination with intensive chemotherapy."	( AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group. Alonzo, TA; Arceci, RJ; Cooper, TM; Feusner, J; Franklin, J; Gamis, A; Gerbing, RB; Hirsch, B; Hurwitz, C; Iannone, R; Lavey, RS; Mathew, P; Meshinchi, S; Raimondi, SC; Smith, FO, 2012)	0.38
" A causality assessment of the adverse reaction identified the antibiotic as the most probable cause of the observation."	( A case of severe toxicity during coadministration of vincristine and piperacillin: are drug transporters involved in vincristine hypersensitivity and drug-drug interactions? Andres, CR; Benz-de Bretagne, I; Gendrot, C; Jonville-Bera, AP; Jourdain, A; Le Guellec, C; Tarfaoui, N, 2012)	0.38
" For the DNR conjugated with Fe3O4 NPs nanocomposites, the side effect of DNR was visibly cut down, and the time to cause the side neurotoxicity was apparently shortened."	( The real-time neurotoxicity analysis of Fe3O4 nanoparticles combined with daunorubicin for rat brain in vivo. Cai, X; Chen, B; Jiang, H; Li, J; Wang, C; Wang, X; Xu, P; Zhang, H, 2012)	0.61
"Despite the shown in vitro effect of nsSNPs in reductase genes on anthracycline metabolic rate, on their own these SNPs do not explain enough variability in cardiotoxicity to be useful markers of this adverse event."	( Single-nucleotide polymorphisms in aldo-keto and carbonyl reductase genes are not associated with acute cardiotoxicity after daunorubicin chemotherapy. Graham, J; Grigliatti, TA; Heffner, D; Hogge, D; Liu, J; Lubieniecka, JM; Reid, R; Riggs, WK, 2012)	0.59
" Our results suggest that PI-103 in combination with DNR may be a potent and less toxic therapy for targeting LSCs and deserve further preclinical and clinical studies in the treatment of AML."	( PI-103 sensitizes acute myeloid leukemia stem cells to daunorubicin-induced cytotoxicity. Chen, Y; Ding, Q; Gu, R; Liang, J; Zhang, X, 2013)	0.64
"The clinical data of 25 AL patients, including 14 cases for induction chemotherapy, 8 for consolidation chemotherapy and 3 for reinduction therapy, which were treated with HD- DNR (DNR dosage of 90 mg/m(2)× 3 d) between June 2010 and August 2012 in our hospital were retrospectively analyzed, the adverse reaction of chemotherapy, especially cardiac toxicity and therapeutic effect were evaluated."	( [Organ toxicity and efficacy of high-dose daunorubicin-based chemotherapy in the treatment of acute leukemia]. Li, SZ; Liu, QG; Mi, YC; Wu, LH; Xu, N; Zhao, X, 2013)	0.65
"Most of the adverse reactions were mild, including cardiac toxicity, and no patient discontinued therapy because of HD-DNR related toxicities."	( [Organ toxicity and efficacy of high-dose daunorubicin-based chemotherapy in the treatment of acute leukemia]. Li, SZ; Liu, QG; Mi, YC; Wu, LH; Xu, N; Zhao, X, 2013)	0.65
"The adverse reaction of HD-DNR based chemotherapy for AL treatment was mild, no obvious cardiac adverse reaction occurred."	( [Organ toxicity and efficacy of high-dose daunorubicin-based chemotherapy in the treatment of acute leukemia]. Li, SZ; Liu, QG; Mi, YC; Wu, LH; Xu, N; Zhao, X, 2013)	0.65
"The role of metabolism in daunorubicin (DAUN)- and doxorubicin (DOX)-associated toxicity in cancer patients is dependent on whether the parent drugs or major metabolites, doxorubicinol (DOXol) and daunorubicinol (DAUNol), are the more toxic species."	( A correlation between cytotoxicity and reductase-mediated metabolism in cell lines treated with doxorubicin and daunorubicin. Bains, OS; Cragg, GE; Grigliatti, TA; Lubieniecka, JM; Reid, RE; Riggs, KW; Szeitz, A, 2013)	0.9
" Herein, we investigate how pretreatment characteristics relate to early adverse outcomes in such patients, studying 205 consecutive individuals receiving curative-intent induction chemotherapy with cytarabine and an anthracycline ("7 + 3"; n = 175) or a "7 + 3"-like regimen (n = 30)."	( Prediction of adverse events during intensive induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes. Abkowitz, JL; Buckley, SA; Estey, EH; Othus, M; Vainstein, V; Walter, RB, 2014)	0.4
" However, molecular determinants of the toxic damage and associated myocardial remodeling remain to be established."	( Molecular remodeling of left and right ventricular myocardium in chronic anthracycline cardiotoxicity and post-treatment follow up. Adamcová, M; Geršl, V; Jirkovský, E; Lenčo, J; Lenčová-Popelová, O; Mazurová, Y; Šimůnek, T; Štěrba, M, 2014)	0.4
"CC50 for LDE-oDNR and DNR in melanoma cells were 200 μm and 15 μm, respectively, but LDE-oDNR was less toxic against fibroblasts than DNR."	( Association of daunorubicin to a lipid nanoemulsion that binds to low-density lipoprotein receptors enhances the antitumour action and decreases the toxicity of the drug in melanoma-bearing mice. Contente, TC; Filippin-Monteiro, FB; Kretzer, IF; Maranhão, RC; Maria, DA, 2014)	0.76
" The risk of serious adverse events was higher in patients aged ≥10 years compared to those aged 9 or younger (P < 0·0001) and novel age-specific patterns of treatment-related toxicity were observed."	( Efficacy and toxicity of a paediatric protocol in teenagers and young adults with Philadelphia chromosome negative acute lymphoblastic leukaemia: results from UKALL 2003. Goulden, N; Hough, R; Mitchell, C; Moorman, A; Rowntree, C; Vora, A; Wade, R, 2016)	0.43
" To facilitate the safety assessment of NMPs, we aimed to gain insight into toxic effects specific for NMPs by systematically analyzing the available toxicity data on approved NMPs in the European Union."	( Nanomedicinal products: a survey on specific toxicity and side effects. Bosselaers, IE; Brand, W; De Jong, WH; Geertsma, RE; Giannakou, C; Kooi, MW; Noorlander, CW; Park, MV; Scholl, JH; Vandebriel, RJ, 2017)	0.46
" In-hospital major adverse events occurred in one patient (0."	( Safety and feasibility of a low frame rate protocol for percutaneous coronary intervention to chronic total occlusions: preliminary experience. Fan, B; Ge, J; Ge, L; Lu, H; Ma, J; Qian, J; Zhong, X, 2018)	0.48
"Our results provide the primary evidence that it appears to be safe and feasible to carry out the low frame rate protocol for CTO-PCI."	( Safety and feasibility of a low frame rate protocol for percutaneous coronary intervention to chronic total occlusions: preliminary experience. Fan, B; Ge, J; Ge, L; Lu, H; Ma, J; Qian, J; Zhong, X, 2018)	0.48
"Cardiotoxicity was ascertained through adverse event monitoring over the course of follow-up among 1,022 pediatric patients with acute myeloid leukemia treated in the Children's Oncology Group trial AAML0531."	( Occurrence of Treatment-Related Cardiotoxicity and Its Impact on Outcomes Among Children Treated in the AAML0531 Clinical Trial: A Report From the Children's Oncology Group. Alonzo, T; Aplenc, R; Gamis, A; Gerbing, RB; Getz, KD; Ky, B; Leahy, AB; Leger, KJ; Sack, L; Sung, L; Woods, WG, 2019)	0.51
" Gastrointestinal adverse events (GI-AEs) have not yet been reported in association with CART."	( Gastrointestinal Adverse Events Observed After Chimeric Antigen Receptor T-Cell Therapy. Abu-Sbeih, H; Ali, FS; Curry, JL; Foo, WC; Ge, PS; Luo, W; Neelapu, SS; Okhuysen, PC; Richards, DM; Tang, T; Wang, Y; Westin, JR, 2019)	0.51
" The most common serious adverse events were febrile neutropenia (19%), pneumonia (10%), and infection (8%)."	( Final safety and efficacy results from the CPX-351 early access program for older patients with high-risk or secondary acute myeloid leukemia. An, Q; Chiarella, M; Larson, ML; Lin, TL; Louie, AC; Roboz, GJ; Rubenstein, SE; Schiller, GJ; Solomon, SR, 2020)	0.56
" The secondary outcomes included adverse events and cytogenetic risk in subgroup analyses."	( The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials. Lu, Y; Wang, H; Wu, Y; Xiao, Q; Xiao, X, 2020)	0.86
" When it comes to adverse drug reactions, it is not a significant difference."	( The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials. Lu, Y; Wang, H; Wu, Y; Xiao, Q; Xiao, X, 2020)	0.86
"L-DNR proved to be an effective drug within a multiagent approach, which shows a favorable overall profile, as well as similar adverse events when compared with IDA in HR-ALL."	( Efficacy and safety of induction chemotherapy with daunorubicin or idarubicin in the treatment of an adult with acute lymphoblastic leukemia. Wang, D; Wang, ZD; Zhang, CH; Zhang, Q, 2022)	0.97
" A bisdioxopiperazine agent dexrazoxane (DEX) has been developed as a cardioprotective drug to prevent these adverse events, but it is uncertain whether it is the best representative of the class."	( Prodrug of ICRF-193 provides promising protective effects against chronic anthracycline cardiotoxicity in a rabbit model in vivo. Adamcová, M; Holečková, M; Jirkovská, A; Karabanovich, G; Kocúrová-Lengvarská, J; Kollárová-Brázdová, P; Kubeš, J; Lenčová-Popelová, O; Mazurová, Y; Roh, J; Šimůnek, T; Štěrba, M; Štěrbová-Kovaříková, P; Váňová, N, 2021)	0.62
"Cardiotoxicity is the major side effect of anthracyclines (doxorubicin, daunorubicin, epirubicin, and idarubicin), though being the most commonly used chemotherapy drugs and the mainstay of therapy in solid and hematological neoplasms."	( The Role of Mitochondrial Quality Control in Anthracycline-Induced Cardiotoxicity: From Bench to Bedside. Bai, R; Chang, X; Li, L; Li, Y; Lin, R; Liu, N; Liu, X; Peng, X; Ruan, Y; Tang, R; Wang, X; Wen, S, 2022)	0.95
"Chemotherapy-phototherapy (CTPT) combination drugs co-loaded by targeted DNA nanostructures can achieve controlled drug delivery, reduce toxic side effects and overcome multidrug resistance."	( Spectroscopic, calorimetric and cytotoxicity studies on the combined binding of daunorubicin and acridine orange to a DNA tetrahedron. Li, X; Liu, J; Liu, M; Wang, D; Wang, L; Wang, Q; Weng, T; Wu, Y; Yuan, L; Zhang, X, 2023)	1.14
" Overall, liposomal formulations were considerably less toxic to hiPSC-CM than their free-drug counterparts."	( Lower cardiotoxicity of CPX-351 relative to daunorubicin plus cytarabine free-drug combination in hiPSC-derived cardiomyocytes in vitro. Fortin, MC; Grammatopoulos, TN; LaCroix, AS; Manca, D; Tan, L; Wang, Q, 2023)	1.17

Excerpt	Reference	Relevance
" Detorubicin can thus be considered a prodrug of Adriamycin with very distinct pharmacokinetic and perhaps therapeutic properties."	( Pharmacokinetic, toxicologic, and chemotherapeutic properties of detorubicin in mice: a comparative study with daunorubicin and adriamycin. Baurain, R; Deprez-de Campeneere, D; Trouet, A, 1979)	0.47
" Pharmacokinetic studies revealed that Adriamycin (and/or its metabolites) accumulated in the neoplastic tissue more promptly, in significantly greater quantities and for longer periods than Daunomycin."	( Antineoplastic activity and pharmacokinetics of adriamycin and daunomycin in tumor bearing mice. Donelli, NG; Fogar-Ottaviano, EF; Garattini, S; Mantovani, A; Martini, A; Morasca, L; Pacciarini, MA; Spreafico, FS, 1977)	0.26
" The AUCs obtained for unchanged drugs were proportional to the dose, and the dose-independent pharmacokinetic parameters were very similar for the two drugs: total plasma clearance (39."	( Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients. Hurteloup, P; Rigal-Huguet, F; Robert, J, )	0.38
" The IDAol terminal half-life and mean residence time (MRT) were significantly increased in patients with impaired kidney function [MRT: group N, 63."	( Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study. Camaggi, CM; Carisi, P; Efthymiopoulos, C; Guaraldi, M; Martoni, A; Pannuti, F; Strocchi, E; Strolin-Benedetti, M; Tononi, A, 1992)	0.28
" The corresponding cytotoxicities were measured, and then applied to the pharmacodynamic model."	( Use of plasma cytotoxic activity to model cytotoxic pharmacodynamics of anticancer drugs. Cuddy, DP; de Valeriola, DL; Egorin, MJ; Forrest, A; Ross, DD, 1991)	0.28
" Calculated inhibitory concentrations 50 (IC50) were compared to maximal concentrations determined by pharmacokinetic studies."	( Pharmacokinetics of daunorubicin and daunorubicinol in plasma, P388 and B16 tumours. Comparison with in vitro cytotoxicity data. Abikhalil, F; Arnould, R; Atassi, G; Dubois, J; Hanocq, M, )	0.45
" To elucidate this discrepancy, pharmacokinetic analysis and MTT assay were conducted using the KRN8602-sensitive MX-1 and KRN8602-insensitive R-27."	( Antitumor activity and pharmacokinetics of a morpholino-anthracycline derivative (KRN8602) against human breast carcinoma xenografts serially transplanted into nude mice. Abe, O; Asanuma, F; Ishibiki, K; Josui, K; Kawamura, E; Koh, J; Kubota, T; Shiina, E; Suto, A; Yamada, Y, 1990)	0.28
" Due to its protracted half-life (64 hr in this study), this metabolite progressively accumulated and the ratio of the areas under the curve (0-24) idarubicinol/idarubicin increased from day to day."	( Pharmacokinetics of idarubicin after oral administration in elderly leukemic patients. Huet, S; Hurteloup, P; Pris, J; Rigal-Huguet, F; Robert, J, 1990)	0.28
" There was substantial variability in idarubicin elimination among patients, but no indication of dose-dependent or of schedule-dependent changes in pharmacokinetic parameters."	( Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report. Ames, MM; Hammond, GD; Krailo, MD; Pendergrass, TW; Reid, JM, 1990)	0.28
" We report here the results of pharmacokinetic and systemic bioavailability studies of menogaril in three species (mouse, dog, and monkey)."	( Pharmacokinetics and systemic bioavailability of menogaril, an anthracycline antitumor agent, in the mouse, dog, and monkey. Adams, WJ; Brewer, JE; Dalm, EA; Hosley, JD; McGovren, JP, 1989)	0.28
" In pharmacokinetic studies, HL-60/AR cells exposed to different extracellular concentrations of [14C]DNR consistently accumulated less radioactive drug than the parent HL-60 cells."	( Intracellular distribution and pharmacokinetics of daunorubicin in anthracycline-sensitive and -resistant HL-60 cells. Baker, MA; Bhalla, K; Gervasoni, JE; Hindenburg, AA; Krishna, S; Lutzky, J; Rosado, M; Stewart, VJ; Taub, RN, 1989)	0.53
" No correlation was found between the pharmacokinetic parameters and the time to final progression."	( Pharmacokinetics of oral idarubicin in breast cancer patients with reference to antitumor activity and side effects. Bastholt, L; Dalmark, M; Ebbehøj, E; Elbaek, K; Jakobsen, A; Juul, P; Rasmussen, SN; Steiness, E, 1989)	0.28
" Pharmacokinetic studies showed that the rise in plasma concentration during infusion was first-order, with a half-life of 11."	( Phase I and pharmacokinetic study of menogaril administered as a 72-hour continuous i.v. infusion. Long, HJ; Moertel, CG; Powis, G; Schutt, AJ, 1987)	0.27
" The drug disappeared from plasma biexponentially with a mean elimination half-life of 38 +/- 3 h; the mean apparent volume of distribution and the plasma clearance were 805 +/- 91 1/m2 and 14 +/- 2 1/h per m2."	( Pharmacokinetics of 7-con-O-methylnogarol in patients with solid tumors. D'Incalci, M; Figoli, F; Monfardini, S; Sorio, R; Tirelli, U; Zadro, D; Zanette, ML, 1987)	0.27
" The mean harmonic half-life was 11."	( Phase I clinical and pharmacokinetic trial of oral menogaril administered on three consecutive days. Crespeigne, N; de Valeriola, D; Dodion, P; Joggi, J; Kenis, Y; Peeters, B; Piccart, M; Tueni, E; van Berchem, C; Wery, F, 1988)	0.27
"In an attempt to identify pharmacokinetic factors that determine the response of acute myeloid leukemia (AML) patients to induction chemotherapy, we determined the concentrations of daunorubicin (DNR) and the main metabolite daunorubicinol (DOL) in vivo and particularly evaluated the concentrations in blood and bone marrow nucleated cells."	( Cellular pharmacokinetics of daunorubicin: relationships with the response to treatment in patients with acute myeloid leukemia. Hagenbeek, A; Kokenberg, E; Löwenberg, B; Sizoo, W; Sonneveld, P, 1988)	0.76
" Each molecule is characterized by original metabolic and pharmacokinetic features, which can be compared to those of the reference anthracyclines, doxorubicin and daunorubicin."	( [Pharmacokinetics of new anthracyclines]. Robert, J, 1988)	0.47
" Pharmacokinetic parameters calculated for the intravenous plasma drug concentration, time data revealed a terminal half-life of 12."	( Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer. Gillies, HC; Harper, PG; Herriott, D; Liang, R; Ohashi, K; Rogers, HJ, 1987)	0.54
" All pharmacokinetic parameters in plasma and white cells did not correlate with response to therapy."	( Pharmacokinetics of daunorubicin as a determinant of response in acute myeloid leukemia. Kokenberg, E; Löwenberg, B; Nooter, K; Sonneveld, P; van der Steuijt, K, 1987)	0.6
" For unchanged idarubicin, similar pharmacokinetic parameters were exhibited after the 1st and the 5th injection."	( Pharmacokinetics of idarubicin after daily intravenous administration in leukemic patients. Harousseau, JL; Huet, S; Hurteloup, P; Pris, J; Reiffers, J; Rigal-Huguet, F; Robert, J; Tamassia, V, 1987)	0.27
"Although they differ only slightly from each other, the various anthracyclines have their own metabolic pathways and pharmacokinetic parameters."	( [Pharmacokinetics and metabolism of anthracyclines in man]. Robert, J, 1987)	0.27
" Pharmacokinetic parameters of DOL obtained after injection of DOL were different from those calculated for DNR and those calculated for DOL after injection of DNR."	( Pharmacokinetics of daunorubicinol in the rabbit: comparison with daunorubicin. Baurain, R; Lesne, M; Maniez-Devos, DM; Trouet, A, )	0.45
" Carminomycinol appeared very quickly and surpassed carminomycin levels in 10 min-4 hr, disappearing very slowly, with a half-life of 40-98 hr."	( Pharmacokinetics of carminomycin in man: biweekly schedule vs single dose every three weeks. de Planque, MM; Lankelma, J; McVie, JG; Pinedo, HM; Ten Bokkel Huinink, WW; Weenen, H, 1984)	0.27
" When the in vivo cell survival was related to the cellular retention of daunorubicin, the DNA complex was slightly more toxic than free drug, which can be explained by the higher peak concentration obtained."	( Significance of cellular pharmacokinetics for the cytotoxic effects of daunorubicin. Andersson, B; Beran, M; Peterson, C; Tribukait, B, 1982)	0.73
" this confirmed earlier animal data indicating a different pharmacokinetic behavior of D when it was administered linked to DNA."	( Pharmacokinetics of daunorubicin after administration as free drug or as DNA complex in leukemic patients. Andersson, B; Beran, M; Ehrsson, H; Eksborg, S; Nilsson, SO, 1981)	0.59
" The terminal half-life of drug was 86 h in dogs and 20 h in humans."	( Pharmacokinetics of carminomycin in dogs and humans. Preliminary report. Comis, RL; Crooke, ST; Fandrich, SE; Finkelstein, TT; Florczyk, AP; Reich, SD; Schurig, JE, 1981)	0.26
" Selected KS and solid-tumor patients underwent pharmacokinetic evaluation."	( Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. Cabriales, S; Espina, BM; Esplin, JA; Forssen, E; Gill, PS; Levine, AM; Liebman, HA; Muggia, F; Ross, ME; Tulpule, A, 1995)	0.53
"The area under the plasma concentration curve (AUC) ranged from 16."	( Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. Cabriales, S; Espina, BM; Esplin, JA; Forssen, E; Gill, PS; Levine, AM; Liebman, HA; Muggia, F; Ross, ME; Tulpule, A, 1995)	0.53
"DaunoXome has an improved pharmacokinetic profile compared with free daunorubicin, and is well tolerated."	( Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. Cabriales, S; Espina, BM; Esplin, JA; Forssen, E; Gill, PS; Levine, AM; Liebman, HA; Muggia, F; Ross, ME; Tulpule, A, 1995)	0.76
" However, the apparent elimination half-life of daunorubicinol was longer than that of daunorubicin in most tissues, including the plasma (23."	( Daunorubicin and daunorubicinol pharmacokinetics in plasma and tissues in the rat. Cusack, BJ; Olson, RD; Young, SP, 1995)	1.99
" There were no significant differences between patients who went into complete remission (12/23) compared with those who did not respond for the following pharmacokinetic parameters: DNR and DOL plasma AUC (area under the curve) and DNR plasma half-life and clearance."	( Daunorubicin pharmacokinetics and the correlation with P-glycoprotein and response in patients with acute leukaemia. Boutagy, J; Galettis, P; Ma, DD, 1994)	1.73
"To determine the feasibility of escalating the hydrophilic topoisomerase I (topo I)-inhibitor topotecan (TPT) above myelosuppressive doses in adults with refractory or relapsed acute leukemias and to assess pharmacodynamic determinants of TPT action."	( Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. Adjei, A; Burke, PJ; Cheng, YC; Donehower, RC; Gore, SD; Grochow, LB; Jones, RJ; Kaufmann, SH; Rowinsky, EK, 1994)	0.29
" Although idarubicin was given in one-fifth of the dose, the intracellular peak concentration was 70% of that of daunorubicin."	( Comparison of the intracellular pharmacokinetics of daunorubicin and idarubicin in patients with acute leukemia. Paul, C; Sundman-Engberg, B; Tidefelt, U, 1994)	0.75
" The average terminal half-life was 30."	( Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve. Braess, J; Hiddemann, W; Kaufmann, CC; Kern, W; Kühn, S; Rührs, H; Schleyer, E; Sträubel, G; Unterhalt, M, 1996)	0.29
" The half-life of daunorubicin in the vitreous was about 5 hours."	( Noninvasive monitoring of intraocular pharmacokinetics of daunorubicin using fluorophotometry. el-Sayed, S; Khoobehi, B; Kizhakkethara, I; Li, X; Moshfeghi, DM; Peyman, GA; Rahimy, M, )	0.71
" The plasma concentration time course of Ida was most properly described by the three-compartment pharmacokinetic model, independent of administration time."	( Plasma pharmacokinetics of idarubicin and its 13-dihydro metabolite--a comparison of bolus versus 2 h infusion during a 3 day course. Björkholm, M; Eksborg, S; Fagerlund, E; Hast, R, 1997)	0.3
" The average terminal half-life was 30."	( Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve. Braess, J; Hiddemann, W; Kaufmann, CC; Kern, W; Kühn, S; Rührs, H; Schleyer, E; Sträubel, G; Unterhalt, M, 1997)	0.3
" With respect to cellular resistance mechanisms, 2 different pharmacodynamic phases can be distinguished: intracellular distribution and cellular reaction."	( Intracellular pharmacokinetics of anthracyclines in human leukemia cells: correlation of DNA-binding with apoptotic cell death. Brieden, T; Gieseler, F; Kunze, J; Nüssler, V; Valsamas, S, 1998)	0.3
"An in vitro pharmacokinetic simulation system that can simulate plasma pharmacokinetics was established to evaluate the cytotoxicity of two representative antileukemic agents, 1-beta-D-arabinofuranosylcytosine (ara-C) and daunorubicin."	( Evaluation of cell-killing effects of 1-beta-D-arabinofuranosylcytosine and daunorubicin by a new computer-controlled in vitro pharmacokinetic simulation system. Goto, N; Kishi, S; Nakamura, T; Ueda, T, 1999)	0.72
"The reversal effect of itraconazole on P-glycoprotein (P-gp)-mediated resistance of vinblastine, daunorubicin and doxorubicin was analyzed from a cellular pharmacokinetic point of view, namely by [3H]azidopine photoaffinity labeling, intracellular accumulation and transcellular transport experiments."	( Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs. Komada, F; Nishiguchi, K; Okumura, K; Sakaeda, T; Takara, K; Tanigawara, Y, 1999)	0.52
" Various pharmacokinetic profiles, with and without clinically relevant peak concentrations, were simulated in vitro."	( Induction of apoptosis by idarubicin: how important is the plasma peak? Clark, M; Gieseler, F; Puschmann, M; Stiebeling, K; Valsamas, S, 2000)	0.31
" We simulated a bolus application and a continuous infusion using two different pharmacokinetic profiles of idarubicin with comparable AUCs (area under the time curve)."	( Induction of apoptosis by idarubicin: how important is the plasma peak? Clark, M; Gieseler, F; Puschmann, M; Stiebeling, K; Valsamas, S, 2000)	0.31
"Our data show that there are no significant differences in the pharmacokinetic parameters of daunorubicin in patients receiving DaunoXome in combination with indinavir and ritonavir compared with those in patients not receiving PIs."	( The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma. Careddu, A; D'Incalci, M; Fumagalli, L; Lazzarin, A; Parisi, I; Viganò, MG; Zecca, B; Zucchetti, M, 2000)	0.78
"To clarify the pharmacokinetic properties of idarubicin (IDA) in Japanese patients and to clarify the relationship between the pharmacokinetic parameters of IDA or idarubicinol (IDAol), an active metabolite of IDA, and leukocytopenia or neutropenia, we examined the pharmacokinetics of IDA in patients with malignant lymphoma."	( A pharmacokinetic study of idarubicin in Japanese patients with malignant lymphoma: relationship with leukocytopenia and neutropenia. Fukushima, T; Goto, N; Kuraishi, Y; Ogawa, M; Ohno, R; Okabe, KI; Ueda, T; Urabe, A; Yamashita, T, 2001)	0.31
" The plasma concentration-time data were analysed, assuming a biexponential disposition curve, both by the traditional (two-stage) method and by population pharmacokinetic modelling."	( Pharmacokinetics and toxicity of idarubicin in the rat. Hofmann, S; Kuhlmann, O; Weiss, M, )	0.13
" The pharmacokinetic parameters of idarubicin found after duodenal administration of the two formulations were different: area under the curve of concentration versus time (AUC) and elimination half-life were approximately 21 times and 30 times, respectively, higher after IDA-SLN administration than after the solution administration."	( Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats. Bargoni, A; Cavalli, R; Fundarò, A; Gasco, MR; Vighetto, D; Zara, GP, 2002)	0.31
" For pharmacokinetic analysis, plasma sampling was performed during the first course and assayed using a validated high-performance liquid chromatographic assay with mass spectrometric detection."	( Phase I and pharmacokinetic studies of PNU-159548, a novel alkycycline, administered intravenously to patients with advanced solid tumours. Bosch, SV; de Jonge, MJ; Fiorentini, F; Hess, D; Lechuga, MJ; Mantel, MA; Mora, O; Planting, AS; Sessa, C; Valota, O; van der Gaast, A; Verweij, J, 2002)	0.31
" Overall, 214 samples were analysed for daunorubicin using capillary electrophoresis, and population pharmacokinetic modelling was performed using NONMEM."	( Population pharmacokinetics of liposomal daunorubicin in children. Boos, J; Creutzig, U; Hempel, G; Reinhardt, D, 2003)	0.85
" Pharmacokinetic and pharmacodynamic properties of zosuquidar."	( Population pharmacokinetic model for daunorubicin and daunorubicinol coadministered with zosuquidar.3HCl (LY335979). Aarons, L; Burgess, M; Callies, S; de Alwis, DP; Mehta, A, 2004)	0.6
"A three-compartment pharmacokinetic model adequately described daunorubicin concentration-time profiles."	( Population pharmacokinetic model for daunorubicin and daunorubicinol coadministered with zosuquidar.3HCl (LY335979). Aarons, L; Burgess, M; Callies, S; de Alwis, DP; Mehta, A, 2004)	0.84
" A pharmacokinetic model was developed to assess the disposition of the coencapsulated drugs in mice, including the free and encapsulated fractions after measurement of the total plasma concentrations."	( Pharmacokinetics of CPX-351 (cytarabine/daunorubicin HCl) liposome injection in the mouse. Bayne, WF; Mayer, LD; Swenson, CE, 2009)	0.62
" Cmax was 63."	( [Relationship between pharmacokinetics and efficacy and toxicity of daunorubicin in children with acute leukemia]. Chai, YH; Lü, H; Sun, YN; Xu, YJ, 2009)	0.59
"(1) There is a large inter-individual difference in pharmacokinetic parameters of DNR in children."	( [Relationship between pharmacokinetics and efficacy and toxicity of daunorubicin in children with acute leukemia]. Chai, YH; Lü, H; Sun, YN; Xu, YJ, 2009)	0.59
"There is an extreme paucity of pharmacokinetic data for anticancer agents in infants."	( Pharmacokinetics of daunorubicin and daunorubicinol in infants with leukemia treated in the interfant 99 protocol. Barisone, E; Boos, J; De Lorenzo, P; de Rossi, G; Hempel, G; Pieters, R; Relling, MV; Stary, J; Valsecchi, MG, 2010)	0.68
"8 years), who received daunorubicin in an earlier investigation, were used for pharmacokinetic model building using the software NONMEM."	( Pharmacokinetics of daunorubicin and daunorubicinol in infants with leukemia treated in the interfant 99 protocol. Barisone, E; Boos, J; De Lorenzo, P; de Rossi, G; Hempel, G; Pieters, R; Relling, MV; Stary, J; Valsecchi, MG, 2010)	0.99
" No age-dependency in any of the BSA-normalized pharmacokinetic parameters was observed."	( Pharmacokinetics of daunorubicin and daunorubicinol in infants with leukemia treated in the interfant 99 protocol. Barisone, E; Boos, J; De Lorenzo, P; de Rossi, G; Hempel, G; Pieters, R; Relling, MV; Stary, J; Valsecchi, MG, 2010)	0.68
" Pharmacokinetic parameters were dose-independent and exhibited low inter-patient variability."	( Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia. Chiarella, MT; Feldman, EJ; Kolitz, JE; Lancet, JE; Liboiron, BD; Louie, AC; Mayer, LD; Swenson, CE; Trang, JM, 2012)	0.6
" Population pharmacokinetic parameters were estimated by the NLME software."	( [SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. Chen, Y; Gao, P; He, X; Li, J; Niu, C; Wang, C; Wang, Y; Zhang, H, 2014)	0.4
" Pharmacokinetic analysis demonstrated a vitreous half-life of 29 days with a maximum DNR concentration of 178 ng/mL and a minimum concentration of 29 ng/mL at day 84."	( A Novel Approach of Daunorubicin Application on Formation of Proliferative Retinopathy Using a Porous Silicon Controlled Delivery System: Pharmacodynamics. Cheng, L; Freeman, WR; Hou, H; Huffman, K; Rios, S; Sailor, MJ, 2015)	0.74
" None of the evaluated covariates had a clinically significant impact on plasma exposure to total cytarabine or daunorubicin, while bilirubin and formulation showed statistically significant effects on pharmacokinetic parameters of cytarabine and daunorubicin, respectively."	( Population Pharmacokinetics and Exposure-Response Analyses for CPX-351 in Patients With Hematologic Malignancies. Banerjee, K; Gibbons, JA; Marier, JF; Vasilinin, G; Wang, Q, 2019)	0.73

Excerpt	Reference	Relevance
"Rubomycin or dipin in combination with diacarb had higher toxicity and antitumor activity as compared to administration of the cytostatic agents alone to mice with transplanted lymphosarcoma, strain L10-1."	( [Toxicity and antitumor activity of the antibiotic rubomycin and dipin in combination with diuretics (diacarb)]. Stepanova, ES, 1976)	0.26
"Three hundred twenty-six patients with acute myelocytic leukemia were randomly and prospectively assigned to four therapeutic regimens: cytosine arabinoside either alone or in combination with daunorubicin, 6-mercaptopurine, or 6-thioguanine."	( Comparative study of cytosine arabinoside therapy alone and combined with thioguanine, mercaptopurine, or daunorubicin in acute myelocytic leukemia. Blom, J; Carey, RW; Cuttner, J; Eagan, RT; Ellison, RR; Glidewell, O; Harley, JB; Haurani, F; Holland, JH; Kyle, R; Lee, ST; Levy, RN; Moon, JH; Ribas-Mundo, M; Silver, R; Spurr, CL, 1975)	0.66
" Together, our studies show that GM-CSF can safely be administered to AML patients in combination with induction chemotherapy to recruit leukemic cells into the cell cycle."	( Treatment of de novo acute myelogenous leukemia with recombinant granulocyte macrophage-colony-stimulating factor in combination with standard induction chemotherapy: effect of granulocyte macrophage-colony-stimulating factor on white blood cell counts. Andreeff, M; Bettelheim, P; Geissler, K; Lechner, K; Schulz, G; Sillaber, C; Tafuri, A; Valent, P; Vieder, L, 1992)	0.28
"A randomized clinical trial was undertaken to compare the therapeutic effectiveness of idarubicin (IDR) to daunorubicin (DNR), and both were given in combination with cytarabine (CA) in acute myelogenous leukemic (AML) patients."	( A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. Banks, PL; Bartolucci, AA; Flaum, MA; Gerber, MC; Omura, GA; Velez-Garcia, E; Vogler, WR; Weiner, RS, 1992)	0.76
"The cytotoxic effect of the anticancer drug, Daunorubicin, combined with the anti human AFP horse antibody (Conjugate) on AFP-producing cells and non producing cells was studied in vitro."	( [Cytotoxic effect of anticancer drug combined with anti-AFP antibody on human hepatoma cell in vitro]. Kukita, K, 1990)	0.54
" Dose-response curves were obtained for VCR, DNR and 6-TG in the presence and absence of isotretinoin Isotretinoin showed additive leukemic cell kills in combination with VCR and DNR."	( Cytotoxic effects of vitamin A in combination with vincristine, daunorubicin and 6-thioguanine upon cells from lymphoblastic leukemic patients. Hählen, K; Huismans, DR; Loonen, AH; Pieters, R; Veerman, AJ, 1991)	0.52
" rhGM-CSF (250 micrograms/m2/d, continuous intravenous infusion) was administered in 18 pts suffering from de novo AML in combination with standard induction chemotherapy (3 + 7 = daunorubicin 45 mg/m2 days 1 through 3, cytosine-arabinoside [Ara-C] 200 mg/m2 continuous infusion days 1 through 7)."	( Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Andreeff, M; Bettelheim, P; Gorischek, C; Haas, O; Haimi, J; Muhm, M; Sillaber, C; Tafuri, A; Valent, P; Vieder, L, 1991)	0.47
" Therefore, the effects of the anthracycline antibiotics on skin tumor promotion were evaluated in combination with the Ca2+ antagonist verapamil (VRP) and the protein kinase C (PKC) inhibitor palmitoylcarnitine (PC), compounds known to circumvent drug resistance."	( Inhibition of mouse skin tumor promotion by adriamycin and daunomycin in combination with verapamil or palmitoylcarnitine. Perchellet, JP; Satyamoorthy, K, 1990)	0.28
" Further investigation of this drug combination in untreated patients with ANLL is warranted."	( Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol. Andreeff, M; Arlin, ZA; Berman, E; Gaynor, J; Gee, T; Kempin, SJ; Mertelsmann, R; Miller, W; Nahmias, N; Reich, L, 1989)	0.5
" This reversal was inhibited when menogarol was combined with melphalan."	( Synergistic combination of menogarol and melphalan and other two drug combinations. Adams, EG; Bhuyan, BK; Crampton, SL; Johnson, M, 1985)	0.27
"The effects of vincristine (VCR) in combination with methotrexate (MTX) and other antitumor agents were evaluated by cell growth inhibition assay using a human acute lymphoblastic leukemia cell line (MOLT-3)."	( Effects of vincristine in combination with methotrexate and other antitumor agents in human acute lymphoblastic leukemia cells in culture. Holland, JF; Kano, Y; Ohnuma, T; Okano, T, 1988)	0.27
"We have investigated the effect of ICRF-159 on the toxicity of daunorubicin (DR) and doxorubicin (DX) given iv, and the effectiveness of ICRF-159 combined with DR or DX on the growth of transplantable MLV-M (murine leukemia virus-Moloney) leukemia, MS-2 solid sarcoma, and pulmonary MS-2 metastases in mice."	( Studies in mice treated with ICRF-159 combined with daunorubicin or doxorubicin. Casazza, AM; Di Marco, A; Giuliani, F; Savi, G, )	0.62
"In an 18-month period, 340 consecutive adult patients with acute leukemia were treated using a 7-day continuous infusion of Ara-C in combination with rubidazone, vincristine and prednisone (ROAP)."	( Rubidazone in combination with Ara-C, vincristine and prednisone (ROAP) in the treatment of adult acute leukemia. A Southwest Oncology Group Study. Amare, M; Balcerzak, S; Benjamin, R; Costanzi, JJ; Hussein, K; Morrison, FS; Pendleton, OJ; Ryan, DH, 1982)	0.26
"In parallel to the clinical study CMEA 0102 and an experimental study with animal models the effectivity of carminomycin (CRM) in combination with dibromodulcitol (DBD) was tested on human mesothelioma cells in vitro."	( [The effectivity of carminomycin in combination with dibromodulcitol on human tumor cells in vitro (author's transl)]. Nissen, E; Projan, A; Tanneberger, S, 1981)	0.26
" A second relapse occurred in May, 1994, and intermittent-dose ara-C/mitoxantrone, combined with granulocyte colony-stimulating factor (G-CSF), led to a third remission."	( [Intermittent-dose ara-C/daunomycin therapy combined with cyclosporin-A and G-CSF led to a fourth remission in a patient with acute promyelocytic leukemia]. Anzai, S; Fujimaki, K; Fujisawa, S; Fukawa, H; Hattori, M; Motomura, S; Okubo, T, 1995)	0.29
" for 7 days) in combination with a fixed dose of DNR (50 mg/m2 intravenously on days 5, 6 and 7) in patients with advanced leukemia to determine whether this combination could be given safely and whether plasma levels of 10 microM, the effective in vitro MDR modulator concentration, could be achieved."	( Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia. Berman, E; Lin, S; McBride, M; Menedez-Botet, C; Tong, W, 1995)	0.51
" The type of interaction was different between patients, and depends on the drug combination and concentrations."	( Drug combination testing in acute lymphoblastic leukemia using the MTT assay. Hählen, K; Kaspers, GJ; Pieters, R; Van Wering, ER; Van Zantwijk, I; Veerman, AJ, 1995)	0.29
" MDS-AML patients in this pilot study did respond better, and with minimal toxicity, when standard induction chemotherapy was given in combination with rhGM-CSF."	( Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in acute myeloid leukemia evolving from myelodysplastic syndromes: a pilot study. Bernell, P; Hast, R; Kimby, E, 1994)	0.29
" In this work we compared in vitro the effects of IDA and 2HIDA used alone and in combination with 2 microM cyclosporin A (CyA) in the MDR leukemic cell lines FLCR and K562R and in their sensitive parent cell lines FLC and K562."	( Comparative activity of idarubicin and idarubicinol in combination with cyclosporin A in multidrug-resistant leukemia cells. Abbadessa, V; Cajozzo, A; Gancitano, RA; Musso, M; Perricone, R; Porretto, F; Tolomeo, M, 1996)	0.29
" Forty patients with ALL, aged 55 years or older, and with good performance status (ECOG <3) were prospectively treated according to an age-adapted regimen: induction therapy was derived from the LALA87 protocol while the feasibility of treatment with interferon combined with chemotherapy was assessed during maintenance."	( Age-adapted induction treatment of acute lymphoblastic leukemia in the elderly and assessment of maintenance with interferon combined with chemotherapy. A multicentric prospective study in forty patients. French Group for Treatment of Adult Acute Lymphobl Bouabdallah, R; Broustet, A; Cahn, JY; Cazin, B; Cony-Makhoul, P; Cordonnier, C; Delannoy, A; Dreyfus, F; Fière, D; Gay, C; Michaux, JL; Sadoun, A; Sebban, C; Vernant, JP, 1997)	0.3
" Local chemotherapy diffusing from bone cement combined with postoperative radiotherapy was highly effective in the experimental system studied."	( Combined modality treatment of bone metastases: response of the rhabdomyosarcoma R1H of the rat to postoperative irradiation combined with local release of daunorubicin from acrylic cement. Beck-Bornholdt, HP; Carl, UM; Fröschle, G; Zieron, JO, 1998)	0.5
"It is necessary to decrease the doses of daunorubicin and etoposide when they are administered with PSC-833, presumably because of the effect of the modulator on the pharmacokinetics of these agents."	( Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leukemia g Baer, M; Caligiuri, M; Dodge, RK; George, SL; Lee, EJ; Lemke, S; Powell, BL; Schiffer, CA; Smith, R; Szatrowski, TP, 1999)	0.86
"To explore the reversal effect of cyclosporin A(CsA) in combination with cytokines on multidrug resistant cell line K562/A02."	( [In vitro reversal effect of cyclosporin A in combination with cytokines on multidrug resistant cell line K562/A02]. Lou, F; Pu, J; Zhou, Q, 1999)	0.3
" CsA in combination with IL-2 didn't show a synergistic effect."	( [In vitro reversal effect of cyclosporin A in combination with cytokines on multidrug resistant cell line K562/A02]. Lou, F; Pu, J; Zhou, Q, 1999)	0.3
"The AML-BFM REZ 97 study included two reinduction blocks with L-DNR (2 x 60 mg/m (2) n = 38, since 2/1999 3 x 60 mg/m (2) n = 31) combined with cytarabine (500 mg/m (2) 4 d)."	( [Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children]. Boos, J; Creutzig, U; Fleischhack, G; Hempel, G; Reinhardt, D; Schulz, A, )	0.52
"To identify the optimal schedule for infusion of cytarabine (ara-C) given with cladribine (2-CdA) to pediatric patients with acute myeloid leukemia (AML), and to compare the effects of the two schedules on the pharmacokinetics of ara-C triphosphate (ara-CTP) in leukemic cells."	( Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. Behm, FG; Crews, KR; Gandhi, V; Plunkett, W; Pui, CH; Raimondi, SC; Razzouk, BI; Ribeiro, RC; Rubnitz, JE; Srivastava, DK; Stewart, CF; Tong, X, 2002)	0.31
"Intracellular accumulation of ara-CTP is increased when 2-CdA is given with ara-C, but no schedule-dependent differences in this effect were seen."	( Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. Behm, FG; Crews, KR; Gandhi, V; Plunkett, W; Pui, CH; Raimondi, SC; Razzouk, BI; Ribeiro, RC; Rubnitz, JE; Srivastava, DK; Stewart, CF; Tong, X, 2002)	0.31
" It is concluded that Valspodar 10 mg/kg per 24 h in combination with daunorubicin 45 mg/m(2) for 3 days and cytarabine 1 g/m(2) twice daily for 4 days is tolerable in this heavily pre-treated group of patients."	( A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia. Björkholm, M; Brinch, L; Evensen, S; Gruber, A; Gustavsson, B; Hedenus, M; Juliusson, G; Liliemark, J; Löfvenberg, E; Nesthus, I; Paul, C; Simonsson, B; Sjo, M; Stenke, L; Tangen, JM; Tidefelt, U; Udén, AM, 2003)	0.78
" Thus, the efficacy of other antileukemic agents combined with ZOL should be evaluated experimentally."	( Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines. Kimura, S; Kuroda, J; Maekawa, T; Nogawa, M; Ottmann, OG; Sato, K; Segawa, H; Yuasa, T, 2004)	0.32
" STI571 combined with VCR significantly suppressed the proliferation of K562-n/VCR cells."	( STI571 combined with vincristine greatly suppressed the tumor formation of multidrug-resistant K562 cells in a human-nude mice xenograft model. Chen, L; Fei, XH; Gao, L; Qiu, HY; Wang, JM; Zhou, H, 2006)	0.33
" VCR combined with STI571 had an excellent tumor-suppressing effect on both K562-n/VCR and K562-n in the human-nude mice xenograft model."	( STI571 combined with vincristine greatly suppressed the tumor formation of multidrug-resistant K562 cells in a human-nude mice xenograft model. Chen, L; Fei, XH; Gao, L; Qiu, HY; Wang, JM; Zhou, H, 2006)	0.33
" This effect was less pronounced when FK866 was used in combination with another alkylating agent, melphalan."	( Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents. Azzam, K; Hasmann, M; Nüssler, V; Pelka-Fleischer, R; Pogrebniak, A; Schemainda, I, 2006)	0.33
" In vitro, CI-994 in combination with cytarabine (ara-C), daunorubicin and mitoxantrone, resulted in moderate synergism."	( CI-994 (N-acetyl-dinaline) in combination with conventional anti-cancer agents is effective against acute myeloid leukemia in vitro and in vivo. Comijn, EM; Hubeek, I; Kaspers, GJ; Merriman, RL; Padron, JM; Peters, GJ; Van der Wilt, CL, 2008)	0.59
"This study was aimed to investigate the reversal effect of 5-bromotetrandrine (5-BrTet) and magnetic nanoparticle of Fe(3)O(4) (Fe(3)O(4)-MNPs) combined with DNR in vivo."	( Reversal of multidrug resistance in xenograft nude-mice by magnetic Fe(3)O(4) nanoparticles combined with daunorubicin and 5-bromotetrandrine. Chen, BA; Chen, WJ; Cheng, J; Ding, JH; Gao, C; Gao, F; Li, GH; Li, XM; Liu, LJ; Sun, XC; Wang, XM; Wu, YN; Xu, WL, 2009)	0.57
"We have investigated the effect of cloretazine (VNP40101M or Laromustine), a novel sulfonylhydrazine alkylating agent with significant antileukaemic activity, alone, or combined with cytarabine or daunorubicin, on the proliferation, viability and apoptosis of cell lines and acute myeloid leukaemia blast cells in vitro."	( Effect of cloretazine (VNP40101M) on acute myeloid leukaemia blast cells in vitro as a single agent and combined with cytarabine and daunorubicin. Adams, JA; Liu Yin, JA; Morris, KL, 2009)	0.75
"To observe the clinical efficacy of Chinese drugs combined with chemotherapy in the treatment of acute myeloid leukemia (AML) and to investigate the prognostic relevance of the main parameters in AML treated with integrative medicine."	( Effect and prognostic analysis of treatment for acute myeloid leukemia using Chinese drugs combined with chemotherapy. Hu, NP; Hu, XM; Li, L; Liu, C; Liu, F; Ma, R; Wang, HZ; Xiao, HY; Xu, YG; Yang, XH; Zhang, SS; Zheng, CM, 2009)	0.35
"We have previously shown that inhibition of translation initiation, using the small molecule inhibitor silvestrol, induces apoptosis in a pre-clinical murine lymphoma model when combined with daunorubicin."	( Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acute myelogenous leukemia cells. Carrier, M; Cencic, R; Minden, M; Pelletier, J; Porco, JA; Trnkus, A, 2010)	0.55
"This study was aimed to investigate the reversal effect of Tetrandrine (TET) combined with daunorubicin (DNR) on multidrug resistance (MDR) of K562/A02 cells and its relation to P21, P-gp and their genes so as to provide the new theoretic evidence for clinical use of TET."	( [Effect of tetrandrine combined with daunorubicin on expressions of P21 and P-gp in K562/A02 cells]. Chen, BA; Chen, J; Ding, JH; Gao, C; Gao, F; Li, J; Sun, XC; Wang, XM; Wu, YN; Xu, WL; Zhu, MS, 2009)	0.85
" The aim of this study was to investigate the cytotoxic effects of this agent in combination with conventional antileukemic agents."	( The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro. Akutsu, M; Furukawa, Y; Izumi, T; Kano, Y; Mano, H; Miyawaki, S; Tanaka, M; Tsunoda, S; Yazawa, Y, 2009)	0.35
"The cytotoxic effects of GO in combination with antileukemic agents were studied against human CD33 antigen-positive leukemia HL-60, U937, TCC-S and NALM20 cells."	( The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro. Akutsu, M; Furukawa, Y; Izumi, T; Kano, Y; Mano, H; Miyawaki, S; Tanaka, M; Tsunoda, S; Yazawa, Y, 2009)	0.35
" Imatinib mesylate, a recently introduced specific tyrosine kinase inhibitor of BCR-ABL, in combination with chemotherapy, resulted in more than 90% hematologic CR in adult Ph-positive ALL, including molecular CR in more than 50% of patients."	( Treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia with imatinib in combination with chemotherapy. Ohno, R, 2006)	0.33
" We conducted a Phase 1 study of the c-kit inhibitor, imatinib mesylate (IM), in combination with cytarabine and daunorubicin (7+3) in c-kit+ relapsed AML."	( A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia. Advani, AS; Bates, J; Copelan, EA; Cotta, CV; Egorin, MJ; Howard, M; Hsi, E; Jin, T; Kalaycio, M; Lim, K; Maciejewski, J; Noon, E; Price, C; Rush, ML; Salvado, A; Saunthararajah, Y; Sekeres, MA; Sobecks, R; Tiu, R; Tripp, B, 2010)	0.8
"The aim of this study was to investigate the effect of sorafenib combined with daunorubicin on leukemic k562 cell line."	( [Effect of sorafenib combined with daunorubicin on K562 cell line]. Chen, Y; He, CM; Lin, DJ; Ruan, XX; Wang, LL; Xiao, RZ, 2010)	0.87
"To assess effects of proteasome inhibitor Bortezomib (Bor) in combination with Daunorubicin (DNR) on proliferation, apoptosis and the expression of Bcl-2 mRNA in primary leukemia cells in vitro."	( [Effects of bortezomib combined with daunorubicin on proliferation and apoptosis in primary adult acute leukemia]. Gong, YP; Yang, X; Zheng, BH; Zhou, RQ, 2010)	0.86
" Combined with Bor (5, 10 nmol/L),the IC50 of DNR decreased from (102 +/- 27) nmol/L to (73 +/- 26), (55 +/- 22) nmol/L respectively."	( [Effects of bortezomib combined with daunorubicin on proliferation and apoptosis in primary adult acute leukemia]. Gong, YP; Yang, X; Zheng, BH; Zhou, RQ, 2010)	0.63
"Bor combined with DNR shows synergetic effect in promoting the apoptosis of adult acute leukemia primary cells as well as inhibitory effect on the proliferation of leukemia cells."	( [Effects of bortezomib combined with daunorubicin on proliferation and apoptosis in primary adult acute leukemia]. Gong, YP; Yang, X; Zheng, BH; Zhou, RQ, 2010)	0.63
"This study was aimed to investigate the relevance of nilotinib in combination with tetrandrine (Tet) on reversing multidrug resistance and inducing apoptosis of K562/A02 cell line and its mechanism."	( [Inducing apoptosis and reversal effect of nilotinib in combination with tetrandrine on multidrug resistance of K562/A02 cell line]. Bao, W; Chen, BA; Cheng, J; Cui, TY; Ding, JH; Gao, C; Gao, F; Schmitt, A; Schmitt, M; Shan, XY; Xia, GH; Zhong, YJ, 2011)	0.37
"The purpose of this study was to investigate the effect of magnetic nanoparticle of Fe3O4 combined with daunorubicin on lymphoma cell line Raji."	( [Effect of magnetic nanoparticle of Fe3O4 combined with daunorubicin on lymphoma cell line Raji]. Jing, HM; Ke, XY; Wang, J; Yang, P, 2011)	0.83
" In vitro Southern Blot analysis and cytopathic effect assays demonstrate high anti-glioma potency, which was significantly increased in combination with temozolomide (TMZ), daunorubicin and cisplatin."	( YB-1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach to eradicate malignant glioma. Anton, M; Gänsbacher, B; Haczek, C; Holm, PS; Holzmüller, R; Kasajima, A; Lage, H; Mantwill, K; Rognoni, E; Schlegel, J; Schuster, T; Treue, D; Weichert, W, 2011)	0.56
"This trial determined that it is safe and feasible to include gemtuzumab ozogamicin in combination with intensive chemotherapy."	( AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group. Alonzo, TA; Arceci, RJ; Cooper, TM; Feusner, J; Franklin, J; Gamis, A; Gerbing, RB; Hirsch, B; Hurwitz, C; Iannone, R; Lavey, RS; Mathew, P; Meshinchi, S; Raimondi, SC; Smith, FO, 2012)	0.38
" In this study, we aimed to assess the antileukemic activity of rapamycin (RAPA) (Sigma-Aldrich Corporation, MO, USA), a mammalian target of rapamycin inhibitor, alone and in combination with daunorubicin (DNR) (Pharmacia & Upjohn Company, Germany) in a Ph+ acute lymphoblastic cell line SUP-B15 and a primary Ph+ ALL sample in vitro."	( Antileukaemia effect of rapamycin alone or in combination with daunorubicin on Ph+ acute lymphoblastic leukaemia cell line. Gong, Y; Guo, Y; He, G; Lin, J; Ma, H; Shan, Q; Shuai, X; Yang, X; Zhou, R, 2012)	0.81
" Both patients received initial IM therapy combined with daunorubicin-based chemotherapy followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT) and IM maintenance treatment after allo-HSCT."	( Prolonged survival with imatinib mesylate combined with chemotherapy and allogeneic stem cell transplantation in de novo Ph+ acute myeloid leukemia. Allan, DS; Huang, H; Luo, Y; Sun, J; Tan, Y; Wang, Z, 2012)	0.62
"Our cases indicate that IM combined with daunorubicin-based chemotherapy followed by allo-HSCT and IM maintenance treatment is associated with a favorable outcome for de novo Ph+ AML, especially when IM is used in an early phase of AML."	( Prolonged survival with imatinib mesylate combined with chemotherapy and allogeneic stem cell transplantation in de novo Ph+ acute myeloid leukemia. Allan, DS; Huang, H; Luo, Y; Sun, J; Tan, Y; Wang, Z, 2012)	0.64
" This study investigated the efficiency of novel multifunctional Fe(3)O(4) magnetic nanoparticles (Fe(3)O(4)-MNP) combined with chemotherapy and hyperthermia for overcoming multidrug resistance in an in vivo model of leukemia."	( Multifunctional magnetic Fe3O4 nanoparticles combined with chemotherapy and hyperthermia to overcome multidrug resistance. Bao, W; Cai, X; Chen, B; Cheng, J; Ding, J; Gao, C; Liu, R; Ren, Y; Song, H; Tian, L; Wang, J; Wang, L; Wang, S; Wang, X; Wu, W; Xia, G; Zhang, H, 2012)	0.38
" We retrospectively evaluated the efficacy and toxicity of fractionated doses of gemtuzumab ozogamicin (GO) combined with a standard 3 + 7 induction regimen in young patients with AML in first relapse."	( Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse. de Revel, T; Eddou, H; Foissaud, V; Konopacki, J; Malfuson, JV; Thepenier, C, 2012)	0.38
" This study showed that 3 mg/m² of GO in combination with enocitabine and daunorubicin may be a recommendable dose for a phase 2 study in Japanese elderly patients with CD33-positive AML."	( Phase 1 trial of gemtuzumab ozogamicin in combination with enocitabine and daunorubicin for elderly patients with relapsed or refractory acute myeloid leukemia: Japan Adult Leukemia Study Group (JALSG)-GML208 study. Gotoh, M; Ito, Y; Mihara, M; Miyawaki, S; Naoe, T; Ohnishi, K; Ohtake, S; Ohyashiki, K; Takada, S; Wakita, A, 2012)	0.84
" Whereas, in high-risk patients, cytarabine (AraC) is often considered useful in combination with anthracycline to prevent relapse, its usefulness in standard-risk APL is uncertain."	( Long-term follow-up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients. Adès, L; Cassinat, B; Chevret, S; Chomienne, C; de Botton, S; Deconinck, E; Degos, L; Dombret, H; Fenaux, P; Ferrant, A; Guerci-Bresler, A; Huguet, F; Lambert, JF; Lamy, T; Lioure, B; Pigneux, A; Quesnel, B; Raffoux, E; Thomas, X; Vekhoff, A; Vey, N, 2013)	0.6
"To explore the therapeutic effect of homoharringtonine (HHT) combined with cytarabine (HA regimen) on CML-MBC and its influence on bone marrow CD34+CD7+ cells."	( Homoharringtonine combined with cytarabine to treat chronic myelogenous leukemia in myeloid blast crisis and its impact on bone marrow CD34+CD7+ cells. Deng, Z; Ding, B; Li, Y; Shi, Y; Zho, J, 2014)	0.4
" The human acute leukemia cell lines and primary blasts were treated with PP242 alone or in combination with daunorubicin (DNR)."	( The antileukemia roles of PP242 alone or in combination with daunorubicin in acute leukemia. Gong, Y; Naren, D; Shi, F; Shi, R; Wu, J; Yang, X, 2015)	0.87
"The present multicenter, open-label, dose-escalation study aimed to evaluate the tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of Debio1143 (formerly AT-406), a new IAP antagonist, when given along with a standard "7 plus 3 regimen" of daunorubicin and cytarabine to poor-risk patients with AML during the induction cycle."	( Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study. Brill, JM; DiPersio, JF; Erba, HP; Larson, RA; Luger, SM; Rouits, E; Sorensen, JM; Tallman, MS; Vuagniaux, G; Zanna, C, 2015)	0.82
"Debio1143 ≤ 400 mg/d showed good tolerability in combination with daunorubicin and cytarabine."	( Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study. Brill, JM; DiPersio, JF; Erba, HP; Larson, RA; Luger, SM; Rouits, E; Sorensen, JM; Tallman, MS; Vuagniaux, G; Zanna, C, 2015)	0.88
"Western blots and real-time RT-PCR were used to determine levels of Mcl-1 after ABT-199 treatment alone or in combination with cytarabine or daunorubicin."	( Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells. Caldwell, JT; Chu, R; Edwards, H; Ge, Y; Lin, H; Ma, J; Niu, X; Taub, JW; Wang, G; Wang, ZJ; Xiang, S; Xie, C; Zhang, X; Zhao, J, 2016)	0.84
"Our results demonstrate that sequestration of Bim by Mcl-1 is a mechanism of intrinsic ABT-199 resistance and supports the clinical development of ABT-199 in combination with cytarabine or daunorubicin for the treatment of AML."	( Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells. Caldwell, JT; Chu, R; Edwards, H; Ge, Y; Lin, H; Ma, J; Niu, X; Taub, JW; Wang, G; Wang, ZJ; Xiang, S; Xie, C; Zhang, X; Zhao, J, 2016)	0.83
"Our data suggest that salvage therapy with fractionated GO combined with intermediate-dose cytarabine and daunorubicin in very high-risk patients may serve as a potential bridge therapy to RIC transplant."	( Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant? Barraco, F; Ducastelle-Leprêtre, S; Labussière-Wallet, H; Nicolini, FE; Paubelle, E; Plesa, A; Salles, G; Thomas, X; Wattel, E, 2017)	0.89
"To evaluate the efficacy and safety of midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation in newly diagnosed FLT3-mutated acute myeloid leukemia (AML)."	( Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia. Kim, M; Williams, S, 2018)	0.7
"Clinical trials evaluating the efficacy and safety of midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation were reviewed for the treatment of newly diagnosed FLT3-mutated AML."	( Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia. Kim, M; Williams, S, 2018)	0.69
" A phase III trial illustrated that midostaurin in combination with standard chemotherapy improved event-free survival, disease-free survival, and overall survival in patients with newly diagnosed FLT3-mutation-positive AML compared with standard chemotherapy alone."	( Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia. Kim, M; Williams, S, 2018)	0.48
"Midostaurin in combination with standard induction and consolidation is safe and efficacious in newly diagnosed FLT3-mutated AML."	( Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia. Kim, M; Williams, S, 2018)	0.48
" For the first time, were combined an in silico approaches like molecular docking and ab initio computational simulation based on Density Functional Theory (DFT) to explain the drug-drug interaction mechanism of aforementioned chemotherapy ligands with the transmembrane ligand extrusion binding domains (TMDs) of ABCB1."	( Modeling drug-drug interactions of AZD1208 with Vincristine and Daunorubicin on ligand-extrusion binding TMD-domains of multidrug resistance P-glycoprotein (ABCB1). Almeida, DV; da Silva Nornberg, BF; de Oliveira, PV; Fagan, SB; González-Durruthy, M; Marins, LF; Marques, MB; Oliveira, BR, 2019)	0.75
" By inhibiting the primary export protein, XPO1, selinexor localizes and activates tumor suppressor proteins in the nucleus and inhibits DNA damage repair, rationalizing combination with DNA-damaging agents."	( Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia. Chavez, J; Cubitt, CL; Dawson, JL; Komrokji, R; Lancet, JE; List, AF; Padron, E; Sallman, DA; Shah, BD; Sullivan, DM; Sweet, K; Turner, JG; Zhou, J, 2020)	0.8
"This was a single-arm phase I clinical trial of selinexor combined with cytarabine and daunorubicin (7+3)."	( Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia. Chavez, J; Cubitt, CL; Dawson, JL; Komrokji, R; Lancet, JE; List, AF; Padron, E; Sallman, DA; Shah, BD; Sullivan, DM; Sweet, K; Turner, JG; Zhou, J, 2020)	1.03
"To ascertain the efficacy and safety of daunorubicin combined with cytarabine comparing with idarubicin combined with cytarabine as a standard induction therapy for acute Myeloid leukemia by a meta-analysis."	( The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials. Lu, Y; Wang, H; Wu, Y; Xiao, Q; Xiao, X, 2020)	1.12
" We evaluated and cross-checked the randomized clinical trials (RCTs) comparing daunorubicin combined with cytarabine (DA) and idarubicin combined with cytarabine (IA) by two reviewers independently according to Cochrane Handbook for Systematic Reviewers of Interventions."	( The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials. Lu, Y; Wang, H; Wu, Y; Xiao, Q; Xiao, X, 2020)	1.08
"To study the effect of apoptotic drug Navitoclax (NTX) combined with chemotherapy drug Daunorubicin (DNR) on apoptosis of erythroleukemia cells."	( [Navitoclax Combined with Daunorubicin Promotes Apoptosis of Erythroleukemia Cell Lines K562, HEL and TF-1]. Chen, XY; Duan, YJ; Liu, C; Wu, WQ; Zhang, YC; Zheng, JR; Zhu, XF, 2020)	1.08
"NTX combined with DNR could significantly inhibit the growth of K562, HEL and TF-1 cells; Apoptosis detection results showed that the apoptotic rate of K562, HEL and TF-1 cells in combination group was significantly higher than that in NTX and DNR single group; the expression level of apoptosis-related genes BAK and BAX in K562 cells in combination group was significantly higher than that in two single drug groups, and the expression level of anti-apoptotic protein genes BCL-2 and BCL-xl was significantly lower than that in two single drug groups (P＜0."	( [Navitoclax Combined with Daunorubicin Promotes Apoptosis of Erythroleukemia Cell Lines K562, HEL and TF-1]. Chen, XY; Duan, YJ; Liu, C; Wu, WQ; Zhang, YC; Zheng, JR; Zhu, XF, 2020)	0.86
"NTX combined with DNR can significantly promote the apoptosis of erythroleukemia cell lines K562, HEL and TF-1, and induce the expression of apoptosis-related genes."	( [Navitoclax Combined with Daunorubicin Promotes Apoptosis of Erythroleukemia Cell Lines K562, HEL and TF-1]. Chen, XY; Duan, YJ; Liu, C; Wu, WQ; Zhang, YC; Zheng, JR; Zhu, XF, 2020)	0.86
" However, the efficacy and underlying toxicity of these hybrids in combination with other agents remain unclear."	( Novel SAHA‑bendamustine hybrid NL‑101 in combination with daunorubicin synergistically suppresses acute myeloid leukemia. Guo, W; Huang, J; Huang, S; Huang, X; Jin, J; Li, F; Li, X; Ling, Q; Pan, J; Ye, W, 2020)	0.8
"The present study aimed to investigate the efficacy and safety for alternate application of all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) combined with idarubicin (IDA)/daunorubicin (DNR) in treatment of acute promyelocytic leukemia (APL)."	( Alternate application of all-trans-retinoic acid and arsenic trioxide combined with idarubicin/daunorubicin in treatment of acute promyelocytic leukemia. Mao, Y; Tang, F; Xu, X; Zhu, X, 2022)	1.13
" More importantly, CN0 could inhibit DNA damage repair, resulting in highly efficient accumulation of cytosolic DNA fragments due to unresolved unrepaired DNA lesions when combined with daunorubicin (DNR)."	( Discovery of CN0 as a novel proteolysis-targeting chimera (PROTAC) degrader of PARP1 that can activate the cGAS/STING immunity pathway combined with daunorubicin. Huang, X; Jiang, Q; Lin, S; Lin, Y; Liu, J; Liu, Q; Liu, Y; Tu, G; Wu, L; Xu, J; Yu, Z; Zhang, L, 2022)	1.11

Excerpt	Reference	Relevance
" The therapeutic advantage of combination chemotherapy may reside in the whole organism, reflecting increased bioavailability of drug, reduced dose-limiting toxicity or reduced impairment of host defenses; it may reside in the tumor cells, reflecting the multiple molecular mechanisms of interaction mentioned above."	( Multiple basis of combination chemotherapy. Grindey, GB; Mihich, E, 1977)	0.26
" administration of the drug in another study, the bioavailability of idarubicin alone can be estimated to about 21%, whereas the bioavailability of the sum idarubicin + idarubicinol is about 41%."	( Pharmacokinetics of idarubicin after oral administration in elderly leukemic patients. Huet, S; Hurteloup, P; Pris, J; Rigal-Huguet, F; Robert, J, 1990)	0.28
" dose, and the bioavailability of the oral dose ranged between 9% and 39%."	( Pharmacokinetics of 4-demethoxydaunorubicin in cancer patients. D'Incalci, M; Erranti, D; Freshi, A; Tirelli, U; Zanette, L; Zucchetti, M, 1990)	0.57
" We report here the results of pharmacokinetic and systemic bioavailability studies of menogaril in three species (mouse, dog, and monkey)."	( Pharmacokinetics and systemic bioavailability of menogaril, an anthracycline antitumor agent, in the mouse, dog, and monkey. Adams, WJ; Brewer, JE; Dalm, EA; Hosley, JD; McGovren, JP, 1989)	0.28
" A comparison of the data from the present trial and our previous study with intravenous menogaril indicates a bioavailability of 32 +/- 12%."	( Phase I clinical and pharmacokinetic trial of oral menogaril administered on three consecutive days. Crespeigne, N; de Valeriola, D; Dodion, P; Joggi, J; Kenis, Y; Peeters, B; Piccart, M; Tueni, E; van Berchem, C; Wery, F, 1988)	0.27
" The bioavailability of DMDR given PO was about 39% according to comparison of the areas under the plasma DMDR concentration versus time curves for the two routes, but 45% according to comparison of the 24-h cumulative urinary excretion rates."	( Clinical pharmacology of 4-demethoxydaunorubicin (DMDR). Bodey, GP; Burgess, M; Feun, LG; Kavanagh, J; Loo, TL; Lu, K; Savaraj, N, 1986)	0.55
" routes suggests an oral bioavailability of approximately 24%."	( Clinical pharmacology of oral and intravenous 4-demethoxydaunorubicin. Howell, A; Lucas, SB; Margison, JM; Smith, DB; Wilkinson, PM, 1987)	0.52
" The present study was undertaken to investigate the pharmacokinetics and bioavailability of idarubicin in man."	( Pharmacokinetic study of intravenous and oral idarubicin in cancer patients. Libretti, A; Moro, E; Pacciarini, MA; Piazza, E; Tamassia, V; Vago, G, 1987)	0.27
" Oral bioavailability studies in the mouse showed significant absorption of menogaril from the gastrointestinal tract followed by first-pass metabolism."	( Menogaril: a new anthracycline agent entering clinical trials. Christopher, JP; Cradock, JC; Lassus, M; McGovren, JP; Nelson, KG; Plowman, J, 1984)	0.27
" However, when given by this route at high doses, poor bioavailability was noted."	( Bis-diketopiperazine derivatives in clinical oncology: ICRF-159. Bruno, S; Macdonald, JS; Marsoni, S; Penta, J; Poster, DS, 1980)	0.26
" These perspectives are somewhat hampered by the large variation in bioavailability between individual patients and the obvious requirement to monitor plasma concentration and area-under the curve values (AUC) for an appropriate adjustment of idarubicin dose."	( Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve. Braess, J; Hiddemann, W; Kaufmann, CC; Kern, W; Kühn, S; Rührs, H; Schleyer, E; Sträubel, G; Unterhalt, M, 1996)	0.29
" The bioavailability of both IGF-I and IGF-II is regulated by specific IGF-binding proteins (IGFBPs)."	( Serum levels of insulin-like growth factor-I, -II and insulin-like growth factor binding proteins -2 and -3 in children with acute lymphoblastic leukaemia. Aumann, V; Blum, WF; Kluba, U; Mittler, U; Mohnike, KL; Vorwerk, P, 1996)	0.29
" These perspectives are somewhat hampered by the large variation in bioavailability between individual patients and the obvious requirement to monitor plasma concentration and area-under-the-curve values (AUC) for an appropriate adjustment of idarubicin dose."	( Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve. Braess, J; Hiddemann, W; Kaufmann, CC; Kern, W; Kühn, S; Rührs, H; Schleyer, E; Sträubel, G; Unterhalt, M, 1997)	0.3
" The drug transporting protein, P-glycoprotein (P-gp), which is highly expressed in the intestinal mucosa, could be responsible for the low oral bioavailability of these and other drugs which are substrates for this transporter."	( Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. Blaschke, TF; Duran, GE; Man, MC; Sikic, BI; Washington, CB, 1998)	0.3
" The aim of this research was to study whether the bioavailability of idarubicin can be improved by administering IDA-SLN duodenally to rats."	( Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats. Bargoni, A; Cavalli, R; Fundarò, A; Gasco, MR; Vighetto, D; Zara, GP, 2002)	0.31
" It is interesting that certain types of monoglyceride might be involved in the drug bioavailability by specifically inhibiting the efflux mediated by P-gp."	( A bitter melon extract inhibits the P-glycoprotein activity in intestinal Caco-2 cells: monoglyceride as an active compound. Aizawa, K; Hatsugai, Y; Inakuma, T; Konishi, T; Nagasawa, H; Nagata, S; Sakuda, SH; Satsu, H; Shimizu, M, 2004)	0.32
" These results indicate that extracts and flavone derivatives from the rhizome of Kaempferia parviflora can inhibit P-gp function, which may be useful for overcoming P-gp-mediated multidrug resistance and improving the oral bioavailability of anticancer agents."	( Effects of Kaempferia parviflora extracts and their flavone constituents on P-glycoprotein function. Murakami, T; Nagai, J; Patanasethanont, D; Sripanidkulchai, BO; Sutthanut, K; Takano, M; Yenjai, C; Yumoto, R, 2007)	0.34
" Therefore, the ns-SNPs generating both these mutations may alter bioavailability of these anthracyclines in cancer patients and should be examined in clinical studies as potential biomarkers for DAUN- and DOX-induced adverse effects."	( Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin. Bains, OS; Grigliatti, TA; Karkling, MJ; Reid, RE; Riggs, KW, 2009)	0.56
" The disconnect between the in vitro and in vivo data suggests that P-gp interactions mediated by biochanin A may be limited due to its poor bioavailability and rapid clearance."	( Interactions between the flavonoid biochanin A and P-glycoprotein substrates in rats: in vitro and in vivo. Arnold, RD; Morris, ME; Sagawa, K; Tseng, E; Wang, X; Zhang, S, 2010)	0.36
" (2) Male patients and children older than 6 years had a higher bioavailability and lower metabolism, toxicity may easily occur in such children, therefore they may need lower dose."	( [Relationship between pharmacokinetics and efficacy and toxicity of daunorubicin in children with acute leukemia]. Chai, YH; Lü, H; Sun, YN; Xu, YJ, 2009)	0.59
" These "in combo" PAMPA data were used to predict the human absolute bioavailability of the ampholytes."	( The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. Avdeef, A; Sun, N; Tam, KY; Tsinman, O, 2010)	0.36
" Its hydrochloride salt, 13a·HCl exhibited not only excellent water solubility (1049 μg/mL) but also a high oral bioavailability (57."	( Discovery of 4-anilinofuro[2,3-b]quinoline derivatives as selective and orally active compounds against non-small-cell lung cancers. Chen, YL; Chen, YW; Liang, CC; Lu, PJ; Tseng, CH; Tzeng, CC; Yang, CN; Yao, YC, 2011)	0.37
"Human P-glycoprotein (P-gp) controls drugs bioavailability by pumping structurally unrelated drugs out of cells."	( Understanding polyspecificity within the substrate-binding cavity of the human multidrug resistance P-glycoprotein. Andrieu, T; Arnaud, O; Chang, G; Chaptal, V; Di Pietro, A; Doshi, R; Dussurgey, S; Falson, P; Henin, E; Martinez, L; Tao, H; Tod, M; Zhang, Q, 2014)	0.4
" Paclitaxel (PTX, 25mg/kg) after oral administration with LL-348 (5mg/kg), the optimal dose of LL-348 as an oral absorption enhancer of PTX, improved the relative bioavailability (RB) of PTX to 961%."	( Effect of coumarin derivative-mediated inhibition of P-glycoprotein on oral bioavailability and therapeutic efficacy of paclitaxel. Chae, SW; Kim, HJ; Kim, NH; Lee, HJ; Lee, K; Rhie, S; Xia, Y, 2014)	0.4
"Daunorubicin hydrochloride (DAUN·HCl), due to low oral bioavailability poses the hindrance to be marketed as an oral formulation."	( Daunorubicin oral bioavailability enhancement by surface coated natural biodegradable macromolecule chitosan based polymeric nanoparticles. Ahmad, FJ; Ahmad, N; Ahmad, R; Alam, MA; Amir, M; Jafar, M; Pottoo, FH; Sarafroz, M; Umar, K, 2019)	3.4
" Chitosan (CS)-coated-DAUN-PLGA-poly(lactic-co-glycolic acid)-Nanoparticles (NPs) with an aim to improve oral-DAUN bioavailability and to develop as well as validate UHPLC-MS/MS (ESI/Q-TOF) method for plasma quantification and pharmacokinetic analysis (PK) of DAUN."	( Daunorubicin oral bioavailability enhancement by surface coated natural biodegradable macromolecule chitosan based polymeric nanoparticles. Ahmad, FJ; Ahmad, N; Ahmad, R; Alam, MA; Amir, M; Jafar, M; Pottoo, FH; Sarafroz, M; Umar, K, 2019)	1.96
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" Considering the favorable bioavailability and safety profile of ASP9521, the obtained results encourage further research."	( In Silico and In Vitro Assessment of Carbonyl Reductase 1 Inhibition Using ASP9521-A Potent Aldo-Keto Reductase 1C3 Inhibitor with the Potential to Support Anticancer Therapy Using Anthracycline Antibiotics. Bucki, A; Jamrozik, M; Koczurkiewicz-Adamczyk, P; Kołaczkowski, M; Pękala, E; Piska, K; Sapa, M; Władyka, B, 2023)	0.91

Excerpt	Relevance	Reference
" If these drugs are used; frequent and careful follow-up is necessary, the dosage at which the drug becomes cumulative must be known; and patients with a pre-existing cardiac condition must be exluded from treatment."	( [The heart and drug poisoning, excluding cardiologic treatments]. Bouhour, JB; Chareyre, M; Godin, JF; Nicolas, G; Rozo, L, 1978)	0.26
" The maximum concentrations of the two cytotoxic drugs were chosen to be twice the known peak plasma levels of commonly employed dosage schedules."	( Effect of two cancer chemotherapeutic agents on the antibacterial activity of three antimicrobial agents. Moody, MR; Morris, MJ; Moyé, LA; Schimpff, SC; Wiernik, PH; Young, VM, 1978)	0.26
" 46% complete and 12% partial remissions were obtained in 37 patients treated with cytosine arabinoside and 6-thioguanine doubling the dosage of the above mentioned regimen followed by 3 cycles of TRAP (and COAP)."	( [Induction and maintenance treatment of acute myelogenous leukemia in adults by sequential use of combination chemotherapy (author's transl)]. Fülle, HH, 1977)	0.26
"A colony assay available for a subpopulation of acute myeloblastic leukemia blasts with proliferative potential was used to measure adriamycin (adria) and daunorubicin (dauno) dose-response curves following brief exposure to either drug and washing."	( Cytotoxicity of adriamycin and daunorubicin for normal and leukemia progenitor cells of man. Buick, RN; McCulloch, EA; Messner, HA; Till, JE, 1979)	0.74
" No dose-response relationship could be found between the amount of myocardial lipofuscin and the total dose of rubidomycin."	( Cardiomyopathy in leukemia, with reference to rubidomycin cardiotoxicity. Adolfsson, J; Lagerlöf, B; Lantz, B; Reizenstein, P, 1979)	0.26
" Fifty two patients with various advanced cancers received rubidazone intravenously at the initial unitary dose of 200 mg/m2 in a single injection at three week intervals; this base line dosage had been adapted in function of leuko-platelet variations observed between the injections."	( [Rubidazone (22 050 RP): clinical study. Phase II trial in solid tumors and lymphomas (author's transl)]. Cappelaere, P; Carton, M; Chauvergne, J; Gary-Bobo, J; Klein, T, 1978)	0.26
"In 38 adriamycin experiments and 4 daunorubicin experiments, radioimmunoassay readily and reproducibly detects and estimates these drugs and immunologically similar metabolites in patients' plasma and urine to at least 120 hr after dosing without interference by concurrent medication."	( Plasma adriamycin and daunorubicin levels by fluorescence and radioimmunoassay. Bachur, NR; Green, MR; Langone, JJ; Levine, L; Riggs, CE; Van Vunakis, H, 1977)	0.85
" Dose-response curves were constructed using the percent incidence of cardiomyopathy versus the total dose of daunomycin in mg/m2."	( Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Layard, M; Muggia, FM; Rozencweig, M; Slavik, M; Von Hoff, DD, 1977)	0.26
" The induction therapy was repeated monthly up to the dosage limits imposed by daunorubicin cardiotoxicity in an attempt to lengthen subsequent remission duration."	( Chemotherapy for adult acute nonlymphocytic leukemia with daunorubicin and cytosine arabinoside. Cassileth, PA; Katz, ME, 1977)	0.73
"Adriamycin dosage should be reduced in patients with impaired liver function, since adriamycin disposition is influenced by liver metabolism and biliary excretion."	( Alterations in adriamycin efficacy by phenobarbital. Bachur, NR; Reich, SD, 1976)	0.26
" coli L-asparaginase (L-ase) in the induction phase at a dosage of 6000 U/m2/day x 7 d starting on d 15, as well as vincristine, prednisone, daunorubicin and cyclophosphamide, the last-named by random 1:1."	( Incidence of thrombotic complications in adult patients with acute lymphoblastic leukaemia receiving L-asparaginase during induction therapy: a retrospective study. The GIMEMA Group. Annino, L; Defazio, D; Gugliotta, L; Leone, G; Mandelli, F; Mattioli-Belmonte, M; Mazzucconi, MG; Tura, S, 1992)	0.49
" In protocol ALL VIII/87 the only modification was the reduction of the MTX dosage from 5 g/m2 to 1 g/m2 with an infusion time of 24 hours (leucovorin rescue 15 mg/m2 after 48 and 54 hours)."	( [Experiences with modified BFM protocols in the treatment of children with acute lymphoblastic leukemia (ALL) in East Germany 1981-1991]. Domula, M; Dörffel, W; Eggers, G; Exadaktylos, P; Hermann, J; Hilgenfeld, E; Kotte, W; Malke, H; Reimann, M; Zintl, F, )	0.13
" The drug-polymer conjugates are in principle prevented from entering cells, can efficiently bind to cell surfaces and allow precise dose-response determinations."	( Water-soluble polysaccharide-anthracycline conjugates: biological activity. Cera, C; Palù, G; Palumbo, M; Rassu, M; Stefanelli, S, 1992)	0.28
" The dose-response curves were nearly identical and did not demonstrate differences in modulator potency."	( Comparison of cyclosporin A and SDZ PSC833 as multidrug-resistance modulators in a daunorubicin-resistant Ehrlich ascites tumor. Friche, E; Jensen, PB; Nissen, NI, 1992)	0.51
" The concentrations of itraconazole that reversed drug resistance are comparable to the plasma levels achieved by therapeutic dosage used in the treatment of fungal infections."	( Reversal of daunorubicin resistance in P388/ADR cells by itraconazole. Gollapudi, S; Gupta, S; Kim, J, 1991)	0.66
" The patients were randomised at diagnosis to receive either three further courses of Ara-C (five days) and DNR (two days) in the same dosage or three courses of VP16 100 mg/m2 daily for five days and one dose of mAMSA of 200 mg/m2 as postremission consolidation."	( Acute myeloid leukaemia: results of the New Zealand AML-1 study. The Leukaemia Study Group of the New Zealand Society for Haematology. , 1991)	0.28
" Dose-response curves were obtained for VCR, DNR and 6-TG in the presence and absence of isotretinoin Isotretinoin showed additive leukemic cell kills in combination with VCR and DNR."	( Cytotoxic effects of vitamin A in combination with vincristine, daunorubicin and 6-thioguanine upon cells from lymphoblastic leukemic patients. Hählen, K; Huismans, DR; Loonen, AH; Pieters, R; Veerman, AJ, 1991)	0.52
" Low dosage Dm treatment effectively prevented the development of muscle weakness and its associated electrophysiological abnormality, without inducing detectable toxicity and global immunosuppression."	( Daunomycin treatment prevents clinical expression of experimental autoimmune myasthenia gravis. Christadoss, P; Henderson, R; Keve, S, 1991)	0.28
" Maintenance with the same drugs in a modified dosage schedule continued for approximately 2 years."	( Multiagent chemotherapy in relapsed acute lymphoblastic leukemia in children. Belasco, JB; Luery, N; Scher, C, 1990)	0.28
" We can not currently say what dosage and protocols are necessary to achieve a prevention of secondary cataract."	( [Effect of daunomycin on epithelial cells of the crystalline lens. Experimental and clinical study]. Ducournau, Y; Sourdille, P, )	0.13
" The sensitivity of proliferating AML cells to DNR did not correlate with the clinical response of the patients as identical dose-response curves were obtained for complete responders (n = 6), partial responders (n = 5) and resistant cases (n = 5)."	( Susceptibility of acute myeloid leukemia (AML) cells from clinically resistant and sensitive patients to daunomycin (DNR): assessment in vitro after stimulation with colony stimulating factors (CSFs). Delwel, R; Löwenberg, B; Nooter, K; Santini, V, 1990)	0.28
" Three dosages of drugs were employed to allow the determination of a dose-response curve, which was obtained for all the patients."	( In vitro chemosensitivity testing of leukemic cells: prediction of response to chemotherapy in patients with acute non-lymphocytic leukemia. Bernabei, PA; Bezzini, R; Dal Pozzo, O; Ferrini, PR; Gattei, V; Saccardi, R; Santini, V; Silvestro, L; Viano, I, )	0.13
" Dose-response studies showed that L-histidinol conferred dose-dependent, synergistic improvements on the capacities of both BCNU and cisDDP to increase the life-span of DBA/2J mice bearing P388 leukemia."	( L-histidinol improves the selectivity and efficacy of alkylating agents and daunomycin in mice with P388 leukaemia. Fang, WD; Warrington, RC, 1989)	0.28
" Anthracycline dosage was 129 +/- 42, 307 +/- 68 and 471 +/- 61 mg/m2 and 103 +/- 64, 303 +/- 73 and 536 +/- 93 mg/m2, respectively."	( [Serial determination of anthracycline poisoning in children]. Benson, LN; Chan, H; Langevin, A; Souza, MD; Stein, JI; Wilson, G, 1989)	0.28
" These latter findings should be useful in developing more precise and intelligent dosing schemes for 7-OMEN."	( Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities. Aisner, J; Egorin, MJ; Engisch, KL; Forrest, A; Sigman, LM; Van Echo, DA; Whitacre, MY, 1986)	0.27
"We performed a phase I study of menogaril to determine if dosage reduction was required in patients with hepatic dysfunction and if the relationship between pharmacokinetics and leukopenia, previously defined in patients with normal hepatic and renal function, was altered."	( Phase I study and pharmacokinetics of menogaril (NSC 269148) in patients with hepatic dysfunction. Conley, BA; Egorin, MJ; Forrest, A; Sinibaldi, V; Van Echo, DA; Zuhowski, EG, 1987)	0.27
" This regimen and dosage schedule are well tolerated, with minimal toxicity that included myelosupression; median white blood cell (WBC) count nadir of 2,700 cells/mm3 (range 1,400-7,100 cells/mm3) and median platelet nadir of 162,000 cells/mm3 (range 53,000-390,000 cells/mm3)."	( Phase II trial of menogarol in the treatment of advanced adenocarcinoma of the pancreas. Cheng, EW; Hollander, P; Magill, GB; Sternberg, CN, 1988)	0.27
" at a dosage of 600 mg/m2 on the same day as fluorouracil (600 mg/m2/i."	( Intravenous administration of cyclophosphamide, methotrexate and 5-fluorouracil in metastatic breast cancer. A pilot study. Brandi, M; De Lena, M; Logroscino, A; Lorusso, V; Maiello, E; Paradiso, A, 1988)	0.27
" For determining purity of carminomycin dosage forms the procedure with an external standard was applied."	( [Determination of carminomycin in its preparations by high-performance liquid chromatography]. Aleksandrova, LG; Brazhnikova, MG; Rubasheva, LM; Zbarskiĭ, VB, 1988)	0.27
"0 microM, was included with each agent in dose-response studies, a synergistic enhancement of the antiproliferative effects was observed."	( Synergistic antiproliferative effects on HL-60 cells: deferoxamine enhances cytosine arabinoside, methotrexate, and daunorubicin cytotoxicity. Cohen, A; Estrov, Z; Freedman, MH; Gelfand, EW, 1988)	0.48
" The LVF in 13 pts, with acute non lymphoblastic leukaemia, was analyzed using a Nuclear Stethoscope before and after induction therapy with daunorubicin (DNR) at the total dosage of 135 mg/m2."	( [Evaluation of peak filling rate for the early identification of daunorubicin cardiotoxicity]. Galli, V; Grego, V; Matteoli, S; Trappolini, M, 1988)	0.71
"25 mg/kg body weight or PO at 1 mg/kg body weight, whereas [14C]DNR was dosed IV at 1 mg/kg body weight."	( Disposition and metabolism of [14-14C] 4-demethoxydaunorubicin HCl (idarubicin) and [14-14C]daunorubicin HCl in the rat. A comparative study. Arcamone, F; Lazzati, M; Vicario, GP; Zini, G, 1986)	0.52
" The drug was given in divided doses over 5 days and dosage was repeated every 3 weeks."	( A phase II trial of 4-demethoxydaunorubicin in refractory epithelial ovarian cancer. Copeland, LJ; Edwards, CL; Gershenson, DM; Kavanagh, JJ; Saul, PB, 1986)	0.56
"Twelve patients affected by different types of acute leukemia received idarubicin (4-demethoxy-daunorubicin) by oral route at the total dosage of 45, 60 or 90 mg/m2 distributed over three consecutive days."	( Oral idarubicin in adult acute leukemia: a preliminary experience. Annaloro, C; Lambertenghi-Deliliers, G; Pacciarini, MA; Pogliani, E; Polli, EE, 1986)	0.49
" A striking biphasic dose-response curve was observed for the 4-demethoxy derivatives, suggesting a complex mechanism of interaction among drug, DNA, and enzyme."	( Single-strand DNA breaks induced by chromophore-modified anthracyclines in P388 leukemia cells. Capranico, G; Soranzo, C; Zunino, F, 1986)	0.27
" Cellular D-DNM concentrations were maximal at the end of intravenous dosing and at 2 to 4 hours after D-DNM ingestion."	( Plasma and human leukemic cell pharmacokinetics of oral and intravenous 4-demethoxydaunomycin. Haanen, C; Linssen, PC; Speth, PA; van de Loo, FA; Wessels, HM, 1986)	0.27
" Since there was no severe toxicity, after 2 cycles the dosage was increased to 60 mg/m2 per cycle."	( Phase II study of oral 4-demethoxydaunorubicin in previously treated (except anthracyclines) metastatic breast cancer patients. Kolarić, K; Mechl, Z; Potrebica, V; Sopkova, B, 1987)	0.55
" These data lead us to conclude that verapamil can reverse DNR resistance completely, but that verapamil at non-toxic dosage only reduces DNR resistance by 50% in vivo."	( Effect of verapamil on daunorubicin accumulation in Ehrlich ascites tumor cells. Friche, E; Nissen, NI; Skovsgaard, T, 1987)	0.58
"Daunomycin was administered to one of each pair of litter mate rabbits at a weekly dosage rate of 40 mg/m2."	( Daunomycin-induced cardiomyopathy in rabbits: isolated heart and papillary muscle energetics. Gibbs, CL; Gibson, WR; Kotsanas, G, 1986)	0.27
"Between July 1, 1981 and November 1, 1982, 45 patients with acute nonlymphocytic leukemia (age, greater than or equal to 70 years) were randomly assigned to receive induction chemotherapy using either daunorubicin, cytosine arabinoside, and 6-thioguanine in full dosage (F DAT) or an attenuated schedule of the same drugs (At DAT) as part of an Eastern Cooperative Oncology Group controlled trial."	( Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly. Begg, CB; Bennett, JM; Bonner, H; Glick, JH; Kahn, SB; Mazza, JJ, 1984)	0.74
" Based on our in vitro studies, a dose-response curve was found between increasing intracellular DNR and incorporation of 3H-thymidine."	( Kinetics and sensitivity of daunorubicin in patients with acute leukemia. DeGregorio, MW; Holleran, WM; Linker, CA; Macher, BA; Wilbur, JR, 1984)	0.56
"Daunorubicin (DNR) was administered to one of each pair of litter mate rabbits at a weekly dosage rate of 40 mg/m2."	( Cardiac energetics in daunorubicin-induced cardiomyopathy. Gibbs, CL; Gibson, WR; Kotsanas, G; Woolley, G, 1984)	2.02
" Colony-forming cells from mice, dogs, and humans were all found to have exponential dose-response curves for the agents studied, with variation of the slopes between species and agents."	( Sensitivity of bone marrow hematopoietic colony-forming cells from mice, dogs, and humans to carminomycin, marcellomycin, aclacinomycin A, and N,N-dibenzyldaunorubicin and its relationship to clinical toxicity. Brown, BJ; Marsh, JC; Nierenburg, MM, 1983)	0.46
" A group of 16 patients in relapse received idarubicin at a dosage of 5-6 mg/m2/day for 3 consecutive days; a second group of 6 relapsing and 4 previously untreated cases was treated with a sequential combination of idarubicin and arabinosyl cytosine."	( Therapeutic activity of 4-demethoxydauno-rubicin (idarubicin) in adult acute leukemia. Lambertenghi-Deliliers, G; Maiolo, AT; Pacciarini, MA; Pogliani, E; Polli, EE, 1983)	0.27
" Dose-response curves to cyclophosphamide performed on day 13 of gestation showed increases in SCE as a function of cyclophosphamide concentration in both the mother and the fetus."	( In utero analysis of sister chromatid exchange: alterations in suscptibility to mutagenic damage as a function of fetal cell type and gestational age. Bickings, CK; Bynum, GD; Kram, D; Schneider, EL; Senula, GC, 1980)	0.26
" Treatment with the DNR-DNA complex caused less pronounced thrombocytopenia and fewer 'minor' cardiac abnormalities than treatment with free DNR in the same dosage schedule."	( Comparison of daunorubicin and daunorubicin-DNA complex in the treatment of acute nonlymphoblastic leukemia. Björkholm, M; Christenson, I; Engstedt, L; Gahrton, G; Hast, R; Holm, G; Killander, A; Lantz, B; Lockner, D; Lönnqvist, B; Mellstedt, H; Oberg, G; Palmblad, J; Paul, C; Peterson, C; Simonsson, B; Stalfelt, AM; Udén, AM; Wadman, B, 1981)	0.62
" Dose-response curves for AML blast cells were characterized by an initial shoulder and then an exponential decrease in survival."	( Sensitivities of AML blast stem cells to idarubicin and daunorubicin: a comparison with normal hematopoietic progenitors. Curtis, JE; McCulloch, EA; Minden, MD; Minkin, S, 1995)	0.54
" Anthracycline dose-response curves are characterized by an initial shoulder, followed by exponential decrease in survival with increasing dose."	( Regulation by retinoic acid and hydrocortisone of the anthracycline sensitivity of blast cells of acute myeloblastic leukemia. McCulloch, EA; Minden, MD; Yang, GS, 1994)	0.29
" Notably, the Km of transport was in the range of doxorubicin concentration achievable in human serum after intravenous dosing of doxorubicin."	( Adenosine triphosphate-dependent transport of doxorubicin, daunomycin, and vinblastine in human tissues by a mechanism distinct from the P-glycoprotein. Awasthi, S; Bajpai, KK; Frenkel, EP; Saxena, M; Sharma, R; Singh, SV; Singhal, SS; Srivastava, SK; Ziller, SA; Zimniak, P, 1994)	0.29
" A dose-response relationship was established for the effect of VER on efflux."	( Kinetics of daunorubicin transport in Ehrlich ascites tumor cells with different expression of P-glycoprotein. Maare, C; Nielsen, D; Skovsgaard, T, 1994)	0.67
" Our study concluded that 5 micrograms of intravitreal daunorubicin effectively inhibited PVR in the rabbit eye and the dosage was safe and nontoxic."	( Experimental inhibition of proliferative vitreoretinopathy in retinal detachment using daunorubicin. Bathwal, DP; Khosla, PK; Kumar, A; Tewari, HK, 1994)	0.76
" At non-effect dosage in free drug, HEPC-liposomes with a diameter of 58 or 142 nm showed the greatest inhibitory effect against Yoshida sarcoma among liposomes tested, whereas larger ones (272 nm) had weaker effect."	( Effects of fluidity and vesicle size on antitumor activity and myelosuppressive activity of liposomes loaded with daunorubicin. Kinouchi, Y; Kiwada, H; Nagayasu, A; Shimooka, T; Takeichi, Y; Uchiyama, K, 1994)	0.5
"These data support the concept of a dose-response effect for cytarabine in patients with AML who are 60 years of age or younger."	( Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. Berg, DT; Davis, RB; Frei, E; Mayer, RJ; McIntyre, OR; Moore, JO; Omura, GA; Powell, BL; Schiffer, CA; Schulman, P, 1994)	0.29
" This was associated with delivery of 100% of the planned dosage of vincristine, prednisone, and daunorubicin at induction."	( Poor outcome of intensive chemotherapy for adult acute lymphoblastic leukemia: a possible dose effect. Chan, LC; Chan, TK; Chiu, EK; Kwong, YL; Liang, R; Lie, A; Todd, D, 1994)	0.51
"The long-term results of a therapeutic regimen for adult acute lymphoblastic leukemia (ALL) have been analysed with the main purpose to evaluate the impact of Daunorubicin (DNM) dosage given during the induction."	( Relationship between Daunorubicin dosage delivered during induction therapy and outcome in adult acute lymphoblastic leukemia. Ambrosetti, A; Cassibba, V; Meneghini, V; Nadali, G; Perona, G; Pizzolo, G; Tecchio, C; Todeschini, G; Veneri, D; Zanotti, R, 1994)	0.8
" In the trial, the dosage of granisetron tablet was 2 mg once a day, and the drug was given before each chemotherapy for 6 consecutive days."	( [Study on the inhibitory effect of oral granisetron against nausea/vomiting induced by cytosine arabinoside containing chemotherapy for tumors in the hematopoietic organs]. Gondo, H; Harada, M; Matsuishi, H; Omori, F; Otsuka, T; Shibuya, T; Taniguchi, S; Teshima, T; Yamano, Y; Yamazaki, K, 1993)	0.29
" Transmission electron microscopy showed that FD at a dosage of over 5 micrograms or DL over 20 micrograms was toxic to the retina and that up to 4 mg TA was nontoxic."	( Corticosteroids and daunomycin in the prevention of experimental proliferative vitreoretinopathy induced by macrophages. Cai, YS; Heimann, K; Hui, YN; Kirchhof, B; Liang, HC, 1993)	0.29
" In acute lymphoblastic leukemia (ALL), the role of agreement regarding ANT dosage and schedule, preferable compound, and indications for remission induction and consolidation treatment phases."	( Role of anthracyclines in the treatment of adult acute lymphoblastic leukemia. Barbui, T; Bassan, R; Lerede, T; Rambaldi, A, 1996)	0.29
" Direct perfusion of DaunoXome in isolated hearts of untreated animals resulted in a 12-fold reduction of the accumulation of daunorubicin in heart tissue as compared to the perfusion of free daunorubicin, and did not cause alterations in cardiac function at a dosage for which free daunorubicin induced major alterations."	( Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention. Besse, P; Bonoron-Adèle, S; Gouverneur, G; Pouna, P; Robert, J; Tariosse, L, 1996)	0.5
" The results of this study give evidence that a high dosage of daunorubicin induces lipid peroxidation in renal tissue of rats stimulating the activation of DT-diaphorase and the detoxificative depletion of GSH."	( Lipid peroxidation and antioxidant defense mechanisms in rat renal tissue after daunorubicin administration. Botsoglou, N; Dioudis, C; Grekas, D; Iliadis, S; Papageorgiou, G; Tourkantonis, A; Trakatellis, A; Zilidis, C, 1996)	0.76
" Two patients developed exacerbation of hepatitis when the dosage of prednisolone was reduced after they had ten weeks of high dose prednisolone."	( Exacerbation of hepatitis in hepatitis B carriers following chemotherapy for haematological malignancies. Chong, R; Goh, YT; Lee, LH; Ng, HS; Tan, P; Wong, GC, 1996)	0.29
" In the presence of 1 and 3 microM Taxol, the log dose-response curves for E(2)17G cholestasis were shifted to the right 2-fold and 5-fold, respectively, in a parallel manner."	( MDR1 substrates/modulators protect against beta-estradiol-17beta-D-glucuronide cholestasis in rat liver. Gosland, M; Hoffman, T; Huang, L; Liu, Y; Vore, M, 1996)	0.29
"Echocardiographic reports on 144 adults receiving anthracycline therapy and 18 controls were reviewed for the possible relationship between dosage and ejection fractions."	( [Echocardiographic evaluation of cardiotoxicity induced by anthracycline therapy]. Horikawa, K; Okada, Y; Sano, M, 1997)	0.3
" The aim of this pilot study was to investigate the activity of zorubicin in advanced soft tissue sarcoma, with a dosage supposed to be equihematotoxic to epirubicin 180 mg/m2."	( [A pilot study of high-dose zorubicin in advanced stages of soft tissue sarcoma in adults]. Jelić, S; Kovcin, V; Kreacić, M; Radosavljević, D; Tomasević, Z; Vlajić, M, 1996)	0.29
" Bell-shaped dose-response curves for apoptosis, however, which reflect a switch from the apoptotic to the necrotic death mode with increasing cellular damage tend to limit practicability in clinical testing, because appropriate dose range and time points need to be explored."	( Apoptosis and resistance to daunorubicin in human leukemic cells. Efferth, T; Fabry, U; Osieka, R, 1997)	0.59
" Best results were obtained by using a combined simultaneous analysis of dose-response curve families."	( Estimation of the chemosensitizing activity of modulators of multi-drug resistance via combined simultaneous analysis of sigmoidal dose-response curves. Chiba, P; Ecker, G; Schaper, KJ, 1997)	0.3
" The mean dosage of anthracycline that group A patients received was 219 +/- 95 mg/m2."	( Echocardiographic evaluation of cardiac function in paediatric oncology patients treated with or without anthracycline. Huang, GY; Lau, J; Li, CK; Oppenheimer, SJ; Shing, MK; Sung, RY; Yuen, MP, 1997)	0.3
" These studies provide clinical evidence that a dose-response effect is present for cytarabine in AML."	( Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group. Bishop, JF; Bradstock, K; Lowenthal, RM; Matthews, JP; Young, GA, 1998)	0.3
" These results suggest that increasing DNM dosage in induction is one of the possible approaches to improve the outcome of adult ALL by decreasing the relapse occurrence."	( Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin. April, F; Meneghini, V; Perona, G; Pizzolo, G; Ricetti, MM; Solero, P; Tecchio, C; Todeschini, G; Veneri, D; Zanotti, R, 1998)	0.49
" Sensitivity analyses suggested that the costs and cost-effectiveness results would not differ markedly when evaluated over a range of assumptions, including response rate, neutropenia rate, and dosage variations."	( Cost-effectiveness analysis comparing liposomal anthracyclines in the treatment of AIDS-related Kaposi's sarcoma. Aboulafia, DM; Bennett, CL; Bogner, J; Goebel, FD; Golub, RM; Stewart, S; Stinson, TJ; von Roenn, J, 1998)	0.3
"We evaluated in vitro the toxicity of idarubicin and its active metabolite idarubicinol on haematopoietic progenitors, using human umbilical cord blood and peripheral blood progenitors to obtain dose-response curves."	( Idarubicinol myelotoxicity: a comparison of in vitro data with clinical outcome in patients treated with high-dose idarubicin. Cocorocchio, E; Corsini, C; D'Incalci, M; Ferrucci, PF; Ghielmini, M; Mancuso, P; Martinelli, G; Mezzetti, M; Mori, A; Paolucci, M; Riggi, M; Tealdo, F; Zucchetti, M, 2000)	0.31
" Daunorubicin dose-response curves were generated by non-linear regression of electronically measured cell counts of 72- - 96-h cultures."	( Diverse effects of P-glycoprotein inhibitory agents on human leukemia cells expressing the multidrug resistance protein (MRP). den Boer, M; Lehne, G; Mørkrid, L; Rugstad, HE, 2000)	1.22
" These latter findings are important for establishing the dosing regimens of LY335979 for future clinical studies."	( Modulation by LY335979 of P-glycoprotein function in multidrug-resistant cell lines and human natural killer cells. Green, LJ; Marder, P; Slapak, CA, 2001)	0.31
" We recommend an adequate dosage of 60 mg/m(2)daunorubicin for 3 days in combination with standard dose Ara-C and 6-thioguanine given for induction and consolidation, followed by a prolonged monthly maintenance chemotherapy for a duration of at least 1 year."	( Acute myeloid leukaemia (AML): treatment of the older patient. Büchner, T; Haferlach, T; Heinecke, A; Hiddemann, W; Sauerland, MC; Schoch, C, 2001)	0.57
" A corresponding dose effect in the induction treatment of patients aged 60 years and older has been found with daunorubicin 60 vs 30 mg/m2 as part of the thioguanine/ AraC/daunorubicin (TAD) regimen with the higher dosage significantly increasing the response rate and survival in these older patients who represent a poor-risk group as a whole."	( Remission induction therapy: the more intensive the better? Andreesen, R; Aul, C; Balleisen, L; Berdel, W; Büchner, T; Eimermacher, H; Gassmann, W; Grüneisen, A; Haase, D; Haferlach, T; Hartlapp, J; Heinecke, A; Hiddemann, W; Hirschmann, WD; Löffler, H; Ludwig, WD; Maschmeyer, G; Pielken, HJ; Rasche, H; Reis, HE; Sauerland, MC; Schoch, C; Staib, P; Uhlig, J; Weh, HJ; Wörmann, B, 2001)	0.52
" Dose-response studies at the 60 min time point show that p70S6K1 activity reached its highest level with 150 microM H2O2."	( Signals of oxidant-induced cardiomyocyte hypertrophy: key activation of p70 S6 kinase-1 and phosphoinositide 3-kinase. Bahl, JJ; Chen, QM; Tu, VC, 2002)	0.31
" More experience in the administration of 2-CdA to patients with renal insufficiency will be necessary to determine the need for dosage adjustment."	( Pharmacokinetics of 2-chlorodeoxyadenosine in a child undergoing hemofiltration and hemodialysis for acute renal failure. Crews, KR; Howard, SC; Hudson, JQ; Razzouk, BI; Ribeiro, RC; Wimmer, PS, 2002)	0.31
" Half of the animals from each group were euthanized at the end of the dosing schedule and the remaining animals were euthanized after a recovery period."	( Analysis of rat bone marrow by flow cytometry following in vivo exposure to cyclohexanone oxime or daunomycin HCl. Amacher, DE; Clemo, FA; Schomaker, SJ, 2002)	0.31
" In addition, a time course study with constant dosage of drugs was performed."	( The cell cycle distribution of cultured human retinal pigmented epithelial cells under exposure of anti-proliferative drugs. Kao, YH; Tseng, HY; Wu, WC, 2003)	0.32
" In addition, before the modification, patients with Stage IV disease received a cumulative dose of 15,600 mg/m(2) of cyclophosphamide for 3 years; after 1980, these patients received the same dosage as the other patients (i."	( Lymphoblastic lymphoma of childhood and the LSA2-L2 protocol: the 30-year experience at Memorial-Sloan-Kettering Cancer Center. Filippa, DA; Mora, J; Qin, J; Wollner, N, 2003)	0.32
" coli L-ASP (Medac) which was administered at a dosage of 5000 IU/m (2) 8-times at 3-day intervals."	( Effects of dose-reduced Medac L-asparaginase on coagulation in trial ALL-BFM 2000. Attarbaschi, A; Dworzak, M; Gadner, H; Kronberger, M; Mann, G; Witt, V, )	0.13
"This analysis is the first to show that 5000 IU/m (2) of the Medac L-ASP leads to a less pronounced decrease of the plasma AT III and fibrinogen concentrations during induction therapy (after the 5 (th) L-ASP dose), as compared to previous BFM protocols which used the Medac L-ASP in a dosage of 10 000 IU/m (2)."	( Effects of dose-reduced Medac L-asparaginase on coagulation in trial ALL-BFM 2000. Attarbaschi, A; Dworzak, M; Gadner, H; Kronberger, M; Mann, G; Witt, V, )	0.13
"3HCl dosing regimen led to concentrations in excess of the IC(90) (169."	( Population pharmacokinetic model for daunorubicin and daunorubicinol coadministered with zosuquidar.3HCl (LY335979). Aarons, L; Burgess, M; Callies, S; de Alwis, DP; Mehta, A, 2004)	0.6
" The dosage of corticosteroid was decreased in all of them."	( [Preliminary study of DA or HA regimen chemotherapy for the treatment of refractory and relapsed paroxysmal nocturnal hemoglobinuria]. Bai, J; Cao, YR; Cui, ZZ; Fu, R; He, GS; Jia, HR; Liu, H; Qin, TJ; Shao, ZH; Shi, J; Sun, J; Tu, HF; Wu, YH; Yang, TY; Zhao, MF, 2004)	0.32
"Preclinical studies have established the pharmacologic advantages of liposomal anthracyclines, including pharmacokinetic profiles after bolus dosing that resemble continuous infusion of conventional anthracyclines, increased drug concentrations in tumor cells compared with the surrounding tissues, and reduced toxicity relative to conventional anthracycline treatment."	( Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. Alberts, DS; Carmichael, J; DiBella, NJ; Gabizon, AA; Jahanzeb, M; Kavanagh, JJ; Muggia, FM; Rivera, E; Skubitz, KM; Sparano, JA; Stewart, SJ; Venook, AP; Winer, EP, 2004)	0.32
" This C(i) was designed as a prognostic index by taking the area under the curve as an exact measure of the total dose-response relationship."	( Prediction of individual response to chemotherapy in patients with acute myeloid leukaemia using the chemosensitivity index Ci. Cornely, O; Neurohr, K; Reiser, M; Schinköthe, T; Staib, P; Staltmeier, E, 2005)	0.33
" In analogy to the benefit of patients under the age of 60 years from high-dose AraC there are dosage related therapeutic effects in the patients over 60 years in particular for daunorubicin in the induction treatment, and for maintenance versus no maintenance in the post-remission treatment."	( Treatment of older patients with AML. Aul, C; Balleisen, L; Berdel, WE; Büchner, T; Eimermacher, H; Grüneisen, A; Haferlach, T; Heinecke, A; Hiddemann, W; Kern, W; Kienast, J; Lengfelder, E; Mesters, RM; Rasche, H; Reichle, A; Sauerland, MC; Schnittger, S; Schoch, C; Schumacher, A; Serve, HL; Staib, P; Wörmann, B, 2005)	0.52
" The tablet dosage form of various rubomycin load (from 1 to 60% w/w) was prepared by cold compaction under pressure."	( [Biodegradable polyhydroxyalkanoates as carriers for antitumor agents]. Shishatskaia, EI; Volova, TG; Zhemchugova, AV, 2005)	0.33
" Dose-response curves for transport and the ratio of dye concentration in the secreted fluid to that in the bathing medium (S/M) were determined for Texas Red as well as for P-gp substrates (rhodamine 123, daunorubicin), the organic anion fluorescein and the organic cation quinacrine."	( Transepithelial transport of fluorescent p-glycoprotein and MRP2 substrates by insect Malpighian tubules: confocal microscopic analysis of secreted fluid droplets. Leader, JP; O'Donnell, MJ, 2005)	0.52
" Given the increased number of early treatment-related deaths, future treatment protocols should aim to reduce chemotherapy dosage or intensity whilst maintaining low rates of resistant and recurrent disease."	( Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials. de Graaf, SS; Gibson, BE; Hann, IM; Hills, RK; O'Marcaigh, A; Rao, A; Stiller, C; Webb, DK; Wheatley, K, 2006)	0.33
" These results provide evidence that esiRNA of MDR1 could be an alternative to P-gp inhibitors with the advantage of avoiding non-specific suppression with a lower effective dosage than using a single siRNA duplex, offering a potential therapeutic application of siRNA."	( Reversal of MDR1 gene-dependent multidrug resistance using low concentration of endonuclease-prepared small interference RNA. Huang, W; Li, L; Min, T; Xu, J, 2006)	0.33
" Fixing synergistic drug ratios in pharmaceutical carriers provides an avenue by which anticancer drug combinations can be optimized prospectively for maximum therapeutic activity during preclinical development and differs from current practice in which dosing regimens are developed empirically in late-stage clinical trials based on tolerability."	( Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Bally, MB; Harasym, NL; Harasym, TO; Janoff, AS; Johnstone, SA; Mayer, LD; Ramsay, EC; Shew, CR; Tardi, PG, 2006)	0.33
" Although studies presented here were all done in cell culture systems, we believe the findings could have substantial therapeutic relevance and warrant further investigations, which may provide reasons why drugs often have anomalous pharmacokinetic behavior and disproportionate dose-response relationships in certain patient populations."	( Exposure of cells to hydrogen peroxide can increase the intracellular accumulation of drugs. Funk, RS; Krise, JP, )	0.13
" The slope of the dose-response curve was slowly declined for etoposide, and declined sharply for doxorubicin and daunorubicin."	( Effects of topoisomerase II inhibitors on retinal pigment epithelium and experimental proliferative vitreoretinopathy. Chen, YH; Hu, DN; Kuo, HK; Wu, PC; Wu, YC; Yang, PM, 2007)	0.55
" This study established a robust new methodology for identification of function-altering polymorphisms in human multidrug transporter genes, identified polymorphisms affecting P-gp function, and provided a step toward genotype-determined dosing of chemotherapeutics."	( Function-altering SNPs in the human multidrug transporter gene ABCB1 identified using a Saccharomyces-based assay. Herskowitz, I; Jeong, H; Kroetz, DL; Rine, J, 2007)	0.34
" Hence, this study points out that aroylhydrazone iron chelators can induce a significant cardioprotection against anthracycline cardiotoxicity; however, they share the curious dose-response relationship which is unrelated to the chemical structure or the route of the administration of the chelator."	( Iron chelation-afforded cardioprotection against chronic anthracycline cardiotoxicity: a study of salicylaldehyde isonicotinoyl hydrazone (SIH). Adamcová, M; Gersl, V; Guncová, I; Kaiserová, H; Mazurová, Y; Palicka, V; Ponka, P; Popelová, O; Potácová, A; Simůnek, T; Sterba, M, 2007)	0.34
"An experimental dosage form of rubomycin is developed: the drug is incorporated in absorbable polymeric (polyhydroxybutyrate) matrix in the form of microparticles."	( Evaluation of antitumor activity of rubomycin deposited in absorbable polymeric microparticles. Goreva, AV; Inzhevatkin, EV; Khlebopros, RG; Shishatskaya, EI; Voinova, ON; Volova, TG, 2008)	0.35
" The enhanced efficacy obtained for intermediate dosing frequency in the consolidation setting suggests that the anti-leukemic activity of synergistic drug ratios is dependent on both duration of exposure and maintenance above a therapeutic threshold."	( Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine:daunorubicin formulation, in consolidation treatment against human leukemia xenografts. Ciofani, T; Fan, M; Harasym, TO; Huang, R; Lim, WS; Mayer, LD; Tardi, PG; Xie, X, 2010)	0.59
" On the other side, studied flavonol augmented action of cytostatic drug in case of sensitive tumour cells what suggest, that it might allow to decrease dosage of cytostatic drugs and reduce negative side effects of the treatment."	( Antiproliferative and pro-apoptotic effects of quercetin on human pancreatic carcinoma cell lines EPP85-181P and EPP85-181RDB. Borska, S; Drag-Zalesinska, M; Dumanska, M; Dziegiel, P; Sopel, M; Wysocka, T; Zabel, M, 2010)	0.36
" This decrease suggests that daunorubicin, cytosine arabinoside, etoposide and mitoxantrone may impair the metabolism of other active substances metabolized by this isoenzyme, which should be taken into consideration in planning the dosage scheme in individual patients and considering interactions between drugs."	( Influence of anticancer therapy on oxidation phenotype and acetylation phenotype in patients with acute myeloblastic leukemia. Czarnik-Matusewicz, H; Ganczarski, G; Gąsiorowski, J; Głowacka, K; Kuliczkowski, K; Orzechowska-Juzwenko, K; Wiela-Hojeńska, A; Wołowiec, D; Łapiński, Ł, 2011)	0.66
"Our study suggests that optimized DNR-MNPs formulation possesses sustained drug-release and favorable antitumor properties, which may be used as a conventional dosage form for antitumor therapy."	( Synthesis and antitumor efficacy of daunorubicin-loaded magnetic nanoparticles. Cai, X; Chen, B; Chen, J; Chen, P; Liu, R; Wang, J; Wang, X; Xia, G; Zhang, Y, 2011)	0.64
" The data indicate that selenium in the form of sodium selenite at appropriate dosage (<10."	( Effect of selenium on the interaction between daunorubicin and cardiac myosin. Li, BH; Lin, AH; Liu, Y; Sun, XM; Wang, DB, 2012)	0.64
"Intensive systemic, oral, and intrathecal methotrexate dosing permitted the omission of CNS irradiation in adult patients with ALL."	( Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802. Bloomfield, CD; DeAngelo, DJ; Johnson, JL; Kolitz, JE; Larson, RA; Marcucci, G; McDonnell, D; Mrózek, K; Powell, BL; Stock, W; Stone, RM; Vardiman, JW; Westervelt, P; Wetzler, M, 2013)	0.7
" Non-hematologic effects had onset by 24 units/m(2) with shallow dose-response until maximum frequency and severity were observed at the 101-134 units/m(2) dose levels."	( Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia. Chiarella, MT; Feldman, EJ; Kolitz, JE; Lancet, JE; Liboiron, BD; Louie, AC; Mayer, LD; Swenson, CE; Trang, JM, 2012)	0.6
"This systematic review and meta-analysis compared the efficacy of different anthracyclines and anthracycline dosing schedules for induction therapy in acute myeloid leukaemia in children and adults younger than 60 years of age."	( Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta-analysis. Alonzo, TA; Beyene, J; Lehrnbecher, T; Leibundgut, K; Sung, L; Teuffel, O, 2013)	0.39
" To further intensify anthracycline dosage without increasing cardiotoxicity, we compared potentially less cardiotoxic liposomal daunorubicin (L-DNR) to idarubicin at a higher-than-equivalent dose (80 vs 12 mg/m(2) per day for 3 days) during induction."	( Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004. Bourquin, JP; Creutzig, U; Dworzak, MN; Fleischhack, G; Graf, N; Klingebiel, T; Kremens, B; Lehrnbecher, T; Reinhardt, D; Ritter, J; Sander, A; Schrauder, A; Starý, J; von Neuhoff, C; von Stackelberg, A; Zimmermann, M, 2013)	0.87
"The clinical data of 25 AL patients, including 14 cases for induction chemotherapy, 8 for consolidation chemotherapy and 3 for reinduction therapy, which were treated with HD- DNR (DNR dosage of 90 mg/m(2)× 3 d) between June 2010 and August 2012 in our hospital were retrospectively analyzed, the adverse reaction of chemotherapy, especially cardiac toxicity and therapeutic effect were evaluated."	( [Organ toxicity and efficacy of high-dose daunorubicin-based chemotherapy in the treatment of acute leukemia]. Li, SZ; Liu, QG; Mi, YC; Wu, LH; Xu, N; Zhao, X, 2013)	0.65
" MRD may serve as a biomarker for optimal biologic dosing of ARA-C, and SDAC regimen appears to yield more frequent MRD negativity."	( Minimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemia. Amadori, S; Arcese, W; Buccisano, F; Cerretti, R; De Angelis, G; Del Principe, MI; Di Veroli, A; Ditto, C; Irno-Consalvo, M; Lo-Coco, F; Maurillo, L; Nasso, D; Panetta, P; Piciocchi, A; Refrigeri, M; Sarlo, C; Sconocchia, G; Venditti, A, 2015)	0.42
" Rescue dosage of leucovorin in variant group was higher than that in wild-type group [(312."	( [SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. Chen, Y; Gao, P; He, X; Li, J; Niu, C; Wang, C; Wang, Y; Zhang, H, 2014)	0.4
" Daunorubicin-loaded porous silicon (pSi) particles were dosed 8 to 9 weeks before PVR induction, and PVR severity score was dose dependent (Spearman ρ = -0."	( A Novel Approach of Daunorubicin Application on Formation of Proliferative Retinopathy Using a Porous Silicon Controlled Delivery System: Pharmacodynamics. Cheng, L; Freeman, WR; Hou, H; Huffman, K; Rios, S; Sailor, MJ, 2015)	1.65
" TwHF extract was administered at a dosage of 10 mg three times daily for 12 months."	( Tripterygium wilfordii Hook F extract in cART-treated HIV patients with poor immune response: a pilot study to assess its immunomodulatory effects and safety. Han, Y; Jiang, H; Li, T; Li, Y; Lv, W; Qiu, Z; Routy, JP; Song, X; Sun, M; Wang, F; Xie, J; Zhang, X, )	0.13
"Intensive chemotherapy with cytarabine and an anthracycline for untreated acute myeloid leukemia (AML) has remained largely unchanged over the past 40 years, despite many large trials examining the choice and dosing of these agents."	( Chemotherapy options for previously untreated acute myeloid leukemia. Lynch, RC; Medeiros, BC, 2015)	0.42
"We will review the major published clinical trials for untreated AML that have established the dosing choice and schedule for intensive therapy, as well as trials for patients not eligible for more intensive therapy."	( Chemotherapy options for previously untreated acute myeloid leukemia. Lynch, RC; Medeiros, BC, 2015)	0.42
"While one or two cycles of anthracycline and cytarabine-based combination regimens remain the standard of care for younger and older patients with AML deemed fit to receive induction chemotherapy, controversy remains regarding the optimal selection and dosing schedule for anthracyclines."	( Chemotherapy options for previously untreated acute myeloid leukemia. Lynch, RC; Medeiros, BC, 2015)	0.42
" ML-DS blast cells ex vivo have increased sensitivity to cytarabine (araC) and daunorubicin, suggesting that optimizing drug dosing may improve outcomes while reducing toxicity."	( Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial. Alonzo, TA; Berman, JN; Campana, D; Coustan-Smith, E; Gamis, AS; Ge, Y; Gerbing, RB; Head, D; Hirsch, B; Hitzler, JK; Lacayo, NJ; Mast, K; Mathew, P; Raimondi, S; Sorrell, AD; Taub, JW; Wang, YC, 2017)	0.68
" A lack of clarity regarding the proper dosing of post-remission cytarabine has made consensus building on dosing and schedule a challenge."	( Post-remission therapy in acute myeloid leukemia: Are we ready for an individualized approach? Derman, BA; Larson, RA, 2019)	0.51
" CPX-351 is a liposomal encapsulated formulation of cytarabine and daunorubicin in a 5:1 molar ratio that has been demonstrated to deliver synergistic ratiometric dosing of these drugs in pre-clinical studies."	( Liposomal encapsulated cytarabine and daunorubicin (CPX-351) for older patients with acute myeloid leukemia. Asghari, H; Lancet, J, 2020)	1.07
" In oncology, chemotherapeutic regimens using anthracycline antibiotics rely on the dosage of treatments to minimize the severity of side effects on the patient."	( Drug Loading of Anthracycline Antibiotics on Carbon Dots Using Circular Dichroism Spectrometry. Ferreira, BCLB; Leblanc, RM; Liyanage, PY, 2021)	0.62
" The dosage of adrenal glucocorticoids was reduced by more than half compared with that before chemotherapy."	( Clinical observation of low-dose combination chemotherapy in refractory/recurrent paroxysmal nocturnal hemoglobinuria patients: A single-center retrospective analysis. Chen, Y; Fu, R; Li, L; Liu, C; Liu, H; Liu, Z; Shao, Z; Wang, H; Zhao, X, 2022)	0.72
" However, it requires complicated dosing regimens and is accompanied by increased toxicity."	( Co-Delivery of Daunorubicin and Homoharringtonine in Folic Acid Modified-Liposomes for Enhancing Therapeutic Effect on Acute Myeloid Leukemia. Feng, X; Gao, X; Li, H; Liu, Q; Luo, L; Mao, S; Yang, P; Zhang, D, 2023)	1.26
" However, the current study demonstrates that obesity is not a factor in survival, and strict adherence to body surface area-based dosing is not necessary because dose adjustments do not affect outcomes."	( Obesity in adult acute myeloid leukemia is not associated with inferior response or survival even when dose capping anthracyclines: An ECOG-ACRIN analysis. Bennett, JM; Cripe, LD; Fernandez, HF; Foran, JM; Ketterling, RP; Lai, C; Lazarus, HM; Levine, RL; Litzow, MR; Luger, SM; Paietta, E; Racevskis, J; Rowe, JM; Sun, Z; Tallman, MS; Zhang, Y, 2023)	0.91
" Compared with RATIFY, this study extended midostaurin treatment from 14 days to 21 days, substituted anthracyclines (idarubicin or daunorubicin), and introduced variation in standard combination chemotherapy dosing ("7+3" or "5+2" in more fragile patients)."	( Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trial. Bengoudifa, BR; Caillot, D; Cluzeau, T; Farkas, F; Gilotti, G; Griskevicius, L; Hodzic, S; Legrand, O; Luppi, M; Minotti, C; Montesinos, P; Rambaldi, A; Sierra, J; Thomas, X; Venditti, A, 2023)	1.45

Role	Description
antineoplastic agent	A substance that inhibits or prevents the proliferation of neoplasms.
bacterial metabolite	Any prokaryotic metabolite produced during a metabolic reaction in bacteria.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
aminoglycoside antibiotic
anthracycline	Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.
tetracenequinones
p-quinones	A quinone in which the two oxo groups of the quinone are located para to each other on the 6-membered quinonoid ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE	Homo sapiens (human)	Potency	10.0615	0.0032	45.4673	12,589.2998	AID2517; AID2572; AID2573
Chain A, TYROSYL-DNA PHOSPHODIESTERASE	Homo sapiens (human)	Potency	19.1180	0.0040	23.8416	100.0000	AID485290
Chain A, Breast cancer type 1 susceptibility protein	Homo sapiens (human)	Potency	12.5893	1.2589	20.4409	39.8107	AID892
Chain A, Putative fructose-1,6-bisphosphate aldolase	Giardia intestinalis	Potency	18.2130	0.1409	11.1940	39.8107	AID2451
Chain A, HADH2 protein	Homo sapiens (human)	Potency	31.6228	0.0251	20.2376	39.8107	AID893
Chain B, HADH2 protein	Homo sapiens (human)	Potency	31.6228	0.0251	20.2376	39.8107	AID893
Chain A, 2-oxoglutarate Oxygenase	Homo sapiens (human)	Potency	35.4813	0.1778	14.3909	39.8107	AID2147
Chain A, ATP-DEPENDENT DNA HELICASE Q1	Homo sapiens (human)	Potency	29.9033	0.1259	19.1169	125.8920	AID2549
Chain A, Ferritin light chain	Equus caballus (horse)	Potency	17.7828	5.6234	17.2929	31.6228	AID485281
Luciferase	Photinus pyralis (common eastern firefly)	Potency	8.0875	0.0072	15.7588	89.3584	AID624030
acetylcholinesterase	Homo sapiens (human)	Potency	33.2211	0.0025	41.7960	15,848.9004	AID1347395; AID1347398
phosphopantetheinyl transferase	Bacillus subtilis	Potency	3.1623	0.1413	37.9142	100.0000	AID1490
hypoxia-inducible factor 1 alpha subunit	Homo sapiens (human)	Potency	4.0748	3.1890	29.8841	59.4836	AID1224846; AID1224894
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	10.5909	0.0060	38.0041	19,952.5996	AID1159521
USP1 protein, partial	Homo sapiens (human)	Potency	42.2395	0.0316	37.5844	354.8130	AID504865
PPM1D protein	Homo sapiens (human)	Potency	0.5868	0.0052	9.4661	32.9993	AID1347411
TDP1 protein	Homo sapiens (human)	Potency	0.0272	0.0008	11.3822	44.6684	AID686978; AID686979
GLI family zinc finger 3	Homo sapiens (human)	Potency	0.0290	0.0007	14.5928	83.7951	AID1259369; AID1259392
Microtubule-associated protein tau	Homo sapiens (human)	Potency	14.9291	0.1800	13.5574	39.8107	AID1460; AID1468
AR protein	Homo sapiens (human)	Potency	3.0407	0.0002	21.2231	8,912.5098	AID1259243; AID1259247; AID743035; AID743036; AID743042; AID743053; AID743054; AID743063
caspase 7, apoptosis-related cysteine protease	Homo sapiens (human)	Potency	1.3333	0.0133	26.9810	70.7614	AID1346978
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	39.8107	0.0112	12.4002	100.0000	AID1030
estrogen receptor 2 (ER beta)	Homo sapiens (human)	Potency	2.0005	0.0006	57.9133	22,387.1992	AID1259377; AID1259378; AID1259394
nuclear receptor subfamily 1, group I, member 3	Homo sapiens (human)	Potency	0.0614	0.0010	22.6508	76.6163	AID1224838; AID1224893
progesterone receptor	Homo sapiens (human)	Potency	12.2346	0.0004	17.9460	75.1148	AID1346784; AID1346795; AID1347036
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	13.8029	0.0123	7.9835	43.2770	AID1645841
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	1.8555	0.0002	14.3764	60.0339	AID720691; AID720719
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	0.6823	0.0030	41.6115	22,387.1992	AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alpha	Homo sapiens (human)	Potency	1.6930	0.0008	17.5051	59.3239	AID1159527; AID1159531
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	0.0883	0.0015	30.6073	15,848.9004	AID1224841; AID1224842; AID1259401
farnesoid X nuclear receptor	Homo sapiens (human)	Potency	2.3560	0.3758	27.4851	61.6524	AID743217; AID743220; AID743239
pregnane X nuclear receptor	Homo sapiens (human)	Potency	10.5909	0.0054	28.0263	1,258.9301	AID1346982
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	2.5620	0.0002	29.3054	16,493.5996	AID1259244; AID1259248; AID743069; AID743075; AID743077; AID743078; AID743079; AID743080; AID743091
cytochrome P450 2D6	Homo sapiens (human)	Potency	13.8029	0.0010	8.3798	61.1304	AID1645840
peroxisome proliferator-activated receptor delta	Homo sapiens (human)	Potency	0.4415	0.0010	24.5048	61.6448	AID743212; AID743215
peroxisome proliferator activated receptor gamma	Homo sapiens (human)	Potency	3.7211	0.0010	19.4141	70.9645	AID743094; AID743140; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptor	Homo sapiens (human)	Potency	1.8996	0.0237	23.2282	63.5986	AID743223
caspase-3	Homo sapiens (human)	Potency	1.3333	0.0133	26.9810	70.7614	AID1346978
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	15.8489	0.0355	20.9770	89.1251	AID504332
aryl hydrocarbon receptor	Homo sapiens (human)	Potency	8.8102	0.0007	23.0674	1,258.9301	AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a	Homo sapiens (human)	Potency	3.7578	0.0017	23.8393	78.1014	AID743083
thyroid stimulating hormone receptor	Homo sapiens (human)	Potency	29.8493	0.0016	28.0151	77.1139	AID1259385
activating transcription factor 6	Homo sapiens (human)	Potency	1.8996	0.1434	27.6121	59.8106	AID1159516
v-jun sarcoma virus 17 oncogene homolog (avian)	Homo sapiens (human)	Potency	0.0107	0.0578	21.1097	61.2679	AID1159526; AID1159528
Histone H2A.x	Cricetulus griseus (Chinese hamster)	Potency	0.1527	0.0391	47.5451	146.8240	AID1224845; AID1224896
Caspase-7	Cricetulus griseus (Chinese hamster)	Potency	6.6824	0.0067	23.4960	68.5896	AID1346980
Bloom syndrome protein isoform 1	Homo sapiens (human)	Potency	19.5135	0.5406	17.6392	96.1227	AID2528; AID2585
cellular tumor antigen p53 isoform a	Homo sapiens (human)	Potency	23.7359	0.3162	12.4435	31.6228	AID902; AID924
runt-related transcription factor 1 isoform AML1b	Homo sapiens (human)	Potency	8.0500	0.0200	7.9858	39.8107	AID504370; AID504375
vitamin D3 receptor isoform VDRA	Homo sapiens (human)	Potency	15.8489	0.3548	28.0659	89.1251	AID504847
thyroid hormone receptor beta isoform a	Homo sapiens (human)	Potency	27.4746	0.0100	39.5371	1,122.0200	AID1469; AID1479
caspase-3	Cricetulus griseus (Chinese hamster)	Potency	6.6824	0.0067	23.4960	68.5896	AID1346980
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	0.6072	0.0003	23.4451	159.6830	AID743065; AID743067
core-binding factor subunit beta isoform 2	Homo sapiens (human)	Potency	8.0500	0.0200	7.9858	39.8107	AID504370; AID504375
huntingtin isoform 2	Homo sapiens (human)	Potency	2.2387	0.0006	18.4198	1,122.0200	AID1688
mitogen-activated protein kinase 1	Homo sapiens (human)	Potency	31.6228	0.0398	16.7842	39.8107	AID995
histone-lysine N-methyltransferase 2A isoform 2 precursor	Homo sapiens (human)	Potency	28.1838	0.0103	23.8567	63.0957	AID2662
nuclear factor erythroid 2-related factor 2 isoform 1	Homo sapiens (human)	Potency	26.6011	0.0006	27.2152	1,122.0200	AID743202
nuclear receptor ROR-gamma isoform 1	Mus musculus (house mouse)	Potency	4.2836	0.0079	8.2332	1,122.0200	AID2546; AID2551
geminin	Homo sapiens (human)	Potency	5.3091	0.0046	11.3741	33.4983	AID624297
DNA polymerase kappa isoform 1	Homo sapiens (human)	Potency	8.4646	0.0316	22.3146	100.0000	AID588579
peripheral myelin protein 22	Rattus norvegicus (Norway rat)	Potency	0.1258	0.0056	12.3677	36.1254	AID624044
cytochrome P450 3A4 isoform 1	Homo sapiens (human)	Potency	31.6228	0.0316	10.2792	39.8107	AID884; AID885
histone acetyltransferase KAT2A isoform 1	Homo sapiens (human)	Potency	0.3162	0.2512	15.8432	39.8107	AID504327
lethal factor (plasmid)	Bacillus anthracis str. A2012	Potency	31.6228	0.0200	10.7869	31.6228	AID912
Gamma-aminobutyric acid receptor subunit pi	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)	Potency	15.1861	0.3162	12.7657	31.6228	AID881
Voltage-dependent calcium channel gamma-2 subunit	Mus musculus (house mouse)	Potency	0.0237	0.0015	57.7890	15,848.9004	AID1259244
Interferon beta	Homo sapiens (human)	Potency	1.2725	0.0033	9.1582	39.8107	AID1347407; AID1347411
Cellular tumor antigen p53	Homo sapiens (human)	Potency	0.8894	0.0023	19.5956	74.0614	AID651631; AID720552
Integrin beta-3	Homo sapiens (human)	Potency	15.8489	0.3162	11.4157	31.6228	AID924
Integrin alpha-IIb	Homo sapiens (human)	Potency	15.8489	0.3162	11.4157	31.6228	AID924
Gamma-aminobutyric acid receptor subunit beta-1	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit delta	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Glutamate receptor 1	Rattus norvegicus (Norway rat)	Potency	10.0000	0.0141	8.6024	39.8107	AID2572
Glutamate receptor 2	Rattus norvegicus (Norway rat)	Potency	5.0119	0.0015	51.7393	15,848.9004	AID1259244; AID2572
Glutamate receptor 3	Rattus norvegicus (Norway rat)	Potency	10.0000	0.0141	8.6024	39.8107	AID2572
Glutamate receptor 4	Rattus norvegicus (Norway rat)	Potency	10.0000	0.0141	8.6024	39.8107	AID2572
Gamma-aminobutyric acid receptor subunit alpha-5	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-3	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-1	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-2	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Platelet-activating factor receptor	Homo sapiens (human)	Potency	12.5893	10.0000	25.7810	39.8107	AID892
Gamma-aminobutyric acid receptor subunit alpha-4	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-3	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-6	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Histamine H2 receptor	Cavia porcellus (domestic guinea pig)	Potency	15.1861	0.0063	8.2350	39.8107	AID881
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	2.1955	0.0096	10.5250	35.4813	AID1479145; AID1479148
Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-3	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Inositol monophosphatase 1	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	10.4756	28.1838	AID1457
GABA theta subunit	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
ATPase family AAA domain-containing protein 5	Homo sapiens (human)	Potency	0.4433	0.0119	17.9420	71.5630	AID651632; AID720516
Ataxin-2	Homo sapiens (human)	Potency	0.3758	0.0119	12.2221	68.7989	AID651632
Gamma-aminobutyric acid receptor subunit epsilon	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
ATP-dependent phosphofructokinase	Trypanosoma brucei brucei TREU927	Potency	7.9433	0.0601	10.7453	37.9330	AID492961
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Transthyretin	Homo sapiens (human)	IC50 (µMol)	100.0000	0.1600	4.2921	10.0000	AID1755162
ATP-dependent translocase ABCB1	Homo sapiens (human)	Ki	56.7500	0.0200	2.3594	8.5900	AID681356; AID681383
72 kDa type IV collagenase	Homo sapiens (human)	IC50 (µMol)	1.9000	0.0000	1.2848	10.0000	AID52346
Multidrug resistance-associated protein 1	Homo sapiens (human)	IC50 (µMol)	8.0000	0.0015	3.7110	9.6600	AID679011
Multidrug resistance-associated protein 1	Homo sapiens (human)	Ki	0.5100	0.0700	2.2020	8.1000	AID679010; AID681111
Histone deacetylase 1	Homo sapiens (human)	IC50 (µMol)	0.0470	0.0001	0.5543	9.9000	AID1858585
Reverse transcriptase/RNaseH	Human immunodeficiency virus 1	IC50 (µMol)	139.0000	0.0001	1.0768	10.0000	AID695925
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	Ki	49.4000	4.7000	6.4050	8.1100	AID681596
Histone deacetylase 8	Homo sapiens (human)	IC50 (µMol)	0.2200	0.0007	0.9947	9.9000	AID1858598
Histone deacetylase 6	Homo sapiens (human)	IC50 (µMol)	0.0200	0.0000	0.5376	9.9000	AID1858587
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
NADH-ubiquinone oxidoreductase chain 4	Homo sapiens (human)	IC10 (µMol)	2.0000	2.0000	2.0000	2.0000	AID144381
ATP-dependent translocase ABCB1	Homo sapiens (human)	Km	1.7400	0.0140	3.7172	10.0000	AID681164
Multidrug resistance-associated protein 1	Homo sapiens (human)	Km	1.4000	0.7300	2.6550	5.0000	AID681510
Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)	Kact	2.5000	1.0000	3.7500	7.0000	AID678804
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
lipid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
phospholipid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
apoptotic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of cell population proliferation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of macrophage derived foam cell differentiation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
arachidonic acid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of cell migration	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
prostate gland development	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
regulation of epithelial cell differentiation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of chemokine production	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathway	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of keratinocyte differentiation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of cell cycle	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of growth	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
hepoxilin biosynthetic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
endocannabinoid signaling pathway	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cannabinoid biosynthetic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipoxin A4 biosynthetic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
linoleic acid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipid oxidation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipoxygenase pathway	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
signal transduction	Transthyretin	Homo sapiens (human)
purine nucleobase metabolic process	Transthyretin	Homo sapiens (human)
response to hypoxia	NADH-ubiquinone oxidoreductase chain 4	Homo sapiens (human)
in utero embryonic development	NADH-ubiquinone oxidoreductase chain 4	Homo sapiens (human)
mitochondrial electron transport, NADH to ubiquinone	NADH-ubiquinone oxidoreductase chain 4	Homo sapiens (human)
aerobic respiration	NADH-ubiquinone oxidoreductase chain 4	Homo sapiens (human)
cerebellum development	NADH-ubiquinone oxidoreductase chain 4	Homo sapiens (human)
mitochondrial respiratory chain complex I assembly	NADH-ubiquinone oxidoreductase chain 4	Homo sapiens (human)
response to nicotine	NADH-ubiquinone oxidoreductase chain 4	Homo sapiens (human)
proton motive force-driven mitochondrial ATP synthesis	NADH-ubiquinone oxidoreductase chain 4	Homo sapiens (human)
response to ethanol	NADH-ubiquinone oxidoreductase chain 4	Homo sapiens (human)
electron transport coupled proton transport	NADH-ubiquinone oxidoreductase chain 4	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle G2/M phase transition	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
ER overload response	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
in utero embryonic development	Cellular tumor antigen p53	Homo sapiens (human)
somitogenesis	Cellular tumor antigen p53	Homo sapiens (human)
release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic progenitor cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
T cell proliferation involved in immune response	Cellular tumor antigen p53	Homo sapiens (human)
B cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
T cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
response to ischemia	Cellular tumor antigen p53	Homo sapiens (human)
nucleotide-excision repair	Cellular tumor antigen p53	Homo sapiens (human)
double-strand break repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
protein import into nucleus	Cellular tumor antigen p53	Homo sapiens (human)
autophagy	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
Ras protein signal transduction	Cellular tumor antigen p53	Homo sapiens (human)
gastrulation	Cellular tumor antigen p53	Homo sapiens (human)
neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
protein localization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA replication	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
determination of adult lifespan	Cellular tumor antigen p53	Homo sapiens (human)
mRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
rRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
response to salt stress	Cellular tumor antigen p53	Homo sapiens (human)
response to inorganic substance	Cellular tumor antigen p53	Homo sapiens (human)
response to X-ray	Cellular tumor antigen p53	Homo sapiens (human)
response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of gene expression	Cellular tumor antigen p53	Homo sapiens (human)
cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
viral process	Cellular tumor antigen p53	Homo sapiens (human)
glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
cerebellum development	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell growth	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of telomere maintenance via telomerase	Cellular tumor antigen p53	Homo sapiens (human)
T cell differentiation in thymus	Cellular tumor antigen p53	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of tissue remodeling	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV	Cellular tumor antigen p53	Homo sapiens (human)
multicellular organism growth	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of mitochondrial membrane permeability	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
entrainment of circadian clock by photoperiod	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial DNA repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
transcription initiation-coupled chromatin remodeling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of proteolysis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
response to antibiotic	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
circadian behavior	Cellular tumor antigen p53	Homo sapiens (human)
bone marrow development	Cellular tumor antigen p53	Homo sapiens (human)
embryonic organ development	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Cellular tumor antigen p53	Homo sapiens (human)
protein stabilization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of helicase activity	Cellular tumor antigen p53	Homo sapiens (human)
protein tetramerization	Cellular tumor antigen p53	Homo sapiens (human)
chromosome organization	Cellular tumor antigen p53	Homo sapiens (human)
neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic stem cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
type II interferon-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
cardiac septum morphogenesis	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of programmed necrotic cell death	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Cellular tumor antigen p53	Homo sapiens (human)
thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
necroptotic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to xenobiotic stimulus	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to ionizing radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV-C	Cellular tumor antigen p53	Homo sapiens (human)
stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to actinomycin D	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
replicative senescence	Cellular tumor antigen p53	Homo sapiens (human)
oxidative stress-induced premature senescence	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
oligodendrocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of execution phase of apoptosis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of G1 to G0 transition	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of miRNA processing	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of pentose-phosphate shunt	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
regulation of fibroblast apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of low-density lipoprotein receptor activity	Integrin beta-3	Homo sapiens (human)
positive regulation of protein phosphorylation	Integrin beta-3	Homo sapiens (human)
positive regulation of endothelial cell proliferation	Integrin beta-3	Homo sapiens (human)
positive regulation of cell-matrix adhesion	Integrin beta-3	Homo sapiens (human)
cell-substrate junction assembly	Integrin beta-3	Homo sapiens (human)
cell adhesion	Integrin beta-3	Homo sapiens (human)
cell-matrix adhesion	Integrin beta-3	Homo sapiens (human)
integrin-mediated signaling pathway	Integrin beta-3	Homo sapiens (human)
embryo implantation	Integrin beta-3	Homo sapiens (human)
blood coagulation	Integrin beta-3	Homo sapiens (human)
positive regulation of endothelial cell migration	Integrin beta-3	Homo sapiens (human)
positive regulation of gene expression	Integrin beta-3	Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiation	Integrin beta-3	Homo sapiens (human)
positive regulation of fibroblast migration	Integrin beta-3	Homo sapiens (human)
negative regulation of lipid storage	Integrin beta-3	Homo sapiens (human)
response to activity	Integrin beta-3	Homo sapiens (human)
smooth muscle cell migration	Integrin beta-3	Homo sapiens (human)
positive regulation of smooth muscle cell migration	Integrin beta-3	Homo sapiens (human)
platelet activation	Integrin beta-3	Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathway	Integrin beta-3	Homo sapiens (human)
cell-substrate adhesion	Integrin beta-3	Homo sapiens (human)
activation of protein kinase activity	Integrin beta-3	Homo sapiens (human)
negative regulation of lipid transport	Integrin beta-3	Homo sapiens (human)
regulation of protein localization	Integrin beta-3	Homo sapiens (human)
regulation of actin cytoskeleton organization	Integrin beta-3	Homo sapiens (human)
cell adhesion mediated by integrin	Integrin beta-3	Homo sapiens (human)
positive regulation of cell adhesion mediated by integrin	Integrin beta-3	Homo sapiens (human)
positive regulation of osteoblast proliferation	Integrin beta-3	Homo sapiens (human)
heterotypic cell-cell adhesion	Integrin beta-3	Homo sapiens (human)
substrate adhesion-dependent cell spreading	Integrin beta-3	Homo sapiens (human)
tube development	Integrin beta-3	Homo sapiens (human)
wound healing, spreading of epidermal cells	Integrin beta-3	Homo sapiens (human)
cellular response to platelet-derived growth factor stimulus	Integrin beta-3	Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathway	Integrin beta-3	Homo sapiens (human)
wound healing	Integrin beta-3	Homo sapiens (human)
apoptotic cell clearance	Integrin beta-3	Homo sapiens (human)
regulation of bone resorption	Integrin beta-3	Homo sapiens (human)
positive regulation of angiogenesis	Integrin beta-3	Homo sapiens (human)
positive regulation of bone resorption	Integrin beta-3	Homo sapiens (human)
symbiont entry into host cell	Integrin beta-3	Homo sapiens (human)
platelet-derived growth factor receptor signaling pathway	Integrin beta-3	Homo sapiens (human)
positive regulation of fibroblast proliferation	Integrin beta-3	Homo sapiens (human)
mesodermal cell differentiation	Integrin beta-3	Homo sapiens (human)
positive regulation of smooth muscle cell proliferation	Integrin beta-3	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Integrin beta-3	Homo sapiens (human)
negative regulation of lipoprotein metabolic process	Integrin beta-3	Homo sapiens (human)
negative chemotaxis	Integrin beta-3	Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosol	Integrin beta-3	Homo sapiens (human)
regulation of serotonin uptake	Integrin beta-3	Homo sapiens (human)
angiogenesis involved in wound healing	Integrin beta-3	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Integrin beta-3	Homo sapiens (human)
platelet aggregation	Integrin beta-3	Homo sapiens (human)
cellular response to mechanical stimulus	Integrin beta-3	Homo sapiens (human)
cellular response to xenobiotic stimulus	Integrin beta-3	Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferation	Integrin beta-3	Homo sapiens (human)
blood coagulation, fibrin clot formation	Integrin beta-3	Homo sapiens (human)
maintenance of postsynaptic specialization structure	Integrin beta-3	Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalization	Integrin beta-3	Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trapping	Integrin beta-3	Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreading	Integrin beta-3	Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathway	Integrin beta-3	Homo sapiens (human)
regulation of trophoblast cell migration	Integrin beta-3	Homo sapiens (human)
regulation of extracellular matrix organization	Integrin beta-3	Homo sapiens (human)
cellular response to insulin-like growth factor stimulus	Integrin beta-3	Homo sapiens (human)
negative regulation of endothelial cell apoptotic process	Integrin beta-3	Homo sapiens (human)
positive regulation of T cell migration	Integrin beta-3	Homo sapiens (human)
cell migration	Integrin beta-3	Homo sapiens (human)
G2/M transition of mitotic cell cycle	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic metabolic process	ATP-dependent translocase ABCB1	Homo sapiens (human)
response to xenobiotic stimulus	ATP-dependent translocase ABCB1	Homo sapiens (human)
phospholipid translocation	ATP-dependent translocase ABCB1	Homo sapiens (human)
terpenoid transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
regulation of response to osmotic stress	ATP-dependent translocase ABCB1	Homo sapiens (human)
transmembrane transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
transepithelial transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
stem cell proliferation	ATP-dependent translocase ABCB1	Homo sapiens (human)
ceramide translocation	ATP-dependent translocase ABCB1	Homo sapiens (human)
export across plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
transport across blood-brain barrier	ATP-dependent translocase ABCB1	Homo sapiens (human)
positive regulation of anion channel activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
carboxylic acid transmembrane transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	ATP-dependent translocase ABCB1	Homo sapiens (human)
regulation of chloride transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
angiogenesis	72 kDa type IV collagenase	Homo sapiens (human)
ovarian follicle development	72 kDa type IV collagenase	Homo sapiens (human)
ovulation from ovarian follicle	72 kDa type IV collagenase	Homo sapiens (human)
luteinization	72 kDa type IV collagenase	Homo sapiens (human)
blood vessel maturation	72 kDa type IV collagenase	Homo sapiens (human)
intramembranous ossification	72 kDa type IV collagenase	Homo sapiens (human)
proteolysis	72 kDa type IV collagenase	Homo sapiens (human)
negative regulation of cell adhesion	72 kDa type IV collagenase	Homo sapiens (human)
heart development	72 kDa type IV collagenase	Homo sapiens (human)
embryo implantation	72 kDa type IV collagenase	Homo sapiens (human)
parturition	72 kDa type IV collagenase	Homo sapiens (human)
response to xenobiotic stimulus	72 kDa type IV collagenase	Homo sapiens (human)
response to mechanical stimulus	72 kDa type IV collagenase	Homo sapiens (human)
peripheral nervous system axon regeneration	72 kDa type IV collagenase	Homo sapiens (human)
response to activity	72 kDa type IV collagenase	Homo sapiens (human)
protein metabolic process	72 kDa type IV collagenase	Homo sapiens (human)
extracellular matrix disassembly	72 kDa type IV collagenase	Homo sapiens (human)
protein catabolic process	72 kDa type IV collagenase	Homo sapiens (human)
positive regulation of cell migration	72 kDa type IV collagenase	Homo sapiens (human)
collagen catabolic process	72 kDa type IV collagenase	Homo sapiens (human)
response to retinoic acid	72 kDa type IV collagenase	Homo sapiens (human)
cellular response to reactive oxygen species	72 kDa type IV collagenase	Homo sapiens (human)
response to nicotine	72 kDa type IV collagenase	Homo sapiens (human)
endodermal cell differentiation	72 kDa type IV collagenase	Homo sapiens (human)
response to hydrogen peroxide	72 kDa type IV collagenase	Homo sapiens (human)
response to estrogen	72 kDa type IV collagenase	Homo sapiens (human)
negative regulation of vasoconstriction	72 kDa type IV collagenase	Homo sapiens (human)
ephrin receptor signaling pathway	72 kDa type IV collagenase	Homo sapiens (human)
macrophage chemotaxis	72 kDa type IV collagenase	Homo sapiens (human)
response to electrical stimulus	72 kDa type IV collagenase	Homo sapiens (human)
response to hyperoxia	72 kDa type IV collagenase	Homo sapiens (human)
face morphogenesis	72 kDa type IV collagenase	Homo sapiens (human)
bone trabecula formation	72 kDa type IV collagenase	Homo sapiens (human)
prostate gland epithelium morphogenesis	72 kDa type IV collagenase	Homo sapiens (human)
cellular response to amino acid stimulus	72 kDa type IV collagenase	Homo sapiens (human)
cellular response to interleukin-1	72 kDa type IV collagenase	Homo sapiens (human)
cellular response to estradiol stimulus	72 kDa type IV collagenase	Homo sapiens (human)
cellular response to UV-A	72 kDa type IV collagenase	Homo sapiens (human)
cellular response to fluid shear stress	72 kDa type IV collagenase	Homo sapiens (human)
positive regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway	72 kDa type IV collagenase	Homo sapiens (human)
response to amyloid-beta	72 kDa type IV collagenase	Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation	72 kDa type IV collagenase	Homo sapiens (human)
extracellular matrix organization	72 kDa type IV collagenase	Homo sapiens (human)
response to hypoxia	72 kDa type IV collagenase	Homo sapiens (human)
tissue remodeling	72 kDa type IV collagenase	Homo sapiens (human)
positive regulation of leukocyte migration	Integrin alpha-IIb	Homo sapiens (human)
cell-matrix adhesion	Integrin alpha-IIb	Homo sapiens (human)
integrin-mediated signaling pathway	Integrin alpha-IIb	Homo sapiens (human)
angiogenesis	Integrin alpha-IIb	Homo sapiens (human)
cell-cell adhesion	Integrin alpha-IIb	Homo sapiens (human)
cell adhesion mediated by integrin	Integrin alpha-IIb	Homo sapiens (human)
hematopoietic progenitor cell differentiation	DNA topoisomerase 2-alpha	Homo sapiens (human)
DNA topological change	DNA topoisomerase 2-alpha	Homo sapiens (human)
DNA ligation	DNA topoisomerase 2-alpha	Homo sapiens (human)
DNA damage response	DNA topoisomerase 2-alpha	Homo sapiens (human)
chromosome segregation	DNA topoisomerase 2-alpha	Homo sapiens (human)
female meiotic nuclear division	DNA topoisomerase 2-alpha	Homo sapiens (human)
apoptotic chromosome condensation	DNA topoisomerase 2-alpha	Homo sapiens (human)
embryonic cleavage	DNA topoisomerase 2-alpha	Homo sapiens (human)
regulation of circadian rhythm	DNA topoisomerase 2-alpha	Homo sapiens (human)
positive regulation of apoptotic process	DNA topoisomerase 2-alpha	Homo sapiens (human)
positive regulation of single stranded viral RNA replication via double stranded DNA intermediate	DNA topoisomerase 2-alpha	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	DNA topoisomerase 2-alpha	Homo sapiens (human)
rhythmic process	DNA topoisomerase 2-alpha	Homo sapiens (human)
negative regulation of DNA duplex unwinding	DNA topoisomerase 2-alpha	Homo sapiens (human)
resolution of meiotic recombination intermediates	DNA topoisomerase 2-alpha	Homo sapiens (human)
sister chromatid segregation	DNA topoisomerase 2-alpha	Homo sapiens (human)
xenobiotic metabolic process	Carbonyl reductase [NADPH] 1	Homo sapiens (human)
glucocorticoid metabolic process	Carbonyl reductase [NADPH] 1	Homo sapiens (human)
cyclooxygenase pathway	Carbonyl reductase [NADPH] 1	Homo sapiens (human)
epithelial cell differentiation	Carbonyl reductase [NADPH] 1	Homo sapiens (human)
vitamin K metabolic process	Carbonyl reductase [NADPH] 1	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Carbonyl reductase [NADPH] 1	Homo sapiens (human)
positive regulation of cellular extravasation	Platelet-activating factor receptor	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Platelet-activating factor receptor	Homo sapiens (human)
chemotaxis	Platelet-activating factor receptor	Homo sapiens (human)
inflammatory response	Platelet-activating factor receptor	Homo sapiens (human)
immune response	Platelet-activating factor receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Platelet-activating factor receptor	Homo sapiens (human)
parturition	Platelet-activating factor receptor	Homo sapiens (human)
response to symbiotic bacterium	Platelet-activating factor receptor	Homo sapiens (human)
lipopolysaccharide-mediated signaling pathway	Platelet-activating factor receptor	Homo sapiens (human)
positive regulation of interleukin-6 production	Platelet-activating factor receptor	Homo sapiens (human)
positive regulation of tumor necrosis factor production	Platelet-activating factor receptor	Homo sapiens (human)
inositol trisphosphate biosynthetic process	Platelet-activating factor receptor	Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor signaling pathway	Platelet-activating factor receptor	Homo sapiens (human)
positive regulation of neutrophil degranulation	Platelet-activating factor receptor	Homo sapiens (human)
transcytosis	Platelet-activating factor receptor	Homo sapiens (human)
positive regulation of translation	Platelet-activating factor receptor	Homo sapiens (human)
negative regulation of blood pressure	Platelet-activating factor receptor	Homo sapiens (human)
positive regulation of smooth muscle cell proliferation	Platelet-activating factor receptor	Homo sapiens (human)
positive regulation of inositol phosphate biosynthetic process	Platelet-activating factor receptor	Homo sapiens (human)
cellular response to gravity	Platelet-activating factor receptor	Homo sapiens (human)
cellular response to cAMP	Platelet-activating factor receptor	Homo sapiens (human)
cellular response to fatty acid	Platelet-activating factor receptor	Homo sapiens (human)
response to dexamethasone	Platelet-activating factor receptor	Homo sapiens (human)
positive regulation of leukocyte tethering or rolling	Platelet-activating factor receptor	Homo sapiens (human)
positive regulation of transcytosis	Platelet-activating factor receptor	Homo sapiens (human)
positive regulation of maternal process involved in parturition	Platelet-activating factor receptor	Homo sapiens (human)
positive regulation of gastro-intestinal system smooth muscle contraction	Platelet-activating factor receptor	Homo sapiens (human)
cellular response to 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine	Platelet-activating factor receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Platelet-activating factor receptor	Homo sapiens (human)
leukotriene metabolic process	Multidrug resistance-associated protein 1	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 1	Homo sapiens (human)
response to xenobiotic stimulus	Multidrug resistance-associated protein 1	Homo sapiens (human)
cobalamin transport	Multidrug resistance-associated protein 1	Homo sapiens (human)
sphingolipid biosynthetic process	Multidrug resistance-associated protein 1	Homo sapiens (human)
cellular response to oxidative stress	Multidrug resistance-associated protein 1	Homo sapiens (human)
heme catabolic process	Multidrug resistance-associated protein 1	Homo sapiens (human)
xenobiotic transport	Multidrug resistance-associated protein 1	Homo sapiens (human)
phospholipid translocation	Multidrug resistance-associated protein 1	Homo sapiens (human)
positive regulation of inflammatory response	Multidrug resistance-associated protein 1	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 1	Homo sapiens (human)
cell chemotaxis	Multidrug resistance-associated protein 1	Homo sapiens (human)
transepithelial transport	Multidrug resistance-associated protein 1	Homo sapiens (human)
cyclic nucleotide transport	Multidrug resistance-associated protein 1	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 1	Homo sapiens (human)
sphingolipid translocation	Multidrug resistance-associated protein 1	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 1	Homo sapiens (human)
cellular response to amyloid-beta	Multidrug resistance-associated protein 1	Homo sapiens (human)
carboxylic acid transmembrane transport	Multidrug resistance-associated protein 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Multidrug resistance-associated protein 1	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 1	Homo sapiens (human)
negative regulation of myotube differentiation	Histone deacetylase 1	Homo sapiens (human)
negative regulation of apoptotic process	Histone deacetylase 1	Homo sapiens (human)
positive regulation of signaling receptor activity	Histone deacetylase 1	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Histone deacetylase 1	Homo sapiens (human)
chromatin organization	Histone deacetylase 1	Homo sapiens (human)
chromatin remodeling	Histone deacetylase 1	Homo sapiens (human)
DNA methylation-dependent heterochromatin formation	Histone deacetylase 1	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Histone deacetylase 1	Homo sapiens (human)
protein deacetylation	Histone deacetylase 1	Homo sapiens (human)
endoderm development	Histone deacetylase 1	Homo sapiens (human)
positive regulation of cell population proliferation	Histone deacetylase 1	Homo sapiens (human)
epidermal cell differentiation	Histone deacetylase 1	Homo sapiens (human)
positive regulation of gene expression	Histone deacetylase 1	Homo sapiens (human)
negative regulation of gene expression	Histone deacetylase 1	Homo sapiens (human)
hippocampus development	Histone deacetylase 1	Homo sapiens (human)
neuron differentiation	Histone deacetylase 1	Homo sapiens (human)
negative regulation of cell migration	Histone deacetylase 1	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Histone deacetylase 1	Homo sapiens (human)
circadian regulation of gene expression	Histone deacetylase 1	Homo sapiens (human)
cellular response to platelet-derived growth factor stimulus	Histone deacetylase 1	Homo sapiens (human)
odontogenesis of dentin-containing tooth	Histone deacetylase 1	Homo sapiens (human)
regulation of cell fate specification	Histone deacetylase 1	Homo sapiens (human)
embryonic digit morphogenesis	Histone deacetylase 1	Homo sapiens (human)
negative regulation of apoptotic process	Histone deacetylase 1	Homo sapiens (human)
negative regulation of canonical NF-kappaB signal transduction	Histone deacetylase 1	Homo sapiens (human)
negative regulation by host of viral transcription	Histone deacetylase 1	Homo sapiens (human)
negative regulation of gene expression, epigenetic	Histone deacetylase 1	Homo sapiens (human)
negative regulation of DNA-templated transcription	Histone deacetylase 1	Homo sapiens (human)
positive regulation of DNA-templated transcription	Histone deacetylase 1	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Histone deacetylase 1	Homo sapiens (human)
positive regulation of smooth muscle cell proliferation	Histone deacetylase 1	Homo sapiens (human)
oligodendrocyte differentiation	Histone deacetylase 1	Homo sapiens (human)
positive regulation of oligodendrocyte differentiation	Histone deacetylase 1	Homo sapiens (human)
negative regulation of androgen receptor signaling pathway	Histone deacetylase 1	Homo sapiens (human)
hair follicle placode formation	Histone deacetylase 1	Homo sapiens (human)
eyelid development in camera-type eye	Histone deacetylase 1	Homo sapiens (human)
fungiform papilla formation	Histone deacetylase 1	Homo sapiens (human)
negative regulation of canonical Wnt signaling pathway	Histone deacetylase 1	Homo sapiens (human)
negative regulation of stem cell population maintenance	Histone deacetylase 1	Homo sapiens (human)
positive regulation of stem cell population maintenance	Histone deacetylase 1	Homo sapiens (human)
regulation of stem cell differentiation	Histone deacetylase 1	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway	Histone deacetylase 1	Homo sapiens (human)
heterochromatin formation	Histone deacetylase 1	Homo sapiens (human)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell population proliferation	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of B cell proliferation	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
nuclear DNA replication	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
signal transduction in response to DNA damage	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
isotype switching	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of DNA replication	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of isotype switching to IgG isotypes	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA clamp unloading	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
regulation of mitotic cell cycle phase transition	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of cell cycle G2/M phase transition	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
negative regulation of receptor internalization	Ataxin-2	Homo sapiens (human)
regulation of translation	Ataxin-2	Homo sapiens (human)
RNA metabolic process	Ataxin-2	Homo sapiens (human)
P-body assembly	Ataxin-2	Homo sapiens (human)
stress granule assembly	Ataxin-2	Homo sapiens (human)
RNA transport	Ataxin-2	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Histone deacetylase 8	Homo sapiens (human)
chromatin organization	Histone deacetylase 8	Homo sapiens (human)
mitotic sister chromatid cohesion	Histone deacetylase 8	Homo sapiens (human)
negative regulation of protein ubiquitination	Histone deacetylase 8	Homo sapiens (human)
regulation of protein stability	Histone deacetylase 8	Homo sapiens (human)
regulation of telomere maintenance	Histone deacetylase 8	Homo sapiens (human)
epigenetic regulation of gene expression	Histone deacetylase 8	Homo sapiens (human)
polyamine deacetylation	Histone deacetylase 6	Homo sapiens (human)
spermidine deacetylation	Histone deacetylase 6	Homo sapiens (human)
positive regulation of signaling receptor activity	Histone deacetylase 6	Homo sapiens (human)
protein polyubiquitination	Histone deacetylase 6	Homo sapiens (human)
response to amphetamine	Histone deacetylase 6	Homo sapiens (human)
protein deacetylation	Histone deacetylase 6	Homo sapiens (human)
protein quality control for misfolded or incompletely synthesized proteins	Histone deacetylase 6	Homo sapiens (human)
intracellular protein transport	Histone deacetylase 6	Homo sapiens (human)
autophagy	Histone deacetylase 6	Homo sapiens (human)
actin filament organization	Histone deacetylase 6	Homo sapiens (human)
negative regulation of microtubule depolymerization	Histone deacetylase 6	Homo sapiens (human)
regulation of autophagy	Histone deacetylase 6	Homo sapiens (human)
positive regulation of epithelial cell migration	Histone deacetylase 6	Homo sapiens (human)
negative regulation of hydrogen peroxide metabolic process	Histone deacetylase 6	Homo sapiens (human)

Process	via Protein(s)	Taxonomy
iron ion binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
calcium ion binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
protein binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipid binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
linoleate 13S-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
arachidonate 8(S)-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
arachidonate 15-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
linoleate 9S-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
hormone activity	Transthyretin	Homo sapiens (human)
protein binding	Transthyretin	Homo sapiens (human)
identical protein binding	Transthyretin	Homo sapiens (human)
thyroid hormone binding	Transthyretin	Homo sapiens (human)
NADH dehydrogenase (ubiquinone) activity	NADH-ubiquinone oxidoreductase chain 4	Homo sapiens (human)
ubiquinone binding	NADH-ubiquinone oxidoreductase chain 4	Homo sapiens (human)
NADH dehydrogenase activity	NADH-ubiquinone oxidoreductase chain 4	Homo sapiens (human)
transcription cis-regulatory region binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
core promoter sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
TFIID-class transcription factor complex binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
protease binding	Cellular tumor antigen p53	Homo sapiens (human)
p53 binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity	Cellular tumor antigen p53	Homo sapiens (human)
mRNA 3'-UTR binding	Cellular tumor antigen p53	Homo sapiens (human)
copper ion binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	Cellular tumor antigen p53	Homo sapiens (human)
zinc ion binding	Cellular tumor antigen p53	Homo sapiens (human)
enzyme binding	Cellular tumor antigen p53	Homo sapiens (human)
receptor tyrosine kinase binding	Cellular tumor antigen p53	Homo sapiens (human)
ubiquitin protein ligase binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase regulator activity	Cellular tumor antigen p53	Homo sapiens (human)
ATP-dependent DNA/DNA annealing activity	Cellular tumor antigen p53	Homo sapiens (human)
identical protein binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase binding	Cellular tumor antigen p53	Homo sapiens (human)
protein heterodimerization activity	Cellular tumor antigen p53	Homo sapiens (human)
protein-folding chaperone binding	Cellular tumor antigen p53	Homo sapiens (human)
protein phosphatase 2A binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Cellular tumor antigen p53	Homo sapiens (human)
14-3-3 protein binding	Cellular tumor antigen p53	Homo sapiens (human)
MDM2/MDM4 family protein binding	Cellular tumor antigen p53	Homo sapiens (human)
disordered domain specific binding	Cellular tumor antigen p53	Homo sapiens (human)
general transcription initiation factor binding	Cellular tumor antigen p53	Homo sapiens (human)
molecular function activator activity	Cellular tumor antigen p53	Homo sapiens (human)
promoter-specific chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast growth factor binding	Integrin beta-3	Homo sapiens (human)
C-X3-C chemokine binding	Integrin beta-3	Homo sapiens (human)
insulin-like growth factor I binding	Integrin beta-3	Homo sapiens (human)
neuregulin binding	Integrin beta-3	Homo sapiens (human)
virus receptor activity	Integrin beta-3	Homo sapiens (human)
fibronectin binding	Integrin beta-3	Homo sapiens (human)
protease binding	Integrin beta-3	Homo sapiens (human)
protein disulfide isomerase activity	Integrin beta-3	Homo sapiens (human)
protein kinase C binding	Integrin beta-3	Homo sapiens (human)
platelet-derived growth factor receptor binding	Integrin beta-3	Homo sapiens (human)
integrin binding	Integrin beta-3	Homo sapiens (human)
protein binding	Integrin beta-3	Homo sapiens (human)
coreceptor activity	Integrin beta-3	Homo sapiens (human)
enzyme binding	Integrin beta-3	Homo sapiens (human)
identical protein binding	Integrin beta-3	Homo sapiens (human)
vascular endothelial growth factor receptor 2 binding	Integrin beta-3	Homo sapiens (human)
metal ion binding	Integrin beta-3	Homo sapiens (human)
cell adhesion molecule binding	Integrin beta-3	Homo sapiens (human)
extracellular matrix binding	Integrin beta-3	Homo sapiens (human)
fibrinogen binding	Integrin beta-3	Homo sapiens (human)
protein binding	ATP-dependent translocase ABCB1	Homo sapiens (human)
ATP binding	ATP-dependent translocase ABCB1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
efflux transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
ATP hydrolysis activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
ubiquitin protein ligase binding	ATP-dependent translocase ABCB1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
carboxylic acid transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
phosphatidylcholine floppase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
phosphatidylethanolamine flippase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
ceramide floppase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
floppase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
fibronectin binding	72 kDa type IV collagenase	Homo sapiens (human)
endopeptidase activity	72 kDa type IV collagenase	Homo sapiens (human)
metalloendopeptidase activity	72 kDa type IV collagenase	Homo sapiens (human)
serine-type endopeptidase activity	72 kDa type IV collagenase	Homo sapiens (human)
protein binding	72 kDa type IV collagenase	Homo sapiens (human)
metallopeptidase activity	72 kDa type IV collagenase	Homo sapiens (human)
zinc ion binding	72 kDa type IV collagenase	Homo sapiens (human)
protein binding	Integrin alpha-IIb	Homo sapiens (human)
identical protein binding	Integrin alpha-IIb	Homo sapiens (human)
metal ion binding	Integrin alpha-IIb	Homo sapiens (human)
extracellular matrix binding	Integrin alpha-IIb	Homo sapiens (human)
molecular adaptor activity	Integrin alpha-IIb	Homo sapiens (human)
fibrinogen binding	Integrin alpha-IIb	Homo sapiens (human)
integrin binding	Integrin alpha-IIb	Homo sapiens (human)
magnesium ion binding	DNA topoisomerase 2-alpha	Homo sapiens (human)
DNA binding	DNA topoisomerase 2-alpha	Homo sapiens (human)
chromatin binding	DNA topoisomerase 2-alpha	Homo sapiens (human)
RNA binding	DNA topoisomerase 2-alpha	Homo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activity	DNA topoisomerase 2-alpha	Homo sapiens (human)
protein kinase C binding	DNA topoisomerase 2-alpha	Homo sapiens (human)
protein binding	DNA topoisomerase 2-alpha	Homo sapiens (human)
ATP binding	DNA topoisomerase 2-alpha	Homo sapiens (human)
ATP-dependent activity, acting on DNA	DNA topoisomerase 2-alpha	Homo sapiens (human)
DNA binding, bending	DNA topoisomerase 2-alpha	Homo sapiens (human)
protein homodimerization activity	DNA topoisomerase 2-alpha	Homo sapiens (human)
ubiquitin binding	DNA topoisomerase 2-alpha	Homo sapiens (human)
protein heterodimerization activity	DNA topoisomerase 2-alpha	Homo sapiens (human)
carbonyl reductase (NADPH) activity	Carbonyl reductase [NADPH] 1	Homo sapiens (human)
alcohol dehydrogenase (NADP+) activity	Carbonyl reductase [NADPH] 1	Homo sapiens (human)
oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor	Carbonyl reductase [NADPH] 1	Homo sapiens (human)
oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor	Carbonyl reductase [NADPH] 1	Homo sapiens (human)
15-hydroxyprostaglandin-D dehydrogenase (NADP+) activity	Carbonyl reductase [NADPH] 1	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NADP+) activity	Carbonyl reductase [NADPH] 1	Homo sapiens (human)
prostaglandin-E2 9-reductase activity	Carbonyl reductase [NADPH] 1	Homo sapiens (human)
S-nitrosoglutathione reductase (NADPH) activity	Carbonyl reductase [NADPH] 1	Homo sapiens (human)
lipopolysaccharide binding	Platelet-activating factor receptor	Homo sapiens (human)
lipopolysaccharide immune receptor activity	Platelet-activating factor receptor	Homo sapiens (human)
G protein-coupled receptor activity	Platelet-activating factor receptor	Homo sapiens (human)
platelet activating factor receptor activity	Platelet-activating factor receptor	Homo sapiens (human)
protein binding	Platelet-activating factor receptor	Homo sapiens (human)
phospholipid binding	Platelet-activating factor receptor	Homo sapiens (human)
mitogen-activated protein kinase binding	Platelet-activating factor receptor	Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor activity	Platelet-activating factor receptor	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 1	Homo sapiens (human)
ABC-type vitamin B12 transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
ATPase-coupled lipid transmembrane transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
sphingolipid transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
carboxylic acid transmembrane transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
nucleosomal DNA binding	Histone deacetylase 1	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Histone deacetylase 1	Homo sapiens (human)
RNA polymerase II core promoter sequence-specific DNA binding	Histone deacetylase 1	Homo sapiens (human)
core promoter sequence-specific DNA binding	Histone deacetylase 1	Homo sapiens (human)
transcription corepressor binding	Histone deacetylase 1	Homo sapiens (human)
p53 binding	Histone deacetylase 1	Homo sapiens (human)
transcription corepressor activity	Histone deacetylase 1	Homo sapiens (human)
histone deacetylase activity	Histone deacetylase 1	Homo sapiens (human)
protein binding	Histone deacetylase 1	Homo sapiens (human)
enzyme binding	Histone deacetylase 1	Homo sapiens (human)
protein lysine deacetylase activity	Histone deacetylase 1	Homo sapiens (human)
Krueppel-associated box domain binding	Histone deacetylase 1	Homo sapiens (human)
histone deacetylase binding	Histone deacetylase 1	Homo sapiens (human)
NF-kappaB binding	Histone deacetylase 1	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Histone deacetylase 1	Homo sapiens (human)
E-box binding	Histone deacetylase 1	Homo sapiens (human)
DNA-binding transcription factor binding	Histone deacetylase 1	Homo sapiens (human)
histone decrotonylase activity	Histone deacetylase 1	Homo sapiens (human)
promoter-specific chromatin binding	Histone deacetylase 1	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
protein binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
ATP binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
ATP hydrolysis activity	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA clamp unloader activity	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
RNA binding	Ataxin-2	Homo sapiens (human)
epidermal growth factor receptor binding	Ataxin-2	Homo sapiens (human)
protein binding	Ataxin-2	Homo sapiens (human)
mRNA binding	Ataxin-2	Homo sapiens (human)
histone deacetylase activity	Histone deacetylase 8	Homo sapiens (human)
protein binding	Histone deacetylase 8	Homo sapiens (human)
Hsp70 protein binding	Histone deacetylase 8	Homo sapiens (human)
protein lysine deacetylase activity	Histone deacetylase 8	Homo sapiens (human)
metal ion binding	Histone deacetylase 8	Homo sapiens (human)
Hsp90 protein binding	Histone deacetylase 8	Homo sapiens (human)
DNA-binding transcription factor binding	Histone deacetylase 8	Homo sapiens (human)
histone decrotonylase activity	Histone deacetylase 8	Homo sapiens (human)
acetylspermidine deacetylase activity	Histone deacetylase 6	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Histone deacetylase 6	Homo sapiens (human)
transcription corepressor binding	Histone deacetylase 6	Homo sapiens (human)
actin binding	Histone deacetylase 6	Homo sapiens (human)
histone deacetylase activity	Histone deacetylase 6	Homo sapiens (human)
protein binding	Histone deacetylase 6	Homo sapiens (human)
beta-catenin binding	Histone deacetylase 6	Homo sapiens (human)
microtubule binding	Histone deacetylase 6	Homo sapiens (human)
zinc ion binding	Histone deacetylase 6	Homo sapiens (human)
enzyme binding	Histone deacetylase 6	Homo sapiens (human)
polyubiquitin modification-dependent protein binding	Histone deacetylase 6	Homo sapiens (human)
ubiquitin protein ligase binding	Histone deacetylase 6	Homo sapiens (human)
protein lysine deacetylase activity	Histone deacetylase 6	Homo sapiens (human)
histone deacetylase binding	Histone deacetylase 6	Homo sapiens (human)
tubulin deacetylase activity	Histone deacetylase 6	Homo sapiens (human)
alpha-tubulin binding	Histone deacetylase 6	Homo sapiens (human)
ubiquitin binding	Histone deacetylase 6	Homo sapiens (human)
tau protein binding	Histone deacetylase 6	Homo sapiens (human)
beta-tubulin binding	Histone deacetylase 6	Homo sapiens (human)
misfolded protein binding	Histone deacetylase 6	Homo sapiens (human)
Hsp90 protein binding	Histone deacetylase 6	Homo sapiens (human)
dynein complex binding	Histone deacetylase 6	Homo sapiens (human)
transcription factor binding	Histone deacetylase 6	Homo sapiens (human)
protein binding	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ATP binding	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
organic anion transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
urate transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
biotin transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
efflux transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ATP hydrolysis activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
riboflavin transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
identical protein binding	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
protein homodimerization activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
sphingolipid transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
nucleus	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cytosol	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cytoskeleton	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
plasma membrane	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
adherens junction	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
focal adhesion	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
membrane	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
extracellular exosome	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
extracellular region	Transthyretin	Homo sapiens (human)
extracellular space	Transthyretin	Homo sapiens (human)
azurophil granule lumen	Transthyretin	Homo sapiens (human)
extracellular exosome	Transthyretin	Homo sapiens (human)
extracellular space	Transthyretin	Homo sapiens (human)
mitochondrial inner membrane	NADH-ubiquinone oxidoreductase chain 4	Homo sapiens (human)
mitochondrial respiratory chain complex I	NADH-ubiquinone oxidoreductase chain 4	Homo sapiens (human)
nuclear body	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Cellular tumor antigen p53	Homo sapiens (human)
nucleoplasm	Cellular tumor antigen p53	Homo sapiens (human)
replication fork	Cellular tumor antigen p53	Homo sapiens (human)
nucleolus	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrion	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial matrix	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum	Cellular tumor antigen p53	Homo sapiens (human)
centrosome	Cellular tumor antigen p53	Homo sapiens (human)
cytosol	Cellular tumor antigen p53	Homo sapiens (human)
nuclear matrix	Cellular tumor antigen p53	Homo sapiens (human)
PML body	Cellular tumor antigen p53	Homo sapiens (human)
transcription repressor complex	Cellular tumor antigen p53	Homo sapiens (human)
site of double-strand break	Cellular tumor antigen p53	Homo sapiens (human)
germ cell nucleus	Cellular tumor antigen p53	Homo sapiens (human)
chromatin	Cellular tumor antigen p53	Homo sapiens (human)
transcription regulator complex	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex	Cellular tumor antigen p53	Homo sapiens (human)
glutamatergic synapse	Integrin beta-3	Homo sapiens (human)
nucleus	Integrin beta-3	Homo sapiens (human)
nucleoplasm	Integrin beta-3	Homo sapiens (human)
plasma membrane	Integrin beta-3	Homo sapiens (human)
cell-cell junction	Integrin beta-3	Homo sapiens (human)
focal adhesion	Integrin beta-3	Homo sapiens (human)
external side of plasma membrane	Integrin beta-3	Homo sapiens (human)
cell surface	Integrin beta-3	Homo sapiens (human)
apical plasma membrane	Integrin beta-3	Homo sapiens (human)
platelet alpha granule membrane	Integrin beta-3	Homo sapiens (human)
lamellipodium membrane	Integrin beta-3	Homo sapiens (human)
filopodium membrane	Integrin beta-3	Homo sapiens (human)
microvillus membrane	Integrin beta-3	Homo sapiens (human)
ruffle membrane	Integrin beta-3	Homo sapiens (human)
integrin alphav-beta3 complex	Integrin beta-3	Homo sapiens (human)
melanosome	Integrin beta-3	Homo sapiens (human)
synapse	Integrin beta-3	Homo sapiens (human)
postsynaptic membrane	Integrin beta-3	Homo sapiens (human)
extracellular exosome	Integrin beta-3	Homo sapiens (human)
integrin alphaIIb-beta3 complex	Integrin beta-3	Homo sapiens (human)
glycinergic synapse	Integrin beta-3	Homo sapiens (human)
integrin complex	Integrin beta-3	Homo sapiens (human)
protein-containing complex	Integrin beta-3	Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complex	Integrin beta-3	Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complex	Integrin beta-3	Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complex	Integrin beta-3	Homo sapiens (human)
receptor complex	Integrin beta-3	Homo sapiens (human)
alphav-beta3 integrin-vitronectin complex	Integrin beta-3	Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complex	Integrin beta-3	Homo sapiens (human)
focal adhesion	Integrin beta-3	Homo sapiens (human)
cell surface	Integrin beta-3	Homo sapiens (human)
synapse	Integrin beta-3	Homo sapiens (human)
cytoplasm	ATP-dependent translocase ABCB1	Homo sapiens (human)
plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
cell surface	ATP-dependent translocase ABCB1	Homo sapiens (human)
membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
apical plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
extracellular exosome	ATP-dependent translocase ABCB1	Homo sapiens (human)
external side of apical plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
collagen-containing extracellular matrix	72 kDa type IV collagenase	Homo sapiens (human)
extracellular region	72 kDa type IV collagenase	Homo sapiens (human)
extracellular space	72 kDa type IV collagenase	Homo sapiens (human)
nucleus	72 kDa type IV collagenase	Homo sapiens (human)
mitochondrion	72 kDa type IV collagenase	Homo sapiens (human)
plasma membrane	72 kDa type IV collagenase	Homo sapiens (human)
sarcomere	72 kDa type IV collagenase	Homo sapiens (human)
collagen-containing extracellular matrix	72 kDa type IV collagenase	Homo sapiens (human)
extracellular space	72 kDa type IV collagenase	Homo sapiens (human)
plasma membrane	Integrin alpha-IIb	Homo sapiens (human)
focal adhesion	Integrin alpha-IIb	Homo sapiens (human)
cell surface	Integrin alpha-IIb	Homo sapiens (human)
platelet alpha granule membrane	Integrin alpha-IIb	Homo sapiens (human)
extracellular exosome	Integrin alpha-IIb	Homo sapiens (human)
integrin alphaIIb-beta3 complex	Integrin alpha-IIb	Homo sapiens (human)
blood microparticle	Integrin alpha-IIb	Homo sapiens (human)
integrin complex	Integrin alpha-IIb	Homo sapiens (human)
external side of plasma membrane	Integrin alpha-IIb	Homo sapiens (human)
nucleolus	DNA topoisomerase 2-alpha	Homo sapiens (human)
nuclear chromosome	DNA topoisomerase 2-alpha	Homo sapiens (human)
centriole	DNA topoisomerase 2-alpha	Homo sapiens (human)
chromosome, centromeric region	DNA topoisomerase 2-alpha	Homo sapiens (human)
condensed chromosome	DNA topoisomerase 2-alpha	Homo sapiens (human)
male germ cell nucleus	DNA topoisomerase 2-alpha	Homo sapiens (human)
nucleus	DNA topoisomerase 2-alpha	Homo sapiens (human)
nucleoplasm	DNA topoisomerase 2-alpha	Homo sapiens (human)
nucleolus	DNA topoisomerase 2-alpha	Homo sapiens (human)
cytoplasm	DNA topoisomerase 2-alpha	Homo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) complex	DNA topoisomerase 2-alpha	Homo sapiens (human)
protein-containing complex	DNA topoisomerase 2-alpha	Homo sapiens (human)
ribonucleoprotein complex	DNA topoisomerase 2-alpha	Homo sapiens (human)
nucleus	DNA topoisomerase 2-alpha	Homo sapiens (human)
cytosol	Carbonyl reductase [NADPH] 1	Homo sapiens (human)
extracellular exosome	Carbonyl reductase [NADPH] 1	Homo sapiens (human)
extracellular vesicle	Carbonyl reductase [NADPH] 1	Homo sapiens (human)
plasma membrane	Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor 1	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor 2	Rattus norvegicus (Norway rat)
plasma membrane	Platelet-activating factor receptor	Homo sapiens (human)
membrane	Platelet-activating factor receptor	Homo sapiens (human)
secretory granule membrane	Platelet-activating factor receptor	Homo sapiens (human)
tertiary granule membrane	Platelet-activating factor receptor	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
basal plasma membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
lateral plasma membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
extracellular exosome	Multidrug resistance-associated protein 1	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
plasma membrane	Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)
plasma membrane	Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)
nucleus	Histone deacetylase 1	Homo sapiens (human)
nucleoplasm	Histone deacetylase 1	Homo sapiens (human)
cytoplasm	Histone deacetylase 1	Homo sapiens (human)
cytosol	Histone deacetylase 1	Homo sapiens (human)
NuRD complex	Histone deacetylase 1	Homo sapiens (human)
neuronal cell body	Histone deacetylase 1	Homo sapiens (human)
Sin3-type complex	Histone deacetylase 1	Homo sapiens (human)
histone deacetylase complex	Histone deacetylase 1	Homo sapiens (human)
chromatin	Histone deacetylase 1	Homo sapiens (human)
heterochromatin	Histone deacetylase 1	Homo sapiens (human)
transcription repressor complex	Histone deacetylase 1	Homo sapiens (human)
protein-containing complex	Histone deacetylase 1	Homo sapiens (human)
nucleus	Histone deacetylase 1	Homo sapiens (human)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
Elg1 RFC-like complex	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
nucleus	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
cytoplasm	Ataxin-2	Homo sapiens (human)
Golgi apparatus	Ataxin-2	Homo sapiens (human)
trans-Golgi network	Ataxin-2	Homo sapiens (human)
cytosol	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
membrane	Ataxin-2	Homo sapiens (human)
perinuclear region of cytoplasm	Ataxin-2	Homo sapiens (human)
ribonucleoprotein complex	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
nuclear chromosome	Histone deacetylase 8	Homo sapiens (human)
nucleus	Histone deacetylase 8	Homo sapiens (human)
nucleoplasm	Histone deacetylase 8	Homo sapiens (human)
cytoplasm	Histone deacetylase 8	Homo sapiens (human)
histone deacetylase complex	Histone deacetylase 8	Homo sapiens (human)
nucleus	Histone deacetylase 8	Homo sapiens (human)
nucleus	Histone deacetylase 6	Homo sapiens (human)
nucleoplasm	Histone deacetylase 6	Homo sapiens (human)
cytoplasm	Histone deacetylase 6	Homo sapiens (human)
multivesicular body	Histone deacetylase 6	Homo sapiens (human)
centrosome	Histone deacetylase 6	Homo sapiens (human)
cytosol	Histone deacetylase 6	Homo sapiens (human)
microtubule	Histone deacetylase 6	Homo sapiens (human)
caveola	Histone deacetylase 6	Homo sapiens (human)
inclusion body	Histone deacetylase 6	Homo sapiens (human)
aggresome	Histone deacetylase 6	Homo sapiens (human)
axon	Histone deacetylase 6	Homo sapiens (human)
dendrite	Histone deacetylase 6	Homo sapiens (human)
cell leading edge	Histone deacetylase 6	Homo sapiens (human)
ciliary basal body	Histone deacetylase 6	Homo sapiens (human)
perikaryon	Histone deacetylase 6	Homo sapiens (human)
perinuclear region of cytoplasm	Histone deacetylase 6	Homo sapiens (human)
axon cytoplasm	Histone deacetylase 6	Homo sapiens (human)
histone deacetylase complex	Histone deacetylase 6	Homo sapiens (human)
microtubule associated complex	Histone deacetylase 6	Homo sapiens (human)
nucleoplasm	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
apical plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
brush border membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
mitochondrial membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
membrane raft	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
external side of apical plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1132431	Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 0.39 mg/kg, ip qd administered starting from day 1 to day 9 post challenge relative to control	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Adriamycin analogues. 2. Synthesis of 13-deoxyanthracyclines.
AID681566	TP_TRANSPORTER: intracellular accumulation in Bsep-expressing LLC-PK1 cells	2000	Molecular pharmacology, Jan, Volume: 57, Issue:1	Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein.
AID588219	FDA HLAED, gamma-glutamyl transferase (GGT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID681098	TP_TRANSPORTER: inhibition of LTC4 uptake(LTC4: 0.05 uM, Daunorubicin: 30 uM) in membrane vesicles from SR3A cells	1998	Biochemical and biophysical research communications, Jun-29, Volume: 247, Issue:3	Doxorubicin- and daunorubicin-glutathione conjugates, but not unconjugated drugs, competitively inhibit leukotriene C4 transport mediated by MRP/GS-X pump.
AID1758186	Antiproliferative activity against human MCF7/ADR cells incubated for 48 hrs by CCK-8 assay	2021	European journal of medicinal chemistry, Apr-15, Volume: 216	Design, synthesis and bioactivity study on 5-phenylfuran derivatives as potent reversal agents against P-glycoprotein-mediated multidrug resistance in MCF-7/ADR cell.
AID21848	Compound was evaluated for the change in Tm of isolated helical DNA in solution.	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	N-(cyanomethyl)- and N-(2-methoxy-1-cyanoethyl)anthracyclines and related carboxyl derivatives.
AID111953	Chemotherapeutic activity was evaluated by measuring mean tumor diameter on day 12 at 10 mg/kg/day, sc	1980	Journal of medicinal chemistry, Nov, Volume: 23, Issue:11	Amino acid and dipeptide derivatives of daunorubicin. 2. Cellular pharmacology and antitumor activity on L1210 leukemic cells in vitro and in vivo.
AID659925	Antiproliferative activity against human MONO-MAC-6 cells assessed as inhibition of cell viability at 10'-6 M after 24 hrs by cell counting method	2012	European journal of medicinal chemistry, Jun, Volume: 52	GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexate.
AID1123505	Mutagenic activity in Salmonella typhimurium TA1537 assessed as mutation frequency at 10'4 times D50 after 1 hr	1979	Journal of medicinal chemistry, Mar, Volume: 22, Issue:3	Potential antitumor agents. 30. Mutagenic activity of some 9-anilinoacridines: relationships between structure, mutagenic potential, and antileukemic activity.
AID726432	Cytotoxicity against mouse L5178Y cells expressing p-gp after 24 hrs by MTT assay	2013	Bioorganic & medicinal chemistry, Jan-01, Volume: 21, Issue:1	Development of small-molecule P-gp inhibitors of the N-benzyl 1,4-dihydropyridine type: novel aspects in SAR and bioanalytical evaluation of multidrug resistance (MDR) reversal properties.
AID606437	Selectivity index, ratio of IC50 of human MRC5 cells to IC50 for human NCI-H460 cells	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery of 4-anilinofuro[2,3-b]quinoline derivatives as selective and orally active compounds against non-small-cell lung cancers.
AID119828	Percentage rate of O2 consumption by liver microsomes and NADPH in the presence compared to the rate in presence of doxorubicin.	1982	Journal of medicinal chemistry, Jan, Volume: 25, Issue:1	Enhanced antitumor properties of 3'-(4-morpholinyl) and 3'-(4-methoxy-1-piperidinyl) derivatives of 3'-deaminodaunorubicin.
AID345311	Intrinsic cytotoxicity against mouse NIH/3T3 cells overexpressing MDR1 after 72 hrs by MTT assay	2008	Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22	Bis-pyranobenzoquinones as a new family of reversal agents of the multidrug resistance phenotype mediated by P-glycoprotein in mammalian cells and the protozoan parasite Leishmania.
AID336010	Displacement of methyl green from DNA after 24 hrs by microtiter assay	1992	Journal of natural products, Nov, Volume: 55, Issue:11	A colorimetric microassay for the detection of agents that interact with DNA.
AID515168	Binding affinity to histone H1 containing chromatin in chicken erythroleukemic cells mononucleosomes transformed with Marek's virus by Scatchard plot analysis	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Interaction of daunomycin with acetylated chromatin.
AID355582	Antiproliferative activity against human HT-29 cells at 0.01 ug after 48 hrs by two-layer agar-diffusion method
AID1555343	Cytostatic activity against human WM983B cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Sequence modification of heptapeptide selected by phage display as homing device for HT-29 colon cancer cells to improve the anti-tumour activity of drug delivery systems.
AID1132908	Inhibition of DNA synthesis in mouse L1210 cells	1978	Journal of medicinal chemistry, Aug, Volume: 21, Issue:8	Antitumor anthracycline antibiotics. Structure-activity and structure-cardiotoxicity relationships of rubidazone analogues.
AID40501	Compound was tested for its lambda-phage induction activity against Bacillus subtilis in a disk plate assay at concentration of dose of 0.8 ug/mL; Active	1980	Journal of medicinal chemistry, Nov, Volume: 23, Issue:11	8-Hydroxyanthracyclinones from epsilon-rhodomycinone.
AID292450	Cytotoxicity against MCF7 cells after 72 hrs	2007	Journal of medicinal chemistry, Jul-26, Volume: 50, Issue:15	New analogues of the potent cytotoxic saponin OSW-1.
AID1145427	Inhibition of RNA synthesis in mouse L1210 cells assessed as inhibition of [14C]-uridine incorporation measured per 10'6 cells at 5 uM pretreated for 1 hr followed by radiotracer addition measured after 1 hr by scintillation spectrometric analysis relativ	1976	Journal of medicinal chemistry, May, Volume: 19, Issue:5	Cellular pharmocodynamics of several anthrocycline antibiotics.
AID1638052	Cytotoxicity against mouse 4T1 cells after 72 hrs by MTT assay	2019	European journal of medicinal chemistry, Mar-01, Volume: 165	Synthesis and anticancer evaluation of new lipophilic 1,2,4 and 1,3,4-oxadiazoles.
AID256695	Cytotoxicity against Jurkat T lymphocytes by MTT assay	2005	Journal of medicinal chemistry, Dec-29, Volume: 48, Issue:26	A new bisintercalating anthracycline with picomolar DNA binding affinity.
AID1124720	Toxicity in CDF1 mouse allografted with mouse P388 cells assessed as survival at 2 to 32 mg/kg, ip on days 5, 9 and 13	1979	Journal of medicinal chemistry, Apr, Volume: 22, Issue:4	Synthesis and antitumor activity of sugar-ring hydroxyl analogues of daunorubicin.
AID659659	Drug uptake in human DU145 cell perinuclear region at 1 uM after 4 hrs by confocal microscopic analysis	2012	Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4	Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.
AID726430	Ratio of IC50 for mouse L5178Y cells expressing p-gp to IC50 for mouse L5178Y cells	2013	Bioorganic & medicinal chemistry, Jan-01, Volume: 21, Issue:1	Development of small-molecule P-gp inhibitors of the N-benzyl 1,4-dihydropyridine type: novel aspects in SAR and bioanalytical evaluation of multidrug resistance (MDR) reversal properties.
AID400025	Antitumor activity against mouse P388 cells xenografted in mouse assessed as median survival time at 4.4 mg/kg, ip relative to control
AID1124697	Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as tumor inhibition at 4 mg/kg, ip on days 5, 9 and 13 relative to untreated control	1979	Journal of medicinal chemistry, Apr, Volume: 22, Issue:4	Synthesis and antitumor activity of sugar-ring hydroxyl analogues of daunorubicin.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID704302	Activity of human recombinant His6-tagged carbonyl reductase 1 expressed in Escherichia coli BL21(DE3) using menadione as substrate by Michaelis-Menten plot analysis	2012	European journal of medicinal chemistry, Oct, Volume: 56	Understanding the binding of daunorubicin and doxorubicin to NADPH-dependent cytosolic reductases by computational methods.
AID704301	Activity of human AKR1A1 expressed in Escherichia coli BL21 assessed per mg protein in presence of 0.2 mM NADPH	2012	European journal of medicinal chemistry, Oct, Volume: 56	Understanding the binding of daunorubicin and doxorubicin to NADPH-dependent cytosolic reductases by computational methods.
AID492223	Cytotoxicity against human MCF7 cells at 4 ug/ml after 48 hrs by sulforhodamine B assay relative to control	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Synthesis and antiproliferative evaluation of certain iminonaphtho[2,3-b]furan derivatives.
AID1221962	Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID211116	Ratio of DNA relaxation times by topoisomerase in presence of 2 uM of compound (t1/e(+drug) / t 1/e(-drug))	1994	Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19	Inhibition of topoisomerase I by anthracycline antibiotics: evidence for general inhibition of topoisomerase I by DNA-binding agents.
AID40219	Compound was tested for antibacterial activity against Bacillus cereus WSU-60	1986	Journal of medicinal chemistry, Sep, Volume: 29, Issue:9	Synthesis of anthraquinonyl glucosaminosides and studies on the influence of aglycone hydroxyl substitution on superoxide generation, DNA binding, and antimicrobial properties.
AID624623	Apparent permeability (Papp) from basolateral to apical side determined in MDR1-MDCKII cells	2001	The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2	Rational use of in vitro P-glycoprotein assays in drug discovery.
AID70890	Compound is evaluated for lambda-phage induction activity in Escherichia coli (dose at 3.1 ug/mL)	1980	Journal of medicinal chemistry, Nov, Volume: 23, Issue:11	8-Hydroxyanthracyclinones from epsilon-rhodomycinone.
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID659913	Antiproliferative activity against human MONO-MAC-6 cells assessed as inhibition of cell viability at 10'-9 M after 24 hrs by cell counting method	2012	European journal of medicinal chemistry, Jun, Volume: 52	GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexate.
AID153555	Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388 (1303) for % increase in life span at an optimal dose of 1 mg/kg/injection	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID1132914	In vivo antitumor activity against mouse P388 cells allografted in BDF/CDF mouse assessed as host survival time at 4 mg/kg, ip administered on days 1 to 9 relative to control	1978	Journal of medicinal chemistry, Aug, Volume: 21, Issue:8	Antitumor anthracycline antibiotics. Structure-activity and structure-cardiotoxicity relationships of rubidazone analogues.
AID1221956	Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID396065	Cytotoxicity against human HL60 cells after 48 hrs by trypan blue exclusion method	2008	European journal of medicinal chemistry, Nov, Volume: 43, Issue:11	Synthesis and induction of G0-G1 phase arrest with apoptosis of 3,5-dimethyl-6-phenyl-8-(trifluoromethyl)-5,6-dihydropyrazolo[3,4-f][1,2,3,5]tetrazepin-4(3H)-one.
AID98029	Compound was evaluated for the 50% inhibition of the incorporation of [3H]- thymidine in the DNA (inhibition of synthesis in leukemia L1210 cells)	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	N-(cyanomethyl)- and N-(2-methoxy-1-cyanoethyl)anthracyclines and related carboxyl derivatives.
AID1145742	Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 2 mg/kg, ip qd administered for 9 days relative to control	1976	Journal of medicinal chemistry, Mar, Volume: 19, Issue:3	Adriamycin analogs. Periodate oxidation of adriamycin.
AID1175397	Antiproliferative activity against human MCF7 cells by XTT assay	2015	Bioorganic & medicinal chemistry, Jan-01, Volume: 23, Issue:1	Discovery of 2-[2-(5-nitrofuran-2-yl)vinyl]quinoline derivatives as a novel type of antimetastatic agents.
AID726433	Cytotoxicity against mouse L5178Y cells after 24 hrs by MTT assay	2013	Bioorganic & medicinal chemistry, Jan-01, Volume: 21, Issue:1	Development of small-molecule P-gp inhibitors of the N-benzyl 1,4-dihydropyridine type: novel aspects in SAR and bioanalytical evaluation of multidrug resistance (MDR) reversal properties.
AID1611343	Binding affinity to Tetrahymena thermophila telomeric 7 G-quadruplex DNA assessed as binding constant Kb1 in presence of 10 mM KCl by fluorescence spectroscopy	2019	Bioorganic & medicinal chemistry, 12-15, Volume: 27, Issue:24	Dual mode of binding of anti cancer drug epirubicin to G-quadruplex [d-(TTAGGGT)]
AID94919	Antitumor activity against L-1210 leukemia cell line in BDF1 mice after injecting 0.5 mg/kg ip dose	1990	Journal of medicinal chemistry, Sep, Volume: 33, Issue:9	Synthesis and antitumor activity of novel 4-demethoxyanthracyclines.
AID400026	Antitumor activity against mouse P388 cells xenografted in mouse assessed as median survival time at 6.6 mg/kg, ip relative to control
AID1409614	Overall antiviral activity against SARS-CoV-2 (isolate France/IDF0372/2020) in the Vero E6 cell line at 48 h based on three assays 1) detection of viral RNA by qRT-PCR (targeting the N-gene), 2) plaque assay using lysate 3 days after addition of compound	2020	Nature, 07, Volume: 583, Issue:7816	A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID1409608	AUC (viral infection %) for SARS-CoV-2 in the Vero E6 cell line at 48 h by immunofluorescence-based assay (detecting the viral NP protein in the nucleus of the Vero E6 cells).	2020	Nature, 07, Volume: 583, Issue:7816	A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID1145747	Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 0.06 mg/kg, ip qd administered for 9 days relative to control	1976	Journal of medicinal chemistry, Mar, Volume: 19, Issue:3	Adriamycin analogs. Periodate oxidation of adriamycin.
AID731870	Cellular uptake in mouse DA-3 cell lysosome at 10 uM after 30 mins by LysoTracker green staining-based confocal microscopic analysis relative to control	2013	ACS medicinal chemistry letters, Mar-14, Volume: 4, Issue:3	The structure of anthracycline derivatives determines their subcellular localization and cytotoxic activity.
AID731881	Cytotoxicity against mouse DA-3 cells assessed as reduction in cell viability at 20 uM after 180 mins by XTT assay relative to control	2013	ACS medicinal chemistry letters, Mar-14, Volume: 4, Issue:3	The structure of anthracycline derivatives determines their subcellular localization and cytotoxic activity.
AID681588	TP_TRANSPORTER: ATPase assay in membrane vesicle from BCRP-expressing Lactococcus lactis cells	2003	The Journal of biological chemistry, Jun-06, Volume: 278, Issue:23	Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis.
AID111961	Chemotherapeutic activity was evaluated by measuring mean tumor diameter on day 8 at 10 mg/kg/day, sc	1980	Journal of medicinal chemistry, Nov, Volume: 23, Issue:11	Amino acid and dipeptide derivatives of daunorubicin. 2. Cellular pharmacology and antitumor activity on L1210 leukemic cells in vitro and in vivo.
AID1863044	Growth inhibition of human MDA-MB-231 cells at 0.25 uM	2022	Bioorganic & medicinal chemistry, 09-15, Volume: 70	Discovery of CN0 as a novel proteolysis-targeting chimera (PROTAC) degrader of PARP1 that can activate the cGAS/STING immunity pathway combined with daunorubicin.
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1132443	Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 16 mg/kg, ip qd administered starting on day 5,9 and 13 post challenge relative to control	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Adriamycin analogues. 2. Synthesis of 13-deoxyanthracyclines.
AID40767	Compound was tested for antibacterial activity against Bacillus subtilis ATCC E6051	1986	Journal of medicinal chemistry, Sep, Volume: 29, Issue:9	Synthesis of anthraquinonyl glucosaminosides and studies on the influence of aglycone hydroxyl substitution on superoxide generation, DNA binding, and antimicrobial properties.
AID1132921	Cardiotoxicity in rat EEG model relative to adriamycin	1978	Journal of medicinal chemistry, Aug, Volume: 21, Issue:8	Antitumor anthracycline antibiotics. Structure-activity and structure-cardiotoxicity relationships of rubidazone analogues.
AID231124	Ratio of the extracellular cytotoxicities against MDA MB 361(mammary carcinoma cell line) expressing LacZ and carboxypeptidase stCPG2 of the prodrug.; Not available	1999	Journal of medicinal chemistry, Jul-01, Volume: 42, Issue:13	Self-immolative anthracycline prodrugs for suicide gene therapy.
AID588217	FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1379634	Cytotoxicity in human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Synthesis and biological evaluation of new substituted thioglycolurils, their analogues and derivatives.
AID695925	Inhibition of HIV-1 reverse transcriptase using Poly(rA).p(dT) (12 to 18) as substrate after 30 mins by single point PCR assay	2012	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14	Inhibition of therapeutically important polymerases with high affinity bis-intercalators.
AID98730	In vitro cytotoxic activity was evaluated using the murine leukemia L1210 cell line	2002	Bioorganic & medicinal chemistry letters, Dec-16, Volume: 12, Issue:24	Synthesis and cytotoxic activity of a new potent daunomycinone derivative.
AID153073	Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388 (1303) for change in body weight at an optimal dose of 1 mg/kg/injection	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID659635	Antiproliferative activity against human SKMES1 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4	Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.
AID606427	Anticancer activity against human MCF7 cells	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery of 4-anilinofuro[2,3-b]quinoline derivatives as selective and orally active compounds against non-small-cell lung cancers.
AID39867	Cytotoxicity that caused a 50% reduction in absorbance at 490 nm in B16 mouse melanoma cells using MTS assay.	2000	Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20	Synthesis and cytotoxicity of 4-amino-5-oxopyrido[2,3-d]pyrimidine nucleosides.
AID409954	Inhibition of mouse brain MAOA	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID537733	Binding affinity to Candida albicans CaCdr1p expressed in yeast AD1-8u	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID678783	TP_TRANSPORTER: drug resistance in MRP6-expressing CHO cells	2002	Cancer research, Nov-01, Volume: 62, Issue:21	Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6).
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID685503	HARVARD: Inhibition of blood stage Plasmodium falciparum Dd2 infection	2012	Proceedings of the National Academy of Sciences of the United States of America, May-29, Volume: 109, Issue:22	Liver-stage malaria parasites vulnerable to diverse chemical scaffolds.
AID397122	Inhibition of HIV1 RT
AID153077	Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388 (1303) for % increase in life span at an optimal dose of 1 mg/kg/injection	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID704306	Ratio of Vmax to Km for human aldo-keto reductase 1A1	2012	European journal of medicinal chemistry, Oct, Volume: 56	Understanding the binding of daunorubicin and doxorubicin to NADPH-dependent cytosolic reductases by computational methods.
AID624628	Drug-stimulated Pgp ATPase activity ratio determined in MDR1-Sf9 cell membranes with test compound at a concentration of 20uM	2001	The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2	Rational use of in vitro P-glycoprotein assays in drug discovery.
AID469438	Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay	2009	Journal of natural products, Dec, Volume: 72, Issue:12	Tartrolon D, a cytotoxic macrodiolide from the marine-derived actinomycete Streptomyces sp. MDG-04-17-069.
AID606428	Anticancer activity against human NCI-H460 cells	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery of 4-anilinofuro[2,3-b]quinoline derivatives as selective and orally active compounds against non-small-cell lung cancers.
AID1555337	Cytostatic activity against human HepG2 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Sequence modification of heptapeptide selected by phage display as homing device for HT-29 colon cancer cells to improve the anti-tumour activity of drug delivery systems.
AID659926	Antiproliferative activity against human MONO-MAC-6 cells assessed as inhibition of cell viability at 10'-6 M after 48 hrs by cell counting method	2012	European journal of medicinal chemistry, Jun, Volume: 52	GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexate.
AID1221980	Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK571	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID336011	Displacement of ethidium bromide from calf thymus type 1 DNA after 24 hrs by microtiter assay	1992	Journal of natural products, Nov, Volume: 55, Issue:11	A colorimetric microassay for the detection of agents that interact with DNA.
AID1863054	Growth inhibition of mouse 4T1 cells at 0.25 uM	2022	Bioorganic & medicinal chemistry, 09-15, Volume: 70	Discovery of CN0 as a novel proteolysis-targeting chimera (PROTAC) degrader of PARP1 that can activate the cGAS/STING immunity pathway combined with daunorubicin.
AID259842	Mortality in mice with Dox-resistant K562 xenografts in 20 days at 5-10 mg/kg, ip	2006	Journal of medicinal chemistry, Feb-09, Volume: 49, Issue:3	Discovery of a daunorubicin analogue that exhibits potent antitumor activity and overcomes P-gp-mediated drug resistance.
AID678963	TP_TRANSPORTER: uptake in BCRP-expressing oocyte cells	2003	Molecular pharmacology, Dec, Volume: 64, Issue:6	Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of Xenopus laevis.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID681510	TP_TRANSPORTER: efflux in GLC4/ADR cells	1994	Biochemical pharmacology, Sep-15, Volume: 48, Issue:6	Competitive inhibition by genistein and ATP dependence of daunorubicin transport in intact MRP overexpressing human small cell lung cancer cells.
AID1145595	Inhibition of Murine sarcoma virus (Moloney) foci formation in MEF after 72 hrs	1976	Journal of medicinal chemistry, May, Volume: 19, Issue:5	Stereocontrolled glycosidation of daunomycinone. Synthesis and biological evaluation of 6-hydroxy-L-arabino analogues of antitumor anthracyclines.
AID345313	Resistance index, ratio of IC50 for mouse NIH/3T3 cells expressing MDR1 to IC50 for wild type mouse NIH/3T3 cells	2008	Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22	Bis-pyranobenzoquinones as a new family of reversal agents of the multidrug resistance phenotype mediated by P-glycoprotein in mammalian cells and the protozoan parasite Leishmania.
AID1829604	Cytotoxicity against Wistar rat neonatal ventricular cardiomyocytes at 1.2 uM by LDH assay	2021	Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7	Structure-Activity Relationship Study of Dexrazoxane Analogues Reveals ICRF-193 as the Most Potent Bisdioxopiperazine against Anthracycline Toxicity to Cardiomyocytes Due to Its Strong Topoisomerase IIβ Interactions.
AID1130450	Mutagenicity in Salmonella typhimurium TA98 assessed as number of revertants by Ames test in presence of microsomal activation	1979	Journal of medicinal chemistry, Aug, Volume: 22, Issue:8	Adriamycin analogues. 3. Synthesis of N-alkylated anthracyclines with enhanced efficacy and reduced cardiotoxicity.
AID1202305	Cytotoxicity against human HL60 cells assessed as growth inhibition after 48 hrs by trypan blue staining-based hemocytometric analysis	2015	European journal of medicinal chemistry, , Volume: 96	Synthesis and antiproliferative activity of 3-(2-chloroethyl)-5-methyl-6-phenyl-8-(trifluoromethyl)-5,6-dihydropyrazolo[3,4-f][1,2,3,5]tetrazepin-4-(3H)-one.
AID106327	In vitro cytotoxic activity was evaluated using the human uterine sarcoma cell line MES-SA	2002	Bioorganic & medicinal chemistry letters, Dec-16, Volume: 12, Issue:24	Synthesis and cytotoxic activity of a new potent daunomycinone derivative.
AID1858599	Cytotoxicity against human DU-145 cells assessed as cell growth inhibition	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Paradigm shift of "classical" HDAC inhibitors to "hybrid" HDAC inhibitors in therapeutic interventions.
AID44040	Inhibitory activity against CCRF-CEM(human leukemic lymphoblastic) cells in culture.	1982	Journal of medicinal chemistry, Feb, Volume: 25, Issue:2	Adriamycin analogues. Preparation and biological evaluation of some N-perfluoroacyl analogues of daunorubicin, adriamycin, and N-(trifluoroacetyl)adriamycin 14-valerate and their 9,10-anhydro derivatives.
AID355583	Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay
AID1611344	Binding affinity to Tetrahymena thermophila telomeric 7 G-quadruplex DNA assessed as binding constant Kb2 in presence of 10 mM KCl by fluorescence spectroscopy	2019	Bioorganic & medicinal chemistry, 12-15, Volume: 27, Issue:24	Dual mode of binding of anti cancer drug epirubicin to G-quadruplex [d-(TTAGGGT)]
AID357845	Binding affinity to calf thymus DNA assessed as reduction in DNA peak by pre-incubation method
AID116312	Percent increase in life span of female DBA2 mice subcutaneously inoculated with L1210 leukemia at 11 mg/kg/day, sc	1980	Journal of medicinal chemistry, Nov, Volume: 23, Issue:11	Amino acid and dipeptide derivatives of daunorubicin. 2. Cellular pharmacology and antitumor activity on L1210 leukemic cells in vitro and in vivo.
AID280072	Antiproliferative activity against drug sensitive Messa cell line by Alamar Blue assay	2007	Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5	Potent antitubulin tumor cell cytotoxins based on 3-aroyl indazoles.
AID536034	Displacement of DNA-bound ethidium bromide from calf thymus DNA by fluorescence assay	2010	Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22	Indeno[1,2-c]isoquinolin-5,11-diones conjugated to amino acids: Synthesis, cytotoxicity, DNA interaction, and topoisomerase II inhibition properties.
AID98916	Inhibitory activity was measured against murine L1210 leukemia cells.	1998	Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19	Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy.
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1555342	Cytostatic activity against human M24 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Sequence modification of heptapeptide selected by phage display as homing device for HT-29 colon cancer cells to improve the anti-tumour activity of drug delivery systems.
AID234842	NADH oxidation by the compound was determined	1993	Journal of medicinal chemistry, Jan-08, Volume: 36, Issue:1	6-[(aminoalkyl)amino]-substituted 7H-benzo[e]perimidin-7-ones as novel antineoplastic agents. Synthesis and biological evaluation.
AID1863046	Growth inhibition of human MDA-MB-231 cells at 4 uM	2022	Bioorganic & medicinal chemistry, 09-15, Volume: 70	Discovery of CN0 as a novel proteolysis-targeting chimera (PROTAC) degrader of PARP1 that can activate the cGAS/STING immunity pathway combined with daunorubicin.
AID292452	Cytotoxicity against ARN8 cells after 72 hrs	2007	Journal of medicinal chemistry, Jul-26, Volume: 50, Issue:15	New analogues of the potent cytotoxic saponin OSW-1.
AID121876	Chemotherapeutic activity was evaluated by measuring number of survivors on day 30 / total number of mice at 10 mg/kg/day, iv; 0/18	1980	Journal of medicinal chemistry, Nov, Volume: 23, Issue:11	Amino acid and dipeptide derivatives of daunorubicin. 2. Cellular pharmacology and antitumor activity on L1210 leukemic cells in vitro and in vivo.
AID409956	Inhibition of mouse brain MAOB	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1555350	Cytostatic activity against human PC3 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Sequence modification of heptapeptide selected by phage display as homing device for HT-29 colon cancer cells to improve the anti-tumour activity of drug delivery systems.
AID111955	Chemotherapeutic activity was evaluated by measuring mean tumor diameter on day 12 at 12(mg/kg)/day, sc	1980	Journal of medicinal chemistry, Nov, Volume: 23, Issue:11	Amino acid and dipeptide derivatives of daunorubicin. 2. Cellular pharmacology and antitumor activity on L1210 leukemic cells in vitro and in vivo.
AID345312	Intrinsic cytotoxicity against wild type mouse NIH/3T3 cells after 72 hrs by MTT assay	2008	Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22	Bis-pyranobenzoquinones as a new family of reversal agents of the multidrug resistance phenotype mediated by P-glycoprotein in mammalian cells and the protozoan parasite Leishmania.
AID46154	Thermal denaturation temperature (Tm) of isolated calf thymus helical DNA was measured	1982	Journal of medicinal chemistry, Jan, Volume: 25, Issue:1	Enhanced antitumor properties of 3'-(4-morpholinyl) and 3'-(4-methoxy-1-piperidinyl) derivatives of 3'-deaminodaunorubicin.
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1145425	Inhibition of RNA synthesis in mouse L1210 cells assessed as inhibition of [14C]-uridine incorporation measured per 10'6 cells at 1 uM pretreated for 1 hr followed by radiotracer addition measured after 1 hr by scintillation spectrometric analysis relativ	1976	Journal of medicinal chemistry, May, Volume: 19, Issue:5	Cellular pharmocodynamics of several anthrocycline antibiotics.
AID103913	Compound was tested for its toxicity against human breast cancer cells(MCF-7)	1998	Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8	Epidoxoform: a hydrolytically more stable anthracycline-formaldehyde conjugate toxic to resistant tumor cells.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID718074	Binding affinity to calf thymus DNA assessed as binding constant by spectrofluorimetry based McGhee von Hippel method	2012	Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24	DNA binding acridine-thiazolidinone agents affecting intracellular glutathione.
AID355578	Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay
AID70893	Compound is evaluated for lambda-phage induction activity in Escherichia coli (dose at 6.2 ug/mL); Toxic to culture	1980	Journal of medicinal chemistry, Nov, Volume: 23, Issue:11	8-Hydroxyanthracyclinones from epsilon-rhodomycinone.
AID659662	Drug uptake in human A549 cell nucleus at 1 uM after 4 hrs by confocal microscopic analysis	2012	Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4	Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.
AID1221969	Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko143	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1145424	Inhibition of DNA synthesis in mouse L1210 cells assessed as inhibition of [3H]-thymidine incorporation measured per 10'6 cells at 5 uM pretreated for 1 hr followed by radiotracer addition measured after 1 hr by scintillation spectrometric analysis relati	1976	Journal of medicinal chemistry, May, Volume: 19, Issue:5	Cellular pharmocodynamics of several anthrocycline antibiotics.
AID659918	Antiproliferative activity against human MONO-MAC-6 cells assessed as inhibition of cell viability at 10'-9 M after 72 hrs by cell counting method	2012	European journal of medicinal chemistry, Jun, Volume: 52	GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexate.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID659921	Antiproliferative activity against human MONO-MAC-6 cells assessed as inhibition of cell viability at 10'-8 M after 72 hrs by cell counting method	2012	European journal of medicinal chemistry, Jun, Volume: 52	GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexate.
AID280074	Antiproliferative activity against drug resistant HCT15 cell line expressing MDR1 by Alamar Blue assay	2007	Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5	Potent antitubulin tumor cell cytotoxins based on 3-aroyl indazoles.
AID1555333	Cytostatic activity against human HCT116 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Sequence modification of heptapeptide selected by phage display as homing device for HT-29 colon cancer cells to improve the anti-tumour activity of drug delivery systems.
AID1145760	Binding affinity to calf thymus DNA assessed as decrease in absorptivity of visible maxima of compound at 1:1 to 16:1 compound to DNA ratio by UV-visible spectra analysis	1976	Journal of medicinal chemistry, Mar, Volume: 19, Issue:3	Adriamycin analogs. Periodate oxidation of adriamycin.
AID106319	Resistance factor (RF), ratio between the IC50 on the resistant cells and the IC50 on the corresponding sensitive cells of MES cell line	2002	Bioorganic & medicinal chemistry letters, Dec-16, Volume: 12, Issue:24	Synthesis and cytotoxic activity of a new potent daunomycinone derivative.
AID1145743	Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 1 mg/kg, ip qd administered for 9 days relative to control	1976	Journal of medicinal chemistry, Mar, Volume: 19, Issue:3	Adriamycin analogs. Periodate oxidation of adriamycin.
AID624606	Specific activity of expressed human recombinant UGT1A1	2000	Annual review of pharmacology and toxicology, , Volume: 40	Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID272517	Relative fold, IC50 in absence to presence of verapamil in multidrug resistant P388 cells	2006	Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23	Flavonoid dimers as bivalent modulators for P-glycoprotein-based multidrug resistance: synthetic apigenin homodimers linked with defined-length poly(ethylene glycol) spacers increase drug retention and enhance chemosensitivity in resistant cancer cells.
AID731882	Cytotoxicity against human ES2 cells after 24 hrs by XTT assay	2013	ACS medicinal chemistry letters, Mar-14, Volume: 4, Issue:3	The structure of anthracycline derivatives determines their subcellular localization and cytotoxic activity.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1555345	Cytostatic activity against human PE/CA-PJ15 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Sequence modification of heptapeptide selected by phage display as homing device for HT-29 colon cancer cells to improve the anti-tumour activity of drug delivery systems.
AID1124710	Antitumor activity against mouse B16 cells allografted in CDF1 mouse assessed as tumor inhibition at 4 mg/kg, ip on day 5 relative to untreated control	1979	Journal of medicinal chemistry, Apr, Volume: 22, Issue:4	Synthesis and antitumor activity of sugar-ring hydroxyl analogues of daunorubicin.
AID1221978	Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK571	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1555346	Cytostatic activity against human PECAPJ41 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Sequence modification of heptapeptide selected by phage display as homing device for HT-29 colon cancer cells to improve the anti-tumour activity of drug delivery systems.
AID551550	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	2011	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1	Antiproliferative and apoptotic sesquiterpene lactones from Carpesium faberi.
AID1130441	Antitumor activity against mouse P388 cells allografted in CDF/BDF mouse assessed as survival time at 8 mg/kg, ip administered as qd on day 5, 9, 13	1979	Journal of medicinal chemistry, Aug, Volume: 22, Issue:8	Adriamycin analogues. 3. Synthesis of N-alkylated anthracyclines with enhanced efficacy and reduced cardiotoxicity.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1145734	Binding affinity to calf thymus DNA assessed as increase in melting temperature at 2 x 10'-5 M by UV spectrophotometric analysis	1976	Journal of medicinal chemistry, Mar, Volume: 19, Issue:3	Adriamycin analogs. Periodate oxidation of adriamycin.
AID1858587	Inhibition of HDAC6 (unknown origin)	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Paradigm shift of "classical" HDAC inhibitors to "hybrid" HDAC inhibitors in therapeutic interventions.
AID659646	Inhibition of HDAC6-mediated tubulin acetylation in human DU145 cells at 90 nM after 4 hrs by Western blot analysis	2012	Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4	Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.
AID1221965	Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID83140	In vitro inhibitory concentration against proliferation of HL60R cells	2003	Journal of medicinal chemistry, Jul-31, Volume: 46, Issue:16	Synthesis and biological evaluation of resveratrol and analogues as apoptosis-inducing agents.
AID1123500	Toxicity in Salmonella typhimurium TA98 assessed as growth inhibition after 1 hr	1979	Journal of medicinal chemistry, Mar, Volume: 22, Issue:3	Potential antitumor agents. 30. Mutagenic activity of some 9-anilinoacridines: relationships between structure, mutagenic potential, and antileukemic activity.
AID1201522	Genotoxicity in DNA (unknown origin) incubated for 24 hrs in dark condition by methyl green displacement assay	2015	European journal of medicinal chemistry, May-05, Volume: 95	Discovery of new thienopyrimidinone derivatives displaying antimalarial properties toward both erythrocytic and hepatic stages of Plasmodium.
AID597392	Cytotoxicity against human KB-C2 cells after 6 hrs by MTT assay	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	New 29-nor-cycloartanes with a 3,4-seco- and a novel 2,3-seco-structure from the leaves of Sinocalycanthus chinensis.
AID31433	Cytotoxic activity against DX-100: doxorubicin (100 ng/mL) resistant AML-2 cell line was determined	2003	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24	Synthesis of new 3-arylisoquinolinamines: effect on topoisomerase I inhibition and cytotoxicity.
AID512633	Binding affinity to human c-MYC Pu24I G-quadruplex structure assessed as stabilization of G-quadruplex by NMR spectroscopy	2005	Nature chemical biology, Aug, Volume: 1, Issue:3	Small-molecule interaction with a five-guanine-tract G-quadruplex structure from the human MYC promoter.
AID731884	Cytotoxicity against human SKOV3 cells after 24 hrs by XTT assay	2013	ACS medicinal chemistry letters, Mar-14, Volume: 4, Issue:3	The structure of anthracycline derivatives determines their subcellular localization and cytotoxic activity.
AID588218	FDA HLAED, lactate dehydrogenase (LDH) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID307356	Displacement of methyl green from DNA
AID1130452	Toxicity in Salmonella typhimurium TA98 assessed as concentration required to cause mortality per plate	1979	Journal of medicinal chemistry, Aug, Volume: 22, Issue:8	Adriamycin analogues. 3. Synthesis of N-alkylated anthracyclines with enhanced efficacy and reduced cardiotoxicity.
AID1150091	Inhibition of Escherichia coli RNA polymerase assessed as reduction in RNA transcription at compound/DNA molar ratio of 1	1977	Journal of medicinal chemistry, Sep, Volume: 20, Issue:9	Molecular structural effects involved in the interaction of quinolinemethanolamines with DNA. Implications for antimalarial action.
AID292449	Cytotoxicity against CEM cells after 72 hrs	2007	Journal of medicinal chemistry, Jul-26, Volume: 50, Issue:15	New analogues of the potent cytotoxic saponin OSW-1.
AID280073	Antiproliferative activity against drug resistant Messa/DX5 cell line expressing MDR1 by Alamar Blue assay	2007	Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5	Potent antitubulin tumor cell cytotoxins based on 3-aroyl indazoles.
AID362440	Induction of apoptotic activity in human KB cells at 1 uM after 24 hrs	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID153679	Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388 (1303) for mortality range at an optimal dose of 1 mg/kg/injection	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID492225	Cytotoxicity against human SF268 cells at 4 ug/ml after 48 hrs by sulforhodamine B assay relative to control	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Synthesis and antiproliferative evaluation of certain iminonaphtho[2,3-b]furan derivatives.
AID492231	Selectivity index, ratio of GI50 for human Detroit 551 cells to GI50 for human NCI-H460 cells	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Synthesis and antiproliferative evaluation of certain iminonaphtho[2,3-b]furan derivatives.
AID212912	Inhibitory activity against telomerase at 50 uM concentration (Compound released from underivatized resin	2001	Bioorganic & medicinal chemistry letters, Oct-22, Volume: 11, Issue:20	Small molecule/nucleic acid affinity chromatography: application for the identification of telomerase inhibitors which target its key RNA/DNA heteroduplex.
AID259834	Cytotoxicity against K562 cells by MTS	2006	Journal of medicinal chemistry, Feb-09, Volume: 49, Issue:3	Discovery of a daunorubicin analogue that exhibits potent antitumor activity and overcomes P-gp-mediated drug resistance.
AID624609	Specific activity of expressed human recombinant UGT1A6	2000	Annual review of pharmacology and toxicology, , Volume: 40	Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1555331	Cytostatic activity against human MDA-MB-231 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Sequence modification of heptapeptide selected by phage display as homing device for HT-29 colon cancer cells to improve the anti-tumour activity of drug delivery systems.
AID1145737	Inhibition of DNA synthesis in mouse L1210 cells preincubated for 3 hrs followed by [3H]-thymidine addition measured after 1 hr by scintillation spectrometric analysis	1976	Journal of medicinal chemistry, Mar, Volume: 19, Issue:3	Adriamycin analogs. Periodate oxidation of adriamycin.
AID396070	Induction of apoptosis in multidrug resistant human HL60 cells after 48 hrs	2008	European journal of medicinal chemistry, Nov, Volume: 43, Issue:11	Synthesis and induction of G0-G1 phase arrest with apoptosis of 3,5-dimethyl-6-phenyl-8-(trifluoromethyl)-5,6-dihydropyrazolo[3,4-f][1,2,3,5]tetrazepin-4(3H)-one.
AID469437	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay	2009	Journal of natural products, Dec, Volume: 72, Issue:12	Tartrolon D, a cytotoxic macrodiolide from the marine-derived actinomycete Streptomyces sp. MDG-04-17-069.
AID292456	Cytotoxicity against A549 cells after 72 hrs	2007	Journal of medicinal chemistry, Jul-26, Volume: 50, Issue:15	New analogues of the potent cytotoxic saponin OSW-1.
AID748708	Inhibition of tau K19 (unknown origin) aggregation assessed as inhibition of paired helical filament formation after 10 days by thioflavin S fluorescence assay in presence of heparin	2013	Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11	Progress and developments in tau aggregation inhibitors for Alzheimer disease.
AID659658	Drug uptake in human DU145 cell nucleus at 1 uM after 4 hrs by confocal microscopic analysis	2012	Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4	Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.
AID1600802	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19	Synthesis and antitumor activity of daunorubicin conjugates with of 3,4-methylendioxybenzaldehyde.
AID1123728	Inhibition of RNA synthesis in mouse L1210 cells	1979	Journal of medicinal chemistry, Jan, Volume: 22, Issue:1	Synthesis of daunorubicin analogues with novel 9-acyl substituents.
AID1132920	Cardiotoxicity in rat EEG model	1978	Journal of medicinal chemistry, Aug, Volume: 21, Issue:8	Antitumor anthracycline antibiotics. Structure-activity and structure-cardiotoxicity relationships of rubidazone analogues.
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID1145738	Inhibition of RNA synthesis in mouse L1210 cells preincubated for 3 hrs followed by [3H]-uridine addition measured after 1 hr by scintillation spectrometric analysis	1976	Journal of medicinal chemistry, Mar, Volume: 19, Issue:3	Adriamycin analogs. Periodate oxidation of adriamycin.
AID1132430	Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 0.78 mg/kg, ip qd administered starting from day 1 to day 9 post challenge relative to control	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Adriamycin analogues. 2. Synthesis of 13-deoxyanthracyclines.
AID471987	Cytotoxicity against HEK293 cells at 400 nM after 48 hrs by resazurin conversion-based fluorometric assay	2009	Journal of natural products, Sep, Volume: 72, Issue:9	Halogenated fatty acid amides and cyclic depsipeptides from an eastern Caribbean collection of the cyanobacterium Lyngbya majuscula.
AID624626	Ratio of apparent permeability from basolateral to apical side over apical to basolateral side determined in MDR1-MDCKII cells	2001	The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2	Rational use of in vitro P-glycoprotein assays in drug discovery.
AID400017	Cytotoxicity against human HeLa cells assessed as colony formation at 12.5 ng/ml relative to control
AID678933	TP_TRANSPORTER: increase in brain concentration in mdr1a/1b(-/-) mouse	2001	Pharmaceutical research, Dec, Volume: 18, Issue:12	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein.
AID624629	Inhibition of Pgp expressed in MDR1-MDCKII cells measured by calcein-AM assay	2001	The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2	Rational use of in vitro P-glycoprotein assays in drug discovery.
AID292451	Cytotoxicity against K562 cells after 72 hrs	2007	Journal of medicinal chemistry, Jul-26, Volume: 50, Issue:15	New analogues of the potent cytotoxic saponin OSW-1.
AID292453	Cytotoxicity against human G361 cells after 72 hrs	2007	Journal of medicinal chemistry, Jul-26, Volume: 50, Issue:15	New analogues of the potent cytotoxic saponin OSW-1.
AID1555384	Antitumor activity against human HT-29 cells xenografted in SCID mouse assessed as tumor growth inhibition by measuring decrease in tumor weight at 1 mg/kg, ip administered once a week (on day 13 and 20) starting from 13 days post inoculation measured at	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Sequence modification of heptapeptide selected by phage display as homing device for HT-29 colon cancer cells to improve the anti-tumour activity of drug delivery systems.
AID1379632	Cytotoxicity in human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Synthesis and biological evaluation of new substituted thioglycolurils, their analogues and derivatives.
AID1638053	Cytotoxicity against mouse CT26.WT cells after 72 hrs by MTT assay	2019	European journal of medicinal chemistry, Mar-01, Volume: 165	Synthesis and anticancer evaluation of new lipophilic 1,2,4 and 1,3,4-oxadiazoles.
AID1409609	Cytotoxicity of compound against Vero E6 cells by MTT assay.	2020	Nature, 07, Volume: 583, Issue:7816	A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID1145594	Antiproliferative activity against MEF after 72 hrs	1976	Journal of medicinal chemistry, May, Volume: 19, Issue:5	Stereocontrolled glycosidation of daunomycinone. Synthesis and biological evaluation of 6-hydroxy-L-arabino analogues of antitumor anthracyclines.
AID659493	Inhibition of HDAC1 in human HeLa cell nuclear extract using Fluor de Lys as substrate after 15 mins by fluorometric analysis	2012	Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4	Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.
AID748704	Induction of tau K19 (unknown origin) disaggregation assessed as decrease in paired helical filament formation measured disassembly-inducing half maxima after 10 days by thioflavin S fluorescence assay in presence of heparin	2013	Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11	Progress and developments in tau aggregation inhibitors for Alzheimer disease.
AID83956	Tested for the cytotoxicity(1 hour incubation) against human colon tumor cell lines (HT 29).	1990	Journal of medicinal chemistry, Jan, Volume: 33, Issue:1	Structure-activity relationship of anthracyclines in vitro.
AID1202307	Cytotoxicity against human HL60R cells expressing p-glycoprotein assessed as growth inhibition after 48 hrs by trypan blue staining-based hemocytometric analysis	2015	European journal of medicinal chemistry, , Volume: 96	Synthesis and antiproliferative activity of 3-(2-chloroethyl)-5-methyl-6-phenyl-8-(trifluoromethyl)-5,6-dihydropyrazolo[3,4-f][1,2,3,5]tetrazepin-4-(3H)-one.
AID1175398	Antiproliferative activity against human MDA-MB-231 cells by XTT assay	2015	Bioorganic & medicinal chemistry, Jan-01, Volume: 23, Issue:1	Discovery of 2-[2-(5-nitrofuran-2-yl)vinyl]quinoline derivatives as a novel type of antimetastatic agents.
AID63724	The compound was evaluated for the growth inhibition of Dx5 w/PSC cell lines using MTT assay.	2000	Bioorganic & medicinal chemistry letters, Feb-07, Volume: 10, Issue:3	Synthesis and evaluation of daunorubicin-paclitaxel dimers.
AID1132429	Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 1.56 mg/kg, ip qd administered starting from day 1 to day 9 post challenge relative to control	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Adriamycin analogues. 2. Synthesis of 13-deoxyanthracyclines.
AID588215	FDA HLAED, alkaline phosphatase increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID467955	Cytotoxicity against human KB cells after 48 hrs by MTT assay	2009	Journal of natural products, Aug, Volume: 72, Issue:8	Acylphloroglucinol, biyouyanagiol, biyouyanagin B, and related spiro-lactones from Hypericum chinense.
AID205641	Compound was tested for antibacterial activity against Staphylococcus aureus ATCC 25923	1986	Journal of medicinal chemistry, Sep, Volume: 29, Issue:9	Synthesis of anthraquinonyl glucosaminosides and studies on the influence of aglycone hydroxyl substitution on superoxide generation, DNA binding, and antimicrobial properties.
AID93483	Cytotoxicity against IGROV tumor cell line	1999	Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25	Synthesis and biological evaluation of novel prodrugs of anthracyclines for selective activation by the tumor-associated protease plasmin.
AID1132445	Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 4 mg/kg, ip qd administered starting on day 5,9 and 13 post challenge relative to control	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Adriamycin analogues. 2. Synthesis of 13-deoxyanthracyclines.
AID44202	Effect on cross resistance of CCRF-CEM cells resistant to vincristine.	1990	Journal of medicinal chemistry, Jul, Volume: 33, Issue:7	Structure-activity relationships of antineoplastic agents in multidrug resistance.
AID153680	Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388 (1303) for tumor free survivors at an optimal dose of 1 mg/kg/injection	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID272494	Antiproliferative activity against P388 cells by ELISA	2006	Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23	Flavonoid dimers as bivalent modulators for P-glycoprotein-based multidrug resistance: synthetic apigenin homodimers linked with defined-length poly(ethylene glycol) spacers increase drug retention and enhance chemosensitivity in resistant cancer cells.
AID1638054	Selectivity index, ratio of IC50 for mouse CT26.WT cells to IC50 for mouse 4T1 cells	2019	European journal of medicinal chemistry, Mar-01, Volume: 165	Synthesis and anticancer evaluation of new lipophilic 1,2,4 and 1,3,4-oxadiazoles.
AID101086	Tested for the cytotoxicity (continuous incubation) against L1210 leukemia cells determined by clonogenic assay.	1990	Journal of medicinal chemistry, Jan, Volume: 33, Issue:1	Structure-activity relationship of anthracyclines in vitro.
AID272492	Antiproliferative activity against MDA435/LCC6 cells by ELISA	2006	Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23	Flavonoid dimers as bivalent modulators for P-glycoprotein-based multidrug resistance: synthetic apigenin homodimers linked with defined-length poly(ethylene glycol) spacers increase drug retention and enhance chemosensitivity in resistant cancer cells.
AID23271	Partition coefficient (logD7.4)	1990	Journal of medicinal chemistry, Jul, Volume: 33, Issue:7	Structure-activity relationships of antineoplastic agents in multidrug resistance.
AID57470	Inhibitory activity against dihydrofolate reductase (DHFR) isolated from murine L5178Y tumor cells resistant and sensitive to methotrexate	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	Comparative structure-activity relationships of antifolate triazines inhibiting murine tumor cells sensitive and resistant to methotrexate.
AID659636	Antiproliferative activity against human MCF7 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4	Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.
AID1758195	Inhibition of P-glycoprotein in human MCF7/ADR cells assessed as reversal fold by measuring reduction in daunorubicin IC50 at 5 uM incubated for 48 hrs by CCK-8 assay	2021	European journal of medicinal chemistry, Apr-15, Volume: 216	Design, synthesis and bioactivity study on 5-phenylfuran derivatives as potent reversal agents against P-glycoprotein-mediated multidrug resistance in MCF-7/ADR cell.
AID310119	Cytotoxicity against human A2780 cells after 72 hrs by MTT assay	2007	Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23	New functional assay of P-glycoprotein activity using Hoechst 33342.
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1124698	Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as tumor inhibition at 2 mg/kg, ip on days 5, 9 and 13 relative to untreated control	1979	Journal of medicinal chemistry, Apr, Volume: 22, Issue:4	Synthesis and antitumor activity of sugar-ring hydroxyl analogues of daunorubicin.
AID588216	FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID731877	Displacement of YOYO1 from phage lambda DNA by FID assay	2013	ACS medicinal chemistry letters, Mar-14, Volume: 4, Issue:3	The structure of anthracycline derivatives determines their subcellular localization and cytotoxic activity.
AID1221970	Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko143	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1863056	Growth inhibition of mouse 4T1 cells at 1 uM	2022	Bioorganic & medicinal chemistry, 09-15, Volume: 70	Discovery of CN0 as a novel proteolysis-targeting chimera (PROTAC) degrader of PARP1 that can activate the cGAS/STING immunity pathway combined with daunorubicin.
AID537735	Binding affinity to Candida albicans CaMdr1p expressed in yeast AD1-8u	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID1409611	AUC (cytotoxicity %) of compound against Vero E6 cells by MTT assay.	2020	Nature, 07, Volume: 583, Issue:7816	A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID203867	Maximal binding (nmax) sites to herring sperm DNA. Estimated from Scatchard plots	1980	Journal of medicinal chemistry, Nov, Volume: 23, Issue:11	Amino acid and dipeptide derivatives of daunorubicin. 1. Synthesis, physicochemical properties, and lysosomal digestion.
AID111954	Chemotherapeutic activity was evaluated by measuring mean tumor diameter on day 12 at 11 mg/kg/day, sc	1980	Journal of medicinal chemistry, Nov, Volume: 23, Issue:11	Amino acid and dipeptide derivatives of daunorubicin. 2. Cellular pharmacology and antitumor activity on L1210 leukemic cells in vitro and in vivo.
AID644953	Binding affinity to human pre-hsa-mir-155 miRNA assessed as inhibition of dicer-catalysed (33P)-labelled pre-miRNA processing at 1 mM after 1 hr by PAGE analysis	2012	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4	Pre-microRNA binding aminoglycosides and antitumor drugs as inhibitors of Dicer catalyzed microRNA processing.
AID155079	Inhibition of Pancreatic elastase at 10e-5 M; NI means no inhibition	1992	Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15	Inhibition of collagenase by aranciamycin and aranciamycin derivatives.
AID1472139	Cytotoxicity against HEK293 cells assessed as cell viability after 24 hrs by Alamar blue assay	2017	Journal of medicinal chemistry, 12-28, Volume: 60, Issue:24	Structure-Based Design and Biological Characterization of Selective Histone Deacetylase 8 (HDAC8) Inhibitors with Anti-Neuroblastoma Activity.
AID153090	Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388 (1303) for tumor free survivors at an optimal dose of 1 mg/kg/injection	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID492229	Cytotoxicity against human Detroit 551 cells after 72 hrs by XTT assay	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Synthesis and antiproliferative evaluation of certain iminonaphtho[2,3-b]furan derivatives.
AID1755162	Inhibition of acid-mediated aggregation of TTR V30M mutant (unknown origin) expressed in Escherichia coli pretreated for 30 mins at pH 7 followed by protein dilution in acetate buffer and further incubated for 96 hrs at pH 4.6 by thioflavin-T fluorescence	2021	Bioorganic & medicinal chemistry, 08-15, Volume: 44	Inhibitory activities of anthraquinone and xanthone derivatives against transthyretin amyloidogenesis.
AID110796	Number of mice(with Colon 38 tumors) cured after treatment of 3.9 mg/kg/day dose given as 3 times in a day for 4 days out of 5 mice	2003	Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6	Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridines.
AID94165	In vitro cytotoxic activity was evaluated using the KB-3-1 resistant to adriamycin (ADR) subline KB-A1	2002	Bioorganic & medicinal chemistry letters, Dec-16, Volume: 12, Issue:24	Synthesis and cytotoxic activity of a new potent daunomycinone derivative.
AID1221975	Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko143	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID54144	Compound was tested for antibacterial activity against Corynebacterium diphtheria WSU	1986	Journal of medicinal chemistry, Sep, Volume: 29, Issue:9	Synthesis of anthraquinonyl glucosaminosides and studies on the influence of aglycone hydroxyl substitution on superoxide generation, DNA binding, and antimicrobial properties.
AID1858598	Inhibition of HDAC8 (unknown origin)	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Paradigm shift of "classical" HDAC inhibitors to "hybrid" HDAC inhibitors in therapeutic interventions.
AID212910	Inhibitory activity against telomerase at 50 uM concentration (Compound released from DNA/DNA heteroduplex derivatized resin [sequence (TTAGGG)3)	2001	Bioorganic & medicinal chemistry letters, Oct-22, Volume: 11, Issue:20	Small molecule/nucleic acid affinity chromatography: application for the identification of telomerase inhibitors which target its key RNA/DNA heteroduplex.
AID1145746	Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 0.12 mg/kg, ip qd administered for 9 days relative to control	1976	Journal of medicinal chemistry, Mar, Volume: 19, Issue:3	Adriamycin analogs. Periodate oxidation of adriamycin.
AID550994	Cytotoxicity against human MCF7 cells after 24 hrs by MTS assay	2011	Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1	Cytotoxicity and topoisomerase I/II inhibition of glycosylated 2-phenyl-indoles, 2-phenyl-benzo[b]thiophenes and 2-phenyl-benzo[b]furans.
AID105073	The compound was tested for intracellular cytotoxicity against MDA MB 361(mammary carcinoma cell line) expressing LacZ (beta-galactosidase).	1999	Journal of medicinal chemistry, Jul-01, Volume: 42, Issue:13	Self-immolative anthracycline prodrugs for suicide gene therapy.
AID688708	Antileishmanial activity against promastigotes of wild type Leishmania tropica LRC after 72 hrs by MTT assay	2012	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19	Oxazolo[3,2-a]pyridine. A new structural scaffold for the reversal of multi-drug resistance in Leishmania.
AID1555334	Cytostatic activity against human HT-29 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Sequence modification of heptapeptide selected by phage display as homing device for HT-29 colon cancer cells to improve the anti-tumour activity of drug delivery systems.
AID685500	HARVARD: Cytotoxicity in HepG2 cell line	2012	Proceedings of the National Academy of Sciences of the United States of America, May-29, Volume: 109, Issue:22	Liver-stage malaria parasites vulnerable to diverse chemical scaffolds.
AID685501	HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells	2012	Proceedings of the National Academy of Sciences of the United States of America, May-29, Volume: 109, Issue:22	Liver-stage malaria parasites vulnerable to diverse chemical scaffolds.
AID704305	Activity of human carbonyl reductase 1	2012	European journal of medicinal chemistry, Oct, Volume: 56	Understanding the binding of daunorubicin and doxorubicin to NADPH-dependent cytosolic reductases by computational methods.
AID681111	TP_TRANSPORTER: inhibition of DNP-SG uptake in membrane vesicles from GLC4/ADR cells	1997	Biochimica et biophysica acta, May-22, Volume: 1326, Issue:1	Anthracyclines modulate multidrug resistance protein (MRP) mediated organic anion transport.
AID357846	Binding affinity to yeast tRNA assessed as reduction in tRNA peak by pre-incubation method
AID1600804	Antiproliferative activity against human RD cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19	Synthesis and antitumor activity of daunorubicin conjugates with of 3,4-methylendioxybenzaldehyde.
AID472409	Cytotoxicity against human KB cells after 48 hrs by MTT assay	2010	Bioorganic & medicinal chemistry, Apr-15, Volume: 18, Issue:8	Papyriferic acid derivatives as reversal agents of multidrug resistance in cancer cells.
AID212911	Inhibitory activity against telomerase at 50 uM concentration (Compound released from RNA/DNA heteroduplex derivatized resin [sequence (TTAGGG)3)	2001	Bioorganic & medicinal chemistry letters, Oct-22, Volume: 11, Issue:20	Small molecule/nucleic acid affinity chromatography: application for the identification of telomerase inhibitors which target its key RNA/DNA heteroduplex.
AID70886	Compound is evaluated for lambda-phage induction activity in Escherichia coli (dose at 0.8 ug/mL)	1980	Journal of medicinal chemistry, Nov, Volume: 23, Issue:11	8-Hydroxyanthracyclinones from epsilon-rhodomycinone.
AID103085	Compound was tested for its toxicity against doxorubicin resistant human breast cancer cells (MCF-7/ADR).	1998	Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8	Epidoxoform: a hydrolytically more stable anthracycline-formaldehyde conjugate toxic to resistant tumor cells.
AID50757	Tested for the cytotoxicity (continuous incubation) against human colon tumor cell lines (colon 4)determined by clonogenic assay.	1990	Journal of medicinal chemistry, Jan, Volume: 33, Issue:1	Structure-activity relationship of anthracyclines in vitro.
AID1123760	Toxicity in mouse allografted with mouse P388 cells at 2.9 mg/kg, ip	1979	Journal of medicinal chemistry, Feb, Volume: 22, Issue:2	Synthesis and antitumor activity of 4'-O-methyldaunorubicin, 4'-O-methyladriamycin, and their 4'-epi analogues.
AID1221982	Fraction absorbed in human	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID106329	The compound was evaluated for the growth inhibition of MES-SA uterine tumor cell lines using MTT assay.	2000	Bioorganic & medicinal chemistry letters, Feb-07, Volume: 10, Issue:3	Synthesis and evaluation of daunorubicin-paclitaxel dimers.
AID121877	Chemotherapeutic activity was evaluated by measuring number of survivors on day 30 / total number of mice at 10 mg/kg/day, sc; 0/58	1980	Journal of medicinal chemistry, Nov, Volume: 23, Issue:11	Amino acid and dipeptide derivatives of daunorubicin. 2. Cellular pharmacology and antitumor activity on L1210 leukemic cells in vitro and in vivo.
AID659923	Antiproliferative activity against human MONO-MAC-6 cells assessed as inhibition of cell viability at 10'-7 M after 48 hrs by cell counting method	2012	European journal of medicinal chemistry, Jun, Volume: 52	GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexate.
AID111963	Chemotherapeutic activity was evaluated by measuring mean tumor diameter on day 8 at 12(mg/kg)/day, sc	1980	Journal of medicinal chemistry, Nov, Volume: 23, Issue:11	Amino acid and dipeptide derivatives of daunorubicin. 2. Cellular pharmacology and antitumor activity on L1210 leukemic cells in vitro and in vivo.
AID98034	Concentration of drug necessary to reduce by 50% the incorporation of tritiated uridine in the RNA of actively growing L1210 cells.	1982	Journal of medicinal chemistry, Jan, Volume: 25, Issue:1	Enhanced antitumor properties of 3'-(4-morpholinyl) and 3'-(4-methoxy-1-piperidinyl) derivatives of 3'-deaminodaunorubicin.
AID588214	FDA HLAED, liver enzyme composite activity	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1555385	Toxicity in SCID mouse xenografted with human HT-29 cells assessed as body weight loss at 1 mg/kg, ip administered once a week (on day 13 and 20) starting from 13 days post inoculation measured upto 23 days post inoculation	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Sequence modification of heptapeptide selected by phage display as homing device for HT-29 colon cancer cells to improve the anti-tumour activity of drug delivery systems.
AID683863	Inhibition of human topoisomerase 2-mediated [3H]TdR-labeled catenated kinetoplast DNA decatenation after 15 to 30 mins by scintillation counting	2012	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19	New derivatives of 11-methyl-6-[2-(dimethylamino)ethyl]-6H-indolo[2,3-b]quinoline as cytotoxic DNA topoisomerase II inhibitors.
AID153554	Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388 (1303) for change in body weight at an optimal dose of 1 mg/kg/injection	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID280077	Antiproliferative activity against drug resistant H69AR cell line expressing MRP1 by Alamar Blue assay	2007	Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5	Potent antitubulin tumor cell cytotoxins based on 3-aroyl indazoles.
AID456324	Growth inhibition of human NCI60 cells	2010	Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1	Synthesis and antiproliferative evaluations of certain 2-phenylvinylquinoline (2-styrylquinoline) and 2-furanylvinylquinoline derivatives.
AID681170	TP_TRANSPORTER: drug resistance in MRP1-expressing HEK293 cells	2003	Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 31, Issue:8	Molecular cloning and pharmacological characterization of rat multidrug resistance protein 1 (mrp1).
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID606439	Selectivity index, ratio of IC50 of human MRC5 cells to IC50 for human SF268 cells	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery of 4-anilinofuro[2,3-b]quinoline derivatives as selective and orally active compounds against non-small-cell lung cancers.
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID660074	Antitumor activity against mouse C26 cells allografted in Balb/C mouse assessed as tumor growth inhibition	2012	European journal of medicinal chemistry, Jun, Volume: 52	GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexate.
AID492228	Cytotoxicity against human SF268 cells after 72 hrs by XTT assay	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Synthesis and antiproliferative evaluation of certain iminonaphtho[2,3-b]furan derivatives.
AID659634	Antiproliferative activity against human DU145 cells after 72 hrs by MTS assay	2012	Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4	Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.
AID333400	Cytotoxicity against mouse NS1 cells after 72 hrs by microtiter plate assay	2004	Journal of natural products, Oct, Volume: 67, Issue:10	Blanchaquinone: a new anthraquinone from an Australian Streptomyces sp.
AID681356	TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) in MDR1-expressing MDCK cells	2002	Pharmaceutical research, Jun, Volume: 19, Issue:6	Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa?
AID21036	Tested for the partition coefficient between water and n-octanol.	1990	Journal of medicinal chemistry, Jan, Volume: 33, Issue:1	Structure-activity relationship of anthracyclines in vitro.
AID310118	Cytotoxicity against human A2780/ADR cells after 72 hrs by MTT assay	2007	Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23	New functional assay of P-glycoprotein activity using Hoechst 33342.
AID1130449	Cardiotoxicity in rat assessed as minimum cumulative cardiotoxic dose by Zbinden test	1979	Journal of medicinal chemistry, Aug, Volume: 22, Issue:8	Adriamycin analogues. 3. Synthesis of N-alkylated anthracyclines with enhanced efficacy and reduced cardiotoxicity.
AID1638056	Selectivity index, ratio of IC50 for BHK-21 cells to IC50 for mouse 4T1 cells	2019	European journal of medicinal chemistry, Mar-01, Volume: 165	Synthesis and anticancer evaluation of new lipophilic 1,2,4 and 1,3,4-oxadiazoles.
AID136225	Effect of 3 mg/kg/dose of compound given iv q4d x 3 against sc human ovarian tumor (SK-OV3) in mice expressed as treated/ control ( 1000 mm**3) median tumor volume on day 30	1999	Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18	Drug delivery systems employing 1,4- or 1,6-elimination: poly(ethylene glycol) prodrugs of amine-containing compounds.
AID1555393	Hepatotoxicity in SCID mouse xenografted with human HT-29 cells assessed as decrease in liver weight at 1 mg/kg, ip administered once a week (on days 13 and 20) starting from 13 days post inoculation measured at 23 days post inoculation	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Sequence modification of heptapeptide selected by phage display as homing device for HT-29 colon cancer cells to improve the anti-tumour activity of drug delivery systems.
AID469439	Cytotoxicity against human HT-29 cells after 72 hrs by sulforhodamine B assay	2009	Journal of natural products, Dec, Volume: 72, Issue:12	Tartrolon D, a cytotoxic macrodiolide from the marine-derived actinomycete Streptomyces sp. MDG-04-17-069.
AID1202306	Induction of apoptosis in human HL60 cells after 48 hrs by acridine orange/ethidium bromide staining-based fluorescence microscopic analysis	2015	European journal of medicinal chemistry, , Volume: 96	Synthesis and antiproliferative activity of 3-(2-chloroethyl)-5-methyl-6-phenyl-8-(trifluoromethyl)-5,6-dihydropyrazolo[3,4-f][1,2,3,5]tetrazepin-4-(3H)-one.
AID1123756	Antitumor activity against mouse P388 cells allografted in mouse assessed as average survival time at 2.9 mg/kg, ip relative to untreated control	1979	Journal of medicinal chemistry, Feb, Volume: 22, Issue:2	Synthesis and antitumor activity of 4'-O-methyldaunorubicin, 4'-O-methyladriamycin, and their 4'-epi analogues.
AID23436	Partition coefficient in octanol-phosphate buffer at pH 7.4	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	N-(cyanomethyl)- and N-(2-methoxy-1-cyanoethyl)anthracyclines and related carboxyl derivatives.
AID23702	Partition coefficient (logP)	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	Comparative structure-activity relationships of antifolate triazines inhibiting murine tumor cells sensitive and resistant to methotrexate.
AID1145744	Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 0.5 mg/kg, ip qd administered for 9 days relative to control	1976	Journal of medicinal chemistry, Mar, Volume: 19, Issue:3	Adriamycin analogs. Periodate oxidation of adriamycin.
AID550996	Cytotoxicity against human HepG2 cells after 24 hrs by MTS assay	2011	Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1	Cytotoxicity and topoisomerase I/II inhibition of glycosylated 2-phenyl-indoles, 2-phenyl-benzo[b]thiophenes and 2-phenyl-benzo[b]furans.
AID400016	Cytotoxicity against human HeLa cells assessed as inhibition of colony formation at 25 ng/ml relative to control
AID116310	Chemotherapeutic activity was evaluated by measuring the percent increase in life span of female DBA2 mice subcutaneously inoculated with L1210 leukemia at 12(mg/kg)/day, sc	1980	Journal of medicinal chemistry, Nov, Volume: 23, Issue:11	Amino acid and dipeptide derivatives of daunorubicin. 2. Cellular pharmacology and antitumor activity on L1210 leukemic cells in vitro and in vivo.
AID400023	Cytotoxicity against doxorubicin resistant mouse P388 cells
AID606429	Anticancer activity against human SF268 cells	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery of 4-anilinofuro[2,3-b]quinoline derivatives as selective and orally active compounds against non-small-cell lung cancers.
AID681148	TP_TRANSPORTER: inhibitory effect of typical BSEP inhibitors (Verapamil & Cyclosporin A) in SK-E2 cells (expressing BSEP)	2003	Pharmaceutical research, Apr, Volume: 20, Issue:4	Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites.
AID206365	Compound was tested for antibacterial activity against Staph. epidermidis ATCC 12228	1986	Journal of medicinal chemistry, Sep, Volume: 29, Issue:9	Synthesis of anthraquinonyl glucosaminosides and studies on the influence of aglycone hydroxyl substitution on superoxide generation, DNA binding, and antimicrobial properties.
AID537734	Antifungal activity against yeast AD1-8u expressing Candida albicans CaMdr1p by agar disk diffusion assay	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID659650	Inhibition of HDAC in human DU145 cells assessed as upregulation of p21 expression at IC50 concentration after 4 hrs by Western blot analysis relative to control	2012	Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4	Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.
AID550992	Cytotoxicity against human HepG2 cells assessed as cell viability at 25 uM after 24 hrs by MTS assay	2011	Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1	Cytotoxicity and topoisomerase I/II inhibition of glycosylated 2-phenyl-indoles, 2-phenyl-benzo[b]thiophenes and 2-phenyl-benzo[b]furans.
AID211107	Binding constant was measured against inhibition of DNA relaxation by topoisomerase I at 20 uM concentration	1994	Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19	Inhibition of topoisomerase I by anthracycline antibiotics: evidence for general inhibition of topoisomerase I by DNA-binding agents.
AID681132	TP_TRANSPORTER: ATP hydrolysis in MDR1-expressing Sf9 cells	2001	The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2	Rational use of in vitro P-glycoprotein assays in drug discovery.
AID259837	Cytotoxicity against Dox-resistant K562 cells by MTS at 1 uM and in presence of cyclosporine	2006	Journal of medicinal chemistry, Feb-09, Volume: 49, Issue:3	Discovery of a daunorubicin analogue that exhibits potent antitumor activity and overcomes P-gp-mediated drug resistance.
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID70887	Compound is evaluated for lambda-phage induction activity in Escherichia coli (dose at 1.6 ug/mL)	1980	Journal of medicinal chemistry, Nov, Volume: 23, Issue:11	8-Hydroxyanthracyclinones from epsilon-rhodomycinone.
AID1132432	Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 0.20 mg/kg, ip qd administered starting from day 1 to day 9 post challenge relative to control	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Adriamycin analogues. 2. Synthesis of 13-deoxyanthracyclines.
AID121880	Chemotherapeutic activity was evaluated by measuring number of survivors on day 30 / total number of mice at 12(mg/kg)/day, iv; 6/34	1980	Journal of medicinal chemistry, Nov, Volume: 23, Issue:11	Amino acid and dipeptide derivatives of daunorubicin. 2. Cellular pharmacology and antitumor activity on L1210 leukemic cells in vitro and in vivo.
AID659940	Induction of adhesion in human MONO-MAC-6 cells at 10'-7 M after 1.5 hrs by electrical impedence method relative to control	2012	European journal of medicinal chemistry, Jun, Volume: 52	GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexate.
AID8261	Cytotoxicity against A 498 tumor cell line	1999	Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25	Synthesis and biological evaluation of novel prodrugs of anthracyclines for selective activation by the tumor-associated protease plasmin.
AID550995	Cytotoxicity against human HT-29 cells after 24 hrs by MTS assay	2011	Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1	Cytotoxicity and topoisomerase I/II inhibition of glycosylated 2-phenyl-indoles, 2-phenyl-benzo[b]thiophenes and 2-phenyl-benzo[b]furans.
AID679011	TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 0.05 uM) in membrane vesicle from MRP1-expressing HeLa cells	1996	The Journal of biological chemistry, Apr-19, Volume: 271, Issue:16	ATP-dependent 17 beta-estradiol 17-(beta-D-glucuronide) transport by multidrug resistance protein (MRP). Inhibition by cholestatic steroids.
AID54463	Tested for the binding affinity for DNA by intercalation between adjacent base pairs of the helix.	1990	Journal of medicinal chemistry, Jan, Volume: 33, Issue:1	Structure-activity relationship of anthracyclines in vitro.
AID1132906	Binding affinity to calf thymus DNA assessed as change in melting temperature at 5 uM by spectrophotometer analysis	1978	Journal of medicinal chemistry, Aug, Volume: 21, Issue:8	Antitumor anthracycline antibiotics. Structure-activity and structure-cardiotoxicity relationships of rubidazone analogues.
AID136226	Effect of 3 mg/kg/dose of compound given iv q4d x 3 against sc human ovarian tumor (SK-OV3) in mice expressed as treated/ control mean tumor volume on day 30	1999	Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18	Drug delivery systems employing 1,4- or 1,6-elimination: poly(ethylene glycol) prodrugs of amine-containing compounds.
AID1221961	Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID55168	Tested for binding affinity per DNA base pair in rat	1986	Journal of medicinal chemistry, Sep, Volume: 29, Issue:9	Synthesis of anthraquinonyl glucosaminosides and studies on the influence of aglycone hydroxyl substitution on superoxide generation, DNA binding, and antimicrobial properties.
AID678804	TP_TRANSPORTER: ATP hydrolysis in membrane vesicle from BCRP-expressing Sf9 cells	2001	Biochemical and biophysical research communications, Jul-06, Volume: 285, Issue:1	Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID50756	Tested for the cytotoxicity(1 hour incubation) against human colon tumor cell lines colon 4).	1990	Journal of medicinal chemistry, Jan, Volume: 33, Issue:1	Structure-activity relationship of anthracyclines in vitro.
AID1555356	Drug uptake in nucleus of human HT-29 cells assessed as increase in fluorescence at 50 uM after 90 mins by fluorescence based confocal microscopic analysis	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Sequence modification of heptapeptide selected by phage display as homing device for HT-29 colon cancer cells to improve the anti-tumour activity of drug delivery systems.
AID144381	Concentration of substrate at which the amount of total cytochrome c reduction is decreased by 10%	1993	Journal of medicinal chemistry, Jan-08, Volume: 36, Issue:1	6-[(aminoalkyl)amino]-substituted 7H-benzo[e]perimidin-7-ones as novel antineoplastic agents. Synthesis and biological evaluation.
AID203866	Apparent binding affinity to herring sperm DNA at 25 degree Celsius in PBS buffer with pH 7.4	1980	Journal of medicinal chemistry, Nov, Volume: 23, Issue:11	Amino acid and dipeptide derivatives of daunorubicin. 1. Synthesis, physicochemical properties, and lysosomal digestion.
AID216116	Cytotoxicity against WIDR tumor cell line	1999	Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25	Synthesis and biological evaluation of novel prodrugs of anthracyclines for selective activation by the tumor-associated protease plasmin.
AID1132444	Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 8 mg/kg, ip qd administered starting on day 5,9 and 13 post challenge relative to control	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Adriamycin analogues. 2. Synthesis of 13-deoxyanthracyclines.
AID1132428	Inhibition of RNA synthesis in mouse L1210 cells compound preincubated for 3 hrs followed by [3H]uridine addition measured after 1 hr by scintillation counting	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Adriamycin analogues. 2. Synthesis of 13-deoxyanthracyclines.
AID1202310	Induction of apoptosis in human K562 cells expressing Bcr-Abl after 48 hrs by acridine orange/ethidium bromide staining-based fluorescence microscopic analysis	2015	European journal of medicinal chemistry, , Volume: 96	Synthesis and antiproliferative activity of 3-(2-chloroethyl)-5-methyl-6-phenyl-8-(trifluoromethyl)-5,6-dihydropyrazolo[3,4-f][1,2,3,5]tetrazepin-4-(3H)-one.
AID586923	Resistant index, ratio of EC50 for tafenoquine-resistant promastigotes of Leishmania major R4 to EC50 for promastigotes of Leishmania major MHOM/JL/80/Friedlin	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	Increased glycolytic ATP synthesis is associated with tafenoquine resistance in Leishmania major.
AID659494	Inhibition of HDAC6 in human HeLa cell nuclear extract using Fluor de Lys as substrate after 15 mins by fluorometric analysis	2012	Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4	Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.
AID1555341	Cytostatic activity against human A2058 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Sequence modification of heptapeptide selected by phage display as homing device for HT-29 colon cancer cells to improve the anti-tumour activity of drug delivery systems.
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID597395	Cytotoxicity against human doxorubicin-resistant K562 cells after 6 hrs by MTT assay	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	New 29-nor-cycloartanes with a 3,4-seco- and a novel 2,3-seco-structure from the leaves of Sinocalycanthus chinensis.
AID1555348	Cytostatic activity against human PANC1 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Sequence modification of heptapeptide selected by phage display as homing device for HT-29 colon cancer cells to improve the anti-tumour activity of drug delivery systems.
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1145597	Antitumor activity against mouse Sarcoma 180 cells allografted in mouse assessed as average survival time at 2 mg/kg, ip on day 1 post challenge relative to untreated control	1976	Journal of medicinal chemistry, May, Volume: 19, Issue:5	Stereocontrolled glycosidation of daunomycinone. Synthesis and biological evaluation of 6-hydroxy-L-arabino analogues of antitumor anthracyclines.
AID153081	Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388 (1303) for median day of death at an optimal dose of 1 mg/kg/injection	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID445446	Oral bioavailability in human	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID1132917	In vivo antitumor activity against mouse P388 cells allografted in BDF/CDF mouse assessed as host survival time at 0.5 mg/kg, ip administered on days 1 to 9 relative to control	1978	Journal of medicinal chemistry, Aug, Volume: 21, Issue:8	Antitumor anthracycline antibiotics. Structure-activity and structure-cardiotoxicity relationships of rubidazone analogues.
AID1555330	Cytostatic activity against human MCF7 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Sequence modification of heptapeptide selected by phage display as homing device for HT-29 colon cancer cells to improve the anti-tumour activity of drug delivery systems.
AID467956	Cytotoxicity against human multidrug resistant KB-C2 cells after 48 hrs by MTT assay	2009	Journal of natural products, Aug, Volume: 72, Issue:8	Acylphloroglucinol, biyouyanagiol, biyouyanagin B, and related spiro-lactones from Hypericum chinense.
AID51924	Effect on cross resistance of chinese hamster cells resistant to Actinomycin D.	1990	Journal of medicinal chemistry, Jul, Volume: 33, Issue:7	Structure-activity relationships of antineoplastic agents in multidrug resistance.
AID704307	Ratio of Vmax to Km for human carbonyl reductase 1	2012	European journal of medicinal chemistry, Oct, Volume: 56	Understanding the binding of daunorubicin and doxorubicin to NADPH-dependent cytosolic reductases by computational methods.
AID1132910	Partition coefficient, log P of the compound	1978	Journal of medicinal chemistry, Aug, Volume: 21, Issue:8	Antitumor anthracycline antibiotics. Structure-activity and structure-cardiotoxicity relationships of rubidazone analogues.
AID1132427	Inhibition of DNA synthesis in mouse L1210 cells compound preincubated for 3 hrs followed by [3H]thymidine addition measured after 1 hr by scintillation counting	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Adriamycin analogues. 2. Synthesis of 13-deoxyanthracyclines.
AID1221968	Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko143	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1555332	Cytostatic activity against mouse 4T1 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Sequence modification of heptapeptide selected by phage display as homing device for HT-29 colon cancer cells to improve the anti-tumour activity of drug delivery systems.
AID550993	Cytotoxicity against human HepG2 cells assessed as cell viability at 16 uM after 24 hrs by MTS assay	2011	Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1	Cytotoxicity and topoisomerase I/II inhibition of glycosylated 2-phenyl-indoles, 2-phenyl-benzo[b]thiophenes and 2-phenyl-benzo[b]furans.
AID68285	Cytotoxicity against EVSA-T tumor cell line	1999	Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25	Synthesis and biological evaluation of novel prodrugs of anthracyclines for selective activation by the tumor-associated protease plasmin.
AID679495	TP_TRANSPORTER: efflux in Mrp1-expressing HEK293 cells	1997	Molecular pharmacology, Sep, Volume: 52, Issue:3	Pharmacological characterization of the murine and human orthologs of multidrug-resistance protein in transfected human embryonic kidney cells.
AID1130590	Antitumor activity against mouse P388 cells allografted in ip dosed mouse assessed as minimum effective dose administered as single dose	1979	Journal of medicinal chemistry, Sep, Volume: 22, Issue:9	Antitumor agents. 1. 1,4-Bis[(aminoalkyl)amino]-9,10-anthracenediones.
AID1145423	Inhibition of DNA synthesis in mouse L1210 cells assessed as inhibition of [3H]-thymidine incorporation measured per 10'6 cells at 3 uM pretreated for 1 hr followed by radiotracer addition measured after 1 hr by scintillation spectrometric analysis relati	1976	Journal of medicinal chemistry, May, Volume: 19, Issue:5	Cellular pharmocodynamics of several anthrocycline antibiotics.
AID1555338	Cytostatic activity against human A549 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Sequence modification of heptapeptide selected by phage display as homing device for HT-29 colon cancer cells to improve the anti-tumour activity of drug delivery systems.
AID226867	Inhibitory concentration in presence of MDR inhibitor XR-9576	2004	Bioorganic & medicinal chemistry letters, Feb-23, Volume: 14, Issue:4	Inhibitors of multidrug resistance (MDR) have affinity for MDR substrates.
AID659911	Antiproliferative activity against human MONO-MAC-6 cells assessed as cell viability at 10'-7 M after 24 hrs by cell counting method relative to untreated control	2012	European journal of medicinal chemistry, Jun, Volume: 52	GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexate.
AID1130429	Antitumor activity against mouse P388 cells allografted in CDF/BDF mouse assessed as survival time at 0.78 mg/kg, ip administered as qd for 1 to 9 days relative to control	1979	Journal of medicinal chemistry, Aug, Volume: 22, Issue:8	Adriamycin analogues. 3. Synthesis of N-alkylated anthracyclines with enhanced efficacy and reduced cardiotoxicity.
AID1145745	Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 0.25 mg/kg, ip qd administered for 9 days relative to control	1976	Journal of medicinal chemistry, Mar, Volume: 19, Issue:3	Adriamycin analogs. Periodate oxidation of adriamycin.
AID231135	Ratio of the intracellular cytotoxicities against MDA MB 361(mammary carcinoma cell line) expressing LacZ (beta-galactosidase). between prodrug and drug.; Not available	1999	Journal of medicinal chemistry, Jul-01, Volume: 42, Issue:13	Self-immolative anthracycline prodrugs for suicide gene therapy.
AID597393	Cytotoxicity against human MCF7 cells after 6 hrs by MTT assay	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	New 29-nor-cycloartanes with a 3,4-seco- and a novel 2,3-seco-structure from the leaves of Sinocalycanthus chinensis.
AID659927	Antiproliferative activity against human MONO-MAC-6 cells assessed as inhibition of cell viability at 10'-6 M after 72 hrs by cell counting method	2012	European journal of medicinal chemistry, Jun, Volume: 52	GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexate.
AID1132915	In vivo antitumor activity against mouse P388 cells allografted in BDF/CDF mouse assessed as host survival time at 2 mg/kg, ip administered on days 1 to 9 relative to control	1978	Journal of medicinal chemistry, Aug, Volume: 21, Issue:8	Antitumor anthracycline antibiotics. Structure-activity and structure-cardiotoxicity relationships of rubidazone analogues.
AID659932	Antiproliferative activity against human MONO-MAC-6 cells assessed as cell viability at 10'-9 to 10'-6 M after 72 hrs by cell counting method relative to untreated control	2012	European journal of medicinal chemistry, Jun, Volume: 52	GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexate.
AID116180	Chemotherapeutic activity was evaluated by measuring the percent increase in life span of female DBA2 mice intravenously inoculated with L1210 leukemia at 12(mg/kg)/day, iv	1980	Journal of medicinal chemistry, Nov, Volume: 23, Issue:11	Amino acid and dipeptide derivatives of daunorubicin. 2. Cellular pharmacology and antitumor activity on L1210 leukemic cells in vitro and in vivo.
AID1897359	Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 24 hrs by alamar blue assay
AID1863055	Growth inhibition of mouse 4T1 cells at 0.5 uM	2022	Bioorganic & medicinal chemistry, 09-15, Volume: 70	Discovery of CN0 as a novel proteolysis-targeting chimera (PROTAC) degrader of PARP1 that can activate the cGAS/STING immunity pathway combined with daunorubicin.
AID101742	Cytotoxicity against MCF-7 tumor cell line	1999	Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25	Synthesis and biological evaluation of novel prodrugs of anthracyclines for selective activation by the tumor-associated protease plasmin.
AID1600805	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19	Synthesis and antitumor activity of daunorubicin conjugates with of 3,4-methylendioxybenzaldehyde.
AID624612	Specific activity of expressed human recombinant UGT1A9	2000	Annual review of pharmacology and toxicology, , Volume: 40	Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID659655	Inhibition of topoisomerase 2 in human DU145 cells assessed as stabilization of enzyme-DNA cleavage complex at 90 nM after 72 hrs by immunoblot analysis	2012	Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4	Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.
AID586924	Antileishmanial activity against tafenoquine-resistant promastigotes of Leishmania major R4 assessed as inhibition of parasite growth after 72 hrs by MTT assay	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	Increased glycolytic ATP synthesis is associated with tafenoquine resistance in Leishmania major.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1555335	Cytostatic activity against human WiDr cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Sequence modification of heptapeptide selected by phage display as homing device for HT-29 colon cancer cells to improve the anti-tumour activity of drug delivery systems.
AID551001	Cytotoxicity against african green monkey Vero cells after 3 days by MTS assay	2011	Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1	Cytotoxicity and topoisomerase I/II inhibition of glycosylated 2-phenyl-indoles, 2-phenyl-benzo[b]thiophenes and 2-phenyl-benzo[b]furans.
AID1123502	Toxicity in Salmonella typhimurium TA1537 assessed as growth inhibition after 1 hr	1979	Journal of medicinal chemistry, Mar, Volume: 22, Issue:3	Potential antitumor agents. 30. Mutagenic activity of some 9-anilinoacridines: relationships between structure, mutagenic potential, and antileukemic activity.
AID681613	TP_TRANSPORTER: intracellular accumulation in MDR1-expressing LLC-PK1 cells	2000	Molecular pharmacology, Jan, Volume: 57, Issue:1	Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein.
AID280075	Antiproliferative activity against drug resistant ACHN cell line expressing MDR1 by Alamar Blue assay	2007	Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5	Potent antitubulin tumor cell cytotoxins based on 3-aroyl indazoles.
AID731879	Cytotoxicity against mouse DA-3 cells assessed as reduction in cell viability at 20 uM after 60 mins by XTT assay	2013	ACS medicinal chemistry letters, Mar-14, Volume: 4, Issue:3	The structure of anthracycline derivatives determines their subcellular localization and cytotoxic activity.
AID1555351	Cytostatic activity against human MRC5 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Sequence modification of heptapeptide selected by phage display as homing device for HT-29 colon cancer cells to improve the anti-tumour activity of drug delivery systems.
AID105075	The compound was tested for intracellular cytotoxicity against MDA MB 361(mammary carcinoma cell line) in the presence of CPG2 prodrug	1999	Journal of medicinal chemistry, Jul-01, Volume: 42, Issue:13	Self-immolative anthracycline prodrugs for suicide gene therapy.
AID681121	TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing MDCKII cells	2001	The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2	Rational use of in vitro P-glycoprotein assays in drug discovery.
AID659651	Inhibition of HDAC in human DU145 cells assessed as upregulation of p21 expression at 5 times IC50 concentration after 4 hrs by Western blot analysis relative to control	2012	Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4	Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.
AID659647	Inhibition of HDAC6-mediated tubulin acetylation in human DU145 cells at 500 nM after 4 hrs by Western blot analysis	2012	Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4	Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.
AID63723	The compound was evaluated for the growth inhibition of Dx5 cell lines using MTT assay.	2000	Bioorganic & medicinal chemistry letters, Feb-07, Volume: 10, Issue:3	Synthesis and evaluation of daunorubicin-paclitaxel dimers.
AID259838	Cytotoxicity against Dox-resistant K562 cells by MTS at 1 uM and in absence of cyclosporine	2006	Journal of medicinal chemistry, Feb-09, Volume: 49, Issue:3	Discovery of a daunorubicin analogue that exhibits potent antitumor activity and overcomes P-gp-mediated drug resistance.
AID153678	Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388 (1303) for median day of death at an optimal dose of 1 mg/kg/injection	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID153681	Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388/L-PAM for total dose at an optimal dose of 1 mg/kg/injection	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID1130430	Inhibition of RNA synthesis in mouse L1210 cells	1979	Journal of medicinal chemistry, Aug, Volume: 22, Issue:8	Adriamycin analogues. 3. Synthesis of N-alkylated anthracyclines with enhanced efficacy and reduced cardiotoxicity.
AID105072	The compound was tested for extracellular cytotoxicity against MDA MB 361(mammary carcinoma cell line) in the presence of stCPG2 prodrug	1999	Journal of medicinal chemistry, Jul-01, Volume: 42, Issue:13	Self-immolative anthracycline prodrugs for suicide gene therapy.
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID731883	Cytotoxicity against mouse DA-3 cells after 24 hrs by XTT assay	2013	ACS medicinal chemistry letters, Mar-14, Volume: 4, Issue:3	The structure of anthracycline derivatives determines their subcellular localization and cytotoxic activity.
AID1555344	Cytostatic activity against mouse B16 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Sequence modification of heptapeptide selected by phage display as homing device for HT-29 colon cancer cells to improve the anti-tumour activity of drug delivery systems.
AID355586	Antiproliferative activity against mouse P388 cells at 0.01 ug after 48 hrs by two-layer agar-diffusion method
AID292457	Cytotoxicity against mouse NIH 3T3 cells after 72 hrs	2007	Journal of medicinal chemistry, Jul-26, Volume: 50, Issue:15	New analogues of the potent cytotoxic saponin OSW-1.
AID1202312	Induction of apoptosis in human HepG2 cells after 48 hrs by acridine orange/ethidium bromide staining-based fluorescence microscopic analysis	2015	European journal of medicinal chemistry, , Volume: 96	Synthesis and antiproliferative activity of 3-(2-chloroethyl)-5-methyl-6-phenyl-8-(trifluoromethyl)-5,6-dihydropyrazolo[3,4-f][1,2,3,5]tetrazepin-4-(3H)-one.
AID536031	Binding affinity to calf thymus DNA assessed as change in melting temperature at drug/DNA ratio 1	2010	Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22	Indeno[1,2-c]isoquinolin-5,11-diones conjugated to amino acids: Synthesis, cytotoxicity, DNA interaction, and topoisomerase II inhibition properties.
AID153085	Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388 (1303) for mortality range at an optimal dose of 1 mg/kg/injection	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID1409613	Selectivity ratio: ratio of AUC (viral infection %) of SARS-CoV-2 in the Vero E6 cell line compared to AUC (cytotoxicity %) of compound against Vero E6 cells by MTT assay.	2020	Nature, 07, Volume: 583, Issue:7816	A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID83137	In vitro concentration required to induce apoptosis in HL60R cells	2003	Journal of medicinal chemistry, Jul-31, Volume: 46, Issue:16	Synthesis and biological evaluation of resveratrol and analogues as apoptosis-inducing agents.
AID124505	Chemotherapeutic activity was evaluated by measuring percent change in weight on day 8 at 12(mg/kg)/day, sc	1980	Journal of medicinal chemistry, Nov, Volume: 23, Issue:11	Amino acid and dipeptide derivatives of daunorubicin. 2. Cellular pharmacology and antitumor activity on L1210 leukemic cells in vitro and in vivo.
AID98030	Compound was evaluated for the 50% inhibition of the incorporation of [3H]- thymidine in the RNA (inhibition of synthesis in leukemia L1210 cells)	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	N-(cyanomethyl)- and N-(2-methoxy-1-cyanoethyl)anthracyclines and related carboxyl derivatives.
AID1130428	Binding affinity to calf thymus DNA assessed as change in melting temperature	1979	Journal of medicinal chemistry, Aug, Volume: 22, Issue:8	Adriamycin analogues. 3. Synthesis of N-alkylated anthracyclines with enhanced efficacy and reduced cardiotoxicity.
AID1132918	In vivo antitumor activity against mouse P388 cells allografted in BDF/CDF mouse assessed as host survival time at 0.25 mg/kg, ip administered on days 1 to 9 relative to control	1978	Journal of medicinal chemistry, Aug, Volume: 21, Issue:8	Antitumor anthracycline antibiotics. Structure-activity and structure-cardiotoxicity relationships of rubidazone analogues.
AID1175395	Antiproliferative activity against human H1299 cells by XTT assay	2015	Bioorganic & medicinal chemistry, Jan-01, Volume: 23, Issue:1	Discovery of 2-[2-(5-nitrofuran-2-yl)vinyl]quinoline derivatives as a novel type of antimetastatic agents.
AID144491	Activity of NADH dehydrogenase was determined	1993	Journal of medicinal chemistry, Jan-08, Volume: 36, Issue:1	6-[(aminoalkyl)amino]-substituted 7H-benzo[e]perimidin-7-ones as novel antineoplastic agents. Synthesis and biological evaluation.
AID1221960	Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID83141	In vitro inhibitory concentration against proliferation of HL60R cells along with 5 (uM) verapamil	2003	Journal of medicinal chemistry, Jul-31, Volume: 46, Issue:16	Synthesis and biological evaluation of resveratrol and analogues as apoptosis-inducing agents.
AID114263	In vivo antitumor activity against subcutaneous Colon 38 tumors in mice determined as delay in growth after 3.9 mg/kg/day dose given as 3 times in a day for 4 days	2003	Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6	Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridines.
AID1600803	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19	Synthesis and antitumor activity of daunorubicin conjugates with of 3,4-methylendioxybenzaldehyde.
AID1175396	Antiproliferative activity against human A549 cells by XTT assay	2015	Bioorganic & medicinal chemistry, Jan-01, Volume: 23, Issue:1	Discovery of 2-[2-(5-nitrofuran-2-yl)vinyl]quinoline derivatives as a novel type of antimetastatic agents.
AID492232	Selectivity index, ratio of GI50 for human Detroit 551 cells to GI50 for human SF268 cells	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Synthesis and antiproliferative evaluation of certain iminonaphtho[2,3-b]furan derivatives.
AID272514	Antiproliferative activity against adriamycin resistant P388 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA	2006	Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23	Flavonoid dimers as bivalent modulators for P-glycoprotein-based multidrug resistance: synthetic apigenin homodimers linked with defined-length poly(ethylene glycol) spacers increase drug retention and enhance chemosensitivity in resistant cancer cells.
AID121881	Chemotherapeutic activity was evaluated by measuring number of survivors on day 30 / total number of mice at 12(mg/kg)/day, sc; 3/36	1980	Journal of medicinal chemistry, Nov, Volume: 23, Issue:11	Amino acid and dipeptide derivatives of daunorubicin. 2. Cellular pharmacology and antitumor activity on L1210 leukemic cells in vitro and in vivo.
AID153319	Antitumor efficacy at optimal dose of compound was measured against P388 leukemia in mice	1982	Journal of medicinal chemistry, Jan, Volume: 25, Issue:1	Enhanced antitumor properties of 3'-(4-morpholinyl) and 3'-(4-methoxy-1-piperidinyl) derivatives of 3'-deaminodaunorubicin.
AID1202309	Cytotoxicity against human K562 cells expressing Bcr-Abl assessed as growth inhibition after 48 hrs by trypan blue staining-based hemocytometric analysis	2015	European journal of medicinal chemistry, , Volume: 96	Synthesis and antiproliferative activity of 3-(2-chloroethyl)-5-methyl-6-phenyl-8-(trifluoromethyl)-5,6-dihydropyrazolo[3,4-f][1,2,3,5]tetrazepin-4-(3H)-one.
AID659920	Antiproliferative activity against human MONO-MAC-6 cells assessed as inhibition of cell viability at 10'-8 M after 48 hrs by cell counting method	2012	European journal of medicinal chemistry, Jun, Volume: 52	GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexate.
AID1124696	Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as tumor inhibition at 8 mg/kg, ip on days 5, 9 and 13 relative to untreated control	1979	Journal of medicinal chemistry, Apr, Volume: 22, Issue:4	Synthesis and antitumor activity of sugar-ring hydroxyl analogues of daunorubicin.
AID43843	In vitro growth inhibitory activity against CCRF-CEM (human lymphoblastic leukemic) cells.	1982	Journal of medicinal chemistry, Apr, Volume: 25, Issue:4	Adriamycin analogues. Preparation of 9,10-anhydrodaunorubicin, 9,10-anhydroadriamycin, and some related compounds.
AID1221972	Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK571	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1296362	Cytotoxicity against HEK293 cells assessed as cell viability after 24 hrs by Alamar Blue assay	2016	Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6	Structure-Based Design and Synthesis of Novel Inhibitors Targeting HDAC8 from Schistosoma mansoni for the Treatment of Schistosomiasis.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID597396	Cytotoxicity against human K562 cells after 6 hrs by MTT assay	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	New 29-nor-cycloartanes with a 3,4-seco- and a novel 2,3-seco-structure from the leaves of Sinocalycanthus chinensis.
AID659919	Antiproliferative activity against human MONO-MAC-6 cells assessed as inhibition of cell viability at 10'-8 M after 24 hrs by cell counting method	2012	European journal of medicinal chemistry, Jun, Volume: 52	GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexate.
AID731876	Displacement of SYBR from phage lambda DNA by FID assay	2013	ACS medicinal chemistry letters, Mar-14, Volume: 4, Issue:3	The structure of anthracycline derivatives determines their subcellular localization and cytotoxic activity.
AID292454	Cytotoxicity against HeLa cells after 72 hrs	2007	Journal of medicinal chemistry, Jul-26, Volume: 50, Issue:15	New analogues of the potent cytotoxic saponin OSW-1.
AID537736	Antifungal activity against yeast AD1-8u expressing Candida albicans CaCdr1p by agar disk diffusion assay	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID492233	Cytotoxicity against human K562 cells after 72 hrs by XTT assay	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Synthesis and antiproliferative evaluation of certain iminonaphtho[2,3-b]furan derivatives.
AID138965	Effect of 3 mg/kg/dose of compound given iv q4d x 3 against sc human ovarian tumor (SK-OV3) in mice expressed as % tumor volume change from initial by day 30	1999	Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18	Drug delivery systems employing 1,4- or 1,6-elimination: poly(ethylene glycol) prodrugs of amine-containing compounds.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID492224	Cytotoxicity against human NCI-H460 cells at 4 ug/ml after 48 hrs by sulforhodamine B assay relative to control	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Synthesis and antiproliferative evaluation of certain iminonaphtho[2,3-b]furan derivatives.
AID1130628	Toxicity in mouse P388 cells allografted ip dosed mouse assessed as maximum tolerated dose administered as single dose	1979	Journal of medicinal chemistry, Sep, Volume: 22, Issue:9	Antitumor agents. 1. 1,4-Bis[(aminoalkyl)amino]-9,10-anthracenediones.
AID124501	Chemotherapeutic activity was evaluated by measuring percent change in weight on day 8 at 10 mg/kg/day, sc	1980	Journal of medicinal chemistry, Nov, Volume: 23, Issue:11	Amino acid and dipeptide derivatives of daunorubicin. 2. Cellular pharmacology and antitumor activity on L1210 leukemic cells in vitro and in vivo.
AID1409607	IC50 for antiviral activity against SARS-CoV-2 in the Vero E6 cell line at 48 h by immunofluorescence-based assay (detecting the viral NP protein in the nucleus of the Vero E6 cells).	2020	Nature, 07, Volume: 583, Issue:7816	A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID624622	Apparent permeability (Papp) from apical to basolateral side determined in MDR1-MDCKII cells	2001	The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2	Rational use of in vitro P-glycoprotein assays in drug discovery.
AID1555401	Antitumor activity against human HT-29 cells xenografted in NSG mouse assessed as tumor growth inhibition by measuring decrease in tumor growth at 1 mg/kg, iv administered once per week for 7 times starting from 5 days post inoculation measured at day 50	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Sequence modification of heptapeptide selected by phage display as homing device for HT-29 colon cancer cells to improve the anti-tumour activity of drug delivery systems.
AID685502	HARVARD: Inhibition of blood stage Plasmodium falciparum 3D7 infection	2012	Proceedings of the National Academy of Sciences of the United States of America, May-29, Volume: 109, Issue:22	Liver-stage malaria parasites vulnerable to diverse chemical scaffolds.
AID551002	Cytotoxicity against mouse NIH/3T3 cells after 3 days by MTS assay	2011	Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1	Cytotoxicity and topoisomerase I/II inhibition of glycosylated 2-phenyl-indoles, 2-phenyl-benzo[b]thiophenes and 2-phenyl-benzo[b]furans.
AID354538	Cytotoxicity against rat C6 cells at 50 ug/mL to 2.5 mg/mL after 3 days treated 4 hrs before db-cAMP challenge by MTT assay	1996	Journal of natural products, Dec, Volume: 59, Issue:12	Cell-based screen for identification of inhibitors of tubulin polymerization.
AID101545	Cytotoxicity against H 226 tumor cell line	1999	Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25	Synthesis and biological evaluation of novel prodrugs of anthracyclines for selective activation by the tumor-associated protease plasmin.
AID1123501	Toxicity in Salmonella typhimurium TA100 assessed as growth inhibition after 1 hr	1979	Journal of medicinal chemistry, Mar, Volume: 22, Issue:3	Potential antitumor agents. 30. Mutagenic activity of some 9-anilinoacridines: relationships between structure, mutagenic potential, and antileukemic activity.
AID492230	Selectivity index, ratio of GI50 for human Detroit 551 cells to GI50 for human MCF7 cells	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Synthesis and antiproliferative evaluation of certain iminonaphtho[2,3-b]furan derivatives.
AID272512	Relative fold, IC50 in absence to presence of 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane in multidrug resistant MDA435/LCC6 cells	2006	Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23	Flavonoid dimers as bivalent modulators for P-glycoprotein-based multidrug resistance: synthetic apigenin homodimers linked with defined-length poly(ethylene glycol) spacers increase drug retention and enhance chemosensitivity in resistant cancer cells.
AID1221967	Ratio of intestine AUC in po dosed mdr1 knock out mouse to intestine AUC in po dosed wild type mouse	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID111962	Chemotherapeutic activity was evaluated by measuring mean tumor diameter on day 8 at 11 mg/kg/day, sc	1980	Journal of medicinal chemistry, Nov, Volume: 23, Issue:11	Amino acid and dipeptide derivatives of daunorubicin. 2. Cellular pharmacology and antitumor activity on L1210 leukemic cells in vitro and in vivo.
AID586925	Antileishmanial activity against wild type promastigotes of Leishmania major MHOM/JL/80/Friedlin assessed as inhibition of parasite growth after 72 hrs by MTT assay	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	Increased glycolytic ATP synthesis is associated with tafenoquine resistance in Leishmania major.
AID98033	Concentration of drug necessary to reduce by 50% the incorporation of tritiated thymidine in the DNA of actively growing L1210 cells	1982	Journal of medicinal chemistry, Jan, Volume: 25, Issue:1	Enhanced antitumor properties of 3'-(4-morpholinyl) and 3'-(4-methoxy-1-piperidinyl) derivatives of 3'-deaminodaunorubicin.
AID1638055	Cytotoxicity against BHK21 cells after 72 hrs by MTT assay	2019	European journal of medicinal chemistry, Mar-01, Volume: 165	Synthesis and anticancer evaluation of new lipophilic 1,2,4 and 1,3,4-oxadiazoles.
AID492226	Cytotoxicity against human MCF7 cells after 72 hrs by XTT assay	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Synthesis and antiproliferative evaluation of certain iminonaphtho[2,3-b]furan derivatives.
AID1221957	Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1146806	Induction of Escherichia coli omega enzyme-mediated relaxation of Escherichia coli (RR1) pBR313 closed circular DNA at 40 X 10'-12 mol preincubated for 10 mins followed by enzyme-addition measured after 30 mins by agarose gel electrophoretic analysis	1977	Journal of medicinal chemistry, Aug, Volume: 20, Issue:8	2-Deaminoactinomycin D, synthesis and interaction with deoxyribonucleic acid.
AID168257	Compound was tested for effect of glycoside on superoxide production in rat heart sarcosomes	1986	Journal of medicinal chemistry, Sep, Volume: 29, Issue:9	Synthesis of anthraquinonyl glucosaminosides and studies on the influence of aglycone hydroxyl substitution on superoxide generation, DNA binding, and antimicrobial properties.
AID550988	Cytotoxicity against human MCF7 cells assessed as cell viability at 25 uM after 24 hrs by MTS assay	2011	Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1	Cytotoxicity and topoisomerase I/II inhibition of glycosylated 2-phenyl-indoles, 2-phenyl-benzo[b]thiophenes and 2-phenyl-benzo[b]furans.
AID1221971	Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK571	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID259836	Drug resistance index, ratio of IC50 in Dox-resistant K562 cells over Dox-sensitive cells	2006	Journal of medicinal chemistry, Feb-09, Volume: 49, Issue:3	Discovery of a daunorubicin analogue that exhibits potent antitumor activity and overcomes P-gp-mediated drug resistance.
AID551000	Cytotoxicity against human CRL7761 cells after 3 days by MTS assay	2011	Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1	Cytotoxicity and topoisomerase I/II inhibition of glycosylated 2-phenyl-indoles, 2-phenyl-benzo[b]thiophenes and 2-phenyl-benzo[b]furans.
AID213356	Inhibitory activity against trypsin at 10e-5 M; NI = no inhibition	1992	Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15	Inhibition of collagenase by aranciamycin and aranciamycin derivatives.
AID272491	Antiproliferative activity against multidrug resistant MDA435/LCC6 cells by ELISA	2006	Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23	Flavonoid dimers as bivalent modulators for P-glycoprotein-based multidrug resistance: synthetic apigenin homodimers linked with defined-length poly(ethylene glycol) spacers increase drug retention and enhance chemosensitivity in resistant cancer cells.
AID270162	Cytotoxicity against human HeLa3 cell line by MTT assay	2006	Journal of medicinal chemistry, Sep-07, Volume: 49, Issue:18	Synthesis and cytotoxicity of leinamycin antibiotic analogues.
AID659492	Inhibition of HDAC1/2 in human HeLa cell nuclear extract using Fluor de Lys as substrate after 15 mins by fluorometric analysis	2012	Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4	Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.
AID223791	Antitumor activity against P-388 leukemia cell line in BDF1 mice after injecting 8.0 mg/kg ip dose	1990	Journal of medicinal chemistry, Sep, Volume: 33, Issue:9	Synthesis and antitumor activity of novel 4-demethoxyanthracyclines.
AID550990	Cytotoxicity against human HT-29 cells assessed as cell viability at 25 uM after 24 hrs by MTS assay	2011	Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1	Cytotoxicity and topoisomerase I/II inhibition of glycosylated 2-phenyl-indoles, 2-phenyl-benzo[b]thiophenes and 2-phenyl-benzo[b]furans.
AID1145426	Inhibition of RNA synthesis in mouse L1210 cells assessed as inhibition of [14C]-uridine incorporation measured per 10'6 cells at 3 uM pretreated for 1 hr followed by radiotracer addition measured after 1 hr by scintillation spectrometric analysis relativ	1976	Journal of medicinal chemistry, May, Volume: 19, Issue:5	Cellular pharmocodynamics of several anthrocycline antibiotics.
AID400021	Cytotoxicity against human HeLa cells assessed as inhibition of colony formation relative to control
AID731885	Cytotoxicity against human MCF7 cells after 24 hrs by XTT assay	2013	ACS medicinal chemistry letters, Mar-14, Volume: 4, Issue:3	The structure of anthracycline derivatives determines their subcellular localization and cytotoxic activity.
AID19006	Calculated membrane partition coefficient (Kmemb)	2004	Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7	Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
AID26756	DNA binding dissociation constant as KD	1984	Journal of medicinal chemistry, Apr, Volume: 27, Issue:4	Interactions of antitumor drugs with natural DNA: 1H NMR study of binding mode and kinetics.
AID1863065	Cytotoxicity against human MCF-10A cells assessed as growth inhibition at 0.5 uM	2022	Bioorganic & medicinal chemistry, 09-15, Volume: 70	Discovery of CN0 as a novel proteolysis-targeting chimera (PROTAC) degrader of PARP1 that can activate the cGAS/STING immunity pathway combined with daunorubicin.
AID1863064	Cytotoxicity against human MCF-10A cells assessed as growth inhibition at 0.25 uM	2022	Bioorganic & medicinal chemistry, 09-15, Volume: 70	Discovery of CN0 as a novel proteolysis-targeting chimera (PROTAC) degrader of PARP1 that can activate the cGAS/STING immunity pathway combined with daunorubicin.
AID659914	Cytostatic activity against human MCF7 cells after 4 days by MTT assay	2012	European journal of medicinal chemistry, Jun, Volume: 52	GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexate.
AID681164	TP_TRANSPORTER: ATP hydrolysis in membrane fraction from High Five (BTI-TN5B1-4) cells	2001	Pharmaceutical research, Dec, Volume: 18, Issue:12	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein.
AID1221976	Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko143	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID209299	Compound was tested for antibacterial activity against Strep. pyogenes ATCC 19615	1986	Journal of medicinal chemistry, Sep, Volume: 29, Issue:9	Synthesis of anthraquinonyl glucosaminosides and studies on the influence of aglycone hydroxyl substitution on superoxide generation, DNA binding, and antimicrobial properties.
AID1555336	Cytostatic activity against mouse CT26.WT cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Sequence modification of heptapeptide selected by phage display as homing device for HT-29 colon cancer cells to improve the anti-tumour activity of drug delivery systems.
AID400022	Cytotoxicity against mouse P388 cells
AID101085	Tested for the cytotoxicity(1 hour incubation) against L1210 leukemia cells.	1990	Journal of medicinal chemistry, Jan, Volume: 33, Issue:1	Structure-activity relationship of anthracyclines in vitro.
AID659633	Inhibition of Topoisomerase 2 assessed as kinetoplast DNA decatenation at 50 uM after 10 mins by electrophoretic analysis	2012	Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4	Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.
AID1555329	Cytostatic activity against human U87 cells preincubated for 24 hrs under serum free condition followed by compound washout and further incubation for 48 hrs in presence of serum by MTT assay	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Sequence modification of heptapeptide selected by phage display as homing device for HT-29 colon cancer cells to improve the anti-tumour activity of drug delivery systems.
AID1124695	Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as tumor inhibition at 16 mg/kg, ip on days 5, 9 and 13 relative to untreated control	1979	Journal of medicinal chemistry, Apr, Volume: 22, Issue:4	Synthesis and antitumor activity of sugar-ring hydroxyl analogues of daunorubicin.
AID659922	Antiproliferative activity against human MONO-MAC-6 cells assessed as inhibition of cell viability at 10'-7 M after 24 hrs by cell counting method	2012	European journal of medicinal chemistry, Jun, Volume: 52	GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexate.
AID259832	Increase in the level of drug uptake in Dox-resistant K562 cells in presence of cyclosporine over its absence	2006	Journal of medicinal chemistry, Feb-09, Volume: 49, Issue:3	Discovery of a daunorubicin analogue that exhibits potent antitumor activity and overcomes P-gp-mediated drug resistance.
AID355584	Antiproliferative activity against mouse P388 cells at 1 ug after 48 hrs by two-layer agar-diffusion method
AID1123727	Inhibition of DNA synthesis in mouse L1210 cells	1979	Journal of medicinal chemistry, Jan, Volume: 22, Issue:1	Synthesis of daunorubicin analogues with novel 9-acyl substituents.
AID386570	Binding affinity to calf thymus DNA in BPES buffer assessed as binding constant K/10'5 by fluorescence titration	2008	Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19	Hydration of drug-DNA complexes: greater water uptake for adriamycin compared to daunomycin.
AID679990	TP_TRANSPORTER: growth inhibition in hMRP1-expressing tobacco	2006	Plant molecular biology, Jun, Volume: 61, Issue:3	Heterologous expression of a mammalian ABC transporter in plant and its application to phytoremediation.
AID400032	Toxicity in mouse P388 cells xenografted mouse assessed as induction of death at 4.4 mg/kg, ip
AID472410	Cytotoxicity against human multidrug-resistant KB-C2 cells after 48 hrs by MTT assay	2010	Bioorganic & medicinal chemistry, Apr-15, Volume: 18, Issue:8	Papyriferic acid derivatives as reversal agents of multidrug resistance in cancer cells.
AID1863045	Growth inhibition of human MDA-MB-231 cells at 1 uM	2022	Bioorganic & medicinal chemistry, 09-15, Volume: 70	Discovery of CN0 as a novel proteolysis-targeting chimera (PROTAC) degrader of PARP1 that can activate the cGAS/STING immunity pathway combined with daunorubicin.
AID1446670	Growth inhibition of human MCF7/ADR cells after 48 hrs by SRB assay
AID153093	Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388 (1303) for total dose at an optimal dose of 1 mg/kg/injection	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
AID688705	Cytotoxicity against PMA-stimulated human THP1 cells after 72 hrs by MTT assay	2012	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19	Oxazolo[3,2-a]pyridine. A new structural scaffold for the reversal of multi-drug resistance in Leishmania.
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1179426	Genotoxicity in Salmonella typhimurium TA102 at 3 ug/plate assessed as number of revertants per plate (Rvb = 301 +/- 5.2 no unit)	2014	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 24, Issue:14	Synthesis and evaluation of novel dapsone-thalidomide hybrids for the treatment of type 2 leprosy reactions.
AID688707	Antileishmanial activity against promastigotes of multidrug-resistant Leishmania tropica after 72 hrs by MTT assay	2012	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19	Oxazolo[3,2-a]pyridine. A new structural scaffold for the reversal of multi-drug resistance in Leishmania.
AID355251	Inhibition of HIV1 recombinant reverse transcriptase p66/p51 expressed in Escherichia coli	1997	Journal of natural products, Sep, Volume: 60, Issue:9	In vitro anti-HIV activity of biflavonoids isolated from Rhus succedanea and Garcinia multiflora.
AID1221963	Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1600801	Cytotoxicity against human HEK293 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19	Synthesis and antitumor activity of daunorubicin conjugates with of 3,4-methylendioxybenzaldehyde.
AID333401	Antibacterial activity against Bacillus subtilis ATCC 6633 after 24 hrs by microtiter plate assay	2004	Journal of natural products, Oct, Volume: 67, Issue:10	Blanchaquinone: a new anthraquinone from an Australian Streptomyces sp.
AID1221979	Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK571	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1130630	Antitumor activity against mouse P388 cells allografted in ip dosed mouse assessed as dose providing 40% increase in life span administered as single dose	1979	Journal of medicinal chemistry, Sep, Volume: 22, Issue:9	Antitumor agents. 1. 1,4-Bis[(aminoalkyl)amino]-9,10-anthracenediones.

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	3129 (40.29)	18.7374
1990's	1764 (22.71)	18.2507
2000's	1400 (18.03)	29.6817
2010's	1179 (15.18)	24.3611
2020's	294 (3.79)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	886 (10.75%)	5.53%
Reviews	407 (4.94%)	6.00%
Case Studies	680 (8.25%)	4.05%
Observational	7 (0.08%)	0.25%
Other	6,259 (75.97%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (358)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
ALinC 17, Classification ©), B-precursor Induction Treatment (I) [NCT01225874]		3,762 participants (Actual)	Interventional	1999-12-31	Completed
A Prospective Randomized Comparison of Idarubicin and High-dose Daunorubicin in Combination With Cytarabine in the Induction Chemotherapy for Acute Myeloid Leukemia [NCT01145846]	Phase 3	316 participants (Anticipated)	Interventional	2010-05-31	Recruiting
"A Phase III Trial Comparing ARA-C/High-Dose Mitoxantrone (ALL-2') to A Standard Vincristine/Prednisone Based Regimen ('L-20') as Induction Therapy For Adult Patients With Acute Lymphoblastic Leukemia (ALL): The ALL-4 Protocol" [NCT00002766]	Phase 3	170 participants (Actual)	Interventional	1996-03-31	Completed
A Phase 1b Study of JNJ-75276617 in Combination With AML-Directed Therapies for Participants With Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations [NCT05453903]	Phase 1	150 participants (Anticipated)	Interventional	2022-10-04	Recruiting
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With [NCT01275677]	Phase 3	3,270 participants (Actual)	Interventional	2011-01-06	Active, not recruiting
A Phase 1b Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Entospletinib (ENTO) as Monotherapy in Japanese Subjects With Relapsed or Refractory Hematologic Malignancies and in Combination With Chemotherapy in Japanese Subjects With [NCT03135028]	Phase 1	9 participants (Actual)	Interventional	2017-05-19	Terminated(stopped due to No signal of efficacy with Entospletinib)
A Phase 1/2 Study of CPX-351 (NSC# 775341) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children With Relapsed Acute Myeloid Leukemia (AML) [NCT02642965]	Phase 1/Phase 2	38 participants (Actual)	Interventional	2016-05-02	Completed
Phase I Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk, Acute Myelogenous Leukemia (AML) [NCT01265199]	Phase 1	29 participants (Actual)	Interventional	2011-02-28	Terminated(stopped due to Study was terminated before a MTD was determined for administrative reasons)
Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil - a Prospective Collaborative Study [NCT05959720]		180 participants (Anticipated)	Observational [Patient Registry]	2023-09-05	Recruiting
Open-Label Phase 2 Trial of Vyxeos in Patients With Intermediate and High-Risk Acute Myeloid Leukemia Who Have Failed an Initial Cycle of Standard Cytarabine and Daunorubicin Chemotherapy [NCT04049539]	Phase 1/Phase 2	28 participants (Anticipated)	Interventional	2021-01-29	Recruiting
A Multicenter，Open-label，Radonmized Study on the Treatment of Older Adult Acute Myeloid Leukemia Patients Aged 55 to 65 Years Old [NCT02432872]		300 participants (Anticipated)	Interventional	2015-04-30	Recruiting
Phase 1b Study of Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve Subjects With Acute Myelogenous Leukemia [NCT03709758]	Phase 1	64 participants (Anticipated)	Interventional	2018-10-17	Recruiting
A Phase II Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma: A Window Period for Bioimmunotherapy Before Chemotherapy [NCT02427620]	Phase 2	131 participants (Anticipated)	Interventional	2015-06-03	Active, not recruiting
A Pilot Study of Low-Dose Daunorubicin in Patients With Relapsed/Refractory Acute Leukemia [NCT02914977]	Phase 1	18 participants (Actual)	Interventional	2016-11-30	Completed
A Phase II Study of Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) as Front-Line Therapy for Adults With Acute Lymphoblastic Leukemia/Lymphoma [NCT03023046]	Phase 2	54 participants (Actual)	Interventional	2017-02-23	Completed
Total XV - Total Therapy Study XV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia [NCT00137111]	Phase 3	501 participants (Actual)	Interventional	2000-07-08	Completed
Phase 1b, Open-label, Dose Escalation Study of Quizartinib in Combination With Induction and Consolidation Chemotherapy in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) [NCT02834390]	Phase 1	7 participants (Actual)	Interventional	2016-08-12	Completed
A Randomized, Risk and Age Adapted Comparison of the Dose-Dense Regimen S-HAM (Sequential High Dose Cytosine Arabinoside and Mitoxantrone) Versus Standard Double Induction for Initial Chemotherapy of Adult Patients With Acute Myeloid Leukemia [NCT01382147]	Phase 3	396 participants (Actual)	Interventional	2009-07-01	Completed
CHOA-AML: A Pilot Study for Newly Diagnosed Pediatric Patients With Acute Myeloid Leukemia (AML) [NCT04326439]	Phase 2	8 participants (Actual)	Interventional	2020-01-24	Terminated(stopped due to Due to unforeseen circumstances, the study team was limited in enrolling patients on this trial; thus, it was terminated.)
Multicenter Randomised Clinical Trial in Acute Myeloid Leukemia Treatment Based on Three Anthracyclines, Comparing Two Types of Consolidation With Different ARA-C Doses Followed by One Year Maintenance [NCT01587430]	Phase 4	245 participants (Anticipated)	Interventional	2010-01-31	Active, not recruiting
A Phase II Study of Punctual, Cyclic, and Intensive Chemotherapy With Liposomal Cytarabine (Depocyt®) CNS Prophylaxis for Adults With Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma [NCT02043587]	Phase 2	31 participants (Actual)	Interventional	2014-01-31	Terminated(stopped due to Original investigator for the trial has left)
A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults [NCT00372593]	Phase 3	1,070 participants (Actual)	Interventional	2006-08-31	Completed
Treatment of Late Isolated Extramedullary Relapse From Acute Lymphoblastic Leukemia (ALL) (Initial CR1≥ 18 Months) [NCT00096135]		168 participants (Actual)	Interventional	2004-11-30	Completed
A Multicenter, Phase 1, Open-Label Study of the FGFR Inhibitor Pemigatinib (INCB054828) Administered After Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With Adverse or Intermediate Risk Cytogenetics [NCT04659616]	Phase 1	32 participants (Anticipated)	Interventional	2021-01-14	Recruiting
A Phase I Study of Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin Plus Escalating Doses of Inotuzumab Ozogamicin (DA-EPOCH-InO) in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia [NCT03991884]	Phase 1	24 participants (Actual)	Interventional	2019-09-24	Completed
A Randomized, Placebo-Controlled, Double Blind, Trial of the Administration of the MDR Modulator, Zosuquidar Trihydrochloride (LY335979), During Conventional Induction and Post-Remission Therapy in Patients Greater Than 60 Years of Age With Newly Diagnose [NCT00046930]	Phase 3	449 participants (Actual)	Interventional	2002-09-17	Completed
A Phase I/II Study of CPI-613 in Combination With Induction/Consolidation in Older AML Patients [NCT02472626]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2015-12-31	Withdrawn(stopped due to Drug Supply Issues)
A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations [NCT04293562]	Phase 3	1,400 participants (Anticipated)	Interventional	2020-07-21	Recruiting
A Phase 1 Investigator Sponsored Study of Selinexor in Combination With Daunorubicin and Cytarabine in Patients With Previously Untreated Poor-Risk Acute Myeloid Leukemia [NCT02403310]	Phase 1	21 participants (Actual)	Interventional	2015-06-18	Completed
A Safety and Tolerability Trial of Crenolanib and Chemotherapy With Cytarabine and Anthracyclines in Patients With Newly Diagnosed Acute Myeloid Leukemia With FLT3 Activating Mutations [NCT02283177]	Phase 2	44 participants (Actual)	Interventional	2015-01-31	Completed
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years [NCT00369317]	Phase 3	205 participants (Actual)	Interventional	2007-03-31	Completed
Phase II/III Randomized Study to Improve Overall Survival in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus Mycop [NCT02416388]	Phase 2/Phase 3	3,100 participants (Anticipated)	Interventional	2015-01-31	Recruiting
AML08: A Phase II Randomized Trial of Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Phase II Study Of Natural Killer Cell Transplantation In Patients With Newly Diagnosed Acute Myeloid Leukemia [NCT00703820]	Phase 3	324 participants (Actual)	Interventional	2008-08-04	Completed
A Phase II Study of Dasatinib (Sprycel®) (NSC #732517) as Primary Therapy Followed by Transplantation for Adults >/= 18 Years With Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by CALGB, ECOG and SWOG [NCT01256398]	Phase 2	66 participants (Actual)	Interventional	2010-12-14	Completed
Moscow-Berlin 2015 Multicenter Randomized Study for Treatment of Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults [NCT03390387]		4,000 participants (Anticipated)	Interventional	2015-11-30	Recruiting
A Phase II, Open-label, Single Arm Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Twice Daily Midostaurin (PKC412) Combined With Standard Chemotherapy and as a Single Agent Post-consolidation Therapy in Children With Untreated FLT3-mutate [NCT03591510]	Phase 2	23 participants (Anticipated)	Interventional	2019-03-13	Recruiting
A Pilot Study to Estimate the Safety and Tolerability of the Combination of Polatuzumab Vedotin With Dose Adjusted Rituximab, Etoposide, Cyclophosphamide, and Doxorubicin (DA-EPCH-PR) for Upfront Treatment of Aggressive B-Cell Non-Hodgkin Lymphomas [NCT04231877]	Phase 1	50 participants (Anticipated)	Interventional	2020-10-27	Recruiting
A Prospective Randomized Comparison of High-dose Cytarabine an High-dose Daunorubicin in the Induction Chemothrapy for Acute Myeloid Leukemia [NCT03507842]	Phase 3	380 participants (Actual)	Interventional	2018-03-01	Enrolling by invitation
A Phase II Study to Determine the Response Kinetics, Safety, and Efficacy of Brentuximab Vedotin and Nivolumab Alone and Then Combined With Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone for Patients With Untreated Primary Mediastinal Large B-Ce [NCT04745949]	Phase 2	40 participants (Anticipated)	Interventional	2021-05-10	Recruiting
Phase II Investigator Sponsored Study of CPX-351 in Combination With Ivosidenib for Patients With IDH1 Mutated Acute Myeloid Leukemia or High-Risk MDS [NCT04493164]	Phase 2	30 participants (Anticipated)	Interventional	2020-12-30	Recruiting
A Phase 1b Study of Neratinib, Pertuzumab, and Trastuzumab With Taxol (3HT) in Metastatic and Locally Advanced Breast Cancer, and Phase II Study of 3HT Followed by AC in HER2 + Primary IBC, and Neratinib With Taxol (NT) Followed by AC in HR+ /HER2- Primar [NCT03101748]	Phase 1/Phase 2	43 participants (Actual)	Interventional	2018-01-29	Active, not recruiting
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults [NCT02003222]	Phase 3	488 participants (Actual)	Interventional	2014-05-19	Active, not recruiting
Phase II Study of Combination of Hyper-CVAD and Dasatinib in Patients With Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) [NCT00390793]	Phase 2	107 participants (Actual)	Interventional	2006-09-28	Active, not recruiting
CPX-351 Plus Enasidenib for Relapsed Acute Myelogenous Leukemia Characterized by the IDH2 Mutation [NCT03825796]	Phase 2	2 participants (Actual)	Interventional	2019-04-12	Active, not recruiting
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: PRIME [NCT03878524]	Phase 1	2 participants (Actual)	Interventional	2020-04-01	Active, not recruiting
International Collaborative Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 [NCT03643276]	Phase 3	5,000 participants (Anticipated)	Interventional	2018-07-15	Recruiting
An Investigator-Sponsored Randomized Phase II Study of Selinexor in Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients [NCT02835222]	Phase 2	100 participants (Anticipated)	Interventional	2018-02-02	Recruiting
Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) [NCT02013648]	Phase 3	203 participants (Anticipated)	Interventional	2014-07-31	Active, not recruiting
Phase II Study of Combination of Hyper-CVAD and Ponatinib in Patients With Philadelphia (PH) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) [NCT01424982]	Phase 2	88 participants (Actual)	Interventional	2011-10-05	Active, not recruiting
A Randomized Trial for Adults With Newly Diagnosed Acute Lymphoblastic Leukemia [NCT01085617]	Phase 3	1,033 participants (Actual)	Interventional	2010-12-31	Active, not recruiting
Evaluation of the Efficacy of Induction-consolidation Treatment Using a Double Induction in Patients With AML <60 Years Old, Depending on the Percentage of Blasts in the 14 Day, Residual Disease and Leukemic Hematopoietic Cells [NCT02072811]	Phase 3	400 participants (Anticipated)	Interventional	2014-02-28	Recruiting
A Phase 1b/2 Study of Pinometostat in Combination With Standard Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia With MLL Rearrangement [NCT03724084]	Phase 1/Phase 2	5 participants (Actual)	Interventional	2019-01-25	Terminated(stopped due to Other - Study agent no longer available)
Dose Finding Safety Run-in Phase Followed by a Randomized Phase II Trial of Intensive Chemotherapy With or Without Volasertib (BI 6727) Administered Prior or After Chemotherapy in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and [NCT02198482]	Phase 2	6 participants (Actual)	Interventional	2016-02-29	Terminated(stopped due to development program of study drug volasertib was stopped by Boehringer Ingelheim due to manufacturing problems)
A Phase 3, Prospective, Randomized Multi-center Intervention Trial of Early Intensification in AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance: A MYNERVA-GIMEMA Study [NCT04174612]	Phase 3	172 participants (Anticipated)	Interventional	2020-04-24	Recruiting
Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML) [NCT03836209]	Phase 2	181 participants (Actual)	Interventional	2019-12-06	Active, not recruiting
Phase 1b/2 Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia [NCT02303821]	Phase 1	130 participants (Anticipated)	Interventional	2015-02-16	Recruiting
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy) [NCT02112916]	Phase 3	847 participants (Actual)	Interventional	2014-10-04	Active, not recruiting
"A Novel Pediatric-Inspired Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia" [NCT01920737]	Phase 2	39 participants (Actual)	Interventional	2013-08-31	Active, not recruiting
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT) [NCT04322318]	Phase 2	221 participants (Anticipated)	Interventional	2020-10-19	Recruiting
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones [NCT03007147]	Phase 3	475 participants (Anticipated)	Interventional	2017-08-08	Recruiting
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754) [NCT02180867]	Phase 2/Phase 3	140 participants (Actual)	Interventional	2014-07-11	Active, not recruiting
Intensified Methotrexate, Nelarabine (Compound 506U78) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma [NCT00408005]	Phase 3	1,895 participants (Actual)	Interventional	2007-01-22	Active, not recruiting
High Risk B-Precursor Acute Lymphoblastic Leukemia (ALL) [NCT00075725]	Phase 3	3,154 participants (Actual)	Interventional	2003-12-29	Completed
Comparison of Remission Rate and Leukemic Stem Cell Changes Among Patients With Newly Diagnosed Adult ALL With Liposomal Doxorubicin and Daunorubicin-containing VDCLD Regimen. [NCT03419494]		40 participants (Anticipated)	Observational	2013-10-10	Recruiting
Young Adult Acute Lymphoid Leukemia (ALL): Intensification of Pediatric AIEOP LLA-2000 Treatment [NCT01156883]		76 participants (Actual)	Interventional	2010-04-30	Completed
A PHASE 1 DOSE ESCALATION STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVENOUS PF-06747143, ADMINISTERED AS SINGLE AGENT OR IN COMBINATION WITH STANDARD CHEMOTHERAPY IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA [NCT02954653]	Phase 1	8 participants (Actual)	Interventional	2016-11-28	Terminated(stopped due to The study was terminated due to a change in sponsor prioritization.)
A Phase I/II Multi-center Study of HDM201 Added to Chemotherapy in Adult Subjects With Relapsed/Refractory (R/R) or Newly Diagnosed Acute Myeloid Leukemia (AML) [NCT03760445]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2019-11-15	Withdrawn(stopped due to It was determined that the study design may not be optimal given the changing AML treatment landscape.)
Clinical Evaluation of ASTX727 in Combination With Venetoclax All-Oral Therapy vs Standard of Care Cytarabine and Anthracycline Induction Chemotherapy for Younger FLT3WT Patients With ELN High- Risk Acute Myeloid Leukemia [NCT04817241]	Phase 1/Phase 2	55 participants (Anticipated)	Interventional	2022-02-10	Active, not recruiting
Optimum Induction Therapy of Low-risk Acute Promyelocytic Leukemia With All Oral Drugs [NCT05832320]		74 participants (Anticipated)	Interventional	2023-01-01	Recruiting
A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial) [NCT03013998]	Phase 1/Phase 2	2,000 participants (Anticipated)	Interventional	2016-11-30	Recruiting
A Prospective Study of Heated Intra-Peritoneal Chemotherapy (H.I.P.E.C.) With Doxorubicin and Cisplatin in Pediatric Patients With Pelvic and Abdominal Tumors. The TOAST IT Trial (Trial Of Adjuvant Surgical Treatment With Intraperitoneal Chemotherapy) [NCT04213794]	Early Phase 1	43 participants (Anticipated)	Interventional	2019-11-08	Recruiting
Randomized Phase 2 Study of Daunorubicin and Cytarabine Liposome + Pomalidomide Versus Daunorubicin and Cytarabine Liposome in Newly Diagnosed AML With MDS-Related Changes [NCT04802161]	Phase 2	78 participants (Anticipated)	Interventional	2022-08-24	Recruiting
Effect of Priming With Granulocyte-Macrophage Colony-Stimulating Factor During Chemotherapy and Comparison of Timed Sequential Chemotherapy vs 4 Courses of High Dose Cytarabine as Consolidation in Younger Adults With Newly Diagnosed AML [NCT00880243]	Phase 3	473 participants (Actual)	Interventional	1999-03-31	Completed
A Prospective, Single Arm, Open Label, Clinical Trial to Evaluate the Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage [NCT04440267]	Phase 2	50 participants (Anticipated)	Interventional	2020-06-20	Not yet recruiting
A Dose-escalated Phase Ⅰ Trial to Assess the Tolerance and Pharmacokinetics of Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML Patient [NCT04402723]	Phase 1	8 participants (Actual)	Interventional	2018-11-06	Terminated(stopped due to Corporate policy adjustments)
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT) [NCT03533582]	Phase 2/Phase 3	537 participants (Anticipated)	Interventional	2018-05-24	Recruiting
Evaluation of the Incidence and Prognostic Impact of Molecular and Genetic Abnormalities in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myeloproliferative Neoplasms [NCT02084563]	Phase 2	455 participants (Actual)	Interventional	2012-10-31	Completed
A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old [NCT03257241]	Phase 3	582 participants (Anticipated)	Interventional	2017-07-03	Recruiting
A Phase II Study of Double Induction Chemotherapy for Newly Diagnosed Non-L3 Adult Acute Lymphoblastic Leukemia With Investigation of Minimal Residual Disease and Risk of Relapse Following Maintenance Chemotherapy [NCT00109837]	Phase 2	79 participants (Actual)	Interventional	2005-04-30	Completed
Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute [NCT02036489]	Phase 4	107 participants (Actual)	Interventional	2008-01-31	Completed
A Randomized, Double-blind, Multiple-Dose, Two-Cycle, Parallel-Group, Bioequivalence Pretrial of Daunorubicin Cytarabine Liposome for Injection in Older, Naive AML Patients [NCT04920500]		16 participants (Anticipated)	Interventional	2020-09-04	Recruiting
Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study [NCT05929768]	Phase 3	2,400 participants (Anticipated)	Interventional	2023-09-15	Recruiting
A Phase III Randomized Trial for Patients With De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD [NCT01371981]	Phase 3	1,645 participants (Actual)	Interventional	2011-06-20	Active, not recruiting
A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma [NCT06172296]	Phase 3	478 participants (Anticipated)	Interventional	2024-02-14	Not yet recruiting
A Phase 1b Study of Menin Inhibitor SNDX-5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged Disease. [NCT05886049]	Phase 1	28 participants (Anticipated)	Interventional	2023-12-19	Not yet recruiting
Eradicating Measurable Residual Disease in Patients With Acute Myeloid Leukemia (AML) Prior to StEm Cell Transplantation (ERASE): A MyeloMATCH Treatment Trial [NCT05554419]	Phase 2	184 participants (Anticipated)	Interventional	2024-08-16	Not yet recruiting
A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Patients Wit [NCT04778397]	Phase 3	346 participants (Anticipated)	Interventional	2021-07-01	Active, not recruiting
A Collaboration Phase 2 Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia [NCT05955261]	Phase 2	70 participants (Anticipated)	Interventional	2023-07-25	Recruiting
A Phase 1 Study Combining Venetoclax With a Pediatric-Inspired Regimen for Newly Diagnosed Adults With B Cell Ph-Like Acute Lymphoblastic Leukemia [NCT05157971]	Phase 1	6 participants (Anticipated)	Interventional	2022-03-17	Recruiting
Phase III Open-Label Randomized Study of Amonafide L-Malate in Combination With Cytarabine Compared to Daunorubicin in Combination With Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- The ACCEDE Study [NCT00715637]	Phase 3	420 participants (Anticipated)	Interventional	2007-06-30	Active, not recruiting
Randomized Phase III Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics [NCT03897127]	Phase 3	882 participants (Anticipated)	Interventional	2019-09-04	Recruiting
Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia [NCT00549848]	Phase 3	600 participants (Actual)	Interventional	2007-10-29	Completed
Phase II Study of the Combination of CPX-351 and Glasdegib in Previously Untreated Patients With Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia [NCT04231851]	Phase 2	30 participants (Anticipated)	Interventional	2020-02-19	Recruiting
A Phase I/II Dose Escalation Study of Subcutaneous Campath-1H (NSC #715969, IND #10864) During Intensification Therapy in Adults With Untreated Acute Lymphoblastic Leukemia (ALL) [NCT00061945]	Phase 1/Phase 2	302 participants (Actual)	Interventional	2003-06-30	Completed
Randomized Phase III Study for the Treatment of Newly Diagnosed Disseminated Lymphoblastic Lymphoma or Localized Lymphoblastic Lymphoma [NCT00004228]	Phase 3	393 participants (Actual)	Interventional	2000-06-30	Completed
Impact of Obesity on the Pharmacokinetics of Anticancer Therapy in Children With High Risk Acute Lymphoblastic Leukemia (ALL) [NCT00900445]		0 participants (Actual)	Observational	2008-03-24	Withdrawn
Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer [NCT06058377]	Phase 3	3,680 participants (Anticipated)	Interventional	2023-11-27	Recruiting
A Phase III Trial in Adult Acute Myeloid Leukemia: Daunorubicin Dose-Intensification Prior to Risk-Allocated Autologous Stem Cell Transplantation [NCT00049517]	Phase 3	657 participants (Actual)	Interventional	2002-12-19	Completed
Phase I Study of Inotuzumab Ozogamicin With 3 and 4 Drug Augmented Berlin-Frankfurt-Münster (BFM) Re-Induction for Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) [NCT03962465]	Phase 1	36 participants (Anticipated)	Interventional	2022-07-22	Active, not recruiting
A Single-Arm, Open-Label Phase 2 Pilot Study of Vyxeos (CPX-351) in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia [NCT03575325]	Phase 2	11 participants (Actual)	Interventional	2018-10-11	Completed
A Prospective Phase II Trial of Modified MRC UKALL Ⅻ/ECOG E2993 Regimen in the Treatment of Low Risk Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia for Young Adults [NCT02660762]	Phase 2	100 participants (Anticipated)	Interventional	2016-01-31	Recruiting
Eradicating Measurable Residual Disease in Patients With Acute Myeloid Leukemia (AML) Prior to StEm Cell Transplantation (ERASE): A MyeloMATCH Treatment Trial [NCT05628623]	Phase 2	184 participants (Anticipated)	Interventional	2023-10-23	Not yet recruiting
A Phase II Study of Combination Daunorubicin and Cytarabine (Ara-c) and Nilotinib (Tasigna) (DATA) in Patients Newly Diagnosed With Acute Myeloid Leukemia and KIT Overexpression [NCT01806571]	Phase 2	34 participants (Actual)	Interventional	2015-03-12	Completed
AML 2001: a Phase III Prospective Randomized Study Comparing One or Two High Dose Chemotherapy Regimen Followed by Autologous Stem Cell Transplantation (ASCT) as Consolidation Strategy for Adults Aged 15 to 60 With Acute Myeloid Leukemia (AML) in First Co [NCT01015196]	Phase 2/Phase 3	832 participants (Actual)	Interventional	2001-01-31	Completed
Phase II Study of Maintenance Therapy With Decitabine (NSC #127716) Following Standard Induction and Cytogenetic Risk-Adapted Intensification in Previously Untreated Patients With AML < 60 Years [NCT00416598]	Phase 2	546 participants (Actual)	Interventional	2006-11-15	Completed
A Phase I Study of Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination With Gemtuzumab Ozogamicin (GO) in Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia (AML) [NCT04915612]	Phase 1	18 participants (Anticipated)	Interventional	2021-05-21	Recruiting
Phase 2 Clinical Trial for Comprehensive Treatment Program for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Tagraxofusp (SL-401) in Combination With HCVAD/Mini-CVD and VENETOCLAX [NCT04216524]	Phase 2	40 participants (Anticipated)	Interventional	2020-05-29	Recruiting
Phase 1 Dose Escalation Study of CPX-351 for Patients With Int-2 or High Risk IPSS Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia After Failure to Hypomethylating Agents [NCT03896269]	Phase 1	38 participants (Anticipated)	Interventional	2019-05-14	Recruiting
A Pilot Study of Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination With Gemtuzumab Ozogamicin (GO) in Relapsed Refractory Patients With Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic S [NCT03672539]	Phase 2	50 participants (Anticipated)	Interventional	2018-11-07	Recruiting
Phase II Study of CPX-351 in Combination With Venetoclax in Patients With Acute Myeloid Leukemia (AML) [NCT03629171]	Phase 2	52 participants (Anticipated)	Interventional	2018-10-29	Recruiting
Phase 1B Study of Venetoclax in Combination With Standard Intensive Chemotherapy With Daunorubicin Plus Cytarabine Followed by High-Dose Cytarabine in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia and Advanced Myelodysplastic Syndrome [NCT05342584]	Phase 1	99 participants (Anticipated)	Interventional	2022-05-25	Recruiting
A Phase II Study Evaluating Mechanisms of Resistance Following Treatment With Clofarabine and Daunorubicin in Newly Diagnosed Adult Acute Myeloid Leukemia Patients > or = to 60 Years Old [NCT00814164]	Phase 2	21 participants (Actual)	Interventional	2008-12-31	Terminated(stopped due to Sponsor withdrew support)
A Randomized, Multi-center Phase II Trial to Assess the Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML [NCT00915252]	Phase 2	214 participants (Actual)	Interventional	2009-07-31	Completed
A Randomized Trial of the I-BFM-SG for the Management of Childhood Non-B Acute Lymphoblastic Leukemia [NCT00764907]	Phase 3	4,000 participants (Anticipated)	Interventional	2002-11-30	Recruiting
Phase III Randomized Trial of Autologous and Allogeneic Stem Cell Transplantation Versus Intensive Conventional Chemotherapy in Acute Lymphoblastic Leukemia in First Remission [NCT00002514]	Phase 3	1,929 participants (Actual)	Interventional	1993-05-07	Completed
A Phase II Study of the Impact of Clinicogenetic Risk-Stratified Management on Outcomes of Acute Myeloid Leukemia in Older Patients [NCT03226418]	Phase 2	75 participants (Actual)	Interventional	2017-07-07	Active, not recruiting
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome [NCT02521493]	Phase 3	312 participants (Anticipated)	Interventional	2015-12-23	Active, not recruiting
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma [NCT02306161]	Phase 3	312 participants (Actual)	Interventional	2014-12-12	Active, not recruiting
A Randomized Phase III Study of Intensive Consolidation With High Dose Cytosine Arabinoside in Acute Myelogenous Leukemia (AML-8B) [NCT01324063]	Phase 3	160 participants (Anticipated)	Interventional	1986-11-30	Completed
A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND #101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age With FLT3 Mutated Acute M [NCT00651261]	Phase 3	717 participants (Actual)	Interventional	2008-04-30	Active, not recruiting
Treatment of AML in Adults 50 to 70 Years, Study of Two Anthracyclines and the Interest of Maintenance Treatment With Interleukin 26- ALFA 9801 [NCT00931138]	Phase 3	420 participants	Interventional	1999-12-31	Completed
A RANDOMIZED (1:1), DOUBLE-BLIND, MULTI-CENTER, PLACEBO CONTROLLED STUDY EVALUATING INTENSIVE CHEMOTHERAPY WITH OR WITHOUT GLASDEGIB (PF-04449913) OR AZACITIDINE (AZA) WITH OR WITHOUT GLASDEGIB IN PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA [NCT03416179]	Phase 3	730 participants (Actual)	Interventional	2018-04-20	Completed
A Pilot Induction Regimen Incorporating Chimeric 14.18 Antibody (ch14.18, Dinutuximab) (NSC# 764038) and Sargramostim (GM-CSF) for the Treatment of Newly Diagnosed High-Risk Neuroblastoma [NCT03786783]	Phase 2	42 participants (Actual)	Interventional	2019-01-14	Active, not recruiting
Open-Label, Multicenter Phase Ib/IIa Study For the Evaluation of Dasatinib (Sprycel™) Following Induction and Consolida-tion Therapy as Well as in Maintenance Therapy in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) [NCT00850382]	Phase 1/Phase 2	89 participants (Actual)	Interventional	2009-06-30	Completed
A Pilot Study of Intravenous EZN-2285 (SC-PEG E. Coli L-asparaginase) or Intravenous Oncaspar® in the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia (ALL) [NCT00671034]	Phase 3	166 participants (Actual)	Interventional	2008-07-21	Completed
Multicenter Trial for Treatment of Acute Lymphoblastic Leukemia in Adults (05/93) [NCT00199069]	Phase 4	720 participants	Interventional	1993-04-30	Completed
Intensified Tyrosine Kinase Inhibitor Therapy (Dasatinib NSC# 732517) in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL) [NCT00720109]	Phase 2/Phase 3	63 participants (Actual)	Interventional	2008-07-14	Completed
Gleevec (Imatinib) Plus Multi-Agent Chemotherapy For Newly-Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia [NCT00618501]	Phase 2	50 participants (Anticipated)	Interventional	2005-10-31	Completed
Pilot Study of the Efficacy and Tolerance of the Adjunction of a Fish Oil Emulsion to Daunorubicin and Cytarabine Chemotherapy for the Treatment of Acute MYeloblastic Leukemia of Younger Patients With High-risk Cytogenetics [NCT01999413]	Phase 2	30 participants (Actual)	Interventional	2013-11-30	Completed
A PHASE I-II MULTICENTER STUDY OF THE CLORETAZINE-DAUNORUBICIN-ARACYTINE COMBINATION FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) WITH UNFAVORABLE CYTOGENETICS [NCT00840684]	Phase 1/Phase 2	135 participants (Anticipated)	Interventional	2009-01-31	Completed
A Randomized Trial for Patients With Acute Myeloid Leukemia or High Risk Myelodysplatic Syndrome Aged 60 or Over [NCT00005823]	Phase 3	2,000 participants (Anticipated)	Interventional	1998-12-31	Completed
Treatment of High Risk Adult Acute Lymphoblastic Leukemia [NCT00853008]	Phase 4	100 participants (Anticipated)	Interventional	2003-01-31	Completed
Phase 1 Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Malignancies. [NCT00389428]	Phase 1	48 participants (Actual)	Interventional	2006-09-30	Completed
Phase II Trial of Liposomal Daunorubicin (Daunoxome) and SU5416 (NSC 696819) in Patients With AML, RAEB, RAEB-T or CMML in Transformation Refractory to One Course of Induction Chemotherapy [NCT00005942]	Phase 1/Phase 2	37 participants (Actual)	Interventional	2000-03-31	Completed
Escalating Dose Intravenous Methotrexate Without Leucovorin Rescue Versus Oral Methotrexate and Single Versus Double Delayed Intensification for Children With Standard Risk Acute Lymphoblastic Leukemia [NCT00005945]	Phase 3	3,054 participants (Actual)	Interventional	2000-06-30	Completed
Dose Escalation and Phase II Study of Bortezomib (IND #58443) Added to Standard Daunorubicin and Cytarabine Therapy for Patients With Previously Untreated Acute Myeloid Leukemia Age 60-75 Years [NCT00742625]	Phase 1/Phase 2	95 participants (Actual)	Interventional	2008-09-30	Completed
A Phase III Multicentric Randomized Study of the Combination of Repeated Doses of Gemtuzumab Ozogamicin (GO) With Daunorubicin and Cytarabine Versus Daunorubicin and Cytarabine in Untreated Patients With Acute Myeloid Leukemia (AML) Aged of 50-70 Years Ol [NCT00927498]	Phase 3	280 participants (Actual)	Interventional	2007-12-31	Completed
GIMEMA Guidelines for the Treatment of Adult ALL Affected Patients at Diagnosis [NCT00537550]		0 participants	Interventional	2000-07-31	Completed
Phase I Study Evaluating the Chemosensitizing Effect of Everolimus Administered With Cytarabine and Daunorubicin in Patients With Acute Myeloid Leukemia in Relapse [NCT00544999]	Phase 1	21 participants (Anticipated)	Interventional	2007-09-30	Recruiting
A Collaborative Trial for the Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia [NCT00136084]	Phase 3	238 participants (Actual)	Interventional	2002-08-31	Completed
German Multicenter Trial for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years With Rituximab for Improvement of Prognosis in CD20 Positive Standard Risk ALL (Amend 2) [NCT00199004]	Phase 4	60 participants (Anticipated)	Interventional	2004-04-30	Completed
Phase I/II Study of Bortezomib (VELCADE) Plus Rituximab-HyperCVAD Alternating With Bortezomib Plus Rituximab-High Dose Methotrexate/Cytarabine in Patients With Untreated Aggressive Mantle Cell Lymphoma [NCT00477412]	Phase 1/Phase 2	107 participants (Actual)	Interventional	2007-04-03	Completed
Moscow-Berlin 2008 Multicenter Randomised Study for Treatment of Acute Lymphoblastic Leukemia in Children and Adolescents [NCT01953770]		3,000 participants (Anticipated)	Interventional	2008-02-29	Active, not recruiting
Combined Retinoic Acid,Arsenic Trioxide and Chemotherapy for Newly-diagnosed Acute Promyelocytic Leukemia: Chinese National Multi-center Randomized Study [NCT01987297]	Phase 4	738 participants (Anticipated)	Interventional	2012-06-30	Active, not recruiting
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Dia [NCT02085408]	Phase 3	727 participants (Actual)	Interventional	2011-02-04	Active, not recruiting
A Phase I/II, Open-Label, Multi-Center Study Evaluating the Safety and Efficacy of Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms [NCT03878199]	Phase 1/Phase 2	47 participants (Anticipated)	Interventional	2019-02-20	Recruiting
A Phase I Study of Pomalidomide Given at the Time of Lymphocyte Recovery Following Induction Timed Sequential Chemotherapy With Cytarabine, Daunorubicin and Etoposide (AcDVP16) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk MD [NCT02029950]	Phase 1	50 participants (Actual)	Interventional	2013-12-16	Completed
Protocol for Patients With High Risk (Resistant, Refractory, Relapsed or Adverse Cytogenetic) AML [NCT00005863]	Phase 3	0 participants	Interventional	1998-08-31	Completed
Phase III Randomized Study of Induction Chemotherapy With or Without MDR-Modulation With PSC-833 (NSC # 648265, IND # 41121) Followed by Cytogenetic Risk-Adapted Intensification Therapy Followed by Immunotherapy With rIL-2 (NSC # 373364, IND # 1969) vs. O [NCT00006363]	Phase 3	720 participants (Actual)	Interventional	2000-11-30	Completed
DaunoXome (Liposomal Daunorubicin) Plus Ara-C Versus Daunorubicin Plus Ara-C in Elderly AML Patients.A Randomized Phase III Study. [NCT00589082]	Phase 3	0 participants	Interventional	2001-10-31	Completed
CINJALL: Treatment for Children With Acute Lymphocytic Leukemia [NCT00176462]	Phase 2	60 participants (Actual)	Interventional	2001-02-28	Completed
A Randomized, Open-label, Two-period, Two-way Crossover Bioequivalence Study of Two (Cytarabine: Daunorubicin) Liposome for Injection in Elderly AML Subjects [NCT05801835]		36 participants (Anticipated)	Interventional	2023-08-25	Recruiting
A Phase II Study of CPX-351 in Younger Patients < 60 Years Old With Secondary Acute Myeloid Leukemia [NCT04269213]	Phase 2	46 participants (Anticipated)	Interventional	2021-07-29	Recruiting
A Phase II Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia [NCT03164057]	Phase 2	206 participants (Actual)	Interventional	2017-06-15	Active, not recruiting
Phase I Clinical Trial Assessing the Combination of Chemokine Modulation With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer [NCT04081389]	Phase 1	9 participants (Actual)	Interventional	2019-12-06	Completed
Phase 2 Open Label Study of Durvalumab With Neoadjuvant Chemotherapy in Variant Histology Bladder Cancer [NCT03912818]	Phase 2	7 participants (Actual)	Interventional	2019-04-10	Terminated(stopped due to Difficulty with enrollment)
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies [NCT02419495]	Phase 1	221 participants (Actual)	Interventional	2015-06-26	Active, not recruiting
A Prospective, Single Arm, Multicenter Clinical Study to Evaluate the Efficacy of Venetoclax Combined With Azacytidine or DA Regimen in Prevention the Relapse of Consecutive MRD Positive AML Patients [NCT05361057]	Phase 2	40 participants (Anticipated)	Interventional	2022-05-01	Recruiting
Intensified PEG-Asparaginase in High Risk Acute Lymphoblastic Leukemia (ALL): A Pilot Study [NCT00866307]	Phase 1	104 participants (Actual)	Interventional	2009-02-23	Completed
A Phase 2 Multicenter Study of First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia [NCT01004497]	Phase 2	51 participants (Actual)	Interventional	2010-03-31	Completed
AIEOP LLA 2000 Multicenter Study for the Diagnosis and Treatment of Childhood Acute Lymphoblastic Leukemia [NCT00613457]	Phase 3	2,039 participants (Actual)	Interventional	2000-09-30	Completed
A Pilot Study of a Novel Sequential Treatment Utilizing CPX-351 as Salvage Chemotherapy Followed by Allogeneic Stem-Cell Transplantation (SCT) Utilizing a Haplo-cord Graft for Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome [NCT03393611]	Phase 1	14 participants (Actual)	Interventional	2012-11-30	Completed
International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia - Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination With Induction Chemotherapy [NCT02724163]	Phase 3	700 participants (Anticipated)	Interventional	2016-04-30	Recruiting
A Phase 1 Clinical Study of DSP-2033 (Alvocidib) in Combination With Cytarabine/Mitoxantrone or Cytarabine/Daunorubicin (7+3) in Patients With Acute Myeloid Leukemia [NCT03563560]	Phase 1	10 participants (Actual)	Interventional	2018-05-15	Completed
Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia [NCT05660473]	Phase 2	100 participants (Anticipated)	Interventional	2022-10-31	Recruiting
A Phase 1 Study of AC220 (ASP2689) in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia [NCT01390337]	Phase 1	19 participants (Actual)	Interventional	2011-10-31	Completed
A Pilot Study of Arsenic Trioxide-Based Consolidation Therapy for the Primary Treatment of Acute Promyelocytic Leukemia [NCT00276601]	Phase 2	0 participants	Interventional	2004-10-31	Completed
Multicenter Trial for Treatment Optimization in T-lymphoblastic Lymphoma in Adults and Adolescents Older Than 15 Years (GMALL T-LBL 1/2004) (Amend 1) [NCT00199017]	Phase 4	75 participants (Anticipated)	Interventional	2004-04-30	Completed
A Randomized, Multi-center, Open-label Phase III Bridging Study to Compare Efficacy of Liposomal Cytarabine-Daunorubicin for Injection With Cytarabine and Daunorubicin in Treating Older Patients With High-Risk (Secondary) Acute Myeloid Leukemia [NCT06182592]	Phase 3	120 participants (Anticipated)	Interventional	2024-01-31	Not yet recruiting
A Randomized Phase III Study of the Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia [NCT00186966]	Phase 3	394 participants (Actual)	Interventional	2002-03-31	Completed
AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia(APL) [NCT00180128]	Phase 4	80 participants (Anticipated)	Interventional	2000-01-31	Recruiting
Total Therapy Study XIV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia [NCT00187005]	Phase 3	53 participants (Actual)	Interventional	1998-07-31	Terminated(stopped due to Toxicity)
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy [NCT03701308]	Phase 2/Phase 3	670 participants (Anticipated)	Interventional	2019-03-28	Suspended(stopped due to End of Initial Phase of Multi-phase protocol)
Treatment for Newly Diagnosed Patients With Stage III/IV Non-Hodgkin Lymphoma-Study XIII (A Therapeutic Pilot Study) [NCT00187122]		42 participants (Actual)	Interventional	1993-03-31	Completed
Phase I/II Trial to Study the Dose, Tolerability and the Effectiveness of Imatinib in Combination With Daunorubicine and Cytarabine for Patients With Chronic Myelogenous Leukemia in Myeloid Acute Phase [NCT00219765]	Phase 1/Phase 2	30 participants	Interventional	2001-05-31	Terminated
Pilot Study I for Treatment of Cancer in Children With Ataxia-Telangiectasia [NCT00187057]		6 participants (Actual)	Interventional	2002-09-30	Completed
Pembrolizumab and aMVAC Chemotherapy as Neoadjuvant Therapy in Non-Urothelial Histology Muscle-Invasive Bladder Cancer: A Pilot Trial [NCT04383743]	Phase 2	17 participants (Anticipated)	Interventional	2020-11-24	Recruiting
A Randomized Trial for Patients With High-Grade Myeloid Neoplasms With Measurable Residual Disease (MRD): CPX-351 vs. Immediate Allogeneic Hematopoietic Cell Transplantation [NCT04526288]	Phase 2	1 participants (Actual)	Interventional	2021-08-09	Terminated(stopped due to Terminated due to low accrual)
A Phase II Study of CPX-351 as a Novel Therapeutic Approach for Patients With Myelodysplastic Syndromes (MDS) After Hypomethylating Agent Failure [NCT03957876]	Phase 2	25 participants (Anticipated)	Interventional	2019-07-25	Recruiting
AML Treatment in Untreated Adult Patients According to EORTC-GIMEMA Protocols AML8 and AML10 [NCT00449319]		0 participants	Interventional	1998-11-30	Recruiting
A Phase 3 Trial of Systematic Versus Response-adapted Timed-Sequential Induction in Patients With Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) [NCT00428558]	Phase 3	200 participants (Actual)	Interventional	2007-07-31	Completed
ALL-BFM 2000 Multi-Center Study for the Treatment of Children and Adolescents With Acute Lymphoblastic Leukemia [NCT00430118]	Phase 3	4,559 participants (Actual)	Interventional	2000-07-31	Completed
A RANDOMIZED COMPARISON OF TWO DIFFERENT DOSAGES OF DAUNORUBICIN IN INDUCTION TREATMENT OF ACUTE MYELOGENOUS LEUKEMIA [NCT00474006]	Phase 3	398 participants (Actual)	Interventional	2001-08-31	Completed
PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia [NCT00494897]	Phase 4	374 participants (Actual)	Interventional	1996-06-30	Completed
A Phase 1 Study of Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated Acute Myeloid Leukemia [NCT05024552]	Phase 1	22 participants (Anticipated)	Interventional	2021-08-23	Recruiting
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement [NCT02828358]	Phase 2	78 participants (Actual)	Interventional	2017-04-01	Active, not recruiting
Phase II Study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Patients With Newly Diagnosed AML at High Risk for Induction Mortality [NCT02286726]	Phase 2	56 participants (Actual)	Interventional	2015-05-04	Completed
LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive [NCT00526305]	Phase 4	100 participants (Anticipated)	Interventional	2000-01-31	Completed
LAL-BR/2001: Study Treatment to Low Risk ALL [NCT00526175]	Phase 4	150 participants (Anticipated)	Interventional	2001-06-30	Completed
LAL-AR-N-2005: Study Treatment for Children High Risk Acute Lymphoblastic Leukemia [NCT00526409]	Phase 4	40 participants (Anticipated)	Interventional	2005-06-30	Completed
Modified BFM (Berlin-Frankfurt-Munster)Backbone Therapy for Chinese Children or Adolescents With Newly Diagnosed Lymphoblastic Lymphoma [NCT02845882]	Phase 3	150 participants (Anticipated)	Interventional	2016-01-31	Active, not recruiting
A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; NSC#617807) [NCT00557193]	Phase 3	218 participants (Actual)	Interventional	2008-01-15	Active, not recruiting
A Phase 1 Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia [NCT02236013]	Phase 1	80 participants (Actual)	Interventional	2015-01-07	Completed
LBL 2018 - International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma [NCT04043494]	Phase 3	683 participants (Anticipated)	Interventional	2019-08-23	Recruiting
International Collaborative Treatment Protocol for Infants Under One Year With Acute Lymphoblastic or Biphenotypic Leukemia [NCT00550992]		445 participants (Anticipated)	Interventional	2006-01-31	Recruiting
Ma-Spore ALL 2010 Study [NCT02894645]	Phase 4	500 participants (Anticipated)	Interventional	2008-10-31	Recruiting
A Phase Ib/II Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML [NCT03850535]	Phase 1/Phase 2	24 participants (Actual)	Interventional	2019-03-25	Terminated(stopped due to Sponsor's decision to terminate the study after Phase 1; will not proceed with Phase 2.)
A PedAL/EuPAL Phase 1/2 Trial of IMGN632 in Pediatric Patients With Relapsed or Refractory Leukemia [NCT05320380]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2023-08-01	Withdrawn(stopped due to Withdrawn per CS0150757)
Primary Comparison of Liposomal Anthracycline Based Treatment Versus Conventional Care Strategies Before Allogeneic Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML [NCT04061239]	Phase 2	150 participants (Anticipated)	Interventional	2019-08-19	Recruiting
A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Induction Chemotherapy for Newly Diagnosed Fit Adults With Acute Myeloid Leukemia [NCT04801797]	Phase 2	172 participants (Anticipated)	Interventional	2021-05-20	Recruiting
TREATMENT OF ADULT PATIENTS WITH RELAPSING ACUTE LYMPHOCYTIC LEUKEMIA, A MULTICENTER TRIAL [NCT00002532]	Phase 2	0 participants	Interventional	1993-01-31	Active, not recruiting
ACUTE MYELOID LEUKAEMIA TRIAL 12 [NCT00002658]	Phase 3	2,000 participants (Anticipated)	Interventional	1994-01-31	Active, not recruiting
A RANDOMIZED PHASE III TRIAL COMPARING DEXAMETHASONE WITH PREDNISONE IN INDUCTION TREATMENT AND BONE MARROW TRANSPLANTATION WITH INTENSIVE MAINTENANCE TREATMENT IN ADOLESCENT AND ADULT ACUTE LYMPHOBLASTIC LEUKEMIA (ALL-4) [NCT00002700]	Phase 3	392 participants (Anticipated)	Interventional	1995-08-31	Completed
Treatment of Newly Diagnosed Childhood AML Using a Timed-Sequential Remission Induction and Consolidation Followed by Single Dose Melphalan With Peripheral Stem Cell Rescue: A POG Pilot Study [NCT00004056]	Phase 1	35 participants (Actual)	Interventional	1999-10-31	Completed
The Value of High Dose Versus Standard Dose ARA-C During Induction and of IL-2 After Intensive Consolidation/Autologous Stem Cell Transplantation in Patients (Age 15-60 Years) With Acute Myelogenous Leukemia. A Randomized Phase II Trial of the EORTC and t [NCT00004128]	Phase 3	2,000 participants (Anticipated)	Interventional	1999-09-30	Active, not recruiting
A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination With Induction Therapy and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation [NCT02632708]	Phase 1	153 participants (Actual)	Interventional	2015-12-31	Active, not recruiting
Phase-II Study Evaluating Midostaurin in Induction, Consolidation and Maintenance Therapy Also After Allogeneic Blood Stem Cell Transplantation in Patients With Newly Diagnosed Acute Myeloid Leukemia Exhibiting a FLT3 Internal Tandem Duplication [NCT01477606]	Phase 2	451 participants (Actual)	Interventional	2012-05-31	Completed
A Phase II Study Of Induction With Daunorubicin, Cytarabine, And Cyclosporine All By Continuous IV Infusion For Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) In Patients Of Age 56 Or Older [NCT00066794]	Phase 2	69 participants (Actual)	Interventional	2004-07-31	Completed
Multicenter Therapy-Optimization Trial AML-BFM 2004 for the Treatment of Acute Myeloid Leukemias in Children and Adolescents [NCT00111345]	Phase 2/Phase 3	550 participants (Actual)	Interventional	2004-03-31	Active, not recruiting
Phase 2 Study of Imatinib-Combined Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia [NCT00130195]	Phase 2	100 participants (Actual)	Interventional	2002-09-30	Completed
Phase II Trial of Ixazomib Combined With Gemcitabine and Doxorubicin in Patients With Renal Medullary Carcinoma [NCT03587662]	Phase 2	30 participants (Anticipated)	Interventional	2018-08-17	Recruiting
A Phase III Study of Daunorubicin and Cytarabine +/- G3139 (Genasense, Oblimersen Sodium, NSC #683428, IND #58842), a BCL2 Antisense Oligodeoxynucleotide, in Previously Untreated Patients With Acute Myeloid Leukemia (AML) > / = 60 Years [NCT00085124]	Phase 3	500 participants (Actual)	Interventional	2003-12-31	Completed
A Phase IB, Open-Label Study to Determine the Safety and Pharmacokinetics of Twice Daily Oral Dosing of PKC412 Administered in Combinations Sequentially and Concomitantly With Daunorubicin and Cytarabine for Standard Induction Therapy, and High Dose Cytar [NCT00093600]	Phase 1	69 participants (Actual)	Interventional	2004-02-29	Completed
A Phase I Study of R115777 (Zarnestra) in Combination With Induction Chemotherapy in Patients With Newly Diagnosed, High Risk Acute Myeloid Leukemia [NCT00124644]	Phase 1	30 participants	Interventional	2006-03-31	Terminated(stopped due to "Withdrawn due to toxicity problems")
A Single-arm Open-label Multicenter Clinical Study of Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia [NCT05726110]	Phase 3	50 participants (Anticipated)	Interventional	2023-01-29	Recruiting
Multicentric Study for the Treatment of Children With Acute Lymphoblastic Leukemia [NCT00343369]		550 participants (Anticipated)	Interventional	2003-01-31	Recruiting
Pilot Study of Viral Load and Transcription in Kaposi's Sarcoma Patients Treated With Liposomal Anthracyclines [NCT00427414]	Phase 1	14 participants (Actual)	Interventional	2008-09-30	Terminated(stopped due to Terminated due to slow accrual.)
A Phase I Study Of Therapy With The Farnesyl Transferase Inhibitor R115777 (Zarnestra) Combined With Conventional Induction And Consolidation Chemotherapy For Previously Untreated Patients Over Age 55 With Acute Myeloid Leukemia (AML) [NCT00101153]	Phase 1	24 participants (Actual)	Interventional	2007-04-30	Completed
A Programme of Treatment Development for Older Patients With Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome [NCT00454480]	Phase 2/Phase 3	2,000 participants (Anticipated)	Interventional	2006-08-31	Completed
Randomized Controlled Trial to Test Efficacy of High-Dose Methotrexate Consolidation Therapy for BCR-ABL-Negative Acute Lymphoblastic Leukemia in Adults [NCT00131027]	Phase 3	240 participants (Anticipated)	Interventional	2002-09-30	Recruiting
High-Dose Ara-C Followed by Continuous Infusion Interleukin-2 for Acute Myelogenous Leukemia in First Remission [NCT00136448]	Phase 2	30 participants	Interventional	1993-02-28	Completed
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age. [NCT00788892]	Phase 2	126 participants (Actual)	Interventional	2008-10-31	Completed
Treatment Of Newly Diagnosed Adult Acute Lymphoblastic Leukemia With Intensified Post Remission Therapy Containing PEG-Asparaginase. [NCT00184041]	Phase 2	47 participants (Actual)	Interventional	2004-07-31	Completed
Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects With HR First Relapse B-precursor ALL [NCT02393859]	Phase 3	111 participants (Actual)	Interventional	2015-11-10	Completed
A Phase I-II Study of the Combination of Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL) [NCT02420717]	Phase 2	11 participants (Actual)	Interventional	2015-07-15	Terminated(stopped due to Study was closed early due to low accrual and lack of response.)
Study of the Efficacy and Safety of Venetoclax Plus Azacytidine Versus Daunorubicin Plus Cytarabine in Adult Acute Myeloid Leukemia (AML) Patients With Adverse Risk Features [NCT05939180]	Phase 2/Phase 3	108 participants (Anticipated)	Interventional	2023-07-01	Recruiting
[NCT01540812]		418 participants (Actual)	Observational	2012-02-29	Completed
Induction Intensification in Infant ALL: A Children's Oncology Group Study [NCT00002756]	Phase 2	221 participants (Actual)	Interventional	1996-06-30	Completed
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Infants Less Than 1 Year of Age. [NCT00002785]	Phase 2	0 participants	Interventional	1996-07-31	Completed
A Phase I Study to Determine the Maximum Tolerated Dose of Daunoxome as Therapy for the Treatment of Metastatic Breast Cancer [NCT00004207]	Phase 1	0 participants	Interventional	1997-12-31	Active, not recruiting
Randomised Induction and Post Induction Therapy in Older Patients (≥61 Years of Age) With Acute Myeloid Leukemia (AML) and Refractory Anemia With Excess Blasts (RAEB, RAEB-t) [NCT00121303]	Phase 3	600 participants (Anticipated)	Interventional	2005-01-31	Completed
MULTICENTRE TRIAL OF INTENSIFIED THERAPY FOR ADULT ALL (O5/93) [NCT00002531]	Phase 2	0 participants	Interventional	1993-01-31	Active, not recruiting
A Study of Modified Augmented BFM Therapy for Infants With Acute Lymphoblastic Leukemia [NCT00022126]	Phase 2	6 participants (Actual)	Interventional	2002-11-30	Completed
The Use of Modified BFM +/- Compound 506U78 (Nelarabine) (NSC# 686673, IND #52611) in an Intensive Chemotherapy Regimen for the Treatment of T-Cell Leukemia [NCT00016302]		100 participants (Actual)	Interventional	2001-04-30	Completed
Treatment of Newly Diagnosed Childhood Acute Myeloid Leukemia (AML) Using Intensive MRC-Based Therapy and Gemtuzumab Ozogamicin (GMTZ): A COG Pilot Study [NCT00070174]	Phase 2	350 participants (Actual)	Interventional	2003-12-31	Completed
A Phase I/II Trial of STI-571 and Chemotherapy in Lymphoid Blast Crisis of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoid Leukemia [NCT00015860]	Phase 1/Phase 2	0 participants	Interventional	2001-05-31	Completed
Treatment Protocol for T-Cell and B-Precursor Cell Lymphoblastic Lymphoma of the European Inter-group Co-operation on Childhood Non-Hodgkin-Lymphoma (EICNHL) [NCT00275106]	Phase 3	600 participants (Anticipated)	Interventional	2004-09-30	Terminated(stopped due to Withdrawn due to an excess of toxic deaths)
An Open-Label, Phase I/II, Multicenter Dose Escalation Study of Zosuquidar, Daunorubicin, and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia [NCT00129168]	Phase 1/Phase 2	100 participants (Anticipated)	Interventional	2005-08-31	Completed
PILOT MULTINATIONAL PROTOCOLS IN ACUTE LYMPHOBLASTIC LEUKEMIA AND DIFFUSE NON-HODGKIN'S LYMPHOMA [NCT00018954]	Phase 2	0 participants	Interventional	1992-10-31	Completed
A Children's Oncology Group Pilot Study for the Treatment of Very High Risk Acute Lymphoblastic Leukemia in Children and Adolescents (Imatinib (STI571, GLEEVEC) NSC#716051) [NCT00022737]	Phase 3	220 participants (Actual)	Interventional	2002-10-31	Completed
Pilot Trial of an Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Sarcomas [NCT04199026]	Early Phase 1	20 participants (Anticipated)	Interventional	2024-01-31	Not yet recruiting
A Phase I Study of G3139 ( NSC # 683428) in Combination With Cytarabine and Daunorubicin in Previously Untreated Patients With Acute Myeloid Leukemia (AML)>= 60 Years of Age [NCT00039117]	Phase 1	32 participants (Actual)	Interventional	2002-04-30	Completed
A Randomized Study of Two Methods of CNS Prophylaxis in Patients With Acute Lymphoblastic Leukemia [NCT00019409]	Phase 3	0 participants (Actual)	Interventional	1999-10-31	Withdrawn
A Phase II Study Of Daunomycin And ARA-C, Both Given By Continous IV Infusion For Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) In Patients Of Age 56 Or Older [NCT00023777]	Phase 2	71 participants (Actual)	Interventional	2001-08-31	Completed
Cytarabine Plus Continuous Infusion Daunorubicin Induction Therapy for Adults With Acute Myeloid Leukemia: A Feasibility Study With Cardiac MRI Monitoring [NCT02971397]	Phase 2	40 participants (Actual)	Interventional	2016-11-30	Active, not recruiting
Protocol for the Treatment of Adults Aged NCT00209833]	Phase 2/Phase 3	200 participants	Interventional	1999-01-31	Active, not recruiting
A Multicenter, Phase 2 Study, to Evaluate Safety and Efficacy of an Acute Lymphoblastic Leukemia (ALL) Intensive Chemotherapy for Adult Lymphoblastic Lymphoma (LL). [NCT00195871]	Phase 2	155 participants (Actual)	Interventional	2004-02-29	Active, not recruiting
Azacitidine Compared to Conventional Chemotherapy in Consolidation of Elderly Patients (65 Years or Older) With AML in First Complete Remission [NCT01794169]	Phase 2	130 participants (Anticipated)	Interventional	2013-03-31	Terminated(stopped due to Poor recruitment)
An Intergroup Phase II Clinical Trial for Adolescents and Young Adults With Untreated Acute Lymphoblastic Leukemia (ALL) [NCT00558519]	Phase 2	318 participants (Actual)	Interventional	2008-03-12	Active, not recruiting
Enhancing Immunotherapy by Targeting the EGFR Pathway in Inflammatory Breast Cancer: A Phase II Study of Panitumumab (PmAb) and Pembrolizumab (Pembro) in Combination With Neoadjuvant Chemotherapy (NAC) in Patients With Newly Diagnosed Triple Negative Infl [NCT05177796]	Phase 2	0 participants (Actual)	Interventional	2022-03-11	Withdrawn(stopped due to 0 participants recruited)
Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AML [NCT03021330]	Phase 3	1,100 participants (Anticipated)	Interventional	2017-02-08	Recruiting
Asia-wide, Multicenter Open-label, Phase II Non-randomised Study Involving Children With Down Syndrome Under 21 Year-old With Newly Diagnosed, Treatment naïve Acute Lymphoblastic Leukemia [NCT03286634]	Phase 2	60 participants (Anticipated)	Interventional	2017-04-18	Recruiting
A Phase II Study of CPX-351 for Treatment of AML or Higher Risk MDS Relapsed or Refractory to Prior Therapy With Hypomethylating (HMA) Agent [NCT02019069]	Phase 2	11 participants (Actual)	Interventional	2014-02-03	Completed
Augmented Berlin-Frankfurt-Munster Therapy for Adolescents/Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma [NCT00866749]	Phase 2	120 participants (Actual)	Interventional	2006-09-12	Completed
A Two-Part Study Evaluating the Combination of Tazemetostat and CPX-351 (Part 1) and Palbociclib With CPX-351 (Part 2) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia [NCT05627232]	Phase 1	24 participants (Anticipated)	Interventional	2023-08-28	Recruiting
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL [NCT03150693]	Phase 3	310 participants (Anticipated)	Interventional	2017-06-01	Suspended(stopped due to Unacceptable Toxicity)
Risk-stratified Therapy for Primary and Secondary AML and MDS. A Randomized Study by AMLCG in Relation to Cytogenetically Defined Prognostic Factors (1) on the Role of High-dose AraC as Part of Double Induction, (2) on G-CSF Priming, and (3) on High-dose [NCT00266136]	Phase 3	3,500 participants (Actual)	Interventional	1999-06-30	Completed
A Phase I Trial of Imatinib Mesylate (Gleevec, Formerly Known as STI571) in Combination With Daunorubicin and Cytarabine for C-kit Positive Relapsed AML [NCT00268229]	Phase 1	21 participants (Actual)	Interventional	2003-07-31	Completed
Randomized Comparison Between Two Dose Levels of Daunorubicin and Between One Versus Two Cycles of Induction Therapy for Adult Patients With Acute Myeloid Leukemia ≤65 Years [NCT02140242]	Phase 3	721 participants (Actual)	Interventional	2014-04-16	Completed
Phase 1 Study of Venetoclax/Azacitidine or Venetoclax in Combination With Ziftomenib or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination With Ziftomenib for the Treatment of Patients With Acute Myeloid Leukemia [NCT05735184]	Phase 1	212 participants (Anticipated)	Interventional	2023-07-18	Recruiting
A Phase Ib Trial With Dose Expansion Evaluating CPX-351 Plus Gemtuzumab Ozogamicin for Relapsed Acute Myelogenous Leukemia [NCT03904251]	Phase 1	13 participants (Actual)	Interventional	2019-07-18	Terminated(stopped due to slow accrual)
A Trial of Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults (ATACC AML) [NCT03568994]	Early Phase 1	26 participants (Actual)	Interventional	2018-07-10	Active, not recruiting
A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy, and Administered as Continuation Therapy in Subjects 18 to 75 Years Old With Newly Diagnosed FLT3-ITD (+) Acute Mye [NCT02668653]	Phase 3	539 participants (Actual)	Interventional	2016-09-01	Completed
A Phase II Multi-Center Open-Label Trial of Six Doses of Pembrolizumab Monotherapy Prior to Limited Chemotherapy as Front-Line Therapy for Patients With Classical Hodgkin Lymphoma, Including Elderly Patients. [NCT06164275]	Phase 2	30 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML) [NCT01627041]	Phase 2	178 participants (Actual)	Interventional	2011-09-16	Active, not recruiting
A Pilot Study of CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome [NCT03572764]	Phase 1	20 participants (Actual)	Interventional	2018-12-14	Active, not recruiting
MidOStaurin + Gemtuzumab OzogAmIcin Combination in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) [NCT04385290]	Phase 1/Phase 2	214 participants (Anticipated)	Interventional	2020-09-04	Recruiting
A Multi-Center, Open-Label, Phase 1/1b Study of Escalating Doses of RO5503781 Administered Orally as 1) a Single Agent, 2) In Combination With Cytarabine, or 3) With Cytarabine and Anthracycline and 4) Assessing PK and Safety of New Optimized Formulation [NCT01773408]	Phase 1	122 participants (Actual)	Interventional	2013-02-28	Completed
"Randomized Phase II Trial of Timed Sequential Therapy (TST) With Alvocidib (Flavopiridol), Ara-C and Mitoxantrone (FLAM) vs. 7+3 for Adults Age 70 and Under With Newly Diagnosed Acute Myelogenous Leukemia (AML)" [NCT01349972]	Phase 2	172 participants (Actual)	Interventional	2011-04-30	Completed
TREATMENT OF ALL IN FIRST BONE MARROW RELAPSE AFTER BFM PROTOCOLS [NCT00002499]	Phase 2/Phase 3	0 participants	Interventional	1990-01-31	Active, not recruiting
IDA VS MTZ IN INDUCTION AND INTENSIFICATION TREATMENT OF AML OR MDS IN CHILDREN, A PHASE III RANDOMIZED STUDY [NCT00002517]	Phase 3	0 participants	Interventional	1993-03-31	Completed
LSA5 PROTOCOL FOR THE TREATMENT OF ADVANCED PEDIATRIC AND ADOLESCENT NON-HODGKIN'S LYMPHOMA (NHL) [NCT00002691]	Phase 2	0 participants	Interventional	1995-08-31	Completed
A Phase II Trial of PET-Directed Therapy Using AVD (Doxorubicin, Vinblastine, and Dacarbazine) Plus Brentuximab Vedotin Induction Chemotherapy, With or Without Brentuximab Vedotin Plus Nivolumab, Followed by Nivolumab Consolidation for Patients With Previ [NCT03233347]	Phase 2	82 participants (Anticipated)	Interventional	2017-10-13	Active, not recruiting
A Phase I Dose Finding and Proof-of-concept Study of the Histone Deacetylase Inhibitor Panobinostat (LBH589) in Combination With Standard Dose Cytarabine and Daunorubicin for Older Patients With Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic [NCT01463046]	Phase 1	29 participants (Actual)	Interventional	2012-01-31	Completed
A Prospective, Multicenter, Single-Arm Pilot Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms [NCT05656248]	Phase 2	25 participants (Anticipated)	Interventional	2023-01-17	Recruiting
A Phase 1/1b Dose Escalation and Expansion of CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed Acute Myeloid Leukemia [NCT05558124]	Phase 1	18 participants (Anticipated)	Interventional	2022-09-22	Recruiting
TREATMENT OF ISOLATED CNS RELAPSE OF ACUTE LYMPHOBLASTIC LEUKEMIA -- A PEDIATRIC ONCOLOGY GROUP-WIDE PHASE II STUDY [NCT00002704]	Phase 2	156 participants (Actual)	Interventional	1996-01-31	Completed
A Pilot Study For The Treatment of Newly-Diagnosed Disseminated Anaplastic Large Cell Ki-1 Lymphoma and T-Large Cell Lymphoma [NCT00002590]	Phase 2	221 participants (Actual)	Interventional	1994-07-31	Completed
Medical Research Council Working Party on Leukaemia in Childhood Acute Myeloid Leukaemia Trial 12 [NCT00003436]	Phase 3	2,000 participants (Anticipated)	Interventional	1998-07-31	Completed
Treatment of Patients With Acute Lymphoblastic Leukemia With Unfavorable Features: A Phase III Group-wide Study [NCT00002812]	Phase 3	2,078 participants (Actual)	Interventional	1996-09-30	Completed
Phase III Study of MDR Modulation With PSC-833 (NSC #648265) Followed by Immunotherapy With rIL-2 (NSC #373364) vs. No Further Therapy in Previously Untreated Patients With AML >60 Years [NCT00003190]	Phase 3	640 participants (Actual)	Interventional	1998-01-31	Completed
Phase III Randomized Study of Concurrent Tretinoin and Chemotherapy With or Without Arsenic Trioxide (AS2O3) (NSC # 706363) as Initial Consolidation Therapy Followed by Maintenance Therapy With Intermittent Tretinoin Versus Intermittent Tretinoin Plus Mer [NCT00003934]	Phase 3	420 participants (Actual)	Interventional	1999-06-30	Completed
Phase II Study in Adults With Untreated Acute Lymphoblastic Leukemia Testing Increased Doses of Daunorubicin During Induction, and Cytarabine During Consolidation, Followed by High-Dose Methotrexate and Intrathecal Methotrexate in Place of Cranial Irradia [NCT00003700]	Phase 2	163 participants (Actual)	Interventional	1999-01-31	Completed
Multicenter Trial for Treatment of Acute Lymphocytic Leukemia in Adults (Pilot Study 06/99) [NCT00199056]	Phase 4	225 participants	Interventional	1999-10-31	Completed
ALinC 17: Protocol for Patients With Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia (ALL): A Phase III Study [NCT00005596]	Phase 3	1,076 participants (Actual)	Interventional	2000-04-30	Completed
A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg®) During Induction Therapy Versus Standard Induction With Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy With Ge [NCT00085709]	Phase 3	637 participants (Actual)	Interventional	2004-07-31	Completed
Phase I Dose Escalation Study of Millennium 9708 in Combination With Induction and Consolidation Chemotherapy in Adults >= 60 Years With Acute Myeloid Leukemia [NCT02582359]	Phase 1	39 participants (Actual)	Interventional	2016-01-31	Completed
German Multicenter Study for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years (Amend 3) (GMALL 07/2003) [NCT00198991]	Phase 4	1,883 participants (Actual)	Interventional	2003-04-30	Completed
Liposomal Cytarabine and Daunorubicin (CPX-351) for Adults With Untreated High-Risk MDS and Non-APL AML at High Risk of Treatment-Related Mortality [NCT01804101]		48 participants (Actual)	Interventional	2013-05-07	Completed
A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia (AML) [NCT02343939]	Phase 1/Phase 2	148 participants (Actual)	Interventional	2015-07-01	Terminated
A Phase II Study of the Aurora A Kinase Inhibitor Alisertib in Combination With 7+3 Induction Chemotherapy in Patients With High-risk Acute Myeloid Leukemia [NCT02560025]	Phase 2	42 participants (Actual)	Interventional	2015-12-31	Completed
A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients >/= 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia [NCT01253070]	Phase 2	54 participants (Actual)	Interventional	2011-04-01	Completed
Randomized Comparisons of Oral Mercaptopurine vs Oral Thioguanine and IT Methotrexate vs ITT for Standard Risk Acute Lymphoblastic Leukemia [NCT00002744]	Phase 3	1,970 participants (Actual)	Interventional	1996-05-31	Completed
A PHASE III STUDY IN CHILDREN WITH UNTREATED ACUTE MYELOGENOUS LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS) [NCT00002798]	Phase 3	880 participants (Actual)	Interventional	1996-08-31	Completed
TREATMENT OF ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: PHASE II TRIALS OF AN INDUCTION REGIMEN INCLUDING PEG-L-ASPARAGINASE, WITH OR WITHOUT PIXY, IN PREVIOUSLY UNTREATED PATIENTS, FOLLOWED BY ALLOGENEIC BONE MARROW TRANSPLANTATION OR FURTHER CHEMOTHERAPY IN FI [NCT00002665]	Phase 2	50 participants (Anticipated)	Interventional	1995-07-31	Completed
Phase III Study of Combination Chemotherapy in Children With T Cell and Pre-B Cell Non-Hodgkin's Lymphoma [NCT00003650]	Phase 3	179 participants (Actual)	Interventional	1997-02-28	Completed
The Value of Dexamethasone Versus Prednisolone During Induction and Maintenance Therapy of Prolonged Versus Conventional Duration of L-Asparaginase Therapy During Consolidation and Late Intensification, and of Corticosteroid + VCR Pulses During Maintenanc [NCT00003728]	Phase 3	1,500 participants (Anticipated)	Interventional	1998-12-31	Active, not recruiting
Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma [NCT02419469]	Phase 2	1 participants (Actual)	Interventional	2015-11-13	Terminated(stopped due to Slow Accrual)
A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma. [NCT00002093]	Phase 3	0 participants	Interventional		Completed
Phase II Trial of Intensive, Short-Course Combination Chemotherapy in the Treatment of Newly Diagnosed Patients With Poor-Risk Nonlymphoblastic Lymphoma and Acute B-Lymphoblastic Leukemia and in Patients With Recurrent Non-Hodgkin's Lymphoma [NCT00002471]	Phase 2	0 participants	Interventional	1990-02-28	Completed
RANDOMIZED PHASE III STUDY OF INDUCTION (ICE VS MICE VS DCE) AND INTENSIVE CONSOLIDATION (IDIA VS NOVIA VS DIA) FOLLOWED BY BONE MARROW TRANSPLANTATION IN ACUTE MYELOGENOUS LEUKEMIA: AML 10 PROTOCOL [NCT00002549]	Phase 3	1,520 participants (Anticipated)	Interventional	1993-11-30	Active, not recruiting
Phase I Study of MDR Modulation With PSC-833 (NSC# 648265) With a Pilot Study of Cytogenetic Risk-Adapted Consolidation Followed by a Phase II Pilot Study of Immunotherapy With RIL-2 (NSC # 373364) in Previously Untreated Patients With AML< 60 Years [NCT00002925]	Phase 1/Phase 2	410 participants (Actual)	Interventional	1997-02-28	Completed
Double-Blind Randomized Evaluation of Clinical Benefits of DOXIL in Patients With AIDS-Related Kaposi's Sarcoma Treated With DOXIL or DaunoXome [NCT00002985]	Phase 3	0 participants	Interventional	1996-11-30	Completed
A Multicenter, Open-Label Feasibility Study of Daratumumab With Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV [NCT04139304]	Early Phase 1	15 participants (Anticipated)	Interventional	2021-05-24	Recruiting
A Phase II Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy Plus Dasatinib (NSC #732517) and Continuation Therapy With Dasatinib Alone in Newly Diagnosed Patients With Core Binding Factor Acute Myeloid Leu [NCT01238211]	Phase 2	61 participants (Actual)	Interventional	2010-12-14	Completed
A Pilot Study of Targeted Daunorubicin Dosing to Overcome Chemotherapeutic Resistance in Children With Relapsed or Refractory Acute Leukemia [NCT04562792]	Phase 2	1 participants (Actual)	Interventional	2020-05-08	Completed
Non-Hodgkin's Lymphoma T Cell Protocol [NCT00003423]	Phase 3	100 participants (Anticipated)	Interventional	1995-05-31	Active, not recruiting
"Clinical Protocol for a Phase II Study of Leridistim (SC-70935) in Adult Patients (Age>55) With Acute Myeloid Leukemia (AML) Receiving Chemotherapy With the Cytarabine and Daunorubicin 7+3 Regimen" [NCT00004215]	Phase 2	0 participants	Interventional	1999-08-31	Completed
ALinC 17: Continuous Intensification for Very High Risk Acute Lymphocytic Leukemia (A.L.L.): A Pediatric Oncology Group Pilot Study [NCT00003783]	Phase 2	36 participants (Actual)	Interventional	1999-03-31	Completed
A Phase I/II Study of Induction Chemotherapy With Daunorubicin, Cytarabine, Topotecan and Etoposide (DATE) for De Novo AML: In the Treatment of Young Patients Ages 16-59 [NCT00005793]	Phase 1/Phase 2	41 participants (Actual)	Interventional	1999-07-31	Completed
A Randomized Multicenter Study of More Intensive Versus Less Intensive Post-Remission Therapy in Elderly Patients With Acute Myelogenous Leukemia (AML) or Transformed Refractory Anemia With Excess Blasts (RAEB-t). [NCT00363025]	Phase 3	465 participants	Interventional	1999-11-30	Terminated
A Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With Local Standard-of-Care Chemotherapy for the Treatment of Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma or as Monotherapy for Kaposi Sarcoma Herpesvirus Associated Multicentric Castlem [NCT03864419]	Phase 1	40 participants (Anticipated)	Interventional	2019-10-24	Recruiting
Treatment Optimization in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment - a Phase IV-trial With a Phase III-part to Evaluate Safety and Efficacy of Ne [NCT02881086]	Phase 3	1,000 participants (Actual)	Interventional	2016-08-31	Active, not recruiting
A Phase 1b Dose-escalation Study of SGN-CD33A in Combination With Standard-of-care for Patients With Newly Diagnosed Acute Myeloid Leukemia [NCT02326584]	Phase 1	116 participants (Actual)	Interventional	2014-12-31	Completed
NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma [NCT01451515]	Phase 2	23 participants (Actual)	Interventional	2012-05-25	Completed
Immunostart: Prephase Tafasitamab, Retifanlimab, and Rituximab (TRR), Followed by TRR-CHOP, for Previously Untreated Diffuse Large B-Cell Lymphoma [NCT05455697]	Phase 1/Phase 2	35 participants (Anticipated)	Interventional	2023-01-26	Recruiting
A Randomized Multi-Center Treatment Study (COALL 08-09) to Improve the Survival of Children With Acute Lymphoblastic Leukemia on Behalf of the German Society of Pediatric Hematology and Oncology [NCT01228331]	Phase 2/Phase 3	745 participants (Actual)	Interventional	2010-10-31	Active, not recruiting
A PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-04449913, AN ORAL HEDGEHOG INHIBITOR, IN COMBINATION WITH INTENSIVE CHEMOTHERAPY, LOW DOSE ARA-C OR DECITABINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC SYNDROME [NCT01546038]	Phase 2	255 participants (Actual)	Interventional	2012-06-27	Completed
A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients With CD30-Positive Peripheral T-Cell Lymphomas [NCT03113500]	Phase 2	48 participants (Actual)	Interventional	2017-05-25	Active, not recruiting
A Phase II Randomized Trial of Immunologic and Chemotherapeutic Agents for Treatment of Patients With Relapsed or Refractory Acute Myelogenous Leukemia [NCT00005962]	Phase 2	0 participants	Interventional	2000-10-04	Completed
Concurrent Ponatinib With Chemotherapy for Young Adults With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia [NCT02776605]	Phase 2	30 participants (Actual)	Interventional	2016-06-30	Active, not recruiting
A Phase 2 Study of Loncastuximab Tesirine and Rituximab (Lonca-R) Followed by DA-EPOCH-R in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma [NCT05600686]	Phase 2	24 participants (Anticipated)	Interventional	2023-05-24	Recruiting
Dasatinib Plus Multi-agent Chemotherapy for New Diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia [NCT02523976]	Phase 2	30 participants (Actual)	Interventional	2015-08-01	Completed
Open-label, Single-arm Trial to Evaluate Antitumor Activity, Safety, and Pharmacokinetics of Isatuximab Used in Combination With Chemotherapy in Pediatric Patients From 28 Days to Less Than 18 Years of Age With Relapsed/Refractory B or T Acute Lymphoblast [NCT03860844]	Phase 2	67 participants (Actual)	Interventional	2019-08-06	Terminated(stopped due to Study was prematurely stopped due to sponsor decision (stage 2 efficacy criteria not met); not due to safety concerns.)
A Phase 1, Open-label, Dose-escalation, Safety and Biomarker Prediction of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) [NCT03298984]	Phase 1	32 participants (Actual)	Interventional	2017-09-25	Completed
Phase II Study of Adult Acute Lymphoblastic Leukaemia (ALL): Imatinib in Combination With Chemotherapy in Ph+ Patients, and Post-remissional Treatment Intensification in High-risk Ph- Patients, With Minimal Residual Disease Monitoring. [NCT00458848]	Phase 2	470 participants (Actual)	Interventional	2004-10-31	Completed
BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1 (BLAST MRD AML-1): A Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination With Conventional Intensive Chemotherapy as F [NCT04214249]	Phase 2	124 participants (Anticipated)	Interventional	2021-02-17	Recruiting
Randomized Phase 2 Trial of CPX-351 (Vyxeos) vs. CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in Medically Less-Fit Adults With Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm [NCT04195945]	Phase 2	60 participants (Anticipated)	Interventional	2020-03-11	Recruiting
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma [NCT03117751]	Phase 2/Phase 3	790 participants (Actual)	Interventional	2017-03-29	Active, not recruiting
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations [NCT02883049]	Phase 3	5,937 participants (Actual)	Interventional	2012-02-29	Active, not recruiting
LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma [NCT00610883]	Phase 2	17 participants (Actual)	Interventional	1990-05-31	Completed
A Phase I Study of Venetoclax Combined With Vyxeos (CPX-351) for Children, Adolescents and Young Adults With Relapsed or Refractory Acute Leukemia [NCT03826992]	Phase 1	21 participants (Anticipated)	Interventional	2018-12-27	Recruiting
A Randomized International Phase 3 Trial of Imatinib and Chemotherapy With or Without Blinatumomab in Patients With Newly-Diagnosed Philadelphia Chromosome-Positive or Philadelphia Chromosome-Like ABL-Class B-Cell Acute Lymphoblastic Leukemia [NCT06124157]	Phase 3	680 participants (Anticipated)	Interventional	2024-01-22	Not yet recruiting
International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia [NCT01117441]	Phase 3	6,136 participants (Actual)	Interventional	2010-06-30	Completed
Medical Research Council Working Party on Leukaemia in Children UK National Lymphoblastic Leukaemia (ALL) Trial [NCT00003437]	Phase 3	1,800 participants (Anticipated)	Interventional	1997-01-31	Active, not recruiting
Treatment of Children With Down Syndrome (DS) and Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Transient Myeloproliferative Disorder (TMD): A Phase III Group-Wide Study [NCT00003593]	Phase 3	254 participants (Actual)	Interventional	1999-06-30	Completed
A Phase II Study of Daunomycin and ARA-C Given by Continuous IV Infusion With PSC-833 for Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) in Patients of Age 56 or Older [NCT00004217]	Phase 2	55 participants (Anticipated)	Interventional	2000-02-29	Completed
ALINC #17 Treatment for Patients With Low Risk Acute Lymphoblastic Leukemia: A Pediatric Oncology Group Phase III Study [NCT00005585]	Phase 3	838 participants (Actual)	Interventional	2000-04-30	Completed
ALinC 17: Protocol for Patients With Newly Diagnosed High Risk Acute Lymphoblastic Leukemia (ALL) - Evaluation of the Augmented BFM Regimen: A Phase III Study [NCT00005603]	Phase 3	276 participants (Actual)	Interventional	2000-03-31	Completed
Protocol for Patients With Newly Diagnosed Better Risk Acute Lymphoblastic Leukemia (ALL): A POG Pilot Study [NCT00003671]	Phase 2	59 participants (Actual)	Interventional	1998-12-31	Completed
A Randomized, Blinded, Placebo-Controlled, Dose Finding Study to Assess the Safety and Efficacy of the Oral Thrombopoietin Receptor Agonist, Eltrombopag, Administered to Subjects With Acute Myelogenous Leukaemia (AML) Receiving Induction Chemotherapy [NCT01890746]	Phase 2	148 participants (Actual)	Interventional	2013-09-05	Completed
A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin With High Dose Cytarabine (IA) Versus IA With Vorinostat (NSC-701852) (IA + V) in Younger Patients With Previously Untreated Acute Myeloid Leukemia (AML) [NCT01802333]	Phase 3	754 participants (Actual)	Interventional	2013-02-12	Completed
Phase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age With Untreated High Risk (Secondary) AML [NCT01696084]	Phase 3	309 participants (Actual)	Interventional	2012-12-13	Completed
Safety and Efficacy of Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Ovarian, Uterine, Appendiceal, Colorectal, and Gastric Cancer Patients With Peritoneal Carcinomatosis (PC) [NCT04329494]	Phase 1	49 participants (Anticipated)	Interventional	2020-08-21	Recruiting
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy [NCT03959085]	Phase 3	4,772 participants (Anticipated)	Interventional	2019-10-31	Recruiting
A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL) [NCT03712202]	Phase 2	155 participants (Actual)	Interventional	2018-11-28	Active, not recruiting
Phase I Study of Pacritinib and Chemotherapy in Patients With Acute Myeloid Leukemia and FLT3 Mutations [NCT02323607]	Phase 1	13 participants (Actual)	Interventional	2016-01-12	Completed
Epacadostat With Idarubicin and Cytarabine (EIC) for First-line Treatment of AML Patients Fit for Intensive Chemotherapy; a Phase I Study [NCT03444649]	Phase 1	0 participants (Actual)	Interventional	2018-09-30	Withdrawn(stopped due to IMP will not be further developed)
Effects of Rolapitant on Nausea/Vomiting in Patients With Sarcoma Receiving Multi-Day Highly Emetogenic Chemotherapy (HEC) With Doxorubicin and Ifosfamide Regimen (AI) [NCT02732015]	Phase 2	37 participants (Actual)	Interventional	2016-10-12	Terminated(stopped due to Terminated per PI's request)
Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials [NCT05564390]	Phase 2	750 participants (Anticipated)	Interventional	2024-02-01	Not yet recruiting
A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) to (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, and Azacitidine + Venetoclax in Patients Aged 59 or Younger With High-Risk (Adverse) Acute Myeloid L [NCT05554406]	Phase 2	268 participants (Anticipated)	Interventional	2024-02-01	Not yet recruiting
A Measurable Residual Disease (MRD) Driven, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients With Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH Clinical Trial [NCT05554393]	Phase 2	153 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
A Prospective, Randomized, Controlled Trial of Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Patients With Acute Myeloid Leukemia With t(8;21) [NCT03026842]	Phase 4	180 participants (Anticipated)	Interventional	2017-01-31	Active, not recruiting
A Phase I Study to Evaluate the Safety and Tolerability of Gemtuzumab Ozogamicin and Midostaurin When Used in Combination With Standard Cytarabine and Daunorubicin Induction for Newly Diagnosed FLT3-mutated Acute Myeloid Leukemia [NCT03900949]	Phase 1	18 participants (Anticipated)	Interventional	2019-03-13	Recruiting
A Phase I/II Study of Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination With Quizartinib in Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) [NCT04128748]	Phase 1/Phase 2	52 participants (Anticipated)	Interventional	2020-05-27	Recruiting
A PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF PF-04449913 (GLASDEGIB), AN ORAL HEDGEHOG INHIBITOR, ADMINISTERED AS A SINGLE AGENT IN JAPANESE PATIENTS WITH SELECT HEMATOLOGIC MALIGNANCIES AND IN [NCT02038777]	Phase 1	48 participants (Actual)	Interventional	2014-03-25	Active, not recruiting
A Randomized Trial Using a Modified COG ABFM Regimen Backbone to Investigate Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL) [NCT05681260]	Phase 3	200 participants (Anticipated)	Interventional	2023-02-06	Recruiting
Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) +/- Rituximab (R) + Tafasitamab-cxix for the Treatment of Newly-Diagnosed Adults With Philadelphia Chromosome-Negative (Ph-) B-cell Lymphoblastic Lymphoma/Leuke [NCT05453500]	Phase 2	30 participants (Anticipated)	Interventional	2023-03-27	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00002766 (1) [back to overview]	Complete Remission (CR)
NCT00004228 (2) [back to overview]	Percentage of Patients With Overall Survival as Assessed by Time to Death
NCT00004228 (2) [back to overview]	Event-free Survival
NCT00046930 (3) [back to overview]	Overall Survival (OS)
NCT00046930 (3) [back to overview]	Response
NCT00046930 (3) [back to overview]	Progression-free Survival (PFS)
NCT00049517 (3) [back to overview]	Overall Survival (Consolidation Phase)
NCT00049517 (3) [back to overview]	Disease-free Survival (Consolidation Phase)
NCT00049517 (3) [back to overview]	Overall Survival (Induction Phase)
NCT00061945 (6) [back to overview]	Minimal Residual Disease (MRD) During Treatment With Alemtuzumab (Phase II)
NCT00061945 (6) [back to overview]	Disease-free Survival, for Only Complete Response Patients
NCT00061945 (6) [back to overview]	Maximum Tolerated Dose (MTD) of Alemtuzumab (Phase I)
NCT00061945 (6) [back to overview]	Number of Participants Achieving Complete Remission
NCT00061945 (6) [back to overview]	Overall Survival
NCT00061945 (6) [back to overview]	Number of Participants Who Proceed to Course V Within 2-6 Weeks of the Last Dose of Alemtuzumab (Phase II)
NCT00075725 (7) [back to overview]	Correlation of Minimal Residual Disease (MRD) Positive With Overall Survival (OS)
NCT00075725 (7) [back to overview]	Correlation of Early Marrow Response Status With MRD Positive.
NCT00075725 (7) [back to overview]	Correlation of Minimal Residual Disease (MRD) Negative With Event Free Survival (EFS).
NCT00075725 (7) [back to overview]	Correlation of Minimal Residual Disease (MRD) Negative With Overall Survival (OS).
NCT00075725 (7) [back to overview]	Comparison of the Increase in Cure Rate of High Risk ALL Without Causing More Serious Side Effects Between Interventions
NCT00075725 (7) [back to overview]	Correlation of Early Marrow Response Status With MRD Negative.
NCT00075725 (7) [back to overview]	Correlation of Minimal Residual Disease (MRD) Positive With Event Free Survival (EFS)
NCT00085709 (3) [back to overview]	Complete Remission
NCT00085709 (3) [back to overview]	2-year Disease-free Survival (DFS)
NCT00085709 (3) [back to overview]	Toxicity
NCT00096135 (1) [back to overview]	Event-free Survival
NCT00109837 (2) [back to overview]	Continuous Complete Remission at 1 Year
NCT00109837 (2) [back to overview]	Toxicity
NCT00136084 (7) [back to overview]	Proportion of Patients Experienced Toxicity of Cytarabine + Daunomycin + Etoposide (ADE) + GO.
NCT00136084 (7) [back to overview]	Relationship of Inhibition of DNA Synthesis and Clinical Response
NCT00136084 (7) [back to overview]	To Assess Whether Inhibition of DNA Synthesis is Greater After High-dose Ara-C (HDAC) Than After Low-dose Ara-C (LDAC) Therapy
NCT00136084 (7) [back to overview]	To Estimate the Overall Event-free Survival (EFS) of AML Patients Who Undergo Risk-adapted and Genotype-directed Therapy
NCT00136084 (7) [back to overview]	Minimal Residual Disease (MRD).
NCT00136084 (7) [back to overview]	Proportion of MRD Reduction After One Course of Cytarabine + Daunomycin + Etoposide (ADE) + GO
NCT00136084 (7) [back to overview]	Proportion of Minimal Residual Disease (MRD)+ Patients Who Become MRD- After One Course of Gemtuzumab Ozogamicin (GO)
NCT00137111 (7) [back to overview]	Circulating Leukemia Cells in Peripheral Blood Change From Prior to the Methotrexate Infusion to Three Days After Between Two Arms (4 Hours vs. 24 Hours)
NCT00137111 (7) [back to overview]	Continuous Complete Remission Since Week 56 Therapy.
NCT00137111 (7) [back to overview]	Mean Difference of Active Methotrexate Polyglutamates (MTXPG) in Leukemia Cells Between Two Arms (4 Hours vs. 24 Hours).
NCT00137111 (7) [back to overview]	Overall Event-free Survival (EFS)
NCT00137111 (7) [back to overview]	Median Difference in CASP1 Gene Expression in Primary Leukemia Cells of Patients in Glucocorticoid-resistant Cells vs Glucocorticoid-sensitive Cells
NCT00137111 (7) [back to overview]	Minimal Residual Disease (MRD)
NCT00137111 (7) [back to overview]	Median Difference in NLRP3 Gene Expression in Primary Leukemia Cells of Patients in Glucocorticoid-resistant Cells vs. Glucocorticoid-sensitive Cells
NCT00176462 (1) [back to overview]	Percentage of Patients With ALL at High Risk of Relapse (Arm 2) Who Were Relapse-free at 5 Years
NCT00369317 (10) [back to overview]	Percentage of Patients Experiencing Grade 3 or 4 Toxicity Assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0
NCT00369317 (10) [back to overview]	Prevalence of of GATA1 Mutations of DS Patients < 4 Years of Age at Diagnosis
NCT00369317 (10) [back to overview]	Proportions of Patients in Morphologic Remission With Positive MRD by Flow Cytometry
NCT00369317 (10) [back to overview]	Prevalence of Leukemia Phenotype of DS Patients < 4 Years of Age at Diagnosis by Flow Cytometry
NCT00369317 (10) [back to overview]	Cytarabine Drug Sensitivity by R-Strip (MicroMath) Curve Fitting Program
NCT00369317 (10) [back to overview]	Cytarabine Drug Sensitivity by R-Strip (MicroMath) Curve Fitting Program
NCT00369317 (10) [back to overview]	Cytarabine Drug Sensitivity by R-Strip (MicroMath) Curve Fitting Program
NCT00369317 (10) [back to overview]	Event-free Survival (EFS) at 3 Years
NCT00369317 (10) [back to overview]	Induction Remission Rate
NCT00369317 (10) [back to overview]	Overall Survival (OS) at 3 Years
NCT00372593 (7) [back to overview]	Toxicities, Including Infectious Complications
NCT00372593 (7) [back to overview]	Overall Survival at 3 Years
NCT00372593 (7) [back to overview]	Remission Induction Rate After 2 Courses of Induction Therapy
NCT00372593 (7) [back to overview]	Time to Marrow Recovery
NCT00372593 (7) [back to overview]	Disease-free Survival (DFS)
NCT00372593 (7) [back to overview]	Event-free Survival at 3 Years
NCT00372593 (7) [back to overview]	Mortality
NCT00408005 (8) [back to overview]	Disease-free Survival (DFS) for Randomized Nelarabine T-ALL Cohort (Arm I vs. Arm II vs. Arm III vs. Arm IV)
NCT00408005 (8) [back to overview]	Cumulative Incidence of CNS Relapse for T-ALL by Risk Group
NCT00408005 (8) [back to overview]	Cumulative Incidence of CNS Relapse for T-ALL by Risk Group
NCT00408005 (8) [back to overview]	Disease-free Survival (DFS) for T-cell Lymphoblastic Lymphoma (T-LLy) Cohort
NCT00408005 (8) [back to overview]	Disease-free Survival (DFS) for Randomized Nelarabine T-ALL Cohort (Arm I + Arm III vs. Arm II + Arm IV)
NCT00408005 (8) [back to overview]	Disease-free Survival (DFS) for T-cell Lymphoblastic Lymphoma (T-LLy) Cohort
NCT00408005 (8) [back to overview]	Disease-free Survival (DFS) for Randomized Methotrexate T-ALL Cohort (Arm I vs. Arm II vs. Arm III vs. Arm IV)
NCT00408005 (8) [back to overview]	Disease-free Survival (DFS) for Randomized Methotrexate T-ALL Cohort (Arm I + Arm II vs. Arm III + Arm IV)
NCT00416598 (2) [back to overview]	Number of Participants Who Completed Maintenance Decitabine.
NCT00416598 (2) [back to overview]	Disease-free Survival (DFS) Rate at 1 Year
NCT00458848 (3) [back to overview]	Number of Patients Reaching Complete Hematological Response After Induction Therapy
NCT00458848 (3) [back to overview]	Percentage of Participants Reaching Overall Survival
NCT00458848 (3) [back to overview]	Percentage of Participants Reaching Disease Free Survival
NCT00477412 (4) [back to overview]	Time to Failure (Phase II)
NCT00477412 (4) [back to overview]	Overall Survival
NCT00477412 (4) [back to overview]	Maximum Tolerated Dose of Bortezomib (Phase I)
NCT00477412 (4) [back to overview]	Number of Participants With Overall Response Rate
NCT00549848 (6) [back to overview]	Percentage of Participants With Continuous Complete Remission of Patients Receiving High-dose and Conventional Dose PEG-asparaginase.
NCT00549848 (6) [back to overview]	Proportion of Participants With Minimal Residual Disease (MRD) on the 15th Day of Remission Induction ≥ 5%
NCT00549848 (6) [back to overview]	Proportion of Participants With Minimal Residual Disease (MRD) at End of Remission Induction ≥ 0.01%
NCT00549848 (6) [back to overview]	Probability of Overall Survival
NCT00549848 (6) [back to overview]	Probability of Event-free Survival
NCT00549848 (6) [back to overview]	Probability of CNS Relapse
NCT00557193 (10) [back to overview]	Percent Probability of Event Free Survival (EFS) by MRD Status and Treatment Arm
NCT00557193 (10) [back to overview]	Describe FLT3 Protein Expression as a Molecular Mechanism of Acquired Resistance to Lestaurtinib in Leukemic Blasts
NCT00557193 (10) [back to overview]	Describe FLT3 Protein Expression as a Molecular Mechanism of Primary Resistance to Lestaurtinib in Leukemic Blasts
NCT00557193 (10) [back to overview]	Describe in Vitro Sensitivity as a Molecular Mechanism of Acquired Resistance to Lestaurtinib in Leukemic Blasts
NCT00557193 (10) [back to overview]	Describe in Vitro Sensitivity as a Molecular Mechanism of Primary Resistance to Lestaurtinib in Leukemic Blasts
NCT00557193 (10) [back to overview]	Number of Patients Who Experienced Lestaurtinib-related Dose Limiting Toxicity (DLT)
NCT00557193 (10) [back to overview]	Percent Probability for Event-free Survival (EFS) for Patients on Arm A
NCT00557193 (10) [back to overview]	Percent Probability for Event-free Survival (EFS) for Patients on Arm C at Dose Level 2 (DL2)
NCT00557193 (10) [back to overview]	Percent Probability for Event-free Survival (EFS) of MLL-R Infants Treated With Combination Chemotherapy With or Without Lestaurtinib at DL2
NCT00557193 (10) [back to overview]	Pharmacodynamics PIA Levels in Infants Given Lestaurtinib at DL2 in Combination With Chemotherapy
NCT00558519 (5) [back to overview]	Disease-free Survival
NCT00558519 (5) [back to overview]	Complete Response Rate
NCT00558519 (5) [back to overview]	Event-free Survival
NCT00558519 (5) [back to overview]	Overall Survival
NCT00558519 (5) [back to overview]	Number of Participants Who Experienced at Least One Grade 3 or Higher Adverse Event at Least Possibly Related to Treatment (Toxicity)
NCT00610883 (1) [back to overview]	Complete Remission
NCT00651261 (5) [back to overview]	Overall Survival (OS)
NCT00651261 (5) [back to overview]	Overall Survival, Censoring Participants Who Receive a Stem Cell Transplant at the Time of the Transplant
NCT00651261 (5) [back to overview]	Event- Free Survival
NCT00651261 (5) [back to overview]	Disease-free Survival (DFS)
NCT00651261 (5) [back to overview]	Complete Response Rate
NCT00671034 (9) [back to overview]	Pharmacokinetics (PK) (Half-life of SC-PEG E. Coli L-asparaginase (EZN-2285) Compared to Pegaspargase During Induction and Consolidation Therapy)
NCT00671034 (9) [back to overview]	Plasma and CSF Concentrations of Asparagine in ug/ml
NCT00671034 (9) [back to overview]	Immunogenicity
NCT00671034 (9) [back to overview]	Pharmacodynamics (PD)
NCT00671034 (9) [back to overview]	Percentage of Participants With Complete Remission at the End of Induction
NCT00671034 (9) [back to overview]	Percentage of Participants With Event-free Survival (EFS)
NCT00671034 (9) [back to overview]	Toxicities During Post Induction Intensification Therapy (All Grades)
NCT00671034 (9) [back to overview]	Percentage of Participants With Minimal Residual Disease (MRD)<0.01% at the End of Induction
NCT00671034 (9) [back to overview]	Asparaginase Level
NCT00703820 (2) [back to overview]	Event-free Survival of Standard Risk Patients Who Receive Chemotherapy Followed by Natural Killer Cell Transplantation.
NCT00703820 (2) [back to overview]	Event-free Survival of Standard Risk Patients Who Receive Chemotherapy Alone.
NCT00720109 (5) [back to overview]	Event-Free Survival (EFS) of Patients With Standard-risk Disease Treated With Dasatinib in Combination With Intensified Chemotherapy
NCT00720109 (5) [back to overview]	Contribution of Dasatinib on Minimal Residual Disease (MRD) After Induction Therapy
NCT00720109 (5) [back to overview]	Feasibility and Toxicity of an Intensified Chemotherapeutic Regimen Incorporating Dasatinib for Treatment of Children and Adolescents With Ph+ ALL Assessed by Examining Adverse Events
NCT00720109 (5) [back to overview]	Percent of Patients MRD Positive (MRD > 0.01%) at End of Consolidation
NCT00720109 (5) [back to overview]	Overall EFS Rate for the Combined Cohort of Standard- and High-Risk Patients (Who Receive the Final Chosen Dose of Dasatinib)
NCT00742625 (4) [back to overview]	Participants Experiencing a Dose-limiting Toxicity (DLT) of Bortezomib When Administered in Combination With Intermediate-dose Cytarabine
NCT00742625 (4) [back to overview]	Disease-free Survival
NCT00742625 (4) [back to overview]	Overall Survival
NCT00742625 (4) [back to overview]	Remission Induction Response
NCT00788892 (6) [back to overview]	Number of Participants With Complete Remission
NCT00788892 (6) [back to overview]	Overall Survival Rate at 1 Year
NCT00788892 (6) [back to overview]	Rate of Stem Cell Transplant
NCT00788892 (6) [back to overview]	Event Free Survival
NCT00788892 (6) [back to overview]	Remission Duration/Time to Remission
NCT00788892 (6) [back to overview]	Aplasia Rate
NCT00814164 (3) [back to overview]	Complete Remission (CR)
NCT00814164 (3) [back to overview]	Overall Survival
NCT00814164 (3) [back to overview]	Disease-free Survival
NCT00866307 (2) [back to overview]	AALL08P1 Safety Outcome
NCT00866307 (2) [back to overview]	AALL08P1 Feasibility Outcome
NCT00866749 (4) [back to overview]	Participants Achieving Negative Minimal Residual Disease (MRD)
NCT00866749 (4) [back to overview]	Participants With a Complete Response (CR)
NCT00866749 (4) [back to overview]	Overall Survival
NCT00866749 (4) [back to overview]	3-Year Event-Free Survival (EFS)
NCT01238211 (7) [back to overview]	30 Day Survival Rate
NCT01238211 (7) [back to overview]	Complete Response Rate
NCT01238211 (7) [back to overview]	Cumulative Incidence of Death
NCT01238211 (7) [back to overview]	Event-free Survival
NCT01238211 (7) [back to overview]	Disease-free Survival
NCT01238211 (7) [back to overview]	Overall Survival
NCT01238211 (7) [back to overview]	Cumulative Incidence of Relapse
NCT01253070 (3) [back to overview]	Event-free Survival
NCT01253070 (3) [back to overview]	OS
NCT01253070 (3) [back to overview]	Overall Survival (OS) Rate
NCT01256398 (6) [back to overview]	Disease Free Survival (DFS)
NCT01256398 (6) [back to overview]	Disease Free Survival Defined From the Date of First Induction Complete Response (CR) to Relapse or Death Due to Any Cause
NCT01256398 (6) [back to overview]	Feasibility of Maintenance Therapy in This Patient Population (Restricted to Those Patients Achieving a CR). Feasibility Will be Defined as the Number of Deaths Ocuring.
NCT01256398 (6) [back to overview]	Overall Survival (OS)
NCT01256398 (6) [back to overview]	Probability of Being BCR-ABL Negative in the Bone Marrow and Peripheral Blood at the Completion of the CNS Prophylaxis Course (Restricted to Those Patients Achieving a CR)
NCT01256398 (6) [back to overview]	Response
NCT01275677 (7) [back to overview]	Toxicity Assessed by Adverse Events
NCT01275677 (7) [back to overview]	Percentage of Patients Alive and Recurrence-Free (RFI)
NCT01275677 (7) [back to overview]	Percentage of Patients Alive and Free From Invasive Disease (IDFS)
NCT01275677 (7) [back to overview]	Percentage of Patients Alive and Free From Distant Recurrence (DRFI)
NCT01275677 (7) [back to overview]	Percentage of Patients Alive and Free From Breast Cancer (BCFS)
NCT01275677 (7) [back to overview]	Percentage of Patients Alive and Disease-Free (DFS-DCIS)
NCT01275677 (7) [back to overview]	Percentage of Patients Alive (Overall Survival)
NCT01349972 (6) [back to overview]	Overall Survival
NCT01349972 (6) [back to overview]	Complete Response Rate
NCT01349972 (6) [back to overview]	Disease-free Survival
NCT01349972 (6) [back to overview]	Incidence of Toxicities, Characterized by Number of Events by Treatment and Grade
NCT01349972 (6) [back to overview]	Number of Patients With Minimal Residual Disease
NCT01349972 (6) [back to overview]	Progression-free Survival
NCT01371981 (18) [back to overview]	Total Scale Score From Parent-reported Multidimensional Fatigue Scale Module
NCT01371981 (18) [back to overview]	Proportion of Patients Experiencing Grade 3 or Higher Non-hematologic Toxicities and Infections While on Protocol Therapy
NCT01371981 (18) [back to overview]	Proportion of High Risk Children Without HR FLT3/ITD+ Converting From Positive MRD at End of Induction I to Negative MRD at the End of Induction II
NCT01371981 (18) [back to overview]	Overall Survival (OS) for Patients Without High Allelic Ratio FLT3/ITD+ Mutations
NCT01371981 (18) [back to overview]	Sorafenib Steady State Concentration
NCT01371981 (18) [back to overview]	OS for Patients on Arm C, Cohort 3
NCT01371981 (18) [back to overview]	OS for Patients on Arm C, Cohort 2
NCT01371981 (18) [back to overview]	OS for Patients on Arm C, Cohort 1
NCT01371981 (18) [back to overview]	Event-free Survival (EFS) for Patients Without High Allelic Ratio FLT3/ITD+ Mutations
NCT01371981 (18) [back to overview]	EFS for Patients on Arm C, Cohort 3
NCT01371981 (18) [back to overview]	Total Scale Score From Parent-reported Pediatric Quality of Life Inventory Module
NCT01371981 (18) [back to overview]	EFS for Patients on Arm C, Cohort 2
NCT01371981 (18) [back to overview]	EFS for Patients on Arm C, Cohort 1
NCT01371981 (18) [back to overview]	Total Scale Score From Parent-reported Cancer Module
NCT01371981 (18) [back to overview]	Change in Shortening Fraction
NCT01371981 (18) [back to overview]	Change in Ejection Fraction
NCT01371981 (18) [back to overview]	Relapse Rate for Patients Without High Allelic Ratio FLT3/ITD+ Mutations
NCT01371981 (18) [back to overview]	Bortezomib Clearance
NCT01451515 (4) [back to overview]	Probability of Event-free Survival (EFS)
NCT01451515 (4) [back to overview]	Probability of Overall Survival (OS)
NCT01451515 (4) [back to overview]	Minimal Disseminated Disease (MDD)
NCT01451515 (4) [back to overview]	Minimal Residual Disease (MRD)
NCT01546038 (70) [back to overview]	Number of Participants With Disease-related Gene Mutations at Phase 1B
NCT01546038 (70) [back to overview]	Number of Participants With Disease-related Gene Mutations at Phase 2 Fit and Unfit
NCT01546038 (70) [back to overview]	Number of Participants With Treatment-emergent Adverse Events (AEs) at Phase 1B (All Causality)
NCT01546038 (70) [back to overview]	Number of Participants With Treatment-emergent AEs at Phase 1B (Treatment-related)
NCT01546038 (70) [back to overview]	Number of Participants With Treatment-emergent AEs at Phase 2 Fit and Unfit (All Causality)
NCT01546038 (70) [back to overview]	Number of Participants With Treatment-emergent AEs at Phase 2 Fit and Unfit (Treatment-related)
NCT01546038 (70) [back to overview]	Number of Participants With Treatment-emergent AEs Categorized by Seriousness at Phase 1B
NCT01546038 (70) [back to overview]	Number of Participants With Treatment-emergent AEs Categorized by Seriousness at Phase 2 Fit and Unfit
NCT01546038 (70) [back to overview]	Overall Survival (OS) at Phase 2 Fit
NCT01546038 (70) [back to overview]	Percentage of Participants With Complete Response (CR) at Phase 2 Fit
NCT01546038 (70) [back to overview]	Percentage of Participants With Disease-specific Efficacy for Acute Myeloid Leukemia (AML) at Phase 2 Fit and Unfit
NCT01546038 (70) [back to overview]	Percentage of Participants With Disease-specific Efficacy for Myelodysplastic Syndrome (MDS) at Phase 2 Fit and Unfit
NCT01546038 (70) [back to overview]	Post-baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 2 Fit - End of Treatment
NCT01546038 (70) [back to overview]	Post-baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 2 Unfit - Cycle 1/Day 1
NCT01546038 (70) [back to overview]	Ratios of mRNA Levels to Baseline Associated With Best Overall Response at Phase 2 Fit
NCT01546038 (70) [back to overview]	Ratios of mRNA Levels to Baseline at Phase 2 Fit - End of Treatment
NCT01546038 (70) [back to overview]	Ratios of mRNA Levels to Baseline at Phase 2 Fit - Induction Cycle 1/Day 3
NCT01546038 (70) [back to overview]	Ratios of mRNA Levels to Baseline at Phase 2 Unfit - End of Treatment
NCT01546038 (70) [back to overview]	Serum Levels of Circulating Protein Analytes at Phase 1B - Baseline
NCT01546038 (70) [back to overview]	Serum Levels of Circulating Protein Analytes at Phase 1B - Induction Cycle 1/Day 10
NCT01546038 (70) [back to overview]	Serum Levels of Circulating Protein Analytes at Phase 2 Fit - Consolidation Cycle 1/Day 1
NCT01546038 (70) [back to overview]	Serum Levels of Circulating Protein Analytes at Phase 2 Fit - Consolidation Cycle 1/Day 10
NCT01546038 (70) [back to overview]	Serum Levels of Circulating Protein Analytes at Phase 2 Fit - End of Treatment
NCT01546038 (70) [back to overview]	Serum Levels of Circulating Protein Analytes at Phase 2 Fit - Induction Cycle 1/Day 10
NCT01546038 (70) [back to overview]	Serum Levels of Circulating Protein Analytes at Phase 2 Fit - Induction Cycle 1/Day 3
NCT01546038 (70) [back to overview]	Serum Levels of Circulating Protein Analytes at Phase 2 Unfit - Cycle 1/Day 10
NCT01546038 (70) [back to overview]	Time to Cmax (Tmax) of Glasdegib in Participants Receiving Glasdegib and LDAC at Phase 1B on Cycle 1/Day 10 and Cycle 1/Day 21
NCT01546038 (70) [back to overview]	Tmax of Daunorubicin and Daunorubicinol in Participants Receiving Glasdegib and Cytarabine/Daunorubicin at Phase 1B on Induction Cycle 1/Day 3
NCT01546038 (70) [back to overview]	Tmax of Decitabine in Participants Receiving Glasdegib and Decitabine at Phase 1B on Cycle 1/Day 1 and Cycle 1/Day 2
NCT01546038 (70) [back to overview]	Tmax of Glasdegib in Participants Receiving Glasdegib and Cytarabine/Daunorubicin at Phase 1B on Induction Cycle 1/Day 3 and Day 10
NCT01546038 (70) [back to overview]	Tmax of Glasdegib in Participants Receiving Glasdegib and Decitabine at Phase 1B on Cycle 1/Day 10 and Cycle 2/Day 1
NCT01546038 (70) [back to overview]	Tmax of LDAC and Ara-U in Participants Receiving Glasdegib and LDAC at Phase 1B on Cycle 1/Day 2 and Cycle 1/Day 10
NCT01546038 (70) [back to overview]	Baseline mRNA Levels Associated With Best Overall Response at Phase 2 Fit
NCT01546038 (70) [back to overview]	AUCtau of Glasdegib in Participants Receiving Glasdegib and LDAC at Phase 2 Unfit on Cycle 1/Day 10
NCT01546038 (70) [back to overview]	Baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 1B
NCT01546038 (70) [back to overview]	Baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 2 Fit
NCT01546038 (70) [back to overview]	Cmax of Glasdegib in Participants Receiving Glasdegib and LDAC at Phase 2 Unfit on Cycle 1/Day 10
NCT01546038 (70) [back to overview]	Number of Participants With Dose-limiting Toxicities (DLTs) at Phase 1B
NCT01546038 (70) [back to overview]	Overall Survival (OS) at Phase 1B
NCT01546038 (70) [back to overview]	Overall Survival (OS) at Phase 2 Unfit
NCT01546038 (70) [back to overview]	Percentage of Participants With Complete Response (CR) at Phase 2 Unfit
NCT01546038 (70) [back to overview]	Percentage of Participants With CR / Complete Response With Incomplete Blood Count Recovery (CRi) at Phase 1B
NCT01546038 (70) [back to overview]	Post-baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 1B - Induction Cycle 1/Day 3
NCT01546038 (70) [back to overview]	Post-baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 1B - Induction Cycle 1/Lead-In
NCT01546038 (70) [back to overview]	Post-baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 2 Fit - Induction Cycle 1/Day 10
NCT01546038 (70) [back to overview]	Post-baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 2 Fit - Induction Cycle 1/Day 3
NCT01546038 (70) [back to overview]	Post-baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 2 Unfit - End of Treatment
NCT01546038 (70) [back to overview]	Pre-dose Plasma Concentration (Ctrough) of Glasdegib in Phase 2 Fit on Induction Cycle 1/Day 10
NCT01546038 (70) [back to overview]	Ratios of mRNA Levels Associated With Best Overall Response at Phase 2 Unfit
NCT01546038 (70) [back to overview]	Serum Levels of Circulating Protein Analytes at Phase 1B - Induction Cycle 1/Day 3
NCT01546038 (70) [back to overview]	Serum Levels of Circulating Protein Analytes at Phase 2 Unfit - Cycle 1/Day 1
NCT01546038 (70) [back to overview]	Tmax of Glasdegib in Participants Receiving Glasdegib and LDAC at Phase 2 Unfit on Cycle 1/Day 10
NCT01546038 (70) [back to overview]	Area Under the Plasma Concentration-time Profile From Time 0 to Dosing Interval (AUCtau) of Glasdegib in Participants Receiving Glasdegib and LDAC at Phase 1B on Cycle 1/Day 10 and Cycle 1/Day 21
NCT01546038 (70) [back to overview]	Area Under the Plasma Concentration-time Profile From Time 0 to Infinity (AUCinf) of LDAC in Participants Receiving Glasdegib and LDAC at Phase 1B on Cycle 1/Day 2 and Cycle 1/Day 10
NCT01546038 (70) [back to overview]	Area Under the Plasma Concentration-time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of LDAC and Ara-U in Participants Receiving Glasdegib and LDAC at Phase 1B on Cycle 1/Day 2 and Cycle 1/Day 10
NCT01546038 (70) [back to overview]	AUCinf of Decitabine in Participants Receiving Glasdegib and Decitabine at Phase 1B on Cycle 1/Day 1 and Cycle 1/Day 2
NCT01546038 (70) [back to overview]	AUCtau of Cytarabine and Ara-U in Participants Receiving Glasdegib and Cytarabine/Daunorubicin at Phase 1B on Induction Cycle 1/Day 3
NCT01546038 (70) [back to overview]	AUCtau of Daunorubicin and Daunorubicinol in Participants Receiving Glasdegib and Cytarabine/Daunorubicin at Phase 1B on Induction Cycle 1/Day 3
NCT01546038 (70) [back to overview]	AUCtau of Glasdegib in Participants Receiving Glasdegib and Cytarabine/Daunorubicin at Phase 1B on Induction Cycle 1/Day 3 and Day 10
NCT01546038 (70) [back to overview]	AUCtau of Glasdegib in Participants Receiving Glasdegib and Decitabine at Phase 1B on Cycle 1/Day 10 and Cycle 2/Day 1
NCT01546038 (70) [back to overview]	Baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 2 Unfit
NCT01546038 (70) [back to overview]	Baseline mRNA Levels Associated With Best Overall Response at Phase 2 Unfit
NCT01546038 (70) [back to overview]	Cmax of Daunorubicin and Daunorubicinol in Participants Receiving Glasdegib and Cytarabine/Daunorubicin at Phase 1B on Induction Cycle 1/Day 3
NCT01546038 (70) [back to overview]	Cmax of Decitabine in Participants Receiving Glasdegib and Decitabine at Phase 1B on Cycle 1/Day 1 and Cycle 1/Day 2
NCT01546038 (70) [back to overview]	Cmax of Glasdegib in Participants Receiving Glasdegib and Cytarabine/Daunorubicin at Phase 1B on Induction Cycle 1/Day 3 and Day 10
NCT01546038 (70) [back to overview]	Cmax of Glasdegib in Participants Receiving Glasdegib and Decitabine at Phase 1B on Cycle 1/Day 10 and Cycle 2/Day 1
NCT01546038 (70) [back to overview]	Cmax of LDAC and Ara-U in Participants Receiving Glasdegib and LDAC at Phase 1B on Cycle 1/Day 2 and Cycle 1/Day 10
NCT01546038 (70) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Glasdegib in Participants Receiving Glasdegib and LDAC at Phase 1B on Cycle 1/Day 10 and Cycle 1/Day 21
NCT01546038 (70) [back to overview]	Number of Participants With Corrected QT Interval Using Fridericia's Formula (QTcF) Values Meeting Predefined Criteria at Phase 1B
NCT01546038 (70) [back to overview]	Number of Participants With Corrected QT Interval Using Fridericia's Formula (QTcF) Values Meeting Predefined Criteria at Phase 2 Fit and Unfit
NCT01696084 (6) [back to overview]	Rate of Achieving Morphologic Leukemia-free State
NCT01696084 (6) [back to overview]	Proportion of Subjects With a Response
NCT01696084 (6) [back to overview]	Proportion of Subjects Receiving a Stem Cell Transplant
NCT01696084 (6) [back to overview]	Event-free Survival
NCT01696084 (6) [back to overview]	Remission Duration
NCT01696084 (6) [back to overview]	Overall Survival
NCT01802333 (10) [back to overview]	EFS of Arm I Compared to Arm II
NCT01802333 (10) [back to overview]	Frequency and Severity of Toxicities
NCT01802333 (10) [back to overview]	Cytogenetic Risk Distribution of Patients on This Study
NCT01802333 (10) [back to overview]	Rate of Allogeneic HCT
NCT01802333 (10) [back to overview]	Prevalence of the Mutation NPM1 in Patients on This Study.
NCT01802333 (10) [back to overview]	Overall Survival (OS)
NCT01802333 (10) [back to overview]	Event-free Survival (EFS)
NCT01802333 (10) [back to overview]	Disease-free Survival (DFS) Among High Risk Patients
NCT01802333 (10) [back to overview]	Disease-free Survival (DFS)
NCT01802333 (10) [back to overview]	Complete Response (CR) Rate
NCT01804101 (2) [back to overview]	Overall Remission Rate (CR+CRp)
NCT01804101 (2) [back to overview]	Treatment-related Mortality Rate. (TRM)
NCT01806571 (5) [back to overview]	Disease Free Survival(DFS) Rate
NCT01806571 (5) [back to overview]	Duration of Complete Response
NCT01806571 (5) [back to overview]	Incidence of Adverse Events as Assessed by NCI CTCAE Version 4.0
NCT01806571 (5) [back to overview]	Overall Survival(OS) Rate
NCT01806571 (5) [back to overview]	Proportion of Complete Responses (CR or CRi) During Induction Therapy
NCT01890746 (44) [back to overview]	Percentage of Patients Who Achieved Platelet Transfusion Independence ≥ 28 Days
NCT01890746 (44) [back to overview]	Overall Survival (OS)
NCT01890746 (44) [back to overview]	Number of Platelet Transfusions Per Week Within Cycles
NCT01890746 (44) [back to overview]	Number of Participants With Liver Events.
NCT01890746 (44) [back to overview]	Number of Participants Who Achieved Platelet Count Recovery by Day 21
NCT01890746 (44) [back to overview]	Maximum Duration (Days) of Platelet Transfusion Independence
NCT01890746 (44) [back to overview]	Daunorubicinol Dose-normalized Plasma: Cmax
NCT01890746 (44) [back to overview]	Daunorubicinol Dose-normalized Plasma: AUC(24-t)
NCT01890746 (44) [back to overview]	Daunorubicinol Dose-normalized Plasma: AUC(24-∞)
NCT01890746 (44) [back to overview]	Daunorubicinol Dose-normalized Plasma: AUC(0-t)
NCT01890746 (44) [back to overview]	Daunorubicinol Dose-normalized Plasma: AUC(0-∞)
NCT01890746 (44) [back to overview]	Daunorubicin Dose-normalized Plasma: Cmax
NCT01890746 (44) [back to overview]	Daunorubicin Dose-normalized Plasma: AUC(24-t)
NCT01890746 (44) [back to overview]	Daunorubicin Dose-normalized Plasma: AUC(0-t)
NCT01890746 (44) [back to overview]	Cycle 2: Daunorubicin Dose-normalized Plasma: Cmax
NCT01890746 (44) [back to overview]	Time to Platelet Count Recovery >=20 Gi/L
NCT01890746 (44) [back to overview]	Cycle 2: Daunorubicinol Dose-normalized Plasma: AUC(0-24)
NCT01890746 (44) [back to overview]	Cycle 2: Daunorubicinol Dose-normalized Plasma: Cmax
NCT01890746 (44) [back to overview]	Daunorubicin Dose-normalized Plasma: AUC(0-∞)
NCT01890746 (44) [back to overview]	Number of Participants With Worst-case Changes From Baseline in the Eastern Cooperative Oncology Group (ECOG) Performance Status
NCT01890746 (44) [back to overview]	Daunorubicin Dose-normalized Plasma: AUC(24-∞)
NCT01890746 (44) [back to overview]	Number of Participants With Worst-case Changes From Baseline in Electrocardiogram (ECG) Values
NCT01890746 (44) [back to overview]	Number of Participants With Any Adverse Events (AE) and Any Serious Adverse Events (SAE) as a Measure of Safety and Tolerability.
NCT01890746 (44) [back to overview]	Number of Participants Who Required Medical Resource Utilization
NCT01890746 (44) [back to overview]	Incidence of Hemorrhagic Events
NCT01890746 (44) [back to overview]	Incidence of Hemorrhagic Events
NCT01890746 (44) [back to overview]	Change From Baseline in the Left Ventricular Ejection Fraction (LVEF).
NCT01890746 (44) [back to overview]	Worst-case Post Baseline Change in Temperature Values From Baseline
NCT01890746 (44) [back to overview]	Worst-case Post Baseline Change in Blood Pressure Values From Baseline
NCT01890746 (44) [back to overview]	Worst-case Change From Baseline in Pulse Rate Values
NCT01890746 (44) [back to overview]	Summary of Platelet Counts Over Time
NCT01890746 (44) [back to overview]	Summary of Platelet Counts Over Time
NCT01890746 (44) [back to overview]	Time to Platelet Recovery >=100 Gi/L
NCT01890746 (44) [back to overview]	Time to Neutrophil Engraftment
NCT01890746 (44) [back to overview]	Plasma Pharmacokinetics (PK) Parameter of Daunorubicinol: Half-life (t1/2)
NCT01890746 (44) [back to overview]	Plasma Pharmacokinetics (PK) Parameter of Daunorubicin: Half-life (t1/2)
NCT01890746 (44) [back to overview]	Cycle 2: Daunorubicin Dose-normalized Plasma: AUC(0-24)
NCT01890746 (44) [back to overview]	Number of Participants With Worst-case Grade Changes From Baseline in the Clinical Chemistry Parameters
NCT01890746 (44) [back to overview]	Summary of Hemoglobin
NCT01890746 (44) [back to overview]	Summary of Hemoglobin
NCT01890746 (44) [back to overview]	Summary of Absolute Neutrophil Counts (ANC)
NCT01890746 (44) [back to overview]	Summary of Absolute Neutrophil Counts (ANC)
NCT01890746 (44) [back to overview]	Percentage of Participants With Disease Response Rate and Type of Response
NCT01890746 (44) [back to overview]	Number of Participants With Worst-case Grade Changes From Baseline in the Hematology Parameters
NCT02019069 (9) [back to overview]	Early Induction Mortality (Day 30 After 1st Induction)
NCT02019069 (9) [back to overview]	Duration of Remission (DOR) Following Induction With CPX-351
NCT02019069 (9) [back to overview]	Complete Response (CR)
NCT02019069 (9) [back to overview]	Complete Response With Incomplete Count Recovery (CRi)
NCT02019069 (9) [back to overview]	Serious Adverse Events
NCT02019069 (9) [back to overview]	Overall Survival (OS)
NCT02019069 (9) [back to overview]	Response Rate (RR)
NCT02019069 (9) [back to overview]	Participants Experiencing of Serious Adverse Events
NCT02019069 (9) [back to overview]	Mortality at Day 60 After 1st Induction
NCT02038777 (68) [back to overview]	Number of Participants With DLTs: Combination Cohort 3
NCT02038777 (68) [back to overview]	Number of Participants With DLTs: Combination Cohort 2
NCT02038777 (68) [back to overview]	Number of Participants With TEAEs, Serious TEAEs, Treatment Related TEAEs, Grade 3 or 4 TEAEs Based on NCI CTCAE v4.0: Combination Cohort 3
NCT02038777 (68) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Treatment Related TEAEs, Grade 3 or 4 TEAEs Based on NCI CTCAE v4.0: Monotherapy Cohort
NCT02038777 (68) [back to overview]	Percentage of Participants With Complete Remission (CR) or CR With Incomplete Blood Count Recovery (CRi) and DMR: Combination Cohort 1
NCT02038777 (68) [back to overview]	Percentage of Participants With CR/CRi and DMR: Combination Cohort 3
NCT02038777 (68) [back to overview]	Single Dose- Area Under the Plasma Concentration Curve: From Time Zero to End of Dosing Interval (AUCtau), From Time Zero to Last Quantifiable Concentration (AUClast) and From Time Zero to Infinity (AUCinf) of PF-04449913 for Monotherapy Cohort
NCT02038777 (68) [back to overview]	Time to Complete Remission (CR) or CR With Incomplete Blood Count Recovery (CRi) and DMR Response: Combination Cohort 3
NCT02038777 (68) [back to overview]	Time to Response: Combination Cohort 1
NCT02038777 (68) [back to overview]	Number of Participants With Worst On-study Laboratory Abnormalities: Combination Cohort 1
NCT02038777 (68) [back to overview]	Number of Participants With Worst On-study Laboratory Abnormalities: Combination Cohort 2
NCT02038777 (68) [back to overview]	Number of Participants With Worst On-study Laboratory Abnormalities: Combination Cohort 3
NCT02038777 (68) [back to overview]	Number of Participants With DLTs: Combination Cohort 1
NCT02038777 (68) [back to overview]	Number of Participants With Clinically Significant Changes From Baseline in Vital Signs Abnormalities: Monotherapy Cohort
NCT02038777 (68) [back to overview]	Number of Participants With Clinically Significant Changes From Baseline in Vital Signs Abnormalities: Combination Cohort 3
NCT02038777 (68) [back to overview]	Number of Participants With Clinically Significant Changes From Baseline in Vital Signs Abnormalities: Combination Cohort 2
NCT02038777 (68) [back to overview]	Number of Participants With Clinically Significant Changes From Baseline in Vital Signs Abnormalities: Combination Cohort 1
NCT02038777 (68) [back to overview]	Multiple Dose- Tmax of PF-04449913: Monotherapy Cohort
NCT02038777 (68) [back to overview]	Multiple Dose- Tmax of Daunorubicinol: Combination Cohort 2
NCT02038777 (68) [back to overview]	Multiple Dose- Tmax of Daunorubicin: Combination Cohort 2
NCT02038777 (68) [back to overview]	Multiple Dose- T1/2 of Daunorubicin: Combination Cohort 2
NCT02038777 (68) [back to overview]	Multiple Dose- Steady State Accumulation Ratio (Rss) of PF-04449913: Monotherapy Cohort
NCT02038777 (68) [back to overview]	Multiple Dose- Clearance (CL/F) of PF-04449913: Monotherapy Cohort
NCT02038777 (68) [back to overview]	Multiple Dose- AUCtau of PF-04449913: Monotherapy Cohort
NCT02038777 (68) [back to overview]	Multiple Dose- AUCtau of Daunorubicinol: Combination Cohort 2
NCT02038777 (68) [back to overview]	Multiple Dose- Accumulation Ratio (Rac) of PF-04449913: Monotherapy Cohort
NCT02038777 (68) [back to overview]	Number of Participants With Worst On-study Laboratory Abnormalities: Monotherapy Cohort
NCT02038777 (68) [back to overview]	Multiple Dose- AUCinf and AUCtau of Cytarabine: Combination Cohort 1
NCT02038777 (68) [back to overview]	Multiple Dose- Cmax, Cmin, Cavg, and Ctrough of Daunorubicinol: Combination Cohort 2
NCT02038777 (68) [back to overview]	Number of Participants With Dose-limiting Toxicities (DLTs): Monotherapy Cohort
NCT02038777 (68) [back to overview]	Overall Survival: Combination Cohort 1
NCT02038777 (68) [back to overview]	Percentage of Participants Achieving Disease Modifying Response (DMR): Expansion Cohort
NCT02038777 (68) [back to overview]	Single Dose- Clearance (CL/F) of PF-04449913: Monotherapy Cohort
NCT02038777 (68) [back to overview]	Single Dose- Maximum Observed Plasma Concentration (Cmax) of PF-04449913: Monotherapy Cohort
NCT02038777 (68) [back to overview]	Single Dose- Terminal Plasma Half-life (T1/2) of PF-04449913: Monotherapy Cohort
NCT02038777 (68) [back to overview]	Single Dose- Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04449913: Monotherapy Cohort
NCT02038777 (68) [back to overview]	Single Dose- Volume of Distribution (Vz/F) of PF-04449913: Monotherapy Cohort
NCT02038777 (68) [back to overview]	Duration of Complete Remission (CR) or CR With Incomplete Blood Count Recovery (CRi) and DMR Response: Combination Cohort 1
NCT02038777 (68) [back to overview]	Duration of Complete Remission (CR) or CR With Incomplete Blood Count Recovery (CRi) and DMR Response: Combination Cohort 3
NCT02038777 (68) [back to overview]	Multiple Dose Cmax, Minimum Observed Plasma Concentration (Cmin), Average Observed Plasma Concentration (Cavg), Trough Plasma Concentration (Ctrough) of PF-04449913: Monotherapy Cohort
NCT02038777 (68) [back to overview]	Multiple Dose- AUCinf and AUCtau of Daunorubicin: Combination Cohort 2
NCT02038777 (68) [back to overview]	Multiple Dose- AUCtau and AUCinf of Azacitidine: Combination Cohort 3
NCT02038777 (68) [back to overview]	Multiple Dose- AUCtau of PF-04449913: Combination Cohort 1
NCT02038777 (68) [back to overview]	Multiple Dose- AUCtau of PF-04449913: Combination Cohort 2
NCT02038777 (68) [back to overview]	Multiple Dose- AUCtau of PF-04449913: Combination Cohort 3
NCT02038777 (68) [back to overview]	Multiple Dose- CL/F of PF-04449913: Combination Cohort 1
NCT02038777 (68) [back to overview]	Multiple Dose- CL/F of PF-04449913: Combination Cohort 2
NCT02038777 (68) [back to overview]	Multiple Dose- CL/F of PF-04449913: Combination Cohort 3
NCT02038777 (68) [back to overview]	Multiple Dose- Cmax, Cmin, and Ctrough of Ara-uridine: Combination Cohort 1
NCT02038777 (68) [back to overview]	Multiple Dose- Cmax, Cmin, Cavg, and Ctrough of Azacitidine: Combination Cohort 3
NCT02038777 (68) [back to overview]	Multiple Dose- Cmax, Cmin, Cavg, and Ctrough of Cytarabine: Combination Cohort 1
NCT02038777 (68) [back to overview]	Multiple Dose- Cmax, Cmin, Cavg, and Ctrough of Daunorubicin: Combination Cohort 2
NCT02038777 (68) [back to overview]	Multiple Dose- Cmax, Cmin, Cavg, and Ctrough of PF-04449913: Combination Cohort 1
NCT02038777 (68) [back to overview]	Multiple Dose- Cmax, Cmin, Cavg, and Ctrough of PF-04449913: Combination Cohort 2
NCT02038777 (68) [back to overview]	Multiple Dose- Cmax, Cmin, Cavg, and Ctrough of PF-04449913: Combination Cohort 3
NCT02038777 (68) [back to overview]	Multiple Dose- T1/2 of Cytarabine: Combination Cohort 1
NCT02038777 (68) [back to overview]	Multiple Dose- Tmax of Ara-uridine: Combination Cohort 1
NCT02038777 (68) [back to overview]	Multiple Dose- Tmax of Azacitidine: Combination Cohort 3
NCT02038777 (68) [back to overview]	Multiple Dose- Tmax of Cytarabine: Combination Cohort 1
NCT02038777 (68) [back to overview]	Multiple Dose- Tmax of PF-04449913: Combination Cohort 1
NCT02038777 (68) [back to overview]	Multiple Dose- Tmax of PF-04449913: Combination Cohort 2
NCT02038777 (68) [back to overview]	Multiple Dose- Tmax of PF-04449913: Combination Cohort 3
NCT02038777 (68) [back to overview]	Number of Participants With Best Response: Combination Cohort 1
NCT02038777 (68) [back to overview]	Number of Participants With Best Response: Combination Cohort 2
NCT02038777 (68) [back to overview]	Number of Participants With Best Response: Combination Cohort 3
NCT02038777 (68) [back to overview]	Number of Participants With Best Response: Monotherapy Cohort
NCT02038777 (68) [back to overview]	Number of Participants With TEAEs, Serious TEAEs, Treatment Related TEAEs, Grade 3 or 4 TEAEs Based on NCI CTCAE v4.0: Combination Cohort 1
NCT02038777 (68) [back to overview]	Number of Participants With TEAEs, Serious TEAEs, Treatment Related TEAEs, Grade 3 or 4 TEAEs Based on NCI CTCAE v4.0: Combination Cohort 2
NCT02085408 (4) [back to overview]	Overall Survival by Donor Status
NCT02085408 (4) [back to overview]	Overall Survival
NCT02085408 (4) [back to overview]	Disease-free Survival for Maintenance
NCT02085408 (4) [back to overview]	Proportion of Patients With Complete Remission
NCT02112916 (6) [back to overview]	EFS for Very High Risk (VHR) T-ALL Patients Treated With High Risk (HR) Berlin-Frankfurt-Munster (BFM) Intensification Blocks Who Become Minimal Residual Disease (MRD) Negative and Those Who Remain MRD Positive at the End of HR Block 3
NCT02112916 (6) [back to overview]	EFS for Very High Risk (VHR) T-LLy Patients Treated With HR Berlin-Frankfurt-Munster (BFM) Intensification Blocks Who Have Complete or Partial Remission and Those Who do Not Respond
NCT02112916 (6) [back to overview]	Toxicity Rates Associated With Modified Standard Therapy, Including Dexamethasone and Additional Pegaspargase
NCT02112916 (6) [back to overview]	Cumulative Incidence Rates of Isolated Central Nervous System (CNS) Relapse for SR and IR T-ALL Patients on the Non-bortezomib Containing Arm on This Study (no CRT) and Similar Patients on AALL0434 (Receive CRT)
NCT02112916 (6) [back to overview]	Event-free Survival (EFS) for Modified Augmented Berlin-Frankfurt-Munster Backbone With or Without Bortezomib in All Randomized Patients
NCT02112916 (6) [back to overview]	EFS for Standard (SR) and Intermediate Risk (IR) T-ALL Patients on the Non-bortezomib Containing Arm on This Study (no Cranial Radiation Therapy [CRT]) and Similar Patients on AALL0434 (Received CRT)
NCT02180867 (6) [back to overview]	Feasible Dose: Pediatric
NCT02180867 (6) [back to overview]	Percentage of Chemoradiotherapy Patients With Positive Pathologic Response at Week 13
NCT02180867 (6) [back to overview]	Percentage of Patients Who Experienced Grade 3 or Higher Toxicity Assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)
NCT02180867 (6) [back to overview]	Percentage of Patients Who Experienced Grade 3 or Higher Toxicity Assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)
NCT02180867 (6) [back to overview]	Percentage of Radiotherapy Patients With Positive Pathologic Response at Week 10
NCT02180867 (6) [back to overview]	Feasible Dose: Adult
NCT02286726 (2) [back to overview]	Number of Participants Who Experienced Dose-limiting Toxicity (DLT)
NCT02286726 (2) [back to overview]	Number of Participants With a Response
NCT02306161 (3) [back to overview]	Overall Survival
NCT02306161 (3) [back to overview]	Event-free Survival
NCT02306161 (3) [back to overview]	Frequency of Toxicity-events
NCT02343939 (9) [back to overview]	Duration of Exposure of Entospletinib
NCT02343939 (9) [back to overview]	Percentage of Participants Who Experienced Laboratory Abnormalities
NCT02343939 (9) [back to overview]	Percentage of Participants With Overall Response at the End of Induction
NCT02343939 (9) [back to overview]	Percentage of Participants With Morphologic Complete Remission (CR) at the End of Induction
NCT02343939 (9) [back to overview]	Percentage of Participants With Composite Complete Remission at the End of Induction
NCT02343939 (9) [back to overview]	Percentage of Participants Experiencing Treatment-Emergent Adverse Events
NCT02343939 (9) [back to overview]	Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs)
NCT02343939 (9) [back to overview]	Overall Survival (OS)
NCT02343939 (9) [back to overview]	Event Free Survival (EFS)
NCT02393859 (12) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related Adverse Events (TRAEs)
NCT02393859 (12) [back to overview]	Number of Participants With Shifts From Baseline Grade 0 or 1 to Worst Postbaseline Grade 3 or 4 Clinical Chemistry and Hematology Values
NCT02393859 (12) [back to overview]	Pharmacokinetics: Clearance (CL) (Blinatumomab Arm Only)
NCT02393859 (12) [back to overview]	Cumulative Incidence of Relapse (CIR)
NCT02393859 (12) [back to overview]	Percentage of Participants With an MRD Response Within 29 Days of Treatment Initiation
NCT02393859 (12) [back to overview]	Number of Participants With TEAEs of Interest
NCT02393859 (12) [back to overview]	Pharmacokinetics: Concentration at Steady State (Css) (Blinatumomab Arm Only)
NCT02393859 (12) [back to overview]	Number of Participants With Anti-Blinatumomab Antibodies Postbaseline (Blinatumomab Arm Only)
NCT02393859 (12) [back to overview]	Kaplan Meier Estimate: EFS (Final Analysis)
NCT02393859 (12) [back to overview]	Kaplan Meier Estimate: Overall Survival (OS)
NCT02393859 (12) [back to overview]	Kaplan Meier Estimate: Event-Free Survival (EFS; Primary Analysis)
NCT02393859 (12) [back to overview]	Kaplan-Meier Estimate of 100-Day Mortality After Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT)
NCT02419469 (1) [back to overview]	Event Free Survival (EFS)
NCT02420717 (4) [back to overview]	Maximal Tolerated Dose (MTD) of Ruxolitinib in Combination With Chemotherapy Defined as the Highest Dose Level at Which no More Than 1 Out of 6 Patients Experience a Dose Limiting Toxicity (Phase I)
NCT02420717 (4) [back to overview]	Overall Survival
NCT02420717 (4) [back to overview]	Progression-free Survival
NCT02420717 (4) [back to overview]	Participants With Complete Response (Complete Response [CR]/CR With Incomplete Marrow Recovery [CRi]) (Phase II)
NCT02560025 (6) [back to overview]	1 Year Overall Survival Rate
NCT02560025 (6) [back to overview]	Median Relapse Free Survival
NCT02560025 (6) [back to overview]	Number of Participants That Achieved Complete Remission
NCT02560025 (6) [back to overview]	Number of Participants That Achieved Complete Remission With Incomplete Blood Count Recovery (CRi)
NCT02560025 (6) [back to overview]	Number of Participants With Serious Adverse Events
NCT02560025 (6) [back to overview]	Median Duration of Remission
NCT02642965 (11) [back to overview]	Liposome-encapsulated Cytarabine Clearance
NCT02642965 (11) [back to overview]	Liposome-encapsulated Cytarabine Time of Maximum Concentration
NCT02642965 (11) [back to overview]	Liposome-encapsulated Cytarabine Volume of Distribution
NCT02642965 (11) [back to overview]	Number of Participants With a Dose-limiting Toxicity
NCT02642965 (11) [back to overview]	Liposome-encapsulated Daunorubicin Clearance
NCT02642965 (11) [back to overview]	Percentage of Responders (Complete Response or Complete Remission With Partial Platelet Recovery) After up to 2 Cycles
NCT02642965 (11) [back to overview]	Percentage of Responders (Complete Response or Complete Remission With Partial or Incomplete Platelet Recovery) After First Cycle of Therapy
NCT02642965 (11) [back to overview]	Liposome-encapsulated Daunorubicin Volume of Distribution
NCT02642965 (11) [back to overview]	Liposome-encapsulated Daunorubicin Time of Maximum Concentration
NCT02642965 (11) [back to overview]	Liposome-encapsulated Cytarabine Area Under the Curve
NCT02642965 (11) [back to overview]	Liposome-encapsulated Daunorubicin Area Under the Curve
NCT02668653 (5) [back to overview]	Composite CR Rate at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
NCT02668653 (5) [back to overview]	Event-free Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
NCT02668653 (5) [back to overview]	Overall Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
NCT02668653 (5) [back to overview]	Number of Participants With Treatment-emergent Adverse Events Occurring in ≥10% Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
NCT02668653 (5) [back to overview]	Complete Remission (CR) Rate at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
NCT02732015 (1) [back to overview]	Number of Participants With Complete Response (CR) of Rolapitant Hydrochloride Administered as a Single-dose
NCT02828358 (5) [back to overview]	Tolerability of Azacitidine in Combination With Interfant-06 Standard Chemotherapy in Evaluable Infant Patients With Newly Diagnosed ALL With KMT2A Gene Rearrangement (KMT2A-R). KMT2A Gene Rearrangement (KMT2A-R)
NCT02828358 (5) [back to overview]	Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 1 Prior to First Course of Azacitidine
NCT02828358 (5) [back to overview]	Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 5 of Second Course of Azacitidine
NCT02828358 (5) [back to overview]	Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 5 of First Course of Azacitidine
NCT02828358 (5) [back to overview]	Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 1 Prior to Second Course of Azacitidine
NCT02834390 (10) [back to overview]	Pharmacokinetic Parameter Area Under the Concentration-Time Curve During Dosing Interval of Quizartinib and Metabolite (AC886) After Daily Dose of 20 mg or 40 mg With Chemotherapy to Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia
NCT02834390 (10) [back to overview]	Pharmacokinetic Parameter Accumulation Ratio (AR) of Quizartinib and Active Metabolite (AC886) After a Daily Dose of 20 mg or 40 mg Combined With Chemotherapy to Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT02834390 (10) [back to overview]	Number of Participants Treatment-Emergent Adverse Events Reported During Induction Phase After a Daily Dose of 20 mg or 40 mg in Combination With Standard Chemotherapy to Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT02834390 (10) [back to overview]	Number of Participants Treatment-Emergent Adverse Events Reported During Consolidation Phase After a Daily Dose of 20 mg or 40 mg in Combination With Standard Chemotherapy to Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT02834390 (10) [back to overview]	Summary of Best Responses After a Daily Dose of 20 mg or 40 mg in Combination With Standard Chemotherapy to Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT02834390 (10) [back to overview]	Summary of Best Response Rates After the First Oral Dose of Quizartinib in Participants With Relapsed or Refractory Acute Myeloid Leukemia
NCT02834390 (10) [back to overview]	Pharmacokinetic Parameter Trough Plasma Concentration (Ctrough) of Quizartinib and Active Metabolite (AC886) After a Daily Dose of 20 mg or 40 mg Combined With Chemotherapy to Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT02834390 (10) [back to overview]	Pharmacokinetic Parameter Time of Maximum Plasma Concentration (Tmax) of Quizartinib and the Active Metabolite (AC886) After a Daily Dose of 20 mg or 40 mg Combined With Chemotherapy to Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT02834390 (10) [back to overview]	Pharmacokinetic Parameter Metabolite to Parent Ratio (MR) of Active Metabolite (AC886) After a Daily Dose of 20 mg or 40 mg Combined With Chemotherapy to Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT02834390 (10) [back to overview]	Pharmacokinetic Parameter Maximum Serum Concentration (Cmax) of Geometric Means of Quizartinib and Active Metabolite (AC886) After Daily Dose of 20 mg or 40 mg Combined With Chemotherapy to Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia
NCT02954653 (9) [back to overview]	Progression Free Survival [Part 1]
NCT02954653 (9) [back to overview]	Objective Response Rate (ORR) - Percentage of Participants With Objective Response [Part 1]
NCT02954653 (9) [back to overview]	Number of Participants With Dose-Limiting Toxicities (DLTs) [Part 1]
NCT02954653 (9) [back to overview]	Duration of Objective Response Rate (ORR) [Part 1]
NCT02954653 (9) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (AEs) by Maximum National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) Grade [Part 1]
NCT02954653 (9) [back to overview]	Number of Participants With Hematology Laboratory Abnormalities by Type and Maximum National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) Grade [Part 1]
NCT02954653 (9) [back to overview]	Number of Participants With Chemistry Laboratory Abnormalities by Type and Maximum National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) Grade [Part 1]
NCT02954653 (9) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) [Part 1]
NCT02954653 (9) [back to overview]	Incidence of Anti-Drug Antibodies (ADA) Against PF-06747143 [Part 1]
NCT03023046 (5) [back to overview]	Overall Survival
NCT03023046 (5) [back to overview]	Number of Participants With Morphological Complete Response Rate
NCT03023046 (5) [back to overview]	Number of Participants With Adverse Events
NCT03023046 (5) [back to overview]	Event-free Survival
NCT03023046 (5) [back to overview]	Number of Participants With Complete Measurable Residual Disease (MRD) Response Rate
NCT03113500 (2) [back to overview]	Overall Survival at 1 Year
NCT03113500 (2) [back to overview]	Complete Response (CR) Rate After Cyclophosphamide, Doxorubicin, Etoposide, Prednisone, and Brentuximab Vedotin (CHEP-BV) Induction Therapy
NCT03135028 (3) [back to overview]	Percentage of Participants With Adverse Events (AEs) and Laboratory Abnormalities Defined as Dose Limiting Toxicities (DLT)
NCT03135028 (3) [back to overview]	Percentage of Participants With AEs and Laboratory Abnormalities Not Defined as DLT
NCT03135028 (3) [back to overview]	Plasma Concentration of ENTO
NCT03298984 (5) [back to overview]	Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) of Alvocidib
NCT03298984 (5) [back to overview]	Maximum Tolerated Dose (MTD) of Alvocidib
NCT03298984 (5) [back to overview]	Antileukemic Activity of Alvocidib Plus 7+3 - Response to Treatment Based on 2017 ELN Response Criteria
NCT03298984 (5) [back to overview]	Minimal Residual Disease (MRD) Using Standardized Techniques
NCT03298984 (5) [back to overview]	Recommended Phase 2 Dose (RP2D) of Alvocidib in Combination With 7+3
NCT03416179 (30) [back to overview]	Intensive Study: Number of Participants With Adverse Events (AEs),Serious Adverse Events (SAEs) and According to Severity AEs Graded by NCI CTCAE v.4.03
NCT03416179 (30) [back to overview]	Non-intensive Study: Percentage of Participants With Partial Remission (PR)
NCT03416179 (30) [back to overview]	Non-intensive Study: Percentage of Participants With Morphologic Leukemia-free State (MLFS)
NCT03416179 (30) [back to overview]	Non-intensive Study: Percentage of Participants With Complete Remission Without Negative Minimal Residual Disease (CRMRD-neg)
NCT03416179 (30) [back to overview]	Non-intensive Study: Percentage of Participants With Complete Remission With Partial Hematologic Recovery (CRh)
NCT03416179 (30) [back to overview]	Non-intensive Study: Percentage of Participants With Complete Remission With Incomplete Hematologic Recovery (CRi)
NCT03416179 (30) [back to overview]	Non-intensive Study: Percentage of Participants With Complete Remission (CR) Including Negative Minimal Residual Disease (CRMRD-neg)
NCT03416179 (30) [back to overview]	Non-intensive Study: Percentage of Participants Who Improved in Fatigue Score Measured by the MDASI-AML/MDS Questionnaire at Week 12
NCT03416179 (30) [back to overview]	Intensive Study: Percentage of Participants With Partial Remission (PR)
NCT03416179 (30) [back to overview]	Intensive Study: Percentage of Participants With Morphologic Leukemia-free State (MLFS)
NCT03416179 (30) [back to overview]	Intensive Study: Percentage of Participants With Complete Remission Without Negative Minimal Residual Disease (CRMRD-neg)
NCT03416179 (30) [back to overview]	Intensive Study: Percentage of Participants With Complete Remission With Incomplete Hematologic Recovery (CRi)
NCT03416179 (30) [back to overview]	Intensive Study: Percentage of Participants With Complete Remission Including Negative Minimal Residual Disease (CRMRD-neg)
NCT03416179 (30) [back to overview]	Intensive Study: Percentage of Participants Who Improved in Fatigue Score Measured by the MD Anderson Symptom Inventory -Acute Myelogenous Leukemia/Myelodysplastic Syndrome (MDASI-AML/MDS) Questionnaire
NCT03416179 (30) [back to overview]	Intensive Study: Overall Survival (OS)
NCT03416179 (30) [back to overview]	Non-intensive Study: Overall Survival (OS)
NCT03416179 (30) [back to overview]	Intensive Study: Plasma Trough Concentration (Ctrough) of Glasdegib
NCT03416179 (30) [back to overview]	Intensive Study: Number of Participants With Treatment Related Adverse Events (AEs) and Serious Adverse Events (SAEs) Graded by NCI CTCAE v.4.03
NCT03416179 (30) [back to overview]	Intensive Study: Number of Participants With Shift From Baseline in Hematological Laboratory Abnormalities Graded by NCI CTCAE v.4.03
NCT03416179 (30) [back to overview]	Intensive Study: Number of Participants With Shift From Baseline in Corrected QT (QTc) Interval
NCT03416179 (30) [back to overview]	Intensive Study: Number of Participants With Shift From Baseline in Coagulation Laboratory Abnormalities Graded by NCI CTCAE v.4.03
NCT03416179 (30) [back to overview]	Intensive Study: Number of Participants With Shift From Baseline in Chemistry Laboratory Abnormalities Graded by NCI CTCAE v.4.03
NCT03416179 (30) [back to overview]	Non-intensive Study: Time to Response
NCT03416179 (30) [back to overview]	Non-intensive Study: Plasma Trough Concentration (Ctrough) of Glasdegib
NCT03416179 (30) [back to overview]	Non-intensive Study: Number of Participants With Treatment Related Adverse Events (AEs) and Serious Adverse Events (SAEs) Graded by NCI CTCAE v.4.03
NCT03416179 (30) [back to overview]	Non-intensive Study: Number of Participants With Shift From Baseline in Hematological Laboratory Abnormalities Graded by NCI CTCAE v.4.03
NCT03416179 (30) [back to overview]	Non-intensive Study: Number of Participants With Shift From Baseline in Corrected QT (QTc) Interval
NCT03416179 (30) [back to overview]	Non-intensive Study: Number of Participants With Shift From Baseline in Coagulation Laboratory Abnormalities Graded by NCI CTCAE v.4.03
NCT03416179 (30) [back to overview]	Non-intensive Study: Number of Participants With Shift From Baseline in Chemistry Laboratory Abnormalities Graded by NCI CTCAE v.4.03
NCT03416179 (30) [back to overview]	Non-intensive Study: Number of Participants With Adverse Events (AEs),Serious Adverse Events (SAEs) and According to Severity AEs Graded by NCI CTCAE v.4.03
NCT03575325 (3) [back to overview]	Progression Free Survival (PFS)
NCT03575325 (3) [back to overview]	Complete Remission Rate (CR) + CR With Incomplete Recovery (CRi)
NCT03575325 (3) [back to overview]	Overall Survival (OS)
NCT03786783 (5) [back to overview]	"Percentage of Participants Who Are Feasibility Failure"
NCT03786783 (5) [back to overview]	Percentage of Participants With Unacceptable Toxicity
NCT03786783 (5) [back to overview]	Response Rate
NCT03786783 (5) [back to overview]	Event-free Survival
NCT03786783 (5) [back to overview]	Overall Survival
NCT03850535 (3) [back to overview]	Number of Participants With at Least One Adverse Event
NCT03850535 (3) [back to overview]	Dose Escalation Phase: Number of Participants With Dose-Limiting Toxicities (DLTs) During the First Cycle of Induction Treatment
NCT03850535 (3) [back to overview]	Number of Participants With Grade ≥3 Adverse Events, Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0)
NCT03860844 (13) [back to overview]	AML: AUC of Isatuximab
NCT03860844 (13) [back to overview]	Number of Participants With Infusion Reactions (IRs)
NCT03860844 (13) [back to overview]	Overall Response Rate (ORR)
NCT03860844 (13) [back to overview]	Percentage of Participants With Complete Response (CR) Rate
NCT03860844 (13) [back to overview]	AML: Plasma Concentration Reached by Isatuximab Before Next Dose Administration (Ctrough)
NCT03860844 (13) [back to overview]	B-ALL and T-ALL: Area Under the Concentration Time Curve (AUC) of Isatuximab
NCT03860844 (13) [back to overview]	B-ALL and T-ALL: Concentrations at the End of Infusion (Ceoi) of Isatuximab
NCT03860844 (13) [back to overview]	CD38 Receptor Occupancy
NCT03860844 (13) [back to overview]	CD38 Receptor Occupancy
NCT03860844 (13) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
NCT03860844 (13) [back to overview]	B-ALL and T-ALL: Plasma Concentration Reached by Isatuximab Before Next Dose Administration (Ctrough)
NCT03860844 (13) [back to overview]	Cluster of Differentiation (CD)38 Receptor Density
NCT03860844 (13) [back to overview]	AML: Ceoi of Isatuximab
NCT03912818 (2) [back to overview]	Proportion of Subjects Who Initiate Study Treatment and Achieve Tumor Stage of pT2 N0 M0 or Better (e.g., pT0, pT1 N0) at Cystectomy
NCT03912818 (2) [back to overview]	Incidence of Grade 3-5 Adverse Events
NCT04081389 (4) [back to overview]	Overall Survival (OS)
NCT04081389 (4) [back to overview]	Recurrence-free Survival (RFS)
NCT04081389 (4) [back to overview]	Number of Patients With Dose Limiting Toxicities
NCT04081389 (4) [back to overview]	Number of Patients With Pathological Complete Response (pCR)
NCT04326439 (8) [back to overview]	Minimal Residual Disease (MRD) Negative Status
NCT04326439 (8) [back to overview]	Event-free Survival (EFS) in Low Risk Patients and High Risk Patients
NCT04326439 (8) [back to overview]	Proportion of Patients Who Develop Infection and/or Febrile Neutropenia During Each Treatment Course
NCT04326439 (8) [back to overview]	Cardiotoxicity in Patients With de Novo AML That Receive the Four-cycle Aflac-AML Regimen With the Inclusion of Dexrazoxane
NCT04326439 (8) [back to overview]	Duration of Hospital Admission in Patients That Developed Infection and Febrile Neutropenia at the End of Each Treatment Cycle
NCT04326439 (8) [back to overview]	Duration of Hospital Admission in Patients That Developed Infection and Febrile Neutropenia at the End of Each Treatment Cycle
NCT04326439 (8) [back to overview]	Disease-free Survival (DFS) for Patients Who Are MRD Negative
NCT04326439 (8) [back to overview]	Overall Survival (OS)
NCT04562792 (4) [back to overview]	Pharmacokinetic Parameters of Low Dose Daunorubicin in Children With Relapsed/Refractory AML and ALL as Assessed by Area Under the Curve.
NCT04562792 (4) [back to overview]	Pharmacokinetic Parameters of Low Dose Daunorubicin in Children With Relapsed/Refractory AML and ALL as Assessed by Elimination Half-life
NCT04562792 (4) [back to overview]	Pharmacokinetic Parameters of Low Dose Daunorubicin in Children With Relapsed/Refractory AML and ALL as Assessed by Maximum Concentration.
NCT04562792 (4) [back to overview]	Pharmacokinetic Parameters of Low Dose Daunorubicin in Children With Relapsed/Refractory AML and ALL as Assessed by Time at Maximum Concentration.

Complete Remission (CR)

complete remission (CR) Disappearance of all clinical evidence of leukemia for a minimum of four weeks. The patient should have a neutrophil count > 1,000 x 10^6/1, a platelet count > 100,000 x 10^9/1, no circulating blasts, and < than or = to blasts on bone marrow differential in a qualitatively normal or hypercellular marrow. Progressive disease or failure: Increasing bone marrow infiltrate or development of organ failure or extramedullary infiltrates due to leukemia. (NCT00002766)
Timeframe: 2 years

Intervention	participants (Number)
	Complete Remission	Complete Response (CR)	Failure	Failure-Progression	Relapse
All-2	50	14	5	8	1
L-20	50	11	14	10	0

Intervention	percentage of participants (Number)
A0 (Localized Disease Stg I/II) Modified CCG BFM	96
A1 (Disseminated, No CNS - CCG Mod BFM w/Out Intens	84
A2 (Disseminated, No CNS - CCG Mod BFM w/Intens	88
B2 (CNS+) NHL/BFM-95 w/Intens Delayed Radiation Therapy	81
B2 (Disseminated,CNS- (< Amend 7B)) NHL/BFM-95 w/Intens	85
B1 (Disseminated CNS-) NHL/BFM-95 w/Out Intens	85
B1 (NHL/BFM-95 w/Out Intens) Additional Enrollment	92

Intervention	Participants (Number)
	Complete Remission	Morphologic Complete Remission	Partial Remission	Relapse	Unevaluable
Placebo	96	12	0	90	23
Zosuquidar	98	12	2	67	33

Intervention	months (Median)
Phase I - Alemtuzumab and Combination Chemotherapy	58.6
Phase II - Alemtuzumab and Combination Chemotherapy	19.8

Intervention	months (Median)
Phase I - Alemtuzumab and Combination Chemotherapy	33.6
Phase II - Alemtuzumab and Combination Chemotherapy	23.1

Intervention	percentage of participants (Number)
Dexamethasone and Capizzi Methotrexate Patients < 10 Years	79.2
Dexamethasone, High Dose Methotrexate (Non Randomly Assigned)	69.9
Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old	65.6
Dexamethasone, High Dose Methotrexate (IM) < 10 Years	86.2
Prednisone, Capizzi Methotrexate <10 Years	93.8
Prednisone, Capizzi Methotrexate >= 10 Years	63.1
Predisone and High Dose Methotrexate < 10 Yrs Old	84.2
Prednisone and High Dose Methotrexate >=10 Years	73.6
Dexamethasone, High Dose Methotrexate (IM) >= 10 Years	74.6

Intervention	percentage of participants (Number)
Dexamethasone and Capizzi Methotrexate Patients < 10 Years	86.4
Dexamethasone, High Dose Methotrexate (Non Randomly Assigned)	93.6
Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old	80.5
Dexamethasone, High Dose Methotrexate (IM) < 10 Years	93.1
Prednisone, Capizzi Methotrexate <10 Years	86.5
Prednisone, Capezzi Methotrexate >= 10 Years	83.4
Prednisone and High Dose Methotrexate < 10 Yrs Old	84.2
Prednisone and High Dose Methotrexate >=10 Years	83.9
Dexamethasone, High Dose Methotrexate (IM) >= 10 Years	85.3
Prednisone, Capezzi Methotrexate (Down's Syndrome)	74.4
Dexamethasone, Capizzi Methotrexate Down Syndrome (Non Random)	25

Intervention	percentage of participants (Number)
Dexamethasone and Capizzi Methotrexate Patients < 10 Years	95.4
Dexamethasone, High Dose Methotrexate (Non Randomly Assigned)	92.9
Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old	87.4
Dexamethasone, High Dose Methotrexate (IM) < 10 Years	98.1
Prednisone, Capizzi Methotrexate <10 Years	93.3
Prednisone, Capizzi Methotrexate >= 10 Years	90.2
Prednisone and High Dose Methotrexate < 10 Yrs Old	94.5
Prednisone and High Dose Methotrexate >=10 Years	90.5
Dexamethasone, High Dose Methotrexate (IM) >= 10 Years	91.6
Prednisone, Capizzi Methotrexate (Down's Syndrome)	78.3
Dexamethasone, Capizzi Methotrexate Down Syndrome (Non Random)	25.0

Intervention	percentage of participants (Number)
Dexamethasone and Capizzi Methotrexate Patients < 10 Years	83.2
Dexamethasone, High Dose Methotrexate (Non Randomly Assigned)	81.6
Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old	69.1
Dexamethasone, High Dose Methotrexate (IM) < 10 Years	91.2
Prednisone, Capizzi Methotrexate <10 Years	82.1
Prednisone, Capezzi Methotrexate >= 10 Years	73.5
Predisone and High Dose Methotrexate < 10 Yrs Old	80.8
Prenisone and High Dose Methotrexate >=10 Years	75.8
Dexamethasone, High Dose Methotrexate (IM) >= 10 Years	77.0
Prenisone, Capezzi Methotrexate (Down's Syndrome)	61.8
Dexamethasone, Capizzi Methotrexate Down Syndrome (Non Random)	44.4

Intervention	percentage of participants (Number)
Dexamethasone and Capizzi Methotrexate Patients < 10 Years	66.5
Dexamethasone, High Dose Methotrexate (Non Randomly Assigned)	43.3
Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old	35.4
Dexamethasone, High Dose Methotrexate (IM) < 10 Years	80
Prednisone, Capizzi Methotrexate <10 Years	34.7
Prednisone, Capizzi Methotrexate >= 10 Years	39
Prednisone and High Dose Methotrexate < 10 Yrs Old	55
Prednisone and High Dose Methotrexate >=10 Years	47.8
Dexamethasone, High Dose Methotrexate (IM) >= 10 Years	49.4

Intervention	Participants with a given type of AE (Number)
	ALT, SGPT (serum glutamic pyruvic transaminase)	AST, SGOT (serum glut. oxaloacetic transaminase)	Acidosis (metabolic or respiratory)	Adult respiratory distress syndrome (ARDS)	Albumin, serum-low (hypoalbuminemia)	Alkaline phosphatase	Alkalosis (metabolic or respiratory)	Allergic reaction/hypersens. (inc drug fever)	Amylase	Anorexia	Apnea	Ataxia (incoordination)	Bicarbonate, serum-low	Bilirubin (hyperbilirubinemia)	Blood/Bone Marrow-Other (Specify)	Bronchospasm, wheezing	Calcium, serum-low (hypocalcemia)	Cardiac Arrhythmia-Other (Specify)	Cardiac General-Other (Specify)	Cardiac troponin I (cTnI)	Cardiac troponin T (cTnT)	Cardiac-ischemia/infarction	Colitis	Colitis, infectious (e.g., Clostridium difficile)	Confusion	Constipation	Cough	Creatinine	DIC (disseminated intravascular coagulation)	Death not assoc with CTCAE term-Multi-organ failu	Dehydration	Diarrhea	Distention/bloating, abdominal	Dizziness	Dysphagia (difficulty swallowing)	Dyspnea (shortness of breath)	Edema, larynx	Edema: limb	Edema: viscera	Enteritis (inflammation of the small bowel)	Esophagitis	Fatigue (asthenia, lethargy, malaise)	Febrile neutropenia	Fever (in the absence of neutropenia)	Fistula, GI - Rectum	Fistula, GU - Vagina	Flu-like syndrome	GGT (gamma-glutamyl transpeptidase)	Glucose, serum-high (hyperglycemia)	Glucose, serum-low (hypoglycemia)	Hematoma	Hemoglobin	Hemolysis	Hemorrhage, CNS	Hemorrhage, GI - Abdomen NOS	Hemorrhage, GI - Jejunum	Hemorrhage, GI - Lower GI NOS	Hemorrhage, GI - Oral cavity	Hemorrhage, GI - Rectum	Hemorrhage, GU - Bladder	Hemorrhage, GU - Kidney	Hemorrhage, GU - Urinary NOS	Hemorrhage, GU - Uterus	Hemorrhage, GU - Vagina	Hemorrhage, pulmonary/upper respiratory - Lung	Hemorrhage, pulmonary/upper respiratory - Nose	Hemorrhage/Bleeding-Other (Specify)	Hepatobiliary/Pancreas-Other (Specify)	Hiccoughs (hiccups, singultus)	Hypertension	Hypotension	Hypoxia	Infec with Grade 3 or 4 neut - Abdomen NOS	Infec with Grade 3 or 4 neut - Anal/perianal	Infec with Grade 3 or 4 neut - Appendix	Infec with Grade 3 or 4 neut - Bladder (urin	Infec with Grade 3 or 4 neut - Blood	Infec with Grade 3 or 4 neut - Bone (osteomy	Infec with Grade 3 or 4 neut - Brain + Spina	Infec with Grade 3 or 4 neut - Bronchus	Infec with Grade 3 or 4 neut - Catheter-rela	Infec with Grade 3 or 4 neut - Cecum	Infec with Grade 3 or 4 neut - Colon	Infec with Grade 3 or 4 neut - Dental-tooth	Infec with Grade 3 or 4 neut - Heart (endoca	Infec with Grade 3 or 4 neut - Lip/perioral	Infec with Grade 3 or 4 neut - Liver	Infec with Grade 3 or 4 neut - Lung (pneumon	Infec with Grade 3 or 4 neut - Meninges (men	Infect with Grade 3 or 4 neut - Mucosa	Infec with Grade 3 or 4 neut - Nerve-periphe	Infec with Grade 3 or 4 neut - Oral cavity-g	Infec with Grade 3 or 4 neut - Pelvis NOS	Infec with Grade 3 or 4 neut- Pharynx	Infec with Grade 3 or 4 neut - Rectum	Infec with Grade 3 or 4 neut - Sinus	Infec with Grade 3 or 4 neut - Skin (celluli	Infec with Grade 3 or 4 neut - Small bowel N	Infec with Grade 3 or 4 neut - Upper airway	Infection with Grade 3 or 4 neut - Urinary tract	Infec with Grade 3 or 4 neut - Vulva	Infec with Grade 3 or 4 neut - Wound	Infec with normal ANC or Grade 1/2 neut - Blood	Infec with norm ANC or Gr 1/2 neut, Catheter-rel	Infec with norm ANC or Grade 1/2 neut - Colon	Infec with norm ANC or Gr 1/2 neutr- Dental-tooth	Infec with norm ANC or Gr 1/2 neut - Heart	Infec with norm ANC or Gr 1/2 neutrophils - Liver	Infec with norm ANC or Gr 1/2 neut-Lung (pneumoni)	Infec with norm ANC or Gr 1/2 neut - Muscle	Inf with norm ANC or Gr 1/2 neut-Oral cavity-gums	Infec with norm ANC or Gr 1/2 neut - Scrotum	Infec with norm ANC or Gr 1/2 neut-Skin	Infec with norm ANC or Gr 1/2 neut-Urinary tract	Infection with unknown ANC - Blood	Infection with unknown ANC - Catheter-related	Infection with unknown ANC - Dental-tooth	Infection with unknown ANC - Joint	Infection with unknown ANC - Liver	Infection with unknown ANC - Lung (pneumonia)	Infection with unknown ANC - Mucosa	Infection with unknown ANC - Sinus	Infection with unknown ANC - Skin (cellulitis)	Infection with unknown ANC - Urinary tract NOS	Infection with unknown ANC - Wound	Infection-Other (Specify)	Left ventricular diastolic dysfunction	Left ventricular systolic dysfunction	Leukocytes (total WBC)	Leukoencephalopathy (radiolographic findings)	Liver dysfunction/failure (clinical)	Lymphopenia	Magnesium, serum-low (hypomagnesemia)	Metabolic/Laboratory-Other (Specify)	Mood alteration - anxiety	Mood alteration - depression	Mucositis/stomatitis (clinical exam) - Esophagus	Mucositis/stomatitis (clinical exam) - Large bowel	Mucositis/stomatitis (clinical exam) - Larynx	Mucositis/stomatitis (clinical exam) - Oral cavity	Mucositis/stomatitis (clinical exam) - Pharynx	Mucositis/stomatitis (func/sympt) - Esophagus	Mucositis/stomatitis (func/sympt)- Oral cavity	Mucositis/stomatitis (func/sympt) - Pharynx	Muscle weakness (func/sym, Whole body/generalized	Nasal cavity/paranasal sinus reactions	Nausea	Necrosis, GI - Rectum	Neurology-Other (Specify)	Neuropathy: motor	Neuropathy: sensory	Neutrophils/granulocytes (ANC/AGC)	Nystagmus	Obstruction/stenosis of airway - Trachea	Ocular/Visual-Other (Specify)	Opportunistic infec assoc with Gr 2 lymphopenia	PTT (Partial thromboplastin time)	Pain - Abdomen NOS	Pain - Anus	Pain - Back	Pain - Bone	Pain - Chest/thorax NOS	Pain - Extremity-limb	Pain - Eye	Pain - Head/headache	Pain - Joint	Pain - Muscle	Pain - Oral-gums	Pain - Rectum	Pain - Throat/pharynx/larynx	Pain-Other (Specify)	Pancreatic endocrine: glucose intolerance	Perforation, GI - Colon	Pericardial effusion (non-malignant)	Pericarditis	Petechiae/purpura	Phosphate, serum-low (hypophosphatemia)	Platelets	Pleural effusion (non-malignant)	Pneumonitis/pulmonary infiltrates	Portal vein flow	Potassium, serum-high (hyperkalemia)	Potassium, serum-low (hypokalemia)	Proctitis	Pulmonary/Upper Respiratory-Other (Specify)	Rash/desquamation	Renal failure	Rigors/chills	Seroma	Serum sickness	Sodium, serum-high (hypernatremia)	Sodium, serum-low (hyponatremia)	Somnolence/depressed level of consciousness	Atrial fibrillation	Sinus tachycardia	Supraventricular arrhythmia NOS	Syncope (fainting)	Syndromes-Other (Specify)	Thrombosis/embolism (vascular access-related)	Thrombosis/thrombus/embolism	Thrombotic microangiopathy	Tumor lysis syndrome	Typhlitis (cecal inflammation)	Uric acid, serum-high (hyperuricemia)	Vasovagal episode	Ventricular arrhythmia - Ventricular fibrillation	Vision-blurred vision	Vomiting
Ara-C Consolidation	22	17	2	2	3	2	0	0	1	2	1	2	0	4	2	0	3	1	0	0	3	4	1	4	0	0	1	0	0	0	1	4	1	3	0	10	0	1	0	0	0	22	183	16	0	0	1	4	15	0	1	144	1	0	0	0	1	2	0	0	0	0	0	1	0	4	12	0	0	2	4	6	0	4	0	4	47	1	0	1	13	1	2	3	0	0	1	22	1	1	0	2	0	1	0	2	9	1	0	6	1	0	6	4	1	0	1	0	9	0	0	1	0	0	7	1	0	2	1	2	1	0	3	0	0	4	1	2	151	1	0	50	1	4	1	0	0	0	0	2	0	0	1	1	2	0	7	1	1	2	1	193	0	1	0	0	1	3	1	1	4	2	1	1	8	0	1	0	0	0	0	0	0	0	0	3	6	226	3	5	0	0	19	0	1	1	0	1	0	0	0	4	0	0	0	0	4	2	1	4	0	0	1	1	1	0	0	5
Ara-C+Daunomycin	11	11	0	0	10	2	1	0	0	13	0	0	0	11	1	0	7	0	2	1	0	1	6	10	1	0	0	2	0	0	0	19	0	0	1	6	1	0	0	0	3	25	196	8	0	0	0	0	12	0	1	87	0	1	1	0	0	0	1	0	0	0	2	1	0	1	5	0	1	3	1	2	0	2	1	1	25	0	1	1	6	0	2	2	1	0	1	27	0	2	0	3	0	1	1	3	3	1	0	6	0	0	0	1	0	0	0	0	0	0	1	0	0	1	3	1	1	0	0	2	0	1	3	1	1	4	0	1	96	0	1	23	1	5	0	1	1	1	1	11	2	2	9	2	1	0	13	0	1	0	0	110	1	0	1	2	0	5	0	0	0	1	1	0	1	0	0	1	0	1	0	0	1	0	0	2	9	130	1	1	0	2	15	1	0	9	6	0	0	0	0	15	0	1	0	0	3	0	1	4	1	2	4	0	0	0	1	5
Ara-C+Daunomycin+Mylotarg	29	32	2	7	15	3	1	6	0	14	0	0	1	14	0	1	13	0	0	0	0	2	2	8	3	1	0	3	2	1	0	5	0	2	1	10	1	0	1	1	1	24	178	6	1	1	0	1	22	1	1	101	0	5	0	1	0	1	1	2	1	1	0	1	5	3	8	3	0	2	5	8	1	0	0	2	30	0	0	0	5	0	5	1	1	1	0	22	0	1	1	2	1	0	0	2	4	0	1	6	0	1	0	0	0	1	0	1	6	1	0	0	2	0	0	3	0	0	0	0	0	1	4	1	0	4	0	1	106	0	4	21	1	3	1	0	0	0	0	6	2	0	4	1	0	1	7	0	1	0	1	111	0	0	0	0	0	8	0	1	0	2	0	0	8	1	0	0	0	0	1	1	0	1	1	6	10	145	1	3	2	4	21	0	1	6	8	0	1	0	2	8	1	0	1	1	1	0	0	4	0	2	3	1	0	1	0	2
Post-consolidation G.O.	2	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	4	22	1	0	0	0	0	2	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	4	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	41	0	0	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	43	0	0	0	1	0	0	1	1	0	0	1	0	1	0	0	0	1	0	0	0	0	0	0	1	1	40	0	0	0	0	3	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1

Intervention	percentage of participants (Number)
CNS Patients - Treatment (Combination Chemotherapy)	64.9
Testicular Relapse Patients (Combination Chemotherapy)	70

Intervention	Participants with a given type of AE (Number)
	ALT, SGPT (serum glutamic pyruvic transaminase)	AST, SGOT (serum glut oxaloacetic transaminase)	Albumin, serum-low (hypoalbuminemia)	Alkaline phosphatase	Anorexia	Ascites (non-malignant)	Bilirubin (hyperbilirubinemia)	Calcium, serum-low (hypocalcemia)	Cholecystitis	Cholesterol, serum-high (hypercholesterolemia)	Coagulation-Other (Specify)	Colitis, infectious (e.g., Clostridium difficile)	Constipation	DIC (disseminated intravascular coagulation)	Death not assoc with CTCAE term-Multi-organ fail	Edema: limb	Fatigue (asthenia, lethargy, malaise)	Febrile neutropenia	Fever (in the abs of neutropenia)	Fibrinogen	Glucose, serum-high (hyperglycemia)	Glucose, serum-low (hypoglycemia)	Hemoglobin	Hypertension	Hypotension	Hypoxia	Ileus, GI (functional obstruction of bowel)	Infec(doc clin or mibio) w/ Gr 3/4 neut-Anal	Infec(doc clin or mibio) w/ Gr 3/4 neut-Bladder	Infec(doc clin or mibio) w/ Gr 3/4 neut-Blood	Infec(doc clin or mibio) w/ Gr 3/4 neut-Bronchus	IInfec(doc clin or mibio) w/ Gr 3/4 neut-Catheter	Infec(doc clin or mibio) w/ Gr 3/4 neut-Eye NOS	Infec(doc clin or mibio) w/ Gr 3/4 neut-Lung	Infec(doc clin or mibio) w/ Gr 3/4 neut-Nose	Infec(doc clin or mibio) w/ Gr 3/4 neut-Pharynx	Infec(doc clin or mibio) w/ Gr 3/4 neut-Ur tract	Infec with nor ANC or Gr 1/2 neut-Lung (pneumonia)	Infection-Other (Specify)	Leukocytes (total WBC)	Lipase	Liver dysfunction/failure (clinical)	Lymphopenia	Magnesium, serum-high (hypermagnesemia)	Mucositis/stomatitis (clinical exam) - Oral cavity	Mucositis/stomatitis (funct/symp) - Oral cavity	Mucositis/stomatitis (func/symp) - Pharynx	Muscle weak,gen spec area-Whole body	Nausea	Neuropathy: motor	Neutrophils/granulocytes (ANC/AGC)	Pain - Abdomen NOS	Pain - Bone	Pain - Neck	Pancreatic endocrine: glucose intolerance	Pancreatitis	Phosphate, serum-low (hypophosphatemia)	Platelets	Potassium, serum-high (hyperkalemia)	Potassium, serum-low (hypokalemia)	Rash/desquamation	Renal failure	Sodium, serum-low (hyponatremia)	Thrombosis/thrombus/embolism	Thrombotic microangiopathy	Triglyceride, serum-high (hypertriglyceridemia)	Tumor lysis syndrome	Typhlitis (cecal inflammation)	Uric acid, serum-high (hyperuricemia)	Vomiting
Induction	17	13	3	2	2	1	6	7	1	2	1	1	1	2	1	1	3	18	1	11	16	1	33	2	3	2	1	1	1	11	1	1	1	1	1	1	2	2	1	43	1	2	19	1	2	1	1	2	3	1	47	1	1	1	1	1	1	44	1	7	1	2	6	1	2	1	5	1	1	1

Intervention	Participants (Number)
	Experienced Grade 3 or 4 toxicities	Did not experience Grade 3 or 4 toxicities
Overall	27	3

Intervention	arbitrary units (Median)
	Prednisolone-sensitive cells	Prednisolone-resistant cells
Total Therapy	341.3	447.9

Intervention	Number of participants (Number)
Arm A: Standard Arm - No GMTZ, AML Pts w/Out Down Syndrome	482
Arm B: Experimental - With GMTZ, AML Pts w/Out Down Syndrome	477
Arm A: Standard Arm - No GMTZ, AML Patients With Down Syndrome	5

Intervention	percentage of participants (Number)
Arm A: Standard Arm - No GMTZ, AML Pts w/Out Down Syndrome	65.4
Arm B: Experimental - With GMTZ, AML Pts w/Out Down Syndrome	69.4
Arm A: Standard Arm - No GMTZ, AML Patients With Down Syndrome	50.0

Intervention	Proportion of participants (Number)
Arm A: Standard Arm - No GMTZ, AML Pts w/Out Down Syndrome	0.851324
Arm B: Experimental - With GMTZ, AML Pts w/Out Down Syndrome	0.882716
Arm A: Standard Arm - No GMTZ, AML Patients With Down Syndrome	0.666667

Intervention	Mean days (Mean)
	During Induction I (days 0 - 28 of therapy)	During Induction II (days 29 - 56 of therapy)	During Intensification I (days 57 - 84 of therapy)
Arm A: Standard Arm - No GMTZ, AML Patients With Down Syndrome	29.17	26.6	24.5
Arm A: Standard Arm - No GMTZ, AML Pts w/Out Down Syndrome	30.56	28.54	27.51
Arm B: Experimental - With GMTZ, AML Pts w/Out Down Syndrome	30.56	28.52	28.10

Intervention	Percentage participants DFS at 3 years (Number)
Arm A: Standard Arm - No GMTZ, AML Pts w/Out Down Syndrome	56.6
Arm B: Experimental - With GMTZ, AML Pts w/Out Down Syndrome	63.0
Arm A: Standard Arm - No GMTZ, AML Patients With Down Syndrome	75.0

Intervention	percentage of participants (Number)
Arm A: Standard Arm - No GMTZ, AML Pts w/Out Down Syndrome	46.9
Arm B: Experimental - With GMTZ, AML Pts w/Out Down Syndrome	53.1
Arm A: Standard Arm - No GMTZ, AML Patients With Down Syndrome	50.0

daunorubicin

Description

Cross-References

Synonyms (128)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (2)

Drug Classes (4)

Protein Targets (111)

Potency Measurements

Inhibition Measurements

Other Measurements

Biological Processes (479)

Molecular Functions (145)

Ceullar Components (97)

Bioassays (687)

Research

Studies (7,766)

Market Indicators

Research Demand Index: 61.42

Study Types

Clinical Trials (358)

Trial Overview

Trial Outcomes

Complete Remission (CR)

Percentage of Patients With Overall Survival as Assessed by Time to Death

Event-free Survival

Overall Survival (OS)

Response

Progression-free Survival (PFS)

Overall Survival (Consolidation Phase)

Disease-free Survival (Consolidation Phase)

Overall Survival (Induction Phase)

Minimal Residual Disease (MRD) During Treatment With Alemtuzumab (Phase II)

Disease-free Survival, for Only Complete Response Patients

Maximum Tolerated Dose (MTD) of Alemtuzumab (Phase I)

Number of Participants Achieving Complete Remission

Overall Survival

Number of Participants Who Proceed to Course V Within 2-6 Weeks of the Last Dose of Alemtuzumab (Phase II)

Correlation of Minimal Residual Disease (MRD) Positive With Overall Survival (OS)

Correlation of Early Marrow Response Status With MRD Positive.

Correlation of Minimal Residual Disease (MRD) Negative With Event Free Survival (EFS).

Correlation of Minimal Residual Disease (MRD) Negative With Overall Survival (OS).

Comparison of the Increase in Cure Rate of High Risk ALL Without Causing More Serious Side Effects Between Interventions

Correlation of Early Marrow Response Status With MRD Negative.

Correlation of Minimal Residual Disease (MRD) Positive With Event Free Survival (EFS)

Complete Remission

2-year Disease-free Survival (DFS)

Toxicity

Event-free Survival

Continuous Complete Remission at 1 Year

Toxicity

Proportion of Patients Experienced Toxicity of Cytarabine + Daunomycin + Etoposide (ADE) + GO.

Relationship of Inhibition of DNA Synthesis and Clinical Response

To Assess Whether Inhibition of DNA Synthesis is Greater After High-dose Ara-C (HDAC) Than After Low-dose Ara-C (LDAC) Therapy

To Estimate the Overall Event-free Survival (EFS) of AML Patients Who Undergo Risk-adapted and Genotype-directed Therapy

Minimal Residual Disease (MRD).

Proportion of MRD Reduction After One Course of Cytarabine + Daunomycin + Etoposide (ADE) + GO

Proportion of Minimal Residual Disease (MRD)+ Patients Who Become MRD- After One Course of Gemtuzumab Ozogamicin (GO)

Circulating Leukemia Cells in Peripheral Blood Change From Prior to the Methotrexate Infusion to Three Days After Between Two Arms (4 Hours vs. 24 Hours)

Continuous Complete Remission Since Week 56 Therapy.

Mean Difference of Active Methotrexate Polyglutamates (MTXPG) in Leukemia Cells Between Two Arms (4 Hours vs. 24 Hours).

Overall Event-free Survival (EFS)

Median Difference in CASP1 Gene Expression in Primary Leukemia Cells of Patients in Glucocorticoid-resistant Cells vs Glucocorticoid-sensitive Cells

Minimal Residual Disease (MRD)

Median Difference in NLRP3 Gene Expression in Primary Leukemia Cells of Patients in Glucocorticoid-resistant Cells vs. Glucocorticoid-sensitive Cells

Percentage of Patients With ALL at High Risk of Relapse (Arm 2) Who Were Relapse-free at 5 Years

Percentage of Patients Experiencing Grade 3 or 4 Toxicity Assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0

Prevalence of of GATA1 Mutations of DS Patients < 4 Years of Age at Diagnosis

Proportions of Patients in Morphologic Remission With Positive MRD by Flow Cytometry

Prevalence of Leukemia Phenotype of DS Patients < 4 Years of Age at Diagnosis by Flow Cytometry

Cytarabine Drug Sensitivity by R-Strip (MicroMath) Curve Fitting Program

Intervention	percent probability (Number)
ARM I (Combination Chemotherapy)	89.01
ARM II (Combination Chemotherapy)	90.53
ARM III (Combination Chemotherapy)	78.07
ARM IV (Combination Chemotherapy)	86.46

Intervention	percent probability (Number)
	Intermediate Risk	High Risk
ARM II (Combination Chemotherapy)	1.08	0
ARM IV (Combination Chemotherapy)	0.85	3.45

Intervention	percent probability (Number)
	Low Risk	Intermediate Risk	High Risk
ARM I (Combination Chemotherapy)	1.85	1.16	3.64
ARM III (Combination Chemotherapy)	1.92	9.1	6.52

Intervention	percent probability (Number)
	High Risk	Induction Failure
ARM II (Combination Chemotherapy)	85.0	100

Intervention	percent probability (Number)
ARM I and ARM III (Combination Chemotherapy)	82.96
ARM II and ARM IV (Combination Chemotherapy)	88.30

Intervention	percent probability (Number)
	Standard Risk	High Risk
ARM I (Combination Chemotherapy)	87.4	85.1

Intervention	percent probability (Number)
ARM I (Combination Chemotherapy)	91.76
ARM II (Combination Chemotherapy)	90.53
ARM III (Combination Chemotherapy)	86.06
ARM IV (Combination Chemotherapy)	84.89

Intervention	percent probability (Number)
ARM I and ARM II (Combination Chemotherapy)	91.45
ARM III and ARM IV (Combination Chemotherapy)	85.78

Intervention	Participants (Count of Participants)
TOTXVI PEG 3500	22
TOTXVI PEG 2500	26
TOTXVI Not Randomized	31
All Eligible Patients in TOTXV	55

Intervention	Percentage of participants (Number)
TOTXVI PEG 3500	97.5
TOTXVI PEG 2500	95.6
TOTVI Not Randomized	90.8
All Eligible Patients in TOTXV	93.5